belgian cancer registry
Cancer Incidence in Belgium
2010
Special issue
Cancer in Children
and Adolescents
Belgian Cancer Registry
belgian cancer registry
Cancer Incidence in Belgium
2010
Special issue
Cancer in Children
and Adolescents
Belgian Cancer Registry
© 2013 Belgian Cancer Registry
Stichting Kankerregister - Fondation Registre du Cancer – Stiftung Krebsregister
Editorial team:
Belgian Cancer Registry: Kris Henau, Nancy Van Damme, Frédéric Calay,
Mia Slabbaert, Linda Thibaut, Julie Francart, Karen Vos, Katia Emmerechts,
Liesbet Van Eycken
BSPHO: Yves Benoit, An Van Damme, Christophe Chantrain, Anne Uyttebroeck
Responsible editor: Liesbet Van Eycken, Koningsstraat 215, 1210 Brussels
Design: www.magelaan.be
D/2013/11.846/1
Use of data
The information in this publication may be used freely on condition of correct
quotation of the source and reference.
Recommended reference:
Cancer in Children and Adolescents, Belgian Cancer Registry, Brussels, 2013
Additional information can be requested at:
Tel. 0032-2-250 10 10
Fax 0032-2-250 10 11
e-mail: info@kankerregister.org info@registreducancer.org
This publication was realized with the specific financial support of
The Belgian Cancer Registry receives financial support of:
Met steun van de
Vlaamse overheid
belgian cancer registry
Abbreviations...........................................................................................................................................................................4
Foreword..................................................................................................................................................................................... 5
Methodology............................................................................................................................................................................6
Notif ication and submission to the Cancer Registry .................................................................................... 7
Quality of incidence data .....................................................................................................................................8
Calculation of incidence, mortality and survival ..........................................................................................10
Childhood cancer in Belgium. ..................................................................................................................................... 12
I-XII All cancers ....................................................................................................................................................13
I
Leukaemias, myeloproliferative and myelodysplastic................................................................................... 18
diseases........................................................................................................................................................ 18
II
Lymphomas and reticuloendothelial neoplasms ..............................................................................22
III
Central nervous system tumours (CNS) and ......................................................................................27
IV
Sympathetic nervous system tumours ................................................................................................32
V
Retinoblastoma .........................................................................................................................................34
VI
Renal tumours ............................................................................................................................................35
VII
Hepatic tumours........................................................................................................................................ 37
VIII
Bone tumours.............................................................................................................................................38
miscellaneous intracranial and intraspinal neoplasms.................................................................................. 27
IX
Soft tissue sarcoma...................................................................................................................................42
X
Germ cell, trophoblastic and other gonadal neoplasms ................................................................................46
XI
Carcinomas and other malignant epithelial neoplasms...............................................................................51
Cancer in Infants.................................................................................................................................................. 59
Reference list.........................................................................................................................................................................60
Appendix.................................................................................................................................................................................. 63
Appendix 1: Notifications by source type in children and in adolescents, Belgium 2004-2009 ..... 64
Appendix 2: Cancer incidence in children and adolescents, Belgium 2004-2009.............................. 68
Cancer in Belgium, 2010................................................................................................................................................. 87
3
introduction
Contents
Abbreviations
ALL
Acutelymphoidleukaemia
BSPHO
BelgianSocietyofPaediatricHaematologyOncology
AML
CBSS
CNS
Acutemyeloidleukaemia
CrossroadsBankforSocialSecurity
Centralnervoussystem
GCT
Germcelltumours
ICCC-3
InternationalClassificationofChildhoodCancer(3rdedition)
GCTOG
ICD10
ICD-O3
Germcelltumours,trophoblasticandothergonadalneoplasms
InternationalClassificationofDiseases(10thedition)
InternationalClassificationofDiseasesforOncology(3rdedition)
MOC
MultidisciplinaryOncologicalConsult
NNSS
NationalNumberforSocialSecurity
NHL
Non-Hodgkinlymphoma
Non-RMS Non-rhabdomyosarcoma
PNET
RMS
Primitiveneuroectodermaltumours
Rhabdomyosarcoma
SNS
Sympatheticnervoussystem
WSR
WorldStandardisedincidenceRates
STS
Softtissuesarcomas
a fruitful collaboration between the Belgian Cancer Registry and the Belgian Society of
belgian cancer registry
Minister Onkelinx in 2008, initiatives were taken to establish a national coordination cell
5
theBSPHO.Thefoundationofthisnationalcellhasfavoredthesetupofasupplementary
introduction
Foreword
The special issue ‘Cancer in Children and Adolescents’ in this publication is the result of
Paediatric Haematology Oncology (BSPHO). With the introduction of the Cancer Plan of
for clinical and scientific research in paediatric haemato- oncology under the umbrella of
childhoodcancerregistrationnetworkwithallthe8Belgianpaediatrichaemato-oncology
centresbesidestheclassiccancerregistrationincludingthepathologyandclinicalregistration
pathways. The specific data has been collected from the incidence year 2004 onwards.
IncidenceandsurvivaldataforchildrenandadolescentsarepresentedforBelgium(5years)
andforFlanders(10years).
Inaddition,thecancerincidencetables2010forallagesareprintedforBelgiumandforthe
threeregions.Theincidencedataareregularlyupdatedandcanbefoundonthewebsiteof
theBelgianCancerRegistry(http://www.kankerregister.org/Statistieken
http://www.registreducancer.org/Statistiques).
Apublicationisalsoanoutstandingmomenttosincerelythankallthephysicians,pathologists
anddatamanagersinthehospitalsfortheirintensivecommitmentandsustainedeffortsin
registration.
Aspecialissueisdevotedtothissubjectbecausecancerinchildrenandadolescentsstrongly
differsfromtheadultmalignancies.Itis,allthemorethaninadults,anemotionallyloaded
subjectandthecoverwaschosenforthisreason.Childrenandadolescentsstandforfuture,
initiatives,dreams,hope…andeverynewcancerdiagnosiscanmakeayounglifeassensitive
asabubble.
Eachyearabout320children(<15years)and180adolescents(15-19years)facethediagnosis
and treatment of cancer. Malignant diseases are rare under the age of 20 years when
compared to adults, where cancer accounts for more than 99% of the total cancer burden.
Everyyear,approximately70patientsyoungerthan20yearsdiefromcancer.
Since the nineteen sixties, mortality rates have dramatically declined for most childhood
cancers. This decrease in mortality reflects an improved cancer survival rate for children.
Survivalincreasedforallchildhoodcancers,butbyvaryingamountsandatdifferentpoints
intime.Theprogressisnotonlylinkedtomoreeffectivedrugs.Mostoftheseimprovements
canbeattributedtotheaccurateuseofalreadyexistingdrugsandeffectivecombinationsof
them,tobetterinsightsinthenaturalbehaviorofthedisease,tobetterdiagnosticmethods,
tobettersurgeryandradiotherapyandtoabetteridentificationofprognosticfactors.
Wehopethatthisworkcanbeanassetforyourdailypracticeandforfurthercollaborations
inordertostrengthenscientificpopulationbasedcancerresearch.
Brussels,February2013
Anne Uyttebroeck
President BSPHO
Liesbet Van Eycken
Director BCR
Methodology
Notif ication and submission to the Cancer Registry
Newlegislationinitiativessince2003andthefoundationoftheBelgianCancerRegistryin
2005,forcedabreakthroughintheBelgiancancerregistration.EspeciallytheRoyalDecree
on the oncological care programs in 2003 with the reimbursement of the multidiscipli-
naryoncologicalconsult(MOC)andthecreationofthespecificlawontheCancerRegistry
in2006providedafirmlegalbasisforcancerregistrationinBelgium.(1)(2)Thislegislation
makescancerregistrationcompulsoryfortheoncologicalcareprogramsandforthelabo-
ratoriesforpathologicalanatomy.Furthermore,thelawauthorizestheuseofthenational
activefollowuponvitalstatusanddateofdeathofthepatients.
A complete description of the data registration and data collection related to hospitals
andpathologylaboratorieswasreportedinthepublication‘CancerIncidenceinBelgium,
2008’(3).Asoftheyearofincidence2004,Belgiancancerincidencedataareavailable.The
generaldataflow(Figure1)reliesonallinformation(notifications)comingfromtheonco-
logicalcareprograms(clinicalnetwork)andallpathologicalanatomylaboratories(pathologynetwork).
Figure 1 Belgian Cancer Registry: dataflow
oncological.care
programs
paediatric centres
for haemato-oncology
MOC
health.insurance.
companies
MOC+
not MOC
laboratories.for.
pathological.anatomy/
haematology
vital status/
date of death
Belgian Cancer Registry
MOC: Multidisciplinary Oncological Consult
CBSS: Crossroads Bank for Social Security
CBSS
7
cancer incidence in belgium 2010
linkagewithothermedicaland/oradministrativedata.Furthermore,throughlinkagewith
theCrossroadsBankforSocialSecurity(CBSS),theNNSSenablestheRegistrytoperform
belgian cancer registry
numberforsocialsecurity(NNSS)astheuniqueidentifierofthepatient.TheNNSSfavours
In2009,aspecificcollaborationhasbeensetupwithallthe8Belgianpaediatriccentresfor
haemato-oncology.Datahasbeencollectedfromtheincidenceyear2004onwards(Table1).
Table 1 Overview paediatric centres for haemato-oncology in Belgium
Universitair Ziekenhuis Gent
ZNA Koningin Paola Kinderziekenhuis, Antwerpen
Universitair Ziekenhuis Leuven
Universitair Ziekenhuis Brussel
Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles
belgian cancer registry
Cliniques Universitaires Saint-Luc, Bruxelles
8
CHR de la Citadelle, Liège
CHC Les Cliniques Saint-Joseph Montegnée, Liège
Quality of incidence data
Completeness of the cancer registry (degree of coverage)
CompletenessistheextenttowhichallincidentcancersintheBelgianpopulationarein-
cludedintheCancerRegistry.Incidencerateswillbeclosetotheirtruevalueifmaximum
completenessincasefindingprocedurescanbeachieved.
Thenumberofnotificationsanddatasourcespertumourisarawindicatorofcomplete-
ness.Thehighertheaverage,themorecompletetheregistrationprocess.Linkageofdata
fromdifferentsourcesandsourcetypesleadstoinformationthatismorecomplete,preciseandreliable.
Number of notifications from paediatric centres for haemato-oncology
InBelgium,between2004and2009,atotalnumberof2,973cancersarediagnosedinchil-
drenandadolescents(0-19years).Theregistrationforthesetumoursoriginatedfrom7,741
notificationsi(onaverage2.6notificationspertumour[range1-8]).In35%ofthecases,a
notificationwasreceivedfromthreedifferentpathways(clinicaloncology+pathological+
paediatriccentre).Duetothelowernumberofadolescentcancersdiagnosedbypaediatric
centres(Figure2),theaveragenumberofnotificationsinthisagegroupislower(2.2)when
comparedtochildrenintheagegroup0-14years(2.8).
Sixtypercentofthe2,973cancersrecordedinchildrenandadolescentswasregisteredby
a paediatric centre for haemato-oncology. Especially under the age of 12 years, the con-
tributionofthepaediatriccentresissubstantial.Inthisagegroup,anotificationfroma
paediatriccentreisreceivedinalmost90percentofthediagnoses.Thenotificationofthe
other10%(registrationbymultidisciplinaryconsult,registrationbypathologyonly,…)are
mostlybraintumours,epithelialneoplasms,lymphomasandleukaemias.Butthisdoes
notautomaticallyimplythatthepaediatriccentresforhaematology-oncologywerenot
involvedinthediagnosticandtherapeuticsettingforthepatient.Aftertheageof16years,
notificationsfrompaediatriccentresarerarebutthisisinlinewithagegroupstreatedin
paediatriccentres.
i. Only.unique.notifications.from.1.source.were.included..If.the.same.source.registered.the.same.diagnosis.more.than.once,..
this.is.counted.as.1.notification.
Figure 2 Notifications of paediatric centres for haemato-oncology by age at diagnosis, Belgium 2004-2009
Notification of paediatric source
No notification of paediatric source
100%
90%
80%
70%
60%
50%
40%
30%
belgian cancer registry
20%
10%
0%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
Number of notifications from paediatric centres for haemato-oncology
by tumour type
cancer incidence in belgium 2010
9
Undertheageof15years,morethan90%ofallleukaemias(I),neuroblastomas(IV),retino-
blastomas(V),renal(VI),hepatic(VII)andbonetumours(VIII)areregisteredbyapaediat-
riccentre(Table2).Lymphomas(II),softtissuesarcomas(IX)andgermcelltumours(X)are
notifiedinmorethan80%ofallcasesbyapaediatriccentre.Forbraintumours(III),this
isonly75%.Epithelialneoplasms(XI)arelessfrequentlyregisteredbyapaediatriccentre.
Themajorityofthesetumourtypesareregisteredbypathologylaboratories(Appendix
1)andarenotnotifiedbyanyothersourcetype.Specialattentionshouldbemadeforthe
clinicalregistrationofthesecases.
Table 2 Notifications from paediatric centres for haemato-oncology by tumour type, Belgium 2004-2009
ICCC-3 Classification
0-14 years
Total
15-19 years
Paediatric
notification
N
N
Total
0-19 years
Paediatric
notification
%
N
N
Total
Paediatric
notification
%
N
N
%
I-XII
All tumours
1,913
1,604
83.8%
1,060
157
14.8%
2,973
1,761
59.2%
I
Leukaemias, myeloproliferative and myelodysplastic diseases
500
480
96.0%
125
32
25.6%
625
512
81.9%
II
Lymphomas and reticuloendothelial neoplasms
238
211
88.7%
264
32
12.1%
502
243
48.4%
III
CNS and miscellaneous intracranial and intraspinal neoplasms
475
356
74.9%
146
25
17.1%
621
381
61.4%
IV
Neuroblastomas and other peripheral nervous cell tumours
128
124
96.9%
2
-
-
130
124
95.4%
V
Retinoblastomas
64
59
92.2%
-
-
-
64
59
92.2%
VI
Renal Tumours
102
97
95.1%
6
3
50.0%
108
100
92.6%
VII
Hepatic tumours
11
10
90.9%
1
-
-
12
10
83.3%
VIII
Malignant bone tumours
99
90
90.9%
77
30
39.0%
176
120
68.2%
IX
Soft tissue and other extraosseous sarcomas
105
90
85.7%
83
17
20.5%
188
107
56.9%
X
Germ cell tumours, trophoblastic tumours and neoplasms of gonads
59
48
81.4%
112
11
9.8%
171
59
34.5%
XI
Other malignant epithelial neoplasms and malignant melanomas
127
38
29.9%
239
7
2.9%
366
45
12.3%
XII
Other and unspecified malignant neoplasms
5
1
20.0%
5
-
-
10
1
10.0%
Number of notifications by data source
A total of 926 tumours (48%) diagnosed in children (0-14 years of age) are notified by the
three main source types (paediatric centres, laboratories for pathological anatomy/clinical
biologyandhospitals/healthinsurancecompanies)(Figure3).
Intotal,1,610(84%)ofalldiagnosesaredeliveredbymorethanonesourcetype.
Theremaining303tumoursareonlyregisteredbyonesourcetypeofwhich83tumours(4.3%)
arenotifiedbyapaediatriccentreonly.Thesetumoursmainlyconcernbraintumours(N=28),
leukaemias(N=17)andlymphomas(N=10).Leukaemiasarenotexpectedtobereportedby
thepathologicalpathway.Anotherimportantpartofthesetumoursareonlydiagnosedon
belgian cancer registry
clinicalbasisandnotconfirmedmicroscopically.The147diagnoses(7.7%)onlyreceivedfrom
10
a laboratory were submitted to an individual and thorough quality control to confirm the
diagnoses.Thisspecificcontrolincludedareviewofthewrittenprotocolsandifnecessary,
thepathologistwascontactedforadditionalinformationaboutthediagnosis.For73tumours
(3.8%)onlyaregistrationfromanoncologicalcareprogramwasreceived.Alsoherethismain-
ly concerns brain tumours (N=35) and leukaemias (N=12). But, this does not automatically
implythatthepeadiatriccentresforhematology-oncologywerenotinvolved.
Figure 3 Notifications for childhood cancer by source type, Belgium 2004-2009
All tumours: notifications by source type (N = 1,913)
Paediatric centres:
N = 1,604 (83.8%)
N = 83
(4.3%)
N = 439
(22.9%)
N = 156
(8.2%)
N = 926
(48.4%)
N = 73
(3.8%)
N = 147
(7.7%)
Pathology/Clinical Biology:
N = 1,318 (68.9%)
N = 89
(4.7%)
Hospitals/Health insurance:
N = 1,527 (79.8%)
Calculation of incidence, mortality and survival
Description of the dataset
TheincidencedatapresentedinthisreportarebasedonthecancerrecordsforBelgianresidentsthatwereavailableattheCancerRegistryinJanuary2012.
Forreportingpurposes,thesetumoursareclassifiedaccordingtotheInternationalClassifica-
tionofChildhoodCancer(ICCC-3)(4).
Mortalitystatistics,usedinthefirstchapter,arerepresentedintheICD-10classification(5).
PopulationdatawereobtainedfromtheDirectorate-GeneralStatisticsBelgium(6).
Thedifferentchaptersincludedinthisdocumentarebasedonthemaintumourtypesasde-
scribedintheICCC-3classification.Foreverytumourtype,generalincidenceandsurvivalresults
arepresented.Whenpossible,amoredetailedanalysisbyagegroup,histologyorprimarysite
(ICD-O3(7))iscarriedout.Additionally,aseparatechapterisdedicatedoncancerininfants(<1year).
Ascancerisararediseaseinchildrenandadolescents,analysesarebasedonsmallnumbers.
Therefore, the data collected over six years are grouped for the calculation of Belgian inci-
denceandsurvivaldata.Theincidenceratesforbothsexesarepresentedseparatelywheneverpossible.Otherwise,dataforboysandgirlsareaggregated.
Incidenceandsurvivalratesalwaysincludechildrenandadolescents,unlessotherwisespecified.Resultsaboutchildrenonlyincludediagnosesintheagegroup0-14yearsofage.Ado-
lescentdiagnosesaretumoursregisteredinpatientsof15-19yearsofage.Cancerininfants
representdiagnosesforpatientsyoungerthan1yearofage.
Incidence and mortality
Incidenceisthenumberofnewcasesoccurringinagiventimeperiodinaspecificpopula-
tion.Itprovidesadirectestimateoftheprobabilityorriskofillness,andcanbeexpressedin
differentways:
11 Thecrudeincidencerateiscalculatedbydividingthenumberofnewcasesobservedduring
agiventimeperiodbythecorrespondingnumberofpeopleinthepopulationatrisk.The
cruderateisexpressedasthenumberofnewcasesper1,000,000personsperyear.
11 The age-specific incidence rate is the number of newly diagnosed cases in a particular
5-yearagegroupoveraspecifiedtimeperiodandexpressedper1,000,000personsperyear.
ardPopulation).Sinceagehasapowerfulinfluenceontheriskofcancer,thisstandardisa-
tionisnecessarywhencomparingseveralpopulationsthatdifferwithrespecttotheirage
structure. In this publication, the World Standard Population is used for standardisation
and consequently World Standardised incidence Rates (WSR) are reported. These are ex-
pressedasthenumberofnewcasesper1,000,000personsperyear.
11 Male/Female(M/F)ratiosarecalculatedbydividingthecorrespondingagestandardised
incidencerates(WSR).
Accordingtointernationalguidelines,incidenceratesforchildrenandadolescentsareexpressed
per1,000,000personyears.Inadults,incidenceratesareexpressedper100,000personyears.
Thesameprinciplesareappliedtocalculatemortalitydata.
Trends in incidence
OnlysixconsecutiveyearsofincidencedataareavailableforBelgium.Moreover,cancerin
childrenisveryrare.Analysisoftrendsandtheinterpretationofresultsiscomplicatedbythe
lownumberofyearlydiagnoses,leadingtoimportantannualfluctuationinincidencerates.
For the Flemish Region, the Belgian Cancer Registry disposes of 11 years of incidence data.
Incidencerateswereaggregatedoverfiveyearandarepresentedasthreemovingaverages
(1999-2003,2002-2006,and2005-2009).
Survival
TheBelgianCancerRegistryperformsactivefollowuponvitalstatusforallpatients.Dataon
vitalstatusisobtainedfromtheCrossroadsBankforSocialSecurity(CBSS)(8),bymeansofthe
nationalnumberforsocialsecurity(NNSS).
Forthispublication,patientsarefollowedupuntil01/01/2012.Between2004and2009atotal
of83patientsarelosttofollowup(2.8%).Atotalof64patients,outofthe83patients,arelost
to follow up due to a missing national number. These patients are excluded from survival
analysis.Theremaining19patientsarecensoredonthelastdatethepatientswereknownto
bealive.Thesepatientsareincludedinthesurvivalanalysis.
ObservedsurvivalratesarecalculatedandpresentedasKaplanMeier(9)survivalcurves.Publishedtablesinappendixwith5or10yearsurvivalratesareaccompaniedwith95%confi-
denceintervals,whicharecalculatedusingtheRothmanmethod.(10)Calculationofsurvival
ratesisonlyperformedforthefirsttumourknownattheregistry.Consequently,theabsolute
numbersusedinthesurvivalanalyseswillbeslightlydifferentfromthosereportedwithin
theframeworkofincidencerates.Whendeterminingthetumoursequence,alltumoursfol-
lowingtheICCC-3classificationareincluded.Sincecancerinchildrenandadolescentsisrare,
thesesurvivalanalysesareoftenbasedonaverylownumberofpatients.Whenthenumbers
ofpatientsatriskdroppedtolessthan10cases,thesurvivaldataarenotpresented.
ForBelgium,5-yearsurvivalratesarecalculatedforallpatientsdiagnosedbetween2004and
2009.Occasionally,10-yearsurvivalratesfortheFlemishRegion(diagnoses1999-2009)are
presented.
11
cancer incidence in belgium 2010
ratesusinganexternalstandardpopulation.Itistheincidencethatwouldbeobservedif
thepopulationhadtheagestructureofthestandardpopulation(EuropeanorWorldStand-
belgian cancer registry
11 The age-standardised incidence rate is a weighted average of the individual age-specific
Childhood cancer in Belgium
I-XII All cancers
Incidence
Cancerisararediseaseinchildren.ComparedtothetotalcancerburdeninBelgium,child-
hoodcancercompriseslessthan1%.Everyyear,about320children(0-14years)and175ado-
lescents(15-19years)arediagnosedwithcancer(Table3).Allsitescombined,morediagnoses
Age group 0-14
Boys
2004
Age group 15-19
Girls
Boys
Age group 0-19
Girls
Boys
Girls
N
WSR
N
WSR
N
WSR
N
WSR
N
WSR
N
WSR
181
205.0
133
158.4
87
278.9
76
254.1
268
221.7
209
180.0
2005
191
214.4
159
187.2
88
278.3
86
283.8
279
228.8
245
208.9
2006
164
183.3
154
177.6
98
303.3
79
255.3
262
210.3
233
195.1
2007
151
168.4
134
155.7
100
304.6
86
272.9
251
199.1
220
182.1
2008
168
184.6
144
165.8
101
303.4
77
241.0
269
211.4
221
182.7
2009
198
219.1
136
154.6
101
302.8
81
252.7
299
238.0
217
176.7
WSR: age-standardised rate, using the World Standard Population (N/1,000,000 person years)
Age specific incidence rates (Figure 4) are higher for the youngest and oldest age groups
when compared to children between 5 and 10 year. Although incidence rates for children
between0-4yearsandthoseaged15-19yearsaresimilar,majordifferencesintumourtypes
canbeobservedbetweentheseagegroups.
Age specific incidence (N / 1,000,000)
Figure 4 Cancer in children and adolescents: age specific incidence rates by sex, Belgium 2004-2009
400.0
Boys
Girls
350.0
300.0
250.0
200.0
150.0
100.0
50.0
0.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
13
cancer incidence in belgium 2010
Table 3 Cancer in children and adolescents by sex, Belgium 2004-2009
belgian cancer registry
areregisteredinboys(55%)thaningirls(45%),correspondingwithamale/femaleratioof1.35.
Leukaemias, brain tumours, lymphomas and carcinomas are the most frequent malignan-
ciesinchildrenandadolescents(Figure5,Figure6).However,theirimportancevariesbyage
group.Intheagegroup0-4years,leukaemiascomprise31%ofalltumourdiagnoses.Thehigh-
estincidenceratesareobservedattheageof2-3years(Figure7).Afterthisage,theincidence
ofleukaemiadecreases.Inadolescents,only12%ofallcancerdiagnosesareleukaemias.Lym-
phomas(25%)andcarcinomas(23%)arethemostcommontumoursinadolescents(Figure
6)andarelesscommonatyoungerage(4%and1%respectivelyintheagegroup0-4years).
belgian cancer registry
Figure 5 Cancer in children and adolescents: new diagnoses by tumour type and age group, Belgium 2004-2009
<1
1-4
5-9
10-14
15-19
Leukaemia - I
Lymphoma - II
Brain/CNS - III
Sympathetic Nerv. - IV
Retinoblastoma - V
Renal - VI
14
Hepatic - VII
Bone - VIII
Soft tissue - IX
Germ cell - X
Carcinomas - XI
Other - XII
0
100
200
300
400
500
600
700
800
Number of diagnoses (N)
Figure 6 Cancer in children and adolescents by tumour type, Belgium 2004-2009
Children (0-14 years)
X; 3%
Adolescents (15-19 years)
XI; 7%
IX; 6%
XII; 0%
I; 26%
I; 12%
XI; 22%
VIII; 5%
VII; 1%
VI; 5%
II; 25%
V; 3%
X; 11%
II; 12%
IV; 7%
IX; 8%
III; 25%
VIII; 7%
IV; 0%
VII; 0%
VI; 1%
III; 14%
Thehighestincidenceratesforneuroblastomasandotherperipheralnervecelltumours(IV),
retinoblastomas(V),renaltumours(VI)andhepatictumours(VII)arefoundininfants(age
<1year).Thesetumoursareseldomdiagnosedinpatientsolderthan9yearsofage.
Germcelltumours(X)andsofttissuesarcomas(IX)arefrequentlydiagnosedinveryyoung
childrenandinadolescents.Theyarelessfrequentinchildrenintheagegroup5-15years.
Bonetumours(VIII)arelessfrequentundertheageof10years.Theirincidenceratesarethe
highestbetweentheageof10to19years.
Leukaemia - I
Brain/CNS - III
120.0
Lymphoma - II
Carcinoma - XI
100.0
80.0
40.0
20.0
Age specific incidence (N / 1,000,000)
0.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
Sympathetic Nerv. - IV
Renal - VI
80.0
Retinoblastoma - V
Hepatic - VII
70.0
60.0
50.0
40.0
30.0
20.0
10.0
Age specific incidence (N / 1,000,000)
0.0
0
1
2
3
4
5
6
7
8
Bone - VIII
50.0
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
Soft tissue - IX
Germ cell - X
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
0
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
belgian cancer registry
60.0
15
cancer incidence in belgium 2010
Age specific incidence (N / 1,000,000)
Figure 7 Cancer in children and adolescents: age specific incidence rates by tumour type, Belgium 2004-2009
Trends
AnalysesfromtheACCIS-project (11)showedanannualincreaseof1.1%inchildhoodcancer
incidenceinEurope.Duetothelownumberofnewdiagnoses,itisnotyetpossibletodraw
reliableconclusionsontrendsfortheBelgiancancerincidencedata.Incidenceratesbetween
1999and2009remainstableintheFlemishRegion(Figure8).
16
Incidence
Figure 9 Cancer in children and adolescents: mortality (WSR) by sex,
Belgium 1960-2009
Mortality
Boys
250.0
WSR (N / 1,000,000)
WSR (N / 1,000,000)
belgian cancer registry
Figure 8 Cancer in children and adolescents: incidence and mortalityii (WSR),
Flemish Region 1999-2009
200.0
150.0
100.0
90.0
80.0
70.0
60.0
50.0
100.0
40.0
50.0
20.0
0.0
Girls
30.0
10.0
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Year
0.0
1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010
Year
(aggregated 5 years mortality data (WSR) from WHO 1960-1999 (12) (13), Belgium 2004, 2005,
2006, 2008 and Flemish Region 2000-2003, 2007, 2009) (14) (15) (16) (6).
Since the nineteen sixties (Figure 9), mortality rates have dramatically declined for most
childhood cancers. This decrease in mortality reflects an improved cancer survival rate for
children.Survivalhasincreasedforallchildhoodcancerssincethelate1960s,butbyvarying
amountsandatdifferentpointsintime.Theseimprovementsarenotlinkedtomoreeffective
drugsalone.Mostoftheseimprovementsarelinkedtotheaccurateuseofalreadyexisting
drugs(effectivecombinations),totheknowledgeofnaturalbehaviourofthedisease,tobetter
diagnosticmethods,tobettersurgeryandradiotherapyandtoabetteridentificationofprog-
nosticfactors.Oneexampleofamajorimprovementinchildhoodcancercareisimproved
efficacyofchemotherapeuticagentsforacutelymphocyticleukaemia(17).
ii. Incidence.and.mortality.are.reported.in.different.classification.systems..Incidence.is.reported.by.means.of.the.ICCC-3.classification(4),.
while.mortality.data.is.classified.according.to.the.ICD10.classification(5)..The.ICCC-3.classification.includes.some.benign.and.borderline.
malignancies.that.are.not.included.in.the.mortality.statistics.
Survival
Childrenandadolescentswithcancerhavearelativelygoodprognosis(Figure10andFigure
11).Five-yearsurvivalratesforgirls(87%)areslightlyhigherthanforboys(84%).Inchildren,
5-yearsurvivalratesforboysandgirlsarealmostthesame,whileinadolescentstheratesfor
girlsarehigherthanforboys.SurvivalratesintheFlemishRegionseemtoimproveslightlyin
thelastdecade(Figure12)from83%to85%.
90%
80%
70%
60%
50%
90%
80%
70%
60%
50%
17
40%
40%
30%
30%
20%
20%
10%
10%
0%
0
1
2
3
Boys
1023
954
904
718
564
431
Girls
830
773
734
603
476
367
0%
0
1
2
Boys
545
516
485
385
296
216
Girls
458
441
428
345
274
198
4
5
Years after diagnosis
N at risk
3
4
5
Years after diagnosis
N at risk
Figure 12 Cancer in children and adolescents: observed survival, Flemish Region 1999-2003, 2002-2006, 2005-2009
Observed survival (%)
Girls
Boys
100%
belgian cancer registry
Girls
100%
Observed survival (%)
Observed survival (%)
Boys
Figure 11 Cancer in adolescents (15-19 year): observed survival by sex,
Belgium 2004-2009
1999-2003
100%
2002-2006
2005-2009
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9
10
Years after diagnosis
1999-2003
1213
1121
1060
1023
1011
1004
996
989
980
772
2002-2006
1279
1185
1125
1098
1080
1071
828
601
386
183
2005-2009
1275
1200
1137
889
664
464
224
N at risk
585
cancer incidence in belgium 2010
Figure 10 Cancer in children (0-14 year): observed survival by sex,
Belgium 2004-2009
I
Leukaemias, myeloproliferative and myelodysplastic
diseases
Incidence
Leukaemia(I)isthemostfrequentcancerinchildren.Between2004and2009atotalnumber
of625newdiagnosesareregisteredinchildren(N=500)andadolescents(N=125)inBelgium
(Table4).Moreboysarediagnosedwithleukaemiathangirls(M/Fratio=1.3).
Therelativefrequencyofleukaemia(Figure13)tothetotalchildhoodcancerburdenvaries
withage.Itincreasesfrom10%atbirthto40%aroundtheageof2-3year.Afterwardsthe
belgian cancer registry
relativeproportionofleukaemiadecreaseswithincreasingagetoabout10%foradolescents.
18
Table 4 New diagnoses of leukaemia, Belgium 2004-2009
Boys
I
Leukaemia
Ib
Acute myeloid leukaemia
Ia
Ic-Ie
Girls
Lymphoid leukaemia
273
236
51
Leukaemia other
Leukaemia
Ib
Acute myeloid leukaemia
Ic-Ie
0-14
362
I
Ia
Total
72
37
20
Total
0-14
15-19
189
162
27
11
10
263
53
Leukaemia other
15-19
31
38
Lymphoid leukaemia
290
21
23
210
37
15
53
16
Figure 13 Relative frequency of leukaemia by age at diagnosis, Belgium 2004-2009
Leukaemia
Other malignancies
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
Themostfrequentsubtype,acute lymphoid leukaemiaiii (ALL: Ia),represents74%ofthetotal
numberofleukaemiacases.Higherincidenceratesareobservedinboys(M/Fratio=1.4).
IninfantsALL(Ia)represents50%ofallleukaemiadiagnoses.Theincidencerates(Figure15)in-
creasesdramaticallytoreachapeakincidenceattheageof2-3years,wheretheratesare5times
higherthanininfants.Thispeakisfullyduetothepeakageoftheprecursor-BALL.Betweenthe
agesof3to9years,incidenceratesdecreaserapidlyandreachtheratesobservedininfants.In
thisagegroup(1-9years)ALL(Ia)represents80%ormoreofallleukaemiadiagnoses.Fromtheage
of10yearsonwards,theincidenceratesforALL(Ia)remainfairlystable.Therelativeproportion
ofALL(Ia)decreasesto73%intheagegroup10-14yearsofageand51%inadolescents(Figure13).
iii. Since.the.subgroup.lymphoid.leukaemia.(Ia).consisted.solely.of.diagnoses.of.acute.lymphoid.leukaemia,.the.abbreviation.ALL.was.used.to.
denote.subgroup.Ia.
The distinctive shape of the age-specific incidence curve for ALL can be well-described by a
mathematical model which assumes that childhood ALL results from two genetic events re-
quiredforfullmalignanttransformationwiththefirstoftheseeventsoccurringinutero(18)(19)(20).
The2ndmostfrequentsubtype,acute myeloid leukaemia (AML: Ib),accountsfor17%oftheleukaemiadiagnoses.Incidenceratesinboysandgirlsarecomparable(M/Fratio=0.9).
The highest proportion of AML (Figure 14) is observed in infants (42%) and in adolescents
(29%).IntheotheragegroupsAMLaccountsfor10to16%ofallleukaemiadiagnoses.
Theremainingleukaemia subtypes (Ic-e)arerareandrepresentslessthan10%ofallnewleu-
Other leukaemia (Ic-Ie)
AML (Ib)
ALL (Ia)
Age specific incidence (N / 1,000,000)
100%
Figure 15 Age specific incidence rates for ALL (Ia) and AML (Ib),
Belgium 2004-2009
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1-4
5-9
10-14
15-19
Age group
100.0
ALL (Ia)
AML (Ib)
90.0
19
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
Trends
WhencomparingincidencedatafromtheFlemishRegionovertime,theincidencerate(WSR)
ofleukaemiaremainsfairlystable(Figure16).Inadolescents,asmalldecreaseinALL(Ia)and
anincreaseinAML(Ib)canbeobserved.Adetailedtrendanalysisiscurrentlynotavailable
duetothelownumberofdiagnoses.
Figure 16 Leukaemia in children and adolescents: age standardised incidence (WSR), Flemish Region 1999-2003, 2002-2006, 2005-2009.
WSR (N/1,000,000)
1999-2003
2002-2006
2005-2009
All ages
60.0
0-14 years
15-19 years
50.0
40.0
30.0
20.0
10.0
0.0
Leukaemia (I)
ALL (Ia)
AML (Ib)
Leukaemia (I)
ALL (Ia)
AML (Ib)
Leukaemia (I)
ALL (Ia)
AML (Ib)
cancer incidence in belgium 2010
Figure 14 Leukaemia by age group, Belgium 2004-2009
belgian cancer registry
kaemiadiagnosesinchildren.
Survival
Theprognosisforleukaemiaisgreatlydependentontheleukaemiasubtype.IntheFlemishRe-
gion,the10-yearssurvivalrateforALL(Ia)is81%(Figure17).The10-yearssurvivalrateforAML(Ib)
isconsiderablylower(61%).Themaindecreaseinthesurvivalratesforbothsubtypesisobserved
inthefirstthreeyearsafterdiagnosis.Afterthreeyearsthesurvivalratesare86%forALLand
63%forAML.Thereaftertheratesremainfairlystable.
Observed survival (%)
belgian cancer registry
Figure 17 Leukaemia in children and adolescents: observed survival for ALL (Ia) and AML (Ib), Flemish Region 1999-2009
ALL (Ia)
100%
AML (Ib)
90%
80%
70%
60%
20
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9
10
Years after diagnosis
ALL (Ia)
432
410
384
340
299
265
224
191
154
123
94
AML (Ib)
99
82
69
57
51
46
39
31
28
22
16
N at risk
The5-yearsurvivalratesinBelgiumforALL(Figure18)areverycomparablebetweenboys(86%)
andgirls(87%).ForAML(Figure19),boysseemtohaveaworseprognosisthangirls(respectively
51%and63%5-yearsurvivalrates).
Boys
100%
Figure 19 AML (Ib): observed survival by sex, Belgium 2004-2009
Girls
Observed survival (%)
Observed survival (%)
Figure 18 ALL (Ia): observed survival by sex, Belgium 2004-2009
90%
80%
70%
60%
50%
40%
Girls
90%
80%
70%
60%
50%
40%
30%
30%
20%
20%
10%
10%
0%
Boys
100%
0%
0
1
2
3
4
5
Years after diagnosis
Boys
267
251
238
186
141
108
Boys
Girls
187
176
167
141
115
89
Girls
N at risk
0
1
2
3
4
5
Years after diagnosis
49
38
30
23
20
17
53
42
37
30
22
14
N at risk
SurvivalofALL(Ia)variesconsiderablywithage(Figure20).Infantshavetheworstprognosis.
Fiveyearsurvivalratesarenotpresentedduetothelownumberofpatientsatrisk.However
ofthe12infantsdiagnosedwithALLinBelgiumbetween2004and2009,5diedwithinthe
firstsixmonthsafterdiagnosis.Prognosisforadolescents(68%)isworsethanforchildren
between1and4years ofage(88%)andchildrenintheagegroup5-9years(93%).Theseobservationsareconsistentwithinternationalfindings.(18)(19)Apossibleexplanationforthedif-
ferenceinprognosisbetweentheagegroupsisadifferenceinbiologicalsubtype.(20)(21)(22)(23)(24)
TheprognosisforthedifferentagegroupsforAML(Ib)ismorecomparable(Figure21).
90%
80%
70%
60%
50%
100%
1-4 years
15-19 years
90%
80%
70%
60%
50%
21
40%
40%
30%
30%
20%
20%
10%
10%
0%
< 1 years
5-14 years
belgian cancer registry
100%
1-4 years
15-19 years
0
1
2
3
0%
4
5
Years after diagnosis
N at risk
0
1
2
3
4
5
Years after diagnosis
N at risk
<1y
12
7
5
3
3
3
<1y
10
7
6
4
4
3
1-4 y
193
185
184
155
129
97
1-4 y
24
17
14
13
8
5
5-14 y
187
179
170
135
101
80
5-14 y
34
30
25
19
16
13
15-19 y
62
56
47
35
25
18
15-19 y
34
26
23
18
15
11
cancer incidence in belgium 2010
< 1 years
5-14 years
Figure 21 AML (Ib): observed survival by age group, Belgium 2004-2009
Observed survival (%)
Observed survival (%)
Figure 20 ALL (Ia): observed survival by age group, Belgium 2004-2009
II
Lymphomas and reticuloendothelial neoplasms
Incidence
Between2004and2009,atotalnumberof502newdiagnosesoflymphoma(II)(Table5)are
registeredinchildren(N=238)andadolescents(N=264)inBelgium.Moreboysareregistered
thangirls(M/Fratio=1.3),adifferencemainlyobservedinchildren(M/Fratio=1.6).Themale/
femaleratioinadolescentsis1.1.Moreboysareregisteredatchildhoodthaninadolescence,
belgian cancer registry
whileforgirlsthisistheopposite.
22
Table 5 New diagnoses of lymphoma, Belgium 2004-2009
Boys
II
IIa
IIb
IIc
IId-e
Girls
II
IIa
IIb
IIc
IId-e
Lymphomas
Total
0-14
15-19
143
56
87
292
Hodgkin
Non-Hodgkin
84
Burkitt
Other lymphoma
Lymphomas
Burkitt
Total
0-14
15-19
120
34
86
15
88
60
26
14
13
16
Other lymphoma
43
38
210
Non-Hodgkin
41
142
47
18
Hodgkin
150
15
9
3
122
34
1
1
Figure 22 Relative frequency of lymphoma by age at diagnosis, Belgium 2004-2009
Other malignancies
Lymphoma
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
Lymphomas(II)arethe3rdmostfrequenttypeofchildhoodcancer(17%).Thepercentageof
lymphoma diagnoses increases with age (Figure 22). In children younger than 5 years, the
proportionoflymphomavariesbetween3%and6%.Betweentheagesof5and14years,the
proportionremainsaround20%.Lymphomaisthemostfrequenttumourtypeinadolescents,
accountingfor25%ofalltumours.
Hodgkin (IIa)
Non-Hodgkin (IIb)
70.0
Burkitt (IIc)
Other lymphoma (IId-IIe)
Figure 24 Lymphoma by age group, Belgium 2004-2009
100%
Non-Hodgkin (IIb)
Burkitt (IIc)
Other lymphoma (IId-IIe)
90%
60.0
80%
50.0
70%
60%
40.0
50%
30.0
40%
30%
20.0
20%
10.0
0.0
Hodgkin (IIa)
10%
0%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
0
1-4
5-9
10-14
15-19
Age group
belgian cancer registry
Age specific incidence (N / 1,000,000)
Figure 23 Lymphoma: age specific incidence, Belgium 2004-2009
23
cancer incidence in belgium 2010
Withmorethanhalfofallnewlymphomadiagnosesinchildrenandadolescents,Hodgkin
lymphoma (IIa)isthemostfrequentlymphoma-subtype(Figure23andFigure24).Although
rareinchildrenyoungerthan10yearsofage,itrepresentsoneofthemostcommonmalignanciesinadolescents.
ThemostcommonsubtypeofHodgkinlymphoma(IIa)isnodularsclerosis(Figure25).This
histologicalsubtyperepresents56%ofalldiagnosesundertheageof10,increasingto70%
inadolescents.
Undertheageof5years,only3childrenarediagnosedwithHodgkinlymphoma.Inchildren
between5and14yearsofage,amalepredominancecanbeobservedthatdisappearsinado-
lescence(Figure26).Themale/femaleratiosare1.9,1.6and1.0fortheagegroups5-9years,
10-14yearsand15-19yearsrespectively.Especiallyinthemixedcellularitysubtype(Figure28),
ahigherincidenceinboyscanbeobserved(M/Fratio=2.9,2.4and0.7intheagegroup5-9,
10-14and15-19yearsrespectively).Fornodularsclerosis,theratesbetweenboysandgirlsare
morecomparable(Figure27).TheseobservationsareconsistentwithinternationalepidemiologicalfeaturesofHodgkinlymphoma.(25)
Figure 25 Hodgkin lymphoma by age group, Belgium 2004-2009
Hodgkin, NOS
Lymphocytic predominance
Mixed cellularity
Nodular sclerosis
Age specific incidence (N / 1,000,000)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Figure 26 Hodgkin lymphoma: age specific incidence rates by sex,
Belgium 2004-2009
0-9
10-14
15-19
Age group
Boys
50.0
Girls
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
0-4
5-9
10-14
15-19
Age group
Girls
Boys
35.0
Figure 28 Hodgkin lymphoma – mixed cellularity subtype:
age specific incidence rates by sex, Belgium 2004-2009
Age specific incidence (N / 1,000,000)
Age specific incidence (N / 1,000,000)
belgian cancer registry
Figure 27 Hodgkin lymphoma – nodular sclerosis subtype:
age specific incidence rates by sex, Belgium 2004-2009
30.0
25.0
20.0
15.0
10.0
5.0
0.0
0-4
5-9
24
10-14
Girls
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
15-19
Age group
Boys
4.0
0-4
5-9
10-14
15-19
Age group
Non-Hodgkin lymphomas (NHL; IIb),the2ndmostfrequentlymphomasubtype,represent29%
of the total number of lymphoma diagnoses in children and adolescents. The overall inci-
denceratesofNHL(IIb)remainrelativelystableuntiltheageof15years(Figure23).Afterthe
ageof15,anincreaseinagespecificincidencerateisobserved.
TherelativecontributionofNHL(IIb)remainsratherstable(20-25%)ineveryagegroup(Fig-
ure24).However,NHLrepresentaheterogeneousgroupofmalignanttumoursandbetween
theagegroupsdifferencescanbeobservedinNHL-subtype(Figure29).Themainsubgroups,
precursorcelllymphomas(IIb1),matureB-celllymphomas(IIb2)andmatureT-andNK-cell
lymphomas(IIb3)areevenlydistributedundertheageof5years.Intheagegroup5-9years,
precursor cell lymphomas (IIb1) and mature T- and NK-cell lymphomas (IIb3) are the most
common subtypes. In the age group 10-19 years the most common histological subtype is
matureB-celllymphoma(IIb2).
Betweenthesexes(Figure30),higherincidenceratescanbeobservedforboysforprecursor
cell(IIb1)andmatureB-celllymphomas(IIb2).TheincidenceratesforT-andNK-celllymphomas(IIb3)areequalinbothsexes.
Figure 29 Non-Hodgkin lymphoma by age group, Belgium 2004-2009
100%
Precursor cell (IIb1)
Mature B-cell (IIb2)
Mature T-cell and NK-cell (IIb3)
Non-Hodgkin, NOS (IIb4)
90%
80%
Figure 30 Non-Hodgkin lymphoma: age standardised incidence (WSR)
by histology and sex, Belgium 2004-2009
Boys
Girls
Precursor cell
(IIb1)
M/F = 1.8
Mature B-cell
(IIb2)
M/F = 1.3
T- and NK-cell
(IIb3)
M/F = 1.0
70%
60%
50%
40%
30%
20%
10%
0%
0-4
5-9
10-14
15-19
Age group
0.0
1.0
2.0
3.0
4.0
5.0
6.0
WSR (N/1,000,000)
Burkitt lymphomas (IIc) represent the 3rd group with 13% of the total lymphoma incidence.
Theyshowamarkedpredominancearoundtheagegroupof5-9years(Figure23).Inthefirst
yearsoflifeandaftertheageof15years,theincidenceratesarelow.Theincidenceratein
boysisalmostthreetimeshigherthaningirls(M/Fratio=2.7).
Theremaininglymphoma subtypes (IId-e) arerare(32cases)andrepresentlessthan10%ofall
newlymphomadiagnosesinchildren.Themajority(26cases)oftheselymphomadiagnoses
aremalignanthistiocytosis(IId).Thissubtypeismostfrequentlydiagnosedininfants.Inoth-
eragegroupstheincidenceratesareverylow.Theremaining6casesarelymphomaNOS(IIe).
belgian cancer registry
Trends
Internationaltrendsshowthatincidenceratesforlymphomas(allsubtypes)increasefaster
inadolescentsthaninchildren.(26)WhencomparingtheincidenceratesintheFlemishRegion
overtime(Figure31),alowerincidencerateforHodgkin(IIa)andnon-Hodgkinlymphoma
(IIb)canbeobservedforadolescentsintheperiod1999-2003whencomparedtotheother
time periods. In childhood lymphoma however, the incidence rates rather seem to decline
25
cancer incidence in belgium 2010
slightly.
Figure 31 Lymphoma: age standardised incidence (WSR), Flemish Region 1999-2003, 2002-2006 and 2005-2009
2002-2006
WSR (N/1,000,000)
1999-2003
80.0
All ages
2005-2009
0-14 years
15-19 years
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0 Lymphoma Hodgkin
(II)
(IIa)
NonHodgkin
(IIb)
Burkitt Lymphoma Hodgkin
(IIc)
(II)
(IIa)
NonHodgkin
(IIb)
Burkitt Lymphoma Hodgkin
(IIc)
(II)
(IIa)
Survival
The 5-year survival rates for the different lymphoma subtypes in children (0-14 year) are
slightly higher than in adolescents (Figure 32 and Figure 33). The 5-year survival rates for
Hodgkinandnon-Hodgkinlymphomaare99%and90%inchildren.Inadolescentstheyare
97%and86%respectively.
Burkittlymphoma(IIc)israrelyseeninadolescentsandthenumberofcasesaretoolowfora
survivalanalysis.Inchildren,Burkittlymphomahavea5-yearsurvivalrateof94%.
NonHodgkin
(IIb)
Burkitt
(IIc)
Hodgkin (IIa)
Burkitt (IIc)
100%
Figure 33 Lymphoma: observed survival in adolescents, Belgium 2004-2009
Non-Hodgkin (IIb)
Observed survival (%)
Observed survival (%)
Figure 32 Lymphoma: observed survival in children, Belgium 2004-2009
90%
80%
70%
60%
50%
Non-Hodgkin (IIb)
90%
80%
70%
60%
50%
40%
40%
30%
30%
20%
20%
10%
10%
0%
Hodgkin (IIa)
100%
0
1
2
3
0%
4
5
Years after diagnosis
N at risk
0
1
2
3
4
5
Years after diagnosis
N at risk
Hodgkin (IIa)
90
89
88
76
63
54
Hodgkin (IIa)
164
163
163
129
105
78
Non-Hodgkin (IIb)
64
62
60
51
41
30
Non-Hodgkin (IIb)
76
71
68
60
46
36
Burkitt (IIc)
52
49
49
43
28
24
belgian cancer registry
26
III
Central nervous system tumours (CNS) and
miscellaneous intracranial and intraspinal neoplasms
Incidence
Tumoursofthecentralnervoussystem(CNS)representthe2ndmostfrequenttumourinchil-
drenandadolescents(21%).InBelgium,621newdiagnosesareregisteredbetween2004and
2009(Table6).Slightlymoreboysarediagnosedthangirls(M/Fratio=1.1).
CNStumoursoccurquitefrequentlyinallagegroups.Inveryyoungchildren(agegroup0-4
diagnoses).
Table 6 New diagnoses of CNS tumours, Belgium 2004-2009
Boys
Total
0-14
33
25
III
CNS tumours
IIIb
Astrocytoma
129
IIId-f
CNS other
121
III
CNS tumours
IIIb
Astrocytoma
IIId-f
CNS other
IIIa
IIIc
Girls
IIIa
IIIc
332
Ependymoma
PNET
PNET
36
Total
0-14
36
33
224
55
28
29
70%
60%
50%
40%
30%
20%
10%
4
5
6
7
8
3
83
Other malignancies
3
65
29
80%
2
15-19
107
90%
1
5
136
100%
0
8
85
Figure 34 Relative frequency of CNS tumours by age at diagnosis, Belgium 2004-2009
0%
81
32
44
34
CNS
15-19
97
49
289
Ependymoma
251
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
5
27
cancer incidence in belgium 2010
yearsofage(Figure34),CNStumoursarethemostfrequentmalignancy(26%ofalltumour
belgian cancer registry
years),CNStumoursaccountfor23%ofalltumourdiagnoses.Inchildrenbetween5and14
TheCNStumoursrepresentaheterogeneouscollectionofmalignancieswithdifferenthistol-
ogy,behaviourandprognosis.Thedistributionofthedifferenthistologicalsubtypesdiffers
byagegroup(Figure35andFigure36).
Ependymomas (IIIa)arethemostimportantCNSsubtypeatinfancy.Theincidenceratesfor
thistumourdecreasefastuntiltheageof4(Figure36).Aftertheageof4,ependymomasare
veryrare.Slightlymoregirlsarediagnosedthanboys(M/Fratio=0.8).Inveryyoungchildren
(0-4year)theincidenceratesingirlsarealmosttwiceashighasinboys(M/Fratio=0.6).In
patientsbetween5and19yearsofage,moreboysarediagnosedwithependymomathan
girls(M/Fratio=1.6).
The ependymoma group (IIIa) contains two subgroups, the ‘real’ ependymoma diagnoses
belgian cancer registry
(IIIa1)andchoroidplexustumours(IIIa2).Whenconsideringallagegroups,twooutofthree
diagnoses are‘real’ ependymoma (IIIa1). The remaining neoplasms are choroid plexus tu-
mours(IIIa2).Thelattergroupisalmostsolelydiagnosedatinfancyandinthefirstyearsof
life,whileonlyhalfoftheependymoma(IIIa1)groupisdiagnosedinthisagegroup(Table7).
Astrocytomas (IIIb)arethemostfrequentCNSsubtype(43%).Intheagegroup5-14yearsthey
representhalfofallthediagnosedCNStumours.Theincidenceratesforgirlsaresomewhat
28
higherthanforboys(allagesM/Fratio=0.9).
Astrocytoma(IIIb)includesawidevarietyoftumourtypesrangingfromslowlygrowingpilo-
cyticastrocytomatoaggressiveglioblastoma.Table7containsaregroupingofthesedifferent
tumour types according to the WHO grading system (27). Half of all astrocytomas are diag-
nosedasgradeI.Theyaremostfrequentlydiagnosedintheagegroup5-9years,wherethey
encompassabout60%oftheastrocytomadiagnoses.ThenumberofgradeIIastrocytomas
increaseswithage.InadolescentstheyarealmostasfrequentasgradeIastrocytoma.Grade
IIIastrocytomasareuncommon.Mostdiagnosesarefoundbetweentheageof5and14years.
GradeIVastrocytomasaremostlydiagnosedaftertheageof10years.For31astrocytomas,a
gradecouldnotbeassigned.Thesetumoursareopticnervegliomas(NOS),almostalldiag-
nosedinthefirstyearsoflife.
Figure 35 CNS tumours by age group, Belgium 2004-2009
Ependymomas (IIIa)
Other gliomas (IIId)
PNET (IIIc)
Other CNS (IIIe-f)
Other CNS (IIIe-IIIf)
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Ependymomas (IIIa)
PNET (IIIc)
Age specific incidence (N / 1,000,000)
100%
Astrocytomas (IIIb)
Figure 36 CNS tumours: age specific incidence rates by histology,
Belgium 2004-2009
0
1-4
5-9
10-14
15-19
Age group
Astrocytomas (IIIb)
Other gliomas (IIId)
25.0
20.0
15.0
10.0
5.0
0.0
0
1-4
5-9
10-14
15-19
Age (in years) at diagnosis
Incidenceratesforprimitive neuroectodermal tumours (IIIc)decreaseslightlywithage.The
majorityofthesemalignanciesarediagnosedinchildrenyoungerthan5yearsofage(Table
7).Aftertheageof10year,incidenceratesareverylow(Figure36).Moreboysarediagnosed
withPNET(IIIc)thangirls(M/Fratio=1.4).Medulloblastomas(IIIc1)arethemostcommon
histologicalsubtype.Theothersubtypesareveryrare.
TheremainingCNS tumours (IIId-f)representaverydiversegroupofraretumours(Table7).
Table 7 CNS tumours: number of new diagnoses by age group, Belgium 2004-2009
IIIa1
IIIa2
IIIb
Ependymomas and choroid plexus tumours
Ependymomas
Choroid plexus tumours
Astrocytomas
IIIc2
IIIc3
IIIc4
IIId
IIId1
IIId2
IIId3
IIIe
IIIe1
IIIe2
IIIe3
IIIe4
IIIe5
IIIf
10-14
15-19
0-19
42
6
10
11
69
21
21
65
136
5
1
17
2
6
Grade unknown
Intracranial and intraspinal embryonal tumours
Medulloblastomas
Primitive neuroectodermal tumours (PNET)
23
34
24
6
2
13
WHO III
3
8
67
42
11
149
72
26
WHO IV
IIIc1
5-9
WHO I
WHO II
IIIc
0-4
190
2
15
3
Medulloepitheliomas
0
0
0
Other gliomas
21
16
23
Mixed and unspecified gliomas
13
14
Other specified intracranial and intraspinal neoplasms
20
Atypical teratoid/rhabdoid tumours
4
2
1
45
24
265
23
64
3
19
621
61
5
20
5
0
26
10
13
11
33
5
6
146
127
16
9
27
10
83
29
16
0
31
8
60
0
0
2
0
7
9
69
15
4
46
21
21
45
107
3
14
5
3
25
Neuronal and mixed neuronal-glial tumours
11
5
6
27
49
Unspecified intracranial and intraspinal neoplasms
8
9
10
28
Oligodendrogliomas
Neuroepithelial glial tumours of uncertain origin
Pituitary adenomas and carcinomas
Tumours of the sellar region (craniopharyngiomas)
Pineal parenchymal tumours
Meningiomas
7
1
0
1
5
2
0
2
0
0
1
6
2
6
0
4
belgian cancer registry
IIIa
CNS and miscellaneous intracranial and intraspinal neoplasms
cancer incidence in belgium 2010
ICCC-3 classification
III
4
1
9
1
5
19
4
17
2
14
Trends
Inthelastdecade,anincreaseintheincidenceratesintheFlemishRegioncanbeobserved
(Figure37).Thisincreaseismainlyobservedinastrocytomainchildrenandinadolescents.
Accordingtointernationaldata(28)(29),incidenceratesforCNStumoursinchildrenandadolescentsannuallyincreasewith1.7%.
Figure 37 CNS tumours: age standardised incidence (WSR) by histology, Flemish Region 1999-2003, 2002-2006 and 2005-2009
2002-2006
30
WSR (N/1,000,000)
belgian cancer registry
1999-2003
2005-2009
All ages
50.0
0-14 years
15-19 years
45.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
CNS
(III)
Ependymoma
(IIIa)
Astrocytoma
(IIIb)
PNET
(IIIc)
CNS
(III)
Ependymoma
(IIIa)
Astrocytoma
(IIIb)
PNET
(IIIc)
CNS
(III)
Ependymoma
(IIIa)
Astrocytoma
(IIIb)
PNET
(IIIc)
Survival
Prognosis for CNS tumours is largerly dependent on the histological diagosis. Of the main
ICCC-3subgroups,PNET(IIIc)havetheworstprognosiswitha5-yearsurvivalrateof61%.The
WHO(27)classifiesthesetumoursashighlymalignant(WHOIV).
Ependymomas(IIIa),astrocytomas(IIIb)andothergliomas(IIId)havecomparable5-yearsur-
vivalratesof83%,81%and80%respectively(Figure38).However,ependymomas(IIIa)and
astrocytomas(IIIb)containdiagnoseswithverydifferentprognosis.Figure39andFigure40
showthesurvivalratesforrespectivelyependymomaandastrocytomabyWHO-grade(27).
No deaths are observed for the 15 patients diagnosed with a WHO I ependymoma. WHO
II ependymomas still have fairly high survival rates around 90%. The worst prognosis for
ependymomasisobservedfortheWHOIIIcaseswitha5-yearsurvivalrateof67%.
GradeIastrocytomasalsohaveaverygoodprognosis(95%5-yearsurvival).SurvivalforWHO
IIastrocytomasdecreasesto81%.TheprognosisforgradeIII-IVastrocytomaistheworstofall
CNStumours.After2years,thesurvivalrateisonly31%.
Thegroupofotherandunspecifiedtumours(IIIe-f)consistmainlyoftumourswithagood
prognosis.Thiscategoryhasaveryhigh5-yearsurvivalrateof95%(Figure38).Asmallsubset
ofraremalignanttumours(mainlymeningiomaandpineoblastoma)inthiscategoryisthe
reasonforthe5%lossofpatientsafter1year.
Ependymoma (IIIa)
PNET (IIIc)
CNS other and NOS (IIIe-f)
100%
Figure 39 Ependymoma: observed survival by WHO-classification, Belgium
2004-2009
Astrocytoma (IIIb)
Other gliomas (IIId)
Observed survival (%)
90%
80%
70%
60%
50%
40%
WHO II
WHO III
90%
80%
70%
60%
50%
30%
30%
20%
10%
10%
0%
0
1
2
3
4
5
Years after diagnosis
IIIa
65
59
55
48
38
29
WHO I
15
15
14
12
11
8
IIIb
253
226
211
166
125
96
WHO II
22
20
18
14
13
0
IIIc
82
67
59
44
30
25
WHO III
28
22
20
16
14
10
N at risk
1
2
3
4
5
Years after diagnosis
N at risk
IIId
64
58
52
38
30
22
IIIe-f
128
122
122
88
71
50
Figure 40 Astrocytomas (IIIb): observed survival by WHO-classification,
Belgium 2004-2009
Observed survival (%)
0
WHO I
100%
WHO II
WHO III-IV
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
Years after diagnosis
WHO I
121
119
117
93
64
48
WHO II
62
55
49
38
33
24
WHO III-IV
39
22
15
9
6
5
N at risk
belgian cancer registry
40%
20%
0%
WHO I
100%
31
cancer incidence in belgium 2010
Observed survival (%)
Figure 38 CNS tumours: Observed survival by histology, Belgium 2004-2009
IV
Sympathetic nervous system tumours
Incidence
InBelgium,130newdiagnosesofsympatheticnervoussystem(SNS)tumoursareregistered
inchildrenandadolescentsbetween2004and2009(Table8).Slightlymoreboysarediagnosedthangirls(M/Fratio=1.3).
The majority (98%) are neuroblastomas (IVa) that occur almost exclusively in infants and
veryyoungchildren.Ininfants,thistumouristhemostfrequentlydiagnosedcancer(25%).
belgian cancer registry
Itsoccurrencedecreaseswithageandbecomesveryrareinolderchildrenandadolescents
32
(Figure41andFigure42).
TheadrenalglandisthemostcommonprimarylocalisationoftheSNStumours(Figure43).
Table 8 New diagnoses of SNS tumours, Belgium 2004-2009
Boys
IV
IVa
SNS tumours
Neuroblastoma
Other SNS tumours
IV
SNS tumours
IVb
Other SNS tumours
IVa
0-14
15-19
72
71
1
74
IVb
Girls
Total
73
2
2
Total
0-14
55
54
56
Neuroblastoma
55
1
1
Figure 41 Relative frequency of SNS tumours by age at diagnosis, Belgium 2004-2009
Sympathetic nervous system tumours
Other malignancies
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
1
0
15-19
1
1
0
Figure 43 SNS tumours: number of new diagnoses (N) by primary site,
Belgium 2004-2009
Adrenal gland
70.0
60.0
19
Other sites
50.0
40.0
Central nervous
system
30.0
Retroperitoneum
20.0
Mediastinum
10.0
0
74
Autonomic
nervous system
12
9
7
5
Soft tissue
4
0%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
10%
20%
Survival
40%
50%
60%
33
Foetalneuroblastomasveryoftendifferentiateintobenignneoplasms.Ininfantsandyoung
children,thenumberofpatientsneedingtherapyforanaggressivevariantincreases.Inolder
children, neuroblastomas are very frequently aggressive malignancies. (30) (31) Age, dichoto-
mizedat18months,isoneimportantparameterindeterminingprognosis.(32)
IntheFlemishRegion,10-yearsurvivalrates(Figure44)areveryhighforchildrenupto18
monthsofage(92%).Forpatientsof18monthsofageandolder,prognosisismuchworse
(50%10-yearsurvivalrates).
Figure 44 SNS tumours: observed survival by age group, Flemish Region 1999-2009
Observed survival (%)
30%
belgian cancer registry
80.0
Age < 18 months
100%
Age 18 months
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9
10
Years after diagnosis
Age < 18 months
50
47
47
41
36
36
32
26
20
15
13
Age > 18 months
66
57
47
35
32
26
22
18
12
8
5
N at risk
cancer incidence in belgium 2010
Age specific incidence (N / 1,000,000)
Figure 42 SNS tumours: age specific incidence rates, Belgium 2009
V
Retinoblastoma
Incidence
Retinoblastoma is a rare disease. In the period 2004-2009 a total of 64 new diagnoses are
registeredinBelgium,39inboysand25ingirls(M/Fratio=1.5).Almostalldiagnosesoccur
undertheageof5years(Figure45andFigure46).Theoldestpatientwasnineyearsofage
34
Figure 45 Relative frequency of retinoblastoma by age at diagnosis,
Belgium 2004-2009
Retinoblastoma
Other malignancies
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Figure 46 Retinoblastoma: age specific incidence rates, Belgium 2004-2009
Age specific incidence (N / 1,000,000)
belgian cancer registry
atthetimeofdiagnosis.Atinfancyretinoblastomasrepresent11%ofalltumourdiagnoses.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
0
1
2
3
4
5
6
7
8
9
Age (in years) at diagnosis
VI
Renal tumours
Incidence
Renaltumoursareararechildhoodmalignancy.InBelgium,108newdiagnosesareregistered
between2004and2009(Table9),55inboysand53ingirls(M/Fratio=1.0).Theyrepresent
lessthan4%ofallmalignanciesinchildrenandadolescents.Themajority(94%)oftherenal
tumoursarenephroblastomas.Renalcarcinoma,themostfrequenttypeofadultrenalcancer,
belgian cancer registry
seldomoccursinchildhood.
Table 9 New diagnoses of renal tumours, Belgium 2004-2009
VI
VIa
VIb
Renal Tumours
VI
Renal Tumours
VIb
Renal carcinomas
VIc
15-19
51
47
4
1
0
Renal carcinomas
Unspecified renal tumours
VIa
0-14
55
Nephroblastomas
VIc
Girls
Total
50
3
2
1
1
Total
0-14
15-19
50
50
0
1
1
0
53
Nephroblastomas
5
52
2
Unspecified renal tumours
1
1
35
1
cancer incidence in belgium 2010
Boys
Mostnephroblastomadiagnosesoccurbeforetheageof6years(Figure47):theyrepresent
approximately10%ofallchildhoodcancermalignancies.Thehighestincidenceratesareob-
served in the first years of life. After the age of 3 years, the incidence rates decline rapidly
(Figure48).Aftertheageof5years,renaltumoursareveryrare.
Figure 47 Relative frequency of renal tumours by age at diagnosis,
Belgium 2004-2009
Renal tumours
Other malignancies
Age specific incidence (N / 1,000,000)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Figure 48 Renal tumours: age specific incidence rates, Belgium 2004-2009
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
30.0
25.0
20.0
15.0
10.0
5.0
0.0
0
1
2
3
4
5-9
10-14 15-19
Age (in years) at diagnosis
Survival
Renaltumourshaveagoodprognosis(Figure49).The5yearsurvivalrateintheFlemishRegionis94%andremainsstablethereafter(92%10yearsurvivalrate).
Observed survival (%)
belgian cancer registry
Figure 49 Observed survival for renal tumours, Flemish Region 1999-2009.
100%
90%
80%
70%
60%
50%
40%
30%
36
20%
10%
0%
0
1
2
3
4
5
6
7
112
109
106
98
91
81
73
60
8
9
10
Years after diagnosis
N at risk
Renal tumours
53
41
30
VII Hepatic tumours
Incidence
Hepatictumoursareanextremelyraredisease.Inchildrenandadolescentstheyrepresent
0.4% of all malignancies. In Belgium, there are only 12 new diagnoses registered between
2004 and 2009, 6 boys and 6 girls. Among the hepatic tumours, there are 10 diagnoses of
hepatoblastomaand2hepatocellularcarcinoma(Table10).Themajorityofthetumoursare
diagnosedinthefirstyearsoflife(Figure50).
1
belgian cancer registry
0
37
0
cancer incidence in belgium 2010
Duetothelowincidencerates,nofurtheranalysesareperformedonhepatictumours.
Table 10 New diagnoses of hepatic tumours, Belgium 2004-2009
Boys
VII
Hepatic tumours
VIIb
Hepatic carcinomas
VIIa
Girls
0-14
15-19
5
5
0
Total
0-14
15-19
5
5
0
6
Hepatoblastomas
VII
Hepatic tumours
VIIb
Hepatic carcinomas
VIIa
Total
1
6
Hepatoblastomas
1
5
0
6
1
Age specific incidence (N / 1,000,000)
Figure 50 Hepatic tumours: age specific incidence rates, Belgium 2004-2009
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
0
1-4
5-9
10-14
15-19
Age (in years) at diagnosis
1
VIII Bone tumours
Incidence
In Belgium, between 2004 and 2009, 176 new diagnoses of bone tumours are registered,
whichrepresent6%ofallcancerdiagnosesinchildrenandadolescents(Table11).Moreboys
arediagnosedthangirls(M/Fratio=1.3).Theincidenceratesforbonetumoursbetweenthe
sexesaremorecomparableinchildren(M/Fratio=1.1)thaninadolescents(M/Fratio=1.5).
Bonetumoursarerareinchildrenyoungerthan5yearsofage.Aftertheageof5,theinci-
belgian cancer registry
dence rates (Figure 52) increase to reach a peak in late childhood (around 15 years of age).
Afterwards,inadolescence,incidenceratesseemtodeclineslightly.Thistrendisalreadyob-
servedininternationalstudies.(33)Intheagegroup10-14yearsbonetumoursrepresent10-15%
ofallchildhoodcancerdiagnoses(Figure51).
Table 11 New diagnoses of bone tumours, Belgium 2004-2009
Boys
38
Total
0-14
15-19
50
23
27
42
27
15
Total
0-14
15-19
Osteosarcomas
36
22
14
Ewing tumours
33
VIII
Bone tumours
VIIIb
Chondrosarcomas
VIIIa
VIIIc
100
Osteosarcomas
4
Ewing tumours
VIIId-e Other bone tumours
Girls
VIII
Bone tumours
VIIIb
Chondrosarcomas
VIIIa
VIIIc
4
76
3
VIIId-e Other bone tumours
4
53
0
3
46
0
23
1
Figure 51 Relative frequency of bone tumours by age at diagnosis, Belgium 2004-2009
Bone tumours
Other malignancies
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
47
4
1
30
3
10
3
Figure 52 Bone tumours: age specific incidence rates by histology,
Belgium 2004-2009
Ewing sarcoma (VIIIc)
Other bone tumours (VIIIb, VIIId, VIIIe)
100%
Chondrosarcoma (VIIIb)
Ewing sarcoma (VIIIc)
Other sarcoma (VIIId-VIIIe)
90%
10.0
80%
70%
8.0
60%
6.0
50%
30%
20%
2.0
10%
0-4
5-9
0%
10-14
15-19
Age (in years) at diagnosis
0-4
5-9
Ewing sarcoma (43%) and osteosarcoma (49%) are the predominant histological subtypes.
Theincidenceratesforbothtumoursincreasedwithage,butwithasomewhatdifferentagepattern(Figure53).
Bonetumoursareveryrareundertheageof5yearsandalmostalldiagnosesareEwingsar-
comas(VIIIc).ThehighestincidencerateofEwingsarcoma(VIIIc)isobservedintheagegroup
10-14years.Osteosarcomas(VIIIa)arerareundertheageof10years.Withtheonsetofado-
lescence,incidenceratesincreaseandaftertheageof10,theybecomethedominantbone
tumourdiagnosis.
Osteosarcoma(VIIIa)andEwingsarcoma(VIIIc)alsodifferinsitedistribution(Figure54).The
longbonesofthelowerlimbsarethepredominantprimarysiteforbonetumours(93diagno-
ses).Threeoutoffourtumoursatthislocalisationareosteosarcoma(VIIIa).Themostfrequent
primarysiteforEwingsarcoma(VIIIc)isthecentralaxis(spinalcolumn-rib-sternum-pelvic
bones-sacrum-coccyx),followedbythelongbonesofthelowerlimbs.
Figure 54 Bone tumours: incidence by primary site and histology, Belgium 2004-2009
Osteosarcoma (VIIIa)
Long bones
lower limbs
Ewing sarcoma (VIIIc)
23
70
Central axis
29
5
Long bones
upper limbs
10
11
Other
0
Short bones
0
4
Skull or face
0
3
100%
80%
60%
40%
20%
0%
6
20%
40%
60%
80%
100%
10-14
15-19
Age group
belgian cancer registry
40%
4.0
0.0
Osteosarcoma (VIIIa)
39
cancer incidence in belgium 2010
Age specific incidence (N / 1,000,000)
Osteosarcoma (VIIIa)
12.0
Figure 53 Bone tumours by age group, Belgium 2004-2009
Trends
Internationalstudiesshowlittleevidenceofconsistentchangesinbonetumourincidence
inchildrenandadolescents.(33)IntheFlemishRegion,incidenceratesinchildrenseemtoin-
creaseslightlyinthelastdecade.Inadolescents,lowerincidenceratesareobservedbetween
2005and2009whencomparedtotheothertimeperiods(Figure55).
Figure 55 Bone tumours: age standardised incidence (WSR) by histology, Flemish Region 1999-2003, 2002-2006 and 2005-2009
40
WSR (N/1,000,000)
belgian cancer registry
1999-2003
2002-2006
2005-2009
All ages
30.0
0-14 years
15-19 years
25.0
20.0
15.0
10.0
5.0
0.0
Bone
tumours
(VIII)
Osteosarcoma
(VIIIa)
Ewing
sarcoma
(VIIIc)
Bone
tumours
(VIII)
Osteosarcoma
(VIIIa)
Ewing
sarcoma
(VIIIc)
Bone
tumours
(VIII)
Osteosarcoma
(VIIIa)
Ewing
sarcoma
(VIIIc)
Survival
The 5-year survival rates for children in Belgium by histology show no difference in prog-
nosis between osteosarcoma (VIIIa) (73%) and Ewing sarcoma (VIIIc) (75%) (Figure 56). For
adolescents(Figure57),prognosisforEwingsarcoma(VIIIc)seemslessthanforosteosarcoma
(VIIIa).Forosteosarcomathe5-yearsurvivalratesare70%,forEwingsarcomathenumbersat
riskarelessthan10andthereforeno5-yearsurvivalrateiscalculated.
PrognosisforEwingsarcoma(VIIIc)dependsontheprimarylocalisation(Figure58):primary
tumoursofthecentralaxishaveaworseprognosisthantumoursonothersites.
Osteosarcoma (VIIIa)
100%
Figure 57 Bone tumours in adolescents: observed survival by histology,
Belgium 2004-2009
Ewing sarcoma (VIIIc)
Observed survival (%)
90%
80%
70%
60%
50%
90%
80%
70%
60%
50%
30%
20%
10%
10%
0%
1
2
3
Osteosarcoma
(VIIIa)
44
42
36
30
24
16
Ewing
sarcoma
(VIIIc)
49
46
42
34
28
20
N at risk
1
2
3
4
5
Years after diagnosis
Osteosarcoma
(VIIIa)
38
35
32
29
25
19
Ewing
sarcoma
(VIIIc)
24
23
19
13
9
6
N at risk
Figure 58 Ewing sarcoma (VIIIc): observed survival by primary site,
Belgium 2004-2009
Observed survival (%)
0
4
5
Years after diagnosis
Central axis
100%
Other localisations
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
Years after diagnosis
29
27
21
15
11
9
Other
44
localisations
42
40
32
26
17
N at risk
belgian cancer registry
30%
20%
0
Central
axis
Ewing sarcoma (VIIIc)
40%
40%
0%
Osteosarcoma (VIIIa)
100%
41
cancer incidence in belgium 2010
Observed survival (%)
Figure 56 Bone tumours in children: observed survival by histology,
Belgium 2004-2009
IX
Soft tissue sarcoma
Incidence
Softtissuesarcomas(STS)areaheterogeneousgroupofneoplasms.Thesetumoursrepresent
6%ofallchildhoodandadolescentcancerdiagnoses.TherelativefrequencyofSTSbyageat
diagnosisisevenlydistributedaround6%(Figure59).AllSTScombined;moreboysarediag-
nosedthangirls(M/Fratio=1.3).
Softtissuesarcomasareclassifiedin2broadcategories:rhabdomyosarcoma(RMS)andnon-
belgian cancer registry
rhabdomyosarcoma(Non-RMS).
Table 12 New diagnoses of soft tissue sarcoma, Belgium 2004-2009
Boys
IX
IXa
IXb-e
Girls
42
IX
IXa
IXb-e
Soft tissue sarcoma
Total
0-14
44
34
106
Rhabdomyosarcoma
Non-rhabdomyosarcoma
62
Soft tissue sarcoma
Non-rhabdomyosarcoma
32
Total
0-14
24
21
82
Rhabdomyosarcoma
66
58
39
18
Figure 59 Soft tissue sarcoma: relative frequency by age at diagnosis, Belgium 2004-2009
Soft tissue sarcoma
Other malignancies
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
15-19
40
10
30
15-19
43
3
40
RMS (IXa)
20.0
Non-RMS (IXb-e)
Figure 61 STS by age group, Belgium 2004-2009
100%
18.0
90%
16.0
80%
14.0
70%
12.0
60%
10.0
50%
8.0
40%
6.0
30%
4.0
20%
2.0
10%
0.0
0
1-4
5-9
10-14
15-19
Age (in years) at diagnosis
0%
RMS (IXa)
0
Non-RMS (IXb-e)
1-4
5-9
10-14
15-19
Age group
43
Rhabdomyosarcoma (IXa) are the most important sarcoma in children under the age of 10
cancer incidence in belgium 2010
years(Figure60andFigure61).AlmosttwiceasmanyboysareregisteredwithRMSthangirls
(M/Fratio=1.7)(Table12).
Two main histological types of rhabdomyosarcoma exist. Embryonal RMS is the most fre-
quentlydiagnosedsubtype(66%ofRMS)andprimarilytargetsinfantsandyoungchildren.
AlveolarRMS(19%ofRMS)becomesmorefrequentinolderchildrenandadolescents(Figure
62).Theremaining10RMSdiagnoses(15%),consistsof6unspecifiedRMS,1pleomorphicRMS
and3spindlecellRMS.
RMSoccuratvarioussitesinthebody.Themostcommonsitesinourdatasetareheadand
neck(29%)andthegenito-urinarytract(28%).EmbryonalRMSaccountsforabout70%ofthe
diagnosesforeverysite,withexceptionofthelimbs(Figure63).Thisresultmustbeinter-
pretedwithcare,sincethereareonly6diagnosesofRMSregisteredatthelimbs.However,
thisobservationiscomparablewithresultsobtainedintheACCISstudy.(35)
Figure 62 Rhabdomyosarcoma by histology, Belgium 2004-2009
100%
Embryonal RMS
Alveolar RMS
RMS: other and NOS
Figure 63 Rhabdomyosarcoma by primary site, Belgium 2004-2009
Embryonal RMS
90%
80%
80%
70%
RMS: other and NOS
70%
60%
60%
50%
50%
40%
40%
30%
30%
20%
20%
10%
0%
Alveolar RMS
100%
90%
10%
0-4
5-9
10-14
15-19
Age group
0%
Genitourinary
Head &
Neck
Limbs
belgian cancer registry
Age specific incidence (N / 1,000,000)
Figure 60 STS: age specific incidence rates by histology, Belgium 2004-2009
Pelvis
Other
All sites
and NOS
Non-rhabdomyosarcoma (IXb-e)aremorefrequentlydiagnosedaftertheageof10years(Fig-
ure60).Inadolescents,theyaccountfor84%ofallSTSdiagnoses.Thisgroupcontainsawide
varietyofdifferenthistologicalsubtypes(Table13).ThemajorityoftheNon-RMSdiagnoses
arefibrohistiocytictumours(23%),synovialsarcomas(15%)andfibrosarcomas(14%).Theremainingsubtypeseachencompasslessthan10%oftheNon-RMS.
Table 13 Non-rhabdomyosarcoma by histology, Belgium 2004-2009
New diagnoses (N)
belgian cancer registry
ICCC-3 Classification
44
IXb-e
Non-rhabdomyosarcomas
IXb
Fibrosarcomas
Total
IXb1
Fibroblastic and myofibroblastic tumours
IXb2
Nerve sheath tumours
%
00-
120 100,0%
05-
10-
15-
13
7
30
70
17
14,2%
4
0
5
8
7
5,8%
3
0
2
2
10
8,3%
1
0
3
6
IXb3
Other fibromatous neoplasms
0
0,0%
0
0
0
0
IXc
Kaposi sarcomas
1
0,8%
0
0
1
0
IXd
Other specified soft tissue sarcomas
93
77,5%
9
6
22
56
IXd1
Ewing tumours and Askin tumours of soft tissue
12
10,0%
1
1
1
9
IXd2
PNET of soft tissue
1
0,8%
0
0
1
0
IXd3
Extrarenal rhabdoid tumours
0
0,0%
0
0
0
0
IXd4
Liposarcomas
4
3,3%
0
0
0
4
28
23,3%
2
2
7
17
6
5,0%
0
0
2
4
IXd5
Fibrohistiocytic tumours
IXd6
Leiomyosarcomas
IXd7
Synovial sarcomas
18
15,0%
1
1
5
11
IXd8
Blood vessel tumours
10
8,3%
4
0
0
6
IXd9
Osseous and chondromatous neoplasms of soft tissue
4
3,3%
0
0
3
1
IXd10
Alveolar soft parts sarcomas
2
1,7%
0
0
0
2
IXd11
Miscellaneous soft tissue sarcomas
8
6,7%
1
2
3
2
Trends
Europeandatashowanannualincreaseof1.8%intheincidenceofsofttissuesarcoma. (35)
However,inWesternEuropethistrendcouldnotbeobserved.Theobservedincidenceratesin
theFlemishRegionratherseemtodecreaseslightly(Figure64),mainlyinchildren.Thelow
numberofnewdiagnosesdidnotallowamoredetailedtrendanalysis.
Figure 64 Soft tissue sarcoma: age standardized incidence (WSR) by histology, Flemish Region 1999-2003, 2002-2006, 2005-2009
WSR (N/1,000,000)
1999-2003
2002-2006
2005-2009
All ages
25.0
0-14 years
15-19 years
20.0
15.0
10.0
5.0
0.0
Sarcoma
(IX)
RMS
(IXa)
Non- RMS
(IXb-e)
Sarcoma
(IX)
RMS
(IXa)
Non- RMS
(IXb-e)
Sarcoma
(IX)
RMS
(IXa)
Non- RMS
(IXb-e)
Survival
Histologyisconsideredasanimportantfactorinprognosis.(34)Inourdata,littledifference
insurvivalisobservedinRMS(82%)versusnon-RMSdiagnoses(76%)(Figure65).Although
basedonsmallnumbers,alargerdifferenceinsurvivalratesisobservedwithinthedifferent
RMSsubtypes,withhighersurvivalratesforembryonalRMSthanforotherhistologicalRMS
subtypes(Figure66).AlveolarRMSismainlyresponsibleforthelowersurvivalrates.Ofthe
12childrenwithalveolarRMSincludedinthesurvivalanalysisinBelgium(2004-2009),5did
Non-RMS (IXb-e)
90%
80%
70%
60%
50%
40%
Other RMS
90%
80%
45
70%
60%
50%
40%
30%
30%
20%
20%
10%
10%
0%
Embryonal RMS
100%
0
1
2
3
0%
4
5
Years after diagnosis
N at risk
0
1
2
3
4
5
Years after diagnosis
N at risk
RMS (IXa)
66
61
54
46
36
23
Embryonal RMS
45
43
40
36
31
22
Non-RMS
(IXb-e)
117
111
103
78
57
43
Other
RMS
21
19
15
11
6
2
cancer incidence in belgium 2010
RMS (IXa)
100%
Figure 66 RMS in children and adolescents: observed survival by histology,
Belgium 2004-2009
Observed survival (%)
Observed survival (%)
Figure 65 STS in children and adolescents: observed survival by histology,
Belgium 2004-2009
belgian cancer registry
notsurvivemorethan2years.
X
Germ cell, trophoblastic and other gonadal neoplasms
Incidence
Germcelltumours,trophoblasticandothergonadalneoplasms(GCTOG)represent6%ofall
tumoursinchildrenandadolescents.Themajorityofthetumoursarefoundinadolescents
wheretheyaccountfor11%ofalltumourdiagnoses.
InBelgium,171newdiagnosesareregisteredbetween2004and2009(Table14).Almosttwice
asmanyboysarediagnosedthangirls(M/Fratio=1.7).Inadolescentsthenumberofnew
belgian cancer registry
diagnoses in boys is five-foldthenumberingirls,correspondingwithamale/femaleratio
46
of5.4.However,inchildren(M/Fratio=0.5),theoppositeisobservedwithtwotimesmore
diagnosesingirlsthaninboys.
Table 14 New diagnoses of GCTOG, Belgium 2004-2009
Boys
X
GCTOG
Xb
Extra-cranial / -gonadal GCT
Xa
Xc
Xd
Xe
Girls
Other and unspecified
10
12
Gonadal GCT
Other and unspecified
5
1
81
Total
0-14
15-19
5
4
1
0
39
21
20
4
0
24
Gonadal carcinoma
5
95
0
56
Intra-cranial / -spinal GCT
20
0
1
Extra-cranial / -gonadal GCT
Xe
22
86
Gonadal carcinoma
Xb
Xd
15-19
6
Gonadal GCT
GCTOG
Xc
0-14
115
Intra-cranial / -spinal GCT
X
Xa
Total
2
0
1
17
1
14
10
1
1
4
Figure 67 GCTOG: relative frequency by age at diagnosis, Belgium 2004-2009
Other malignancies
Germ cell tumours
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0
1
2
3
4
5
6
7
8
9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
Atinfancy,GCTOGrepresent8%ofallcancerdiagnoses(Figure67).Inchildrenbetweenthe
ageof1and13year,theincidenceratesareverylow.Aroundtheageof14-15yearincidence
ratesincreaserapidlywithage,especiallyinboys(Figure68).
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
40.0
35.0
30.0
25.0
20.0
15.0
10.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
5.0
0.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
GCTOGaresubdividedinfivemaingroupsaccordingtothecellsoforigin(germcells(Xa-c),
trophoblasticcells(Xd)orothercells(Xe)).Thegermcelltumours(GCT)arefurtherseparated
bysiteoforigin(gonads(Xc),centralnervoussystem(Xa)orelsewhere(Xb)).
Themajority(64%)ofGCTOGtumours,occurringamongchildrenyoungerthan20yearsof
age,aregonadalgermcelltumours(Xc).However,whenonlychildrenyoungerthan15years
ofageareconsidered,non-gonadalgermcelltumours(XaandXb)aremorecommonthan
gonadal(Xc)germcelltumours(Table14,Figure69andFigure70).
Figure 70 GCTOG by age group, Belgium 2004-2009
100%
Intra-cranial / -spinal GCT (Xa)
Gonadal GCT (Xc)
Extra-cranial / -gonadal GCT (Xb)
Other GCTOG (Xd-e)
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0-4
5-9
10-14
15-19
Age group
Intracranial and intraspinal GCT (Xa)aremorefrequentlydiagnosedinolderchildrenandado-
lescents.Intheagegroup5-9yearsGCTOGareveryrare(9diagnosesinBelgiumbetween
2004and2009).Inthisagegroup,intracranialandintraspinalGCT(Xa),with5diagnosesin
Belgiumbetween2004and2009,arethemostfrequentGCTOGsubtype(Figure70).
belgian cancer registry
Girls
Intra-cranial / -spinal GCT (Xa)
Extra-cranial / -gonadal GCT (Xb)
Gonadal GCT (Xc)
47
cancer incidence in belgium 2010
Boys
90.0
Figure 69 GCT: age specific incidence rates by primary site,
Belgium 2004-2009
Age specific incidence (N / 1,000,000)
Age specific incidence (N / 1,000,000)
Figure 68 GCTOG: age specific incidence rates by sex, Belgium 2004-2009
Almostallintra-cranial/-spinalGCT(Xa)arediagnosedinboys(81%).Themale/femaleratio
is4.1.
IntracranialGCTarefrequentlydiagnosedinendocrineglands(Table15).Sixdiagnosesare
registeredinthepituitaryglandandeightinthepinealgland.Theremaining13diagnoses
areregisteredasprimarybraintumours.
Themostfrequentlydiagnosedhistologicalsubtype(Figure71)inboysandgirlsaregermino-
mas(Xa1)(81%,bothsexescombined).Theremainingtumoursareteratomas(Xa2)ormixed
belgian cancer registry
germcelltumours(Xa6).
48
Table 15 Intracranial and intraspinal GCT (Xa) in children
and adolescents by primary site, Belgium 2004-2009
Primary localisation
N
Cerebrum
2
Cerebral ventricle
3
Brain stem
1
Brain, NOS
7
Pituitary gland
6
Pineal gland
8
Extracranial and extragonadal GCT (Xb) are most frequently diagnosed in infants and very
youngchildren(Figure70).Ofthe27diagnoses,22areregisteredinchildrenyoungerthan3
yearsofage.
IncontrastwiththeotherGCT(XaandXc),wherefarmoreboysarediagnosed,themajority
ofextracranialandextragonadalGCT(Xb)arediagnosedingirls(M/Fratio=0.3).
ExtracranialandextragonadalGCT(Xb)aremostfrequentlydiagnosedinthepelvicregion
(67%). The most frequent histological subtypes are teratomas (Xb2) and yolk sac tumours
(Xb4),respectively44%and30%whenbothsexesarecombined(Figure71).
Gonadal GCT (Xc)arebyfarthemostfrequentdiagnosedGCTOG(64%).Inadolescence,more
boys(testicularGCT)arediagnosedthangirls(ovarianGCT),whileinchildhoodtheopposite
isobserved(Table14).Themale/femaleratiois0.4inchildrenand7.8inadolescents.
The majority of testicular GCT (Figure 71) are of mixed origin (Xc6; 31%), embryonal carci-
noma(Xc3;24%)andteratoma(Xc2;23%).94%ofgonadalGCTarediagnosedinadolescents.
Inchildren,onlyfivetesticularGCTarediagnosed,threeyolksactumoursandtwoimmature
teratomas.
DiagnosesofovarianGCT(Figure71)arepredominantlyteratoma(Xc2;50%).Twooutofthree
ovarianteratomadiagnosesoccurredinchildren.
Figure 71 Germ cell tumours (Xa-c) by histology and sex, Belgium 2004-2009
100%
Embryonal carcinomas
Germinomas
Mixed germ cell tumour
Teratomas
Yolk sac tumours
Choriocarcinomas
90%
80%
70%
60%
50%
40%
30%
belgian cancer registry
20%
10%
0%
Boys
Girls
Intra-cranial/-spinal GCT (Xa)
Boys
Girls
Extra-cranial/-gonadal GCT (Xb)
Boys
Gonadal GCT (Xc)
Girls
Gonadal carcinomas (Xd)areararemalignancyinchildrenandadolescents.InBelgium,between
2004and2009,only4adolescentgirlsarediagnosedwithanovariangonadalcarcinoma.
cancer incidence in belgium 2010
49
TheremainingGCTOGdiagnoses,other and unspecified malignant gonadal tumours (Xe),are
veryrare.OnlythreediagnosesofSertoli-Leydigcelltumourareregisteredinthiscategoryin
Belgiumbetween2004and2009.
Trends
When comparing the incidence data over time in the Flemish Region, an increase in age
standardisedincidence(WSR)canbeobserved.Thisincreasecanalmostentirelybeattribut-
edtoanincreaseintesticularcancer(Xc)inadolescents.Theincreaseinincidenceofadoles-
centtesticulargermcelltumoursiscomparabletotheincreaseintesticularcancerobserved
inyoungadultmales.(3)Inchildren,incidenceratesforGCTOG(X)seemtodecreaseslightly
(Figure72),butduetothelowincidencerates,analysesontrendsarenotpossible.
Figure 72 GCTOG in boys: age standardised incidence (WSR) by age group and primary localisation, Flemish Region 1999-2003, 2002-2006, 2005-2009
2002-2006
WSR (N/1,000,000)
1999-2003
2005-2009
All ages
60.0
0-14 years
15-19 years
50.0
40.0
30.0
20.0
10.0
0.0
GCTOG
(X)
Intracranial/
-spinal
GCT (Xa)
Extracranial/
-gonadal
GCT (Xb)
Gonadal
GCT (Xc)
GCTOG
(X)
Intracranial/
-spinal
GCT (Xa)
Extracranial/
-gonadal
GCT (Xb)
Gonadal
GCT (Xc)
GCTOG
(X)
Intracranial/
-spinal
GCT (Xa)
Extracranial/
-gonadal
GCT (Xb)
Gonadal
GCT (Xc)
Ingirls,duetothelownumberofnewdiagnoses,trendsforGCTOG(X)arenotclear(Figure73).
Figure 73 GCTOG in girls: age standardised incidence (WSR) by age group and primary localisation, Flemish Region 1999-2003, 2002-2006, 2005-2009
2002-2006
WSR (N/1,000,000)
1999-2003
2005-2009
All ages
12.0
0-14 years
15-19 years
10.0
8.0
belgian cancer registry
6.0
50
4.0
2.0
0.0
GCTOG
(X)
Intracranial/
-spinal
GCT (Xa)
Extracranial/
-gonadal
GCT (Xb)
Gonadal
GCT (Xc)
GCTOG
(X)
Intracranial/
-spinal
GCT (Xa)
Extracranial/
-gonadal
GCT (Xb)
Gonadal
GCT (Xc)
GCTOG
(X)
Intracranial/
-spinal
GCT (Xa)
Extracranial/
-gonadal
GCT (Xb)
Gonadal
GCT (Xc)
XI
Carcinomas and other malignant epithelial neoplasms
Incidence
Carcinomasarethemostcommonhistologicalcancertypeinadults.Nevertheless,avariety
ofmalignantepithelialneoplasmsdooccurinchildrenandadolescents.InBelgium,between
2004and2009,127childrenand239adolescentsarediagnosedwithanmalignantepithe-
lialneoplasm.Almosttwooutofthreecarcinomasarediagnosedingirls(Table16).Forall
tumoursites,withtheexceptionoflung(XIf4),colonandrectum(XIf2)andnasopharyngeal
combined,themale/femaleratiois0.6.
Table 16 New diagnoses of malignant epithelial neoplasms, Belgium 2004-2009
XI
XIa
XIb
XIc
XId
XIe
XIf1
XIf2
XIf3
XIf4
XIf10-11
Girls
XI
XIa
Malignant epithelial neoplasms
Adrenocortical carcinomas
Total
0-14
1
1
144
54
15-19
90
0
Thyroid
21
6
15
Malignant melanomas
36
13
23
3
3
0
Nasopharyngeal carcinomas
Skin (non melanoma)
Salivary glands
Colon and rectum
Appendix
Lung
Other and unspecified
Malignant epithelial neoplasms
Adrenocortical carcinomas
5
19
7
4
6
2
39
16
5
1
8
2
Total
0-14
1
0
222
73
1
51
13
cancer incidence in belgium 2010
Boys
5
23
6
4
15-19
149
1
XIb
Thyroid
41
12
29
XId
Malignant melanomas
54
12
42
XIf1
Salivary glands
XIc
XIe
XIf2
XIf3
XIf4
XIf6
XIf7
XIf10-11
Nasopharyngeal carcinomas
Skin (non melanoma)
Colon and rectum
Appendix
Lung
Breast
Cervix uteri
Other and unspecified
3
2
38
20
4
0
9
4
1
18
5
4
55
21
34
3
0
3
6
1
7
1
0
1
belgian cancer registry
carcinomas(XIc),incidenceratesforgirlsarehigherthanforboys(Figure74).Allcarcinomas
5
1
6
Figure 74 Malignant epithelial neoplasms: age standardised incidence (WSR) by primary localisation and sex,
Belgium 2004-2009
belgian cancer registry
Boys
Girls
Appendix (XIf3)
M/F = 0.7
Malignant melanomas (XId)
M/F = 0.7
Thyroid (XIb)
M/F = 0.5
Skin (non melanoma) (XIe)
M/F = 0.5
Lung (XIf4)
M/F = 1.3
Salivary glands (XIf1)
M/F = 0.3
Colon and rectum (XIf2)
M/F = 1.7
Other specified sites (XIf10)
M/F = 0.8
Nasopharyngeal carcinomas (XIc)
M/F = 1.5
Breast (XIf6)
52
M/F = NA*
Unspecified site (XIf11)
M/F = 0.4
Adrenocortical carcinomas (XIa)
M/F = 1.0
Cervix uteri (XIf7)
M/F = NA*
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
WSR (N/1,000,000)
*NA = M/F ratio not applicable due to zero cases in either sex
Thisdiversegroupofmalignantepithelialneoplasmsisthe5thmostfrequenttumourinchil-
drenandthe2ndmostfrequentinadolescents.Inyoungchildrencarcinomasareveryrare.In
latechildhood,theincidenceratesincreasesharplywithage.Inadolescents,theyaccountfor
23%ofallmalignancies(Figure75andFigure76).
Figure 75 Malignant epithelial neoplasms: relative frequency by age at
diagnosis, Belgium 2004-2009
Epithelial neoplasms
Other malignancies
Age specific incidence (N / 1,000,000)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Figure 76 Malignant epithelial neoplasms: age specific incidence rates by
sex, Belgium 2004-2009
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
120.0
Boys
Girls
100.0
80.0
60.0
40.0
20.0
0.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Age (in years) at diagnosis
Themostfrequentmalignantepithelialneoplasmsareendocrinetumours(carcinoids)ofthe
appendix (XIf3). Thistumourismostcommonlydiscoveredbycoincidenceduringroutineap-
pendectomy,wheretheyarefoundin0.3-0.9%ofpatients. (36)(37)Between2004and2009,a
totalof94diagnosesareregisteredinBelgium,39inboysand55ingirls(M/Fratio=0.7).Car-
cinoidsoftheappendix(XIf3)areveryrareinchildrenyoungerthe10yearsofage.Intheage
group5-9yearsofage,only8carcinoidtumoursoftheappendix(XIf3)arediagnosed,6boys
and2girls(M/Fratio=2.8).Theincidenceratesincreasewithage(Figure77).Aftertheageof
10years,moregirlsarediagnosedthanboys(M/Fratiois0.5fortheagegroup10-14yearsand
Boys
20.0
Girls
18.0
16.0
14.0
53
12.0
10.0
8.0
6.0
4.0
2.0
0.0
0-4
5-9
10-14
15-19
Age group
Worldwide,registrationpracticesforcarcinoidtumoursoftheappendixvarybetweenregis-
tries.Thisvariationisconsideredapotentialsourceofartifactwhencomparingdatabetween
regions.(37)TheBelgianCancerRegistryincludesallcarcinoidsoftheappendix,regardlessof
size.RecentupdatesintheICD-O3classification(7)publishedbytheWHO(38),includeanycar-
cinoidoftheappendixinthelistofmalignantneoplasms.
Animportantparameterdeterminingprognosisofcarcinoidsisthesizeofthetumour(Figure
78).Informationonsizeisavailablein67cases(27boysand40girls).Themediansizeis7mm
(range1.5mm–22mm).In76%,21%and3%ofcasesthediameteris<=10mm,>10mm-20mm
and>20mmrespectively.Tumoursdiagnosedingirls(mediansize=7.5mm[range1.5mm–
22mm])areoftenlargerthaninboys(mediansize=7mm[range2mm–15mm]).Ingirls28%
ofthecarcinoiddiagnosesingirlsarelargerthan10mm,whileinboysthisisonly19%.
cancer incidence in belgium 2010
Age specific incidence (N / 1,000,000)
Figure 77 Carcinoid of appendix (XIf3): age specific incidence rates by sex,
Belgium 2004-2009
belgian cancer registry
0.6intheagegroup15-19years).
Figure 78 Carcinoid of the appendix: number of diagnoses by sex and tumour size (N=67)
N
Boys
Girls
9
8
7
6
5
4
belgian cancer registry
3
2
1
0
0-2
3-4
5-6
7-8
9-10
11-12
13-14
15-16
17-18 19-20 > 20
Tumour size (mm)
54
The2ndmostfrequentmalignantepithelialneoplasmismalignant melanoma (XId). Forthe
period2004-2009,atotalof90casesofmelanomaarediagnosedinBelgium(Table16),36
boysand54girls(M/Fratio=0.7).Inchildren,nodifferenceisobservedbetweenthesexes(13
boysand12girls,M/Fratio=1.1)(Figure79).Inadolescentsthediagnosisofmelanomaismade
morefrequentlyingirls(N=42)thaninboys(N=23)(M/Fratio=0.5).
Age specific incidence (N / 1,000,000)
Figure 79 Malignant melanoma (XId): age specific incidence by sex,
Belgium 2004-2009
Boys
25.0
Girls
Figure 80 Malignant melanoma (XId): distribution by primary site and sex,
Belgium 2004-2009
Boys
Girls
Head
Trunk
100%
90%
20.0
80%
15.0
60%
10.0
40%
5.0
20%
70%
50%
30%
10%
0.0
0-4
5-9
10-14
15-19
Age group
0%
Arms
Legs
Unspecified
Inboys,melanomamoreoftenoccuronthetrunkandthehead,whileingirlsmoremelanomaarediagnosedontheupperandlowerlimbs(Figure80).Thispreferentialtumourlo-
calisationiscomparablewiththesitedistributioninadults.(3)
For the 90 melanoma diagnoses in Belgium, information on stage is available in 72 of the
cases.Forregistrationsbetween2004and2009,stageisclassifiedbymeansofthe6thedition
oftheUICCTNM.(42)Afterexcision,theextentofmelanomacanbeclassifiedbyapathological
assessmentoftheprimarytumour(pT-category).Figure81showsanoverviewofthedistri-
butionofcancerswithaknownpT-stage.Themajority(68%)ofthecaseswithknownpatho-
logicalT-valueispT1inbothsexes.ThepT2,pT3andpT4melanomadiagnosesaccountfor
respectively17%,11%and7%.Betweenboysandgirlsadifferentstagedistributionisobserved
(Figure81).Inboys24%ofthediagnosesarepT3-4,whileingirlsthisisonly14%.
Stagingoftheprimarytumour(pT)inmelanomareliesoninformationonthetumourthick-
nessandulceration. (40)Theexacttumorthickness,alsoknownasBreslowindex,isknown
in56ofthemelanomadiagnoses(22boysand34girls)(Figure82).ThemedianBreslowin-
dex(bothsexes)is0.67mm(range0.17-6.08mm).Melanomadiagnosedinboysaregenerally
thicker in size (median Breslow index = 0.89mm [range 0.17-5mm]) than tumours in girls
(medianBreslowindex=0.58mm[range0.22-6.08]).
pT2 (> 1-2mm)
pT4 (> 4mm)
8
55
Boys
90%
80%
70%
60%
50%
Girls
12
6
40%
4
30%
20%
2
10%
0%
10
belgian cancer registry
pT3 (> 2-4mm)
N
100%
pT1 ( 1mm)
Figure 82 Malignant melanoma (XId): new diagnoses (N) by Breslow index
(mm) and sex, Belgium 2004-2009 (N= 56)
Boys
Girls
0
0.3mm > 0.3-0.5mm > 0.5-1mm
pT1
The 3rd most frequent malignant epithelial neoplasms are thyroid carcinomas (XIb). In Bel-
gium,62newcasesarediagnosedbetween2004and2009(Table16).Twotimesmoregirls
(N=41)arediagnosedwiththyroidcancerthanboys(N=21).Inchildrenundertheageof10
years,thyroidcancersarerare.Fromtheageof10years,incidenceratesincreaserapidlyin
boysandgirls(Figure83).
Histologically,fourmaintypesofthyroidcarcinomaaredistinguished(Figure84).Papillary
carcinomaarethemostfrequentsubtype(68%).Follicularcarcinomaandmedullarycarci-
nomaaccountforrespectively22%and8%ofthethyroidcancers.InBelgium,anaplasticcar-
cinoma,thefourthmainthyroidcarcinomatype,isnotobservedinchildrenandadolescents
between2004and2009.
> 1-2mm
pT2
> 2-4mm
pT3
> 4mm
pT4
cancer incidence in belgium 2010
Figure 81 Malignant melanoma (XId) by sex and pT category,
Belgium 2004-2009 (N = 72)
Age specific incidence (N / 1,000,000)
belgian cancer registry
Figure 83 Thyroid cancer (XIb): age specific incidence rates by sex,
Belgium 2004-2009
Boys
18
Figure 84 Thyroid cancer (XIb) by histology, Belgium 2004-2009
Unspecified
1
2%
Girls
Medullary
5
8%
16
14
12
10
Follicular
14
22%
8
6
Papillary
42
68%
4
2
0
0-4
5-9
56
10-14
15-19
Age group
Non-melanoma skin cancers (IXe)arethe4thmostfrequentmalignantepithelialneoplasm.
Between2004and2009,57newcases(19boysand38girls)areregistered(Table16).
Undertheageof10,non-melanomaskincancers(XIe)arerare.Only8newdiagnoses(3boys
and5girls,M/Fratio=0.6)areobserved.Inolderchildren(age10-14year),especiallyingirls,
anincreaseintheincidenceratesisobserved(Figure85).Intotal,18cases(3boysand15girls,
M/Fratio=0.2)areregisteredinthisagegroup.Inadolescents,31newdiagnoses(13boysand
18girls,M/Fratio=0.7)areregistered.
The majority of the non-melanoma skin tumours (XIe) are basocellular carcinomas (81%).
Squamous cell carcinoma account for 14% (Figure 86). These tumours were subjected to a
profoundqualityassessment.Foreveryskincarcinoma,thecorrespondingpathologyreport
hasbeenreevaluatedtoensurecorrectdiagnosis.
Age specific incidence (N / 1,000,000)
Figure 85 Non melanoma skin cancer (IXe): age specific incidence rates by
sex, Belgium 2004-2009
Girls
Boys
12.0
Figure 86 Non melanoma skin cancer (IXe) by histology,
Belgium 2004-2009’
Squamous cell
8
14%
10.0
Other
3
5%
8.0
6.0
4.0
Basocellular
46
81%
2.0
0.0
0-4
5-9
10-14
15-19
Age group
Theremainingepithelialneoplasmsareveryrareandnodetailedanalysisisperformedfor
thesetumoursites.
Trends
In children the incidence rates for malignant epithelial neoplasms in the Flemish Region
seemtodecreaseslightlyingirls(Figure87).Thedecreaseingirlscanberelatedtothelower
incidence rates in thyroid cancer (XIb) and malignantmelanoma(XId)intheperiod2005-
2009.Non-melanomaskincancer(XIe)increasesingirls.Inboys,anincreaseisobservedfor
malignantmelanoma(XId).
2002-2006
Boys
14.0
2005-2009
Girls
12.0
10.0
8.0
57
6.0
4.0
2.0
0.0
Epithelial
Appendix
neoplasms (XI)
(XIf3)
Malignant
melanomas
(XId)
Thyroid
(XIb)
Skin (non
Epithelial
Appendix
melanoma) neoplasms (XI)
(XIf3)
(XIe)
Malignant
melanomas
(XId)
Thyroid
(XIb)
Skin (non
melanoma)
(XIe)
Thyroid
(XIb)
Skin (non
melanoma)
(XIe)
Themaintrendforallmalignantepithelialneoplasms(XI)inadolescents(Figure88)iscom-
parablewiththetrendobservedinchildren.Ingirlstheincidenceratesformalignantepithe-
lialneoplasms(XI)seemtodecrease,whilenotrendisobservedinboys.Thyroidcancer(XIb)
increasesinboysandgirls.
Figure 88 Malignant epithelial neoplasms (XI) in adolescents: age standardized incidence (WSR) by primary localisation and sex,
Flemish Region 1999-2003, 2002-2006, 2005-2009
WSR (N/1,000,000)
1999-2003
2002-2006
80.0
Boys
2005-2009
Girls
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
Epithelial
Appendix
neoplasms (XI)
(XIf3)
Malignant
melanomas
(XId)
Thyroid
(XIb)
Skin (non
Epithelial
Appendix
melanoma) neoplasms (XI)
(XIf3)
(XIe)
Malignant
melanomas
(XId)
cancer incidence in belgium 2010
WSR (N/1,000,000)
1999-2003
belgian cancer registry
Figure 87 Malignant epithelial neoplasms (XI) in children: age standardized incidence (WSR) by primary localisation and sex,
Flemish Region 1999-2003, 2002-2006, 2005-2009
Survival
Malignantepithelialneoplasms(XI)haveaverygoodprognosis.Inchildren,(Figure89)the5
yearsurvivalratesinboys(89%)aresignificantlylowerthantheratesobservedingirls(99%).
Inadolescents(Figure90),theprognosisforboysandgirlsiscomparablewithrespectively
96%and97%5yearsurvivalrates.
Boys
100%
Figure 90 Malignant epithelial neoplasms in adolescents: observed survival
by sex, Belgium 2004-2009
Girls
Observed survival (%)
Observed survival (%)
belgian cancer registry
Figure 89 Malignant epithelial neoplasms in children: observed survival by
sex, Belgium 2004-2009
90%
80%
70%
60%
50%
40%
58
Girls
90%
80%
70%
60%
50%
40%
30%
30%
20%
20%
10%
10%
0%
Boys
100%
0%
0
1
2
3
4
5
Years after diagnosis
Boys
50
48
47
41
35
25
Boys
82
Girls
68
68
67
58
48
36
Girls
142
N at risk
0
1
2
3
4
5
Years after diagnosis
80
80
63
50
34
140
139
111
88
64
N at risk
Cancer in Infants
Between2004and2009,201tumoursarediagnosedinthefirstyearoflife.Cancerininfants
represents11%ofallchildhood(0-14years)cancerdiagnoses.
Neuroblastomas (IV; N=49) are the most frequent tumour type. They represent 24% of all
tumoursininfants.CNStumours(III;N=40)arethe2ndmostfrequentcanceramonginfants,
representing20%.Leukaemia(I;N=24),retinoblastoma(V;N=23)andgermcelltumours(X;
N=16)completethefivemostfrequentlyoccurringtumours(Figure91).
0.0
45
40
35
30
25
20
59
15
10
5
10.0
20.0
30.0
40.0 50.0 60.0 70.0 80.0
Age specific incidence (N / 1,000,000)
0
0
1
2
3
4
5
6
7
8
9
10 11
Months
About1outofevery5cancerininfantsisdiagnosedinthefirstmonthoflife.Someofthese
tumoursarepossiblyalreadydetectedinutero(Figure92).
Observed survival (%)
Figure 93 All tumours: observed survival by age group,
Belgium 2004-2009
Figure 94 Observed survival by histology and age group,
Belgium 2004-2009
Infants (< 1 year)
Children and adolescents (1-19 year)
100%
Infants (< 1 year)
90%
90%
80%
80%
70%
70%
60%
60%
50%
50%
40%
40%
30%
30%
20%
20%
10%
0%
Children and adolescents (1-19 year)
100%
10%
0
1
2
3
4
5
Years after diagnosis
191
169
10
130
104
83
2665
2515
2388
1920
1505
1129
0%
All tumours Neuroblastoma
(I-XII)
IV
N at risk
Infants
(<1 year)
Children
and adolescents (1-19
year)
Overall survival for infants (82%) is slightly poorer than for children and adolescents (86%)
(Figure93).Prognosisislargelydependentonthehistologicalsubtype(Figure94).Neuroblas-
tomahadaverygoodprognosisininfants(96%5yearsurvival),whileforchildrenandadoles-
cents5yearsurvivalis61%.Forbraintumours,thesurvivalratesaresomewhatlessfavourable
forinfantswhencomparedtootherchildrenandadolescents(respectively69%and82%).In
leukaemiathesurvivalratesforinfants(44%)arefarworsethanfortheotherages(83%).
Brain/CNS
III
Leukaemia
I
cancer incidence in belgium 2010
Neuroblastoma - IV
Brain/CNS - III
Leukaemia - I
Retinoblastoma - V
Germ cell - X
Renal - VI
Soft tissue - IX
Lymphoma - II
Hepatic - VII
Other - XII
Bone - VIII
Carcinomas - XI
belgian cancer registry
Figure 92 Infants: new diagnoses by month of age at diagnosis,
Belgium 2004-2009
N
Figure 91 Infants: age specific incidence rates by histology,
Belgium 2004-2009
Reference list
(1)
KoninklijkBesluithoudendevaststellingvandenormenwaaraanhetzorgprogramma
ArrêtéRoyal:Fixelesnormesauxquelleslesprogrammesdesoinsdebaseenoncologie
vooroncologischebasiszorgenhetzorgprogrammavooroncologiemoetenvoldoenom
tewordenerkend.BelgischStaatsblad,21maart2003.
etlesprogrammesdesoinenoncologiedoiventrépondrepourêtreagréés.Moniteur
Belge,21mars2003.
belgian cancer registry
(2) Wethoudendediversebepalingenbetreffendegezondheidvan13december2006,
60
artikel39.BelgischStaatsblad,22december2006.
Loiportantdispositionsdiversesenmatièredesantédu13décembre2006,article39.
MoniteurBelge,22décembre2006.
(3) CancerIncidenceinBelgium,2008.BelgianCancerRegistry,Brussels2011.
(4) Steliarova-FoucherE,StillerC,LacourB,KaatschP.InternationalClassificationof
ChildhoodCancer,ThirdEdition.Cancer2005,Vols.103:1457-1467.
(5) WHO.InternationalClassificationofDiseasesandhealth-relatedproblems-10th
revision.Secondedition.Geneva:WHO,2004.
(6) http://statbel.fgov.be/nl/statistieken/cijfers/bevolking/sterfte_leven/oorzaken/index.
jsp.Belgium:Directorate-generalStatisticsandEconomicinformation.
(7) InternationalClassificationofDiseasesforOncology(ICD-03),thirdedition.Geneva:
WHO,2000.
(8) http://www.ksz-bcss.fgov.be/.[Online]CrossroadsBankforSocialSecurity(CBSS).
(9) KaplanEL,MeierP.Nonparametricestimationfromincompleteobservations.JAm
StatistAss1958,53:457-481.
(10) RothmanKJ.Estimationofconfidencelimitsforthecumulativeprobabilityofsurvival
inlifetableanalysis.JChronDis1978,Vols.31:557-560.
(11) Steliarova-FoucherE,StillerCh,KaatschPetal.Geographicalpatternsandtimetrends
ofcancerincidenceandsurvivalamongchildrenandadolescentsinEuropesincethe
1970s(theACCISproject).Anepidemiologicalstudy.Lancet2004,Vols.364:2097-2105.
(12) WorldHealthOrganization,mortalitydatabase.[Online]WHO.[Cited:25March2011.]
http://www.who.int/whosis/mort/download/en/index.html.
(13) UnitedNations,WorldPopulationProspects,the2008revisionhttp://www.un.org/esa/
population/unpop.htm.
(14) Statistiekvandedoodsoorzaken[Onlinepublicatie].http://www.zorg-en-gezondheid.
be/Cijfers/Sterftecijfers/.Brussel:VlaamsAgentschapZorgenGezondheid,afdeling
informatieenondersteuning,TeamGegevensverwerkingenResultaatsopvolging,2011.
(15) Bulletinsstatistiquesdedécès.Bruxelles:ObservatoiredelaSantéetduSocialde
Bruxelles,2008.
(16) Bulletinsstatistiquesdedécès.MinistèredelaCommunautéfrançaise:Direction
généraledelaSanté-Celluledesstatistiquesdesnaissancesetdesdécès,2008.
(17) PinkelD.Fiveyearfollowupof‘totaltherapy’ofchildhoodlymphocyticleukaemia.
JAMA1971,Vols.216:648-652.
(18) CoeberghJW,ReedijkAM,deVriesEetal.Leukaemiaincidenceandsurvivalinchildren
andadolescentsinEuropeduring1978-1997.ReportfromtheAutomatedChildhood
CancerInformationSystemproject.EurJCancer2006,Vols.42:2019-2036.
(19) SmithMA,GloecklerRiesLA,GurneyJG,RossJA.Leukemia.[bookauth.]RiesLAG,
SmithMA,GurneyJG,LinetM,TamraT,YoungJL,BuninGR(eds).CancerIncidence
andSurvivalamongChildrenandAdolescents:UnitedStatesSEERProgram1975-1995,
NationalCancerInstitute,SEERProgram.Bethesda:MD,Pub.No.99-4649,1999.
(20) TrueworthyR,ShusterJ,LookTetal.Ploidyoflymphoblastsisthestrongestpredictorof
treatmentoutcomeinB-progenitorcellacutelymphoblasticleukemiaofchildhood:A
PediatricOncologyGroupStudy.JClinOncol1992,Vols.10:606-613.
(21) RubnitzJE,DowningJR,PuiCHetal.TELgenerearrangementinacutelymphoblastic
leukemia:anewgeneticmarkerwithprognosticsignificance.JClinOncol1997,Vols.15:
1150-1157.
(22) RubnitzJE,LinkMP,ShusterJJetal.FrequencyandprognosticsignificanceofHRX
rearrangementsininfantacutelymphoblasticleukemia:aPediatricOncologyGroup
study.Blood1994,Vols.84:570-573.
(23) RubnitzJE,ShusterJJ,LandVJetal.CasecontrolstudysuggestsafavorableimpactofTEL
1143-1146.
(24) HildenJM,FrestedtJL,MooreROetal.Molecularanalysisofinfantacutelymphoblastic
leukemia:MLLgenerearrangementandreversetranscriptase-polymerasechain
reactionfort(4;11)(q21;q23).Blood1995,Vols.86:3876-3882.
(25) ClavelJ,Steliarova-FoucherE,BergerCetal.Hodgkin’sdiseaseincidenceandsurvival
inEuropeanchildrenandadolescents(1978-1997):reportfromtheACCISproject.EurJ
Cancer2006,Vols.42:2037-2049.
(26) IzarzugazaMI,Steliarova-FoucherE,MartosC,ZivkovicS.Non-HodgkinLymphomas
incidenceandsurvivalinEuropeanchildrenandadolescents(1978-1997):reportfrom
theACCISproject.EurJCancer2006,Vols.42:2050-2063.
(27) LouisDN,OhgakiH,WiestlerOD,CaveneeWK.WHOClassificationofTumoursofthe
CentralNervousSystem,FourthEdition.Lyon:IARC,2007.
(28) Peris-BonetR,Martínez-GarcíaC,LacourBetal.Childhoodcentralnervoussystem
tumours.IncidenceandsurvivalinEurope(1978-1997):reportfromtheACCISproject.
EurJCancer2006,Vols.42:2064-2080.
(29) StillerCA,DesandesE,DanonSEetal.CancerincidenceandsurvivalinEuropean
adolescents(1978-1997).ReportfromtheAutomatedChildhoodCancerInformation
Systemproject.EurJCancer2006,Vols.42:2006-2018.
(30) BrodeurGM,SawadaT,TsuchidaY,VouteP.Neuroblastoma.ElsevierscienceBV.2000.
(31) BrodeurGM.Neuroblastoma:biologicalinsightsintoaclinicalenigma.NatRevCancer
2003,Vols.3:203-216.
(32) EvansAE,D’AngioGJ.Ageatdiagnosisandprognosisinchildrenwithneuroblastoma.J
ClinOncol2005,Vols.23:6443-6444.
(33) StillerCA,BielackSS,JundtG,Steliarova-FoucherE.BonetumoursinEuropeanchildren
andadolescents,1978-1997.ReportfromtheACCISproject.EurJCancer2006,Vols.42:
2124-2135.
(34) PastoreG,Peris-BonetR,CarliMetal.Childhoodsofttissuesarcomasincidenceand
survivalinEuropeanchildren(1978-97):reportfromACCISproject.EurJCancer2006,
Vols.42:2136-2149.
(35) In‘tHofKH,vanderWalHC,KazemierG,LangeJ.F.CarcinoidTumouroftheAppendix:
AnAnalysisof1,485ConsecutiveEmergencyAppendectomies.JGastrointestSurg2008,
Vols.12:1436-1438.
(36) BosmanFT,CarneiroF,HrubanRH,TheiseND.WHOClassificationofTumoursofthe
DigestiveSystem,FourthEdition.Lyon:IARCWHOClassificationofTumours,No3,2010.
(37) Steliarova-FoucherE,KaatschP,LacourBetal.Quality,comparabilityandmethodsof
analysisofdataonchildhoodcancerinEurope(1978-1997):reportfromtheAutomated
ChildhoodCancerInformationSystemproject.EurJCancer2006,Vols.42:1915-1951.
(38) WHO.WHOClassificationsofdiseases(ICD).ListofICD-O-3updates-Udates2011.
[Online][Cited:6April2012.]http://www.who.int/entity/classifications/icd/updates/
ICDO3Updates2011.pdf.
(39) SobinLH,WittekindCh.TNMClassificationofMalignantTumours,InternationalUnion
AgainstCancer6thedition,Wiley-Liss,Geneva,2002.
61
cancer incidence in belgium 2010
antimetabolite-basedtherapy:aPediatricOncologyGroupstudy.Blood1997,Vols.89:
belgian cancer registry
rearrangementinpatientswithB-lineageacutelymphoblasticleukemiatreatedwith
(40) [Online]UnionforInternationalCancerControl(UICC).[Cited:6April2012.]http://
www.uicc.org/.
(41) FordAM,BennettCA,PriceCMetal.FetaloriginsoftheTEL-AML1fusiongenein
identicaltwinswithleukemia.ProcNatlAcadSciUSA1998,Vols.95:4584-4588.
(42) GaleKB,FordAM,ReppRetal.Backtrackingleukemiatobirth:identificationof
clonotypicgenefusionsequencesinneonatalbloodspots.ProcNatlAcadSciUSA1997,
Vols.94:13950-13954.
belgian cancer registry
(43) JawadMU,CheungMC,MinESetal.Ewingsarcomademonstratesracialdisparitiesin
62
incidence-relatedandsex-relateddifferencesinoutcome:ananalysisof1631casesfrom
theSEERdatabase,1973-2005.Cancer2009,Vols.115:3526-3536.
(44) PetoR,PikeMC,ArmitagePetal.Designandanalysisofrandomizedclinicaltrials
requiringprolongedobservationofeachpatient.II.Analysisandexamples.BrJCancer
1977,Vols.35:1-39.
(45) SmithM,ChenT,SimonR.Age-specificincidenceofacutelymphoblasticleukemiain
U.S.children:inuteroinitiationmodel.JNatlCancerInst1997,Vols.89:1542-1544.
(46) SpixC,PastoreG,SankilaRetal.NeuroblastomaincidenceandsurvivalinEuropean
children(1978-1997):reportfromtheACCIS-project.EurJCancer2006,Vols.42:20812091.
Appendix
Appendix 1: Notifications by source type in children and in adolescents,
Belgium 2004-2009
0-14 years
15-19 years
Leukaemias, myeloproliferative and myelodysplastic diseases:
notifications by source type (N=500)
Leukaemias, myeloproliferative and myelodysplastic diseases:
notifications by source type (N=125)
Paediatric centres:
N=480 (96.0%)
N=17
(3.4%)
Pathology/Clinical Biology:
N=218 (43.6%)
N=54
(10.8%)
N=4
(0.8%)
Paediatric centres:
N=32 (25.6%)
N=0
(0.0%)
N=156
(31.2%)
N=253
(50.6%)
N=4
(0.8%)
N=18
(14.4%)
Lymphomas and reticuloendothelial neoplasms:
notifications by source type (N=238)
Hospitals/Health insurance:
N=105 (84.0%)
N=18
(7.6%)
Paediatric centres:
N=32 (12.1%)
N=1
(0.4%)
N=142
(59.7%)
N=35
(14.7%)
N=6
(2.5%)
Pathology/Clinical Biology:
N=335 (70.5%)
N=138
(52.3%)
N=46
(9.7%)
Hospitals/Health insurance:
N=192 (72.7%)
CNS and miscellaneous intracranial and intraspinal neoplasms: notifications
by source type (N=146)
Paediatric centres:
N=25 (17.1%)
N=1
(0.7%)
N=227
(47.8%)
N=77
(16.2%)
N=71
(26.9%)
N=23
(8.7%)
CNS and miscellaneous intracranial and intraspinal neoplasms:
notifications by source type (N=475)
N=24
(5.1%)
N=0
(0.0%)
N=5
(1.9%)
Hospitals/Health insurance:
N=186 (78.2%)
N=28
(5.9%)
Pathology/Clinical Biology:
N=235 (89.0%)
N=26
(9.8%)
N=3
(1.3%)
Paediatric centres:
N=356 (74.9%)
N=45
(36.0%)
Lymphomas and reticuloendothelial neoplasms:
notifications by source type (N=264)
Pathology/Clinical Biology:
N=190 (79.8%)
N=24
(10.1%)
N=17
(13.6%)
N=31
(24.8%)
Hospitals/Health insurance:
N=425 (85.0%)
N=10
(4.2%)
N=3
(2.4%)
N=11
(8.8%)
N=12
(2.4%)
Paediatric centres:
N=211 (88.7%)
Pathology/Clinical Biology:
N=76 (60.8%)
Pathology/Clinical Biology:
N=115 (78.8%)
N=2
(1.4%)
N=50
(34.2%)
N=18
(12.3%)
N=38
(8.0%)
N=35
(7.4%)
Hospitals/Health insurance:
N=377 (79.4%)
N=4
(2.7%)
N=45
(30.8%)
N=26
(17.8%)
Hospitals/Health insurance:
N=93 (63.7%)
belgian cancer registry
15-19 years
Neuroblastoma and other peripheral nervous cell tumours:
notifications by source type (N=128)
Neuroblastoma and other peripheral nervous cell tumours:
notifications by source type (N=2)
Paediatric centres:
N=124 (96.9%)
Pathology/Clinical Biology:
N=118 (92.2%)
N=15
(11.7%)
N=2
(1.6%)
N=2
(1.6%)
Paediatric centres:
N=0 (0.0%)
Pathology/Clinical Biology:
N=2 (100.0%)
N=0
(0.0%)
N=0
(0.0%)
N=100
(78.1%)
N=7
(5.5%)
N=0
(0.0%)
N=1
(0.8%)
N=0
(0.0%)
N=1
(50.0%)
N=1
(0.8%)
N=0
(0.0%)
Hospitals/Health insurance:
N=109 (85.2%)
Retinoblastoma:
notifications by source type (N=64)
Hospitals/Health insurance:
N=1 (50.0%)
Retinoblastoma:
notifications by source type (N=0)
Paediatric centres:
N=59 (92.2%)
N=8
(12.5%)
Pathology/Clinical Biology:
N=22 (34.4%)
N=0
(0.0%)
N=0
(0.0%)
Paediatric centres:
N=0 (0.0%)
N=0
(0.0%)
N=22
(34.4%)
N=29
(45.3%)
Pathology/Clinical Biology:
N=0 (0.0%)
N=0
(0.0%)
N=0
(0.0%)
N=0
(0.0%)
N=0
(0.0%)
N=0
(0.0%)
Hospitals/Health insurance:
N=56 (87.5%)
Renal Tumours:
notifications by source type (N=102)
N=4
(3.9%)
N=0
(0.0%)
N=0
(0.0%)
N=5
(7.8%)
Paediatric centres:
N=97 (95.1%)
N=1
(50.0%)
Hospitals/Health insurance:
N=0 (0.0%)
Renal Tumours:
notifications by source type (N=6)
Pathology/Clinical Biology:
N=81 (79.4%)
N=10
(9.8%)
N=1
(1.0%)
Paediatric centres:
N=3 (50.0%)
N=0
(0.0%)
N=69
(67.6%)
N=14
(13.7%)
Pathology/Clinical Biology:
N=6 (100.0%)
N=1
(16.7%)
N=0
(0.0%)
N=2
(33.3%)
N=1
(1.0%)
N=3
(2.9%)
Hospitals/Health insurance:
N=87 (85.3%)
N=0
(0.0%)
N=3
(50.0%)
N=0
(0.0%)
Hospitals/Health insurance:
N=5 (83.3%)
65
appendix
0-14 years
0-14 years
15-19 years
Hepatic tumours:
notifications by source type (N=11)
Hepatic tumours:
notifications by source type (N=1)
Paediatric centres:
N=10 (90.9%)
N=0
(0.0%)
Pathology/Clinical Biology:
N=11 (100.0%)
N=2
(18.2%)
N=0
(0.0%)
Paediatric centres:
N=0 (0.0%)
N=0
(0.0%)
N=8
(72.7%)
N=0
(0.0%)
Pathology/Clinical Biology:
N=1 (100.0%)
N=0
(0.0%)
N=0
(0.0%)
N=1
(9.1%)
N=0
(0.0%)
N=0
(0.0%)
N=1
(100.0%)
N=0
(0.0%)
Hospitals/Health insurance:
N=9 (81.8%)
Malignant bone tumours:
notifications by source type (N=99)
Paediatric centres:
N=90 (90.9%)
N=3
(3.0%)
Hospitals/Health insurance:
N=1 (100.0%)
Malignant bone tumours:
notifications by source type (N=77)
Pathology/Clinical Biology:
N=94 (94.9%)
N=8
(8.1%)
N=2
(2.0%)
Paediatric centres:
N=30 (39.0%)
N=0
(0.0%)
N=78
(78.8%)
N=1
(1.0%)
N=6
(6.1%)
N=36
(46.8%)
Hospitals/Health insurance:
N=70 (90.9%)
Soft tissue and other extraosseous sarcomas:
notifications by source type (N=83)
Pathology/Clinical Biology:
N=89 (84.8%)
N=7
(6.7%)
Paediatric centres:
N=17 (20.5%)
N=1
(1.2%)
N=69
(65.7%)
N=8
(7.6%)
N=7
(9.1%)
N=4
(5.2%)
Soft tissue and other extraosseous sarcomas:
notifications by source type (N=105)
N=9
(8.6%)
N=0
(0.0%)
N=0
(0.0%)
Hospitals/Health insurance:
N=86 (86.9%)
N=4
(3.8%)
Pathology/Clinical Biology:
N=73 (94.8%)
N=30
(39.0%)
N=1
(1.0%)
Paediatric centres:
N=90 (85.7%)
N=0
(0.0%)
Pathology/Clinical Biology:
N=75 (90.4%)
N=0
(0.0%)
N=25
(30.1%)
N=15
(18.1%)
N=4
(3.8%)
N=4
(3.8%)
Hospitals/Health insurance:
N=85 (81.0%)
N=1
(1.2%)
N=35
(42.2%)
N=6
(7.2%)
Hospitals/Health insurance:
N=57 (68.7%)
belgian cancer registry
15-19 years
Germ cell tumours, trophoblastic tumours and neoplasms of gonads:
notifications by source type (N=59)
Germ cell tumours, trophoblastic tumours and neoplasms of gonads:
notifications by source type (N=112)
Paediatric centres:
N=48 (81.4%)
N=6
(10.2%)
Pathology/Clinical Biology:
N=39 (66.1%)
N=6
(10.2%)
N=3
(5.1%)
Paediatric centres:
N=11 (9.8%)
N=1
(0.9%)
N=24
(40.7%)
N=12
(20.3%)
N=6
(10.2%)
N=1
(0.9%)
Other malignant epithelial neoplasms and malignant melanomas:
notifications by source type (N=127)
Pathology/Clinical Biology:
N=118 (92.9%)
N=4
(3.1%)
N=68
(60.7%)
N=62
(48.8%)
Hospitals/Health insurance:
N=92 (82.1%)
Other malignant epithelial neoplasms and malignant melanomas:
notifications by source type (N=239)
Paediatric centres:
N=7 (2.9%)
N=0
(0.0%)
N=30
(23.6%)
N=3
(2.4%)
N=19
(17.0%)
N=14
(12.5%)
Hospitals/Health insurance:
N=44 (74.6%)
N=1
(0.8%)
N=0
(0.0%)
N=9
(8.0%)
N=2
(3.4%)
Paediatric centres:
N=38 (29.9%)
Pathology/Clinical Biology:
N=96 (85.7%)
Pathology/Clinical Biology:
N=222 (92.9%)
N=2
(0.8%)
N=113
(47.3%)
N=5
(2.1%)
N=22
(17.3%)
N=5
(3.9%)
Hospitals/Health insurance:
N=60 (47.2%)
N=0
(0.0%)
N=102
(42.7%)
N=17
(7.1%)
Hospitals/Health insurance:
N=124 (51.9%)
67
appendix
0-14 years
15
3
IIe: Unspecified lymphomas
1
69
16
IIIe: Other specified intracranial and intraspinal neoplasms
1
VIc: Unspecified malignant renal tumours
-
1
-
VIIb: Hepatic carcinomas
VIIc: Unspecified malignant hepatic tumours
-
2
2
-
-
8
8
14
-
26
26
1
2
5
VIIa: Hepatoblastomas
6
3
VII: Hepatic tumours
51
VIa: Nephroblastomas and other nonepithelial renal tumours
VIb: Renal carcinomas
55
VI: Renal Tumours
2
39
IVb: Other peripheral nervous cell tumours
V: Retinoblastomas
72
IVa: Neuroblastomas and ganglioneuroblastomas
IV: Neuroblastomas and other peripheral nervous cell tumours
74
36
IIIf: Unspecified intracranial and intraspinal neoplasms
5
49
IIIc: Intracranial and intraspinal embryonal tumours
IIId: Other gliomas
4
6
33
129
IIIa: Ependymomas and choroid plexus tumours
19
-
IIIb: Astrocytomas
332
47
IIc: Burkitt lymphomas
IId: Miscellaneous lymphoreticular neoplasms
III: CNS and miscellaneous intracranial and intraspinal neoplasms
-
84
4
1
143
IIa: Hodgkin lymphomas
IIb: Non-Hodgkin lymphomas
2
5
3
Ie: Unspecified and other specified leukaemias
-
292
21
Id: Myelodysplastic syndromes and other myeloproliferative diseases
-
5
51
14
Ib: Acute myeloid leukaemias
7
Ic: Chronic myeloproliferative diseases
II: Lymphomas and reticuloendothelial neoplasms
0
14
273
I: Leukaemias, myeloproliferative and myelodysplastic diseases
Ia: Lymphoid leukaemias
Tot
362
Belgium: Boys 2004-2009
Belgium: Boys, number of invasive tumours in children and adolescents by tumour type and age in 2004-2009
1
-
-
1
1
1
-
10
11
8
-
16
16
2
3
4
1
5
6
21
-
1
-
1
-
2
-
-
-
6
15
21
2
-
-
1
1
-
-
6
6
8
-
10
10
1
2
1
7
14
3
28
-
1
-
2
-
3
-
3
-
3
36
42
3
-
-
-
-
-
-
9
9
5
-
9
9
2
2
1
3
4
3
15
-
1
3
1
-
5
-
-
-
4
39
43
4
-
-
-
-
-
-
3
3
2
-
3
3
-
3
2
8
8
-
21
-
1
1
1
1
4
-
2
-
-
26
28
5
-
-
-
-
-
1
4
5
-
1
4
5
-
-
2
2
4
-
8
-
-
6
3
3
12
-
1
-
2
13
16
6
-
-
-
-
-
-
1
1
1
-
1
1
-
5
-
1
9
1
16
-
1
2
5
3
11
-
-
-
-
19
19
7
-
-
-
-
-
-
1
1
-
-
1
1
1
5
-
6
4
-
16
1
1
4
3
1
10
-
-
1
2
17
20
8
-
-
-
-
-
-
1
1
-
-
-
-
-
2
3
3
8
2
18
-
-
4
4
8
16
-
1
1
1
10
13
9
-
-
-
-
-
-
1
1
1
-
-
-
-
1
3
-
7
1
12
-
-
4
3
1
8
-
4
-
-
11
15
-
-
1
1
-
-
1
1
-
-
-
-
-
3
5
5
1
-
14
-
1
4
2
9
16
-
-
-
2
12
14
10
11
-
-
-
-
-
1
-
1
-
-
-
-
-
2
2
3
11
2
20
1
-
3
4
1
9
-
2
1
3
8
14
-
-
-
-
-
-
-
-
-
-
-
-
1
1
2
1
5
-
10
-
1
1
3
7
12
-
1
-
-
8
9
12
13
-
-
-
-
-
-
-
-
-
-
-
-
2
1
6
1
5
1
16
-
-
5
3
15
23
-
1
-
2
7
10
-
-
-
-
-
-
2
2
-
1
1
2
1
6
1
1
6
2
17
1
-
1
5
7
14
-
1
2
1
8
12
14
15
-
-
-
-
-
-
2
2
-
-
1
1
1
8
2
2
7
2
22
-
1
-
9
10
20
-
-
3
4
11
18
-
-
-
-
-
-
1
1
-
-
-
-
-
5
-
-
10
-
15
-
-
2
7
16
25
1
3
1
1
13
19
16
17
-
1
-
1
-
-
-
-
-
-
-
-
3
4
-
-
3
4
14
-
1
2
7
20
30
-
-
2
9
4
15
-
-
-
-
-
1
-
1
-
-
-
-
1
5
-
1
7
1
15
-
-
3
8
20
31
-
-
3
3
7
13
18
-
-
-
-
-
-
1
1
-
-
-
-
-
6
1
2
5
1
15
-
1
2
12
21
36
-
2
-
3
2
7
19
Appendix 2: Cancer incidence in children and adolescents, Belgium 2004-2009
6
2
-
44
10
1
IXa: Rhabdomyosarcomas
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms
2
1,628
XIIb: Other unspecified malignant tumours
I-XII: All tumours
1
3
XII: Other and unspecified malignant neoplasms
XIIa: Other specified malignant tumours
19
62
XIe: Skin carcinomas
XIf: Other and unspecified carcinomas
108
1
1
2
-
-
-
5
-
-
-
36
XIc: Nasopharyngeal carcinomas
XId: Malignant melanomas
1
21
XIa: Adrenocortical carcinomas
144
XIb: Thyroid carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
-
1
Xd: Gonadal carcinomas
Xe: Other and unspecified malignant gonadal tumours
-
3
86
Xc: Malignant gonadal germ cell tumours
1
6
3
22
Xa: Intracranial and intraspinal germ cell tumours
Xb: Malignant extracranial and extragonadal germ cell tumours
-
9
7
1
42
115
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads
IXe: Unspecified soft tissue sarcomas
IXd: Other specified soft tissue sarcomas
IXc: Kaposi sarcomas
9
106
IX: Soft tissue and other extraosseous sarcomas
-
1
VIIIe: Unspecified malignant bone tumours
-
3
2
-
-
2
0
VIIId: Other specified malignant bone tumours
42
VIIIc: Ewing tumours and related sarcomas of bone
VIIIa: Osteosarcomas
4
50
VIII: Malignant bone tumours
VIIIb: Chondrosarcomas
Tot
100
Belgium: Boys 2004-2009
Belgium: Boys, number of invasive tumours in children and adolescents by tumour type and age in 2004-2009
90
-
-
-
-
-
1
-
-
-
1
-
-
1
-
-
1
-
-
-
1
7
8
-
-
-
-
-
-
1
105
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
1
-
2
-
-
3
5
-
-
1
-
-
1
2
92
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
5
6
-
-
-
-
-
-
3
65
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
-
-
1
-
-
1
2
-
1
-
-
-
1
4
5
50
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
1
1
-
-
2
-
-
2
51
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
-
1
1
-
-
-
-
-
-
6
7
57
-
-
-
-
1
1
-
-
-
2
-
-
-
-
-
-
1
2
-
-
-
3
1
-
3
-
-
4
59
-
-
-
4
1
2
-
1
-
8
-
-
-
-
-
-
-
1
-
-
1
2
-
-
1
-
-
1
8
50
-
-
-
3
1
1
-
-
-
5
-
-
-
-
2
2
-
-
-
-
1
1
-
-
2
-
3
5
9
59
-
-
-
1
1
1
1
-
-
4
-
-
-
-
-
-
1
-
-
-
2
3
-
1
3
-
2
6
10
60
-
-
-
1
-
-
-
-
-
1
-
-
-
-
2
2
1
2
-
2
1
6
-
-
2
-
5
7
11
48
-
-
-
1
-
1
1
-
1
4
-
-
1
-
1
2
-
7
-
-
1
8
-
-
3
-
-
3
12
80
-
-
-
8
1
1
1
4
-
15
-
-
-
-
1
1
-
1
1
1
1
4
-
-
4
-
7
11
13
14
79
-
-
-
5
1
4
1
1
-
12
-
-
-
1
2
3
-
2
-
2
3
7
-
-
4
-
6
10
1
6
-
137
-
belgian cancer registry
appendix
-
-
5
11
2
8
1
9
2
4
3
1
30
15
-
-
1
25
20
4
-
1
31
5
1
4
-
20
1
1
1
-
3
-
7
2
5
7
4
11
-
19
10
18
113
-
-
-
11
2
3
-
4
-
20
-
-
18
-
1
19
2
9
-
-
2
13
-
-
-
-
2
2
17
114
1
-
1
3
4
4
-
3
-
14
-
-
13
-
2
15
1
3
-
1
3
8
-
-
6
1
9
16
16
114
97
-
-
-
5
-
5
-
1
-
11
-
-
5
-
5
10
1
1
-
-
3
5
-
-
-
1
7
8
15
69
-
15
3
IId: Miscellaneous lymphoreticular neoplasms
36
69
16
IIIe: Other specified intracranial and intraspinal neoplasms
IIIf: Unspecified intracranial and intraspinal neoplasms
-
-
-
1
VIIb: Hepatic carcinomas
VIIc: Unspecified malignant hepatic tumours
5.5
5.5
5
VIIa: Hepatoblastomas
6
1
VII: Hepatic tumours
-
3
VIb: Renal carcinomas
VIc: Unspecified malignant renal tumours
-
21.8
21.8
38.2
-
70.9
70.9
2.7
13.6
2.7
5.5
16.4
10.9
51.8
-
51
55
VIa: Nephroblastomas and other nonepithelial renal tumours
VI: Renal Tumours
2
39
IVb: Other peripheral nervous cell tumours
V: Retinoblastomas
72
IVa: Neuroblastomas and ganglioneuroblastomas
74
49
IIIc: Intracranial and intraspinal embryonal tumours
IIId: Other gliomas
IV: Neuroblastomas and other peripheral nervous cell tumours
33
129
IIIa: Ependymomas and choroid plexus tumours
IIIb: Astrocytomas
III: CNS and miscellaneous intracranial and intraspinal neoplasms
332
10.9
47
IIc: Burkitt lymphomas
IIe: Unspecified lymphomas
-
84
2.7
143
IIa: Hodgkin lymphomas
5.5
-
-
IIb: Non-Hodgkin lymphomas
3
Ie: Unspecified and other specified leukaemias
19.1
13.6
13.6
21
Id: Myelodysplastic syndromes and other myeloproliferative diseases
0
38.2
292
14
Ic: Chronic myeloproliferative diseases
II: Lymphomas and reticuloendothelial neoplasms
51
Ib: Acute myeloid leukaemias
273
I: Leukaemias, myeloproliferative and myelodysplastic diseases
Ia: Lymphoid leukaemias
Tot
362
Belgium: Boys 2004-2009
-
-
2.8
2.8
2.8
-
27.5
30.3
22.0
-
44.0
44.0
5.5
8.3
11.0
2.8
13.8
16.5
57.8
-
2.8
-
2.8
-
5.5
-
-
-
16.5
41.3
57.8
1
-
-
2.8
2.8
-
-
16.6
16.6
22.2
-
27.7
27.7
2.8
5.5
2.8
19.4
38.8
8.3
77.6
-
2.8
-
5.5
-
8.3
-
8.3
-
8.3
99.8
116.4
2
-
-
-
-
-
-
25.1
25.1
13.9
-
25.1
25.1
5.6
5.6
2.8
8.4
11.1
8.4
41.8
-
2.8
8.4
2.8
-
13.9
-
-
-
11.1
108.6
119.7
3
Belgium: Boys, age-specific incidence rates of cancer in children and adolescents, by tumour type in 2004-2009 (N/1,000,000 person years)
4
-
-
-
-
-
-
8.4
8.4
5.6
-
8.4
8.4
-
8.4
5.6
22.4
22.4
-
58.7
-
2.8
2.8
2.8
2.8
11.2
-
5.6
-
-
72.7
78.3
5
-
-
-
-
-
2.8
11.2
14.0
-
2.8
11.2
14.0
-
-
5.6
5.6
11.2
-
22.4
-
-
16.8
8.4
8.4
33.6
-
2.8
-
5.6
36.4
44.7
6
-
-
-
-
-
-
2.8
2.8
2.8
-
2.8
2.8
-
13.9
-
2.8
25.0
2.8
44.4
-
2.8
5.6
13.9
8.3
30.6
-
-
-
-
52.8
52.8
7
-
-
-
-
-
-
2.8
2.8
-
-
2.8
2.8
2.8
13.8
-
16.5
11.0
-
44.1
2.8
2.8
11.0
8.3
2.8
27.6
-
-
2.8
5.5
46.9
55.2
8
-
-
-
-
-
-
2.7
2.7
-
-
-
-
-
5.5
8.2
8.2
22.0
5.5
49.4
-
-
11.0
11.0
22.0
43.9
-
2.7
2.7
2.7
27.5
35.7
9
-
-
-
-
-
-
2.7
2.7
2.7
-
-
-
-
2.7
8.2
-
19.2
2.7
32.8
-
-
10.9
8.2
2.7
21.9
-
10.9
-
-
30.1
41.0
10
-
-
2.7
2.7
-
-
2.7
2.7
-
-
-
-
-
8.1
13.5
13.5
2.7
-
37.9
-
2.7
10.8
5.4
24.4
43.3
-
-
-
5.4
32.5
37.9
11
-
-
-
-
-
2.7
-
2.7
-
-
-
-
-
5.3
5.3
8.0
29.3
5.3
53.3
2.7
-
8.0
10.7
2.7
24.0
-
5.3
2.7
8.0
21.3
37.3
12
-
-
-
-
-
-
-
-
-
-
-
-
2.6
2.6
5.2
2.6
13.1
-
26.2
-
2.6
2.6
7.9
18.4
31.5
-
2.6
-
-
21.0
23.6
13
-
-
-
-
-
-
-
-
-
-
-
-
5.2
2.6
15.5
2.6
12.9
2.6
41.4
-
-
12.9
7.8
38.8
59.5
-
2.6
-
5.2
18.1
25.9
14
-
-
-
-
-
-
5.1
5.1
-
2.6
2.6
5.1
2.6
15.4
2.6
2.6
15.4
5.1
43.5
2.6
-
2.6
12.8
17.9
35.8
-
2.6
5.1
2.6
20.5
30.7
15
-
-
-
-
-
-
5.1
5.1
-
-
2.5
2.5
2.5
20.3
5.1
5.1
17.8
5.1
55.9
-
2.5
-
22.9
25.4
50.8
-
-
7.6
10.2
28.0
45.8
16
-
-
-
-
-
-
2.5
2.5
-
-
-
-
-
12.7
-
-
25.4
-
38.1
-
-
5.1
17.8
40.7
63.6
2.5
7.6
2.5
2.5
33.1
48.3
17
-
2.6
-
2.6
-
-
-
-
-
-
-
-
7.7
10.2
-
-
7.7
10.2
35.8
-
2.6
5.1
17.9
51.1
76.7
-
-
5.1
23.0
10.2
38.4
18
-
-
-
-
-
2.6
-
2.6
-
-
-
-
2.6
12.9
-
2.6
18.1
2.6
38.8
-
-
7.8
20.7
51.8
80.3
-
-
7.8
7.8
18.1
33.7
19
-
-
-
-
-
-
2.6
2.6
-
-
-
-
-
15.7
2.6
5.2
13.1
2.6
39.2
-
2.6
5.2
31.4
54.9
94.2
-
5.2
-
7.8
5.2
18.3
0
5.5
-
10
1
2
1,628
XIIb: Other unspecified malignant tumours
I-XII: All tumours
1
3
XII: Other and unspecified malignant neoplasms
XIIa: Other specified malignant tumours
19
62
XIe: Skin carcinomas
XIf: Other and unspecified carcinomas
294.6
2.7
2.7
5.5
-
-
-
-
5
XIc: Nasopharyngeal carcinomas
-
36
21
XIb: Thyroid carcinomas
XId: Malignant melanomas
1
144
XIa: Adrenocortical carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
-
1
Xd: Gonadal carcinomas
Xe: Other and unspecified malignant gonadal tumours
-
8.2
86
Xc: Malignant gonadal germ cell tumours
2.7
6
8.2
22
Xa: Intracranial and intraspinal germ cell tumours
Xb: Malignant extracranial and extragonadal germ cell tumours
-
9
19.1
2.7
42
115
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads
IXe: Unspecified soft tissue sarcomas
IXd: Other specified soft tissue sarcomas
IXc: Kaposi sarcomas
16.4
44
IXa: Rhabdomyosarcomas
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms
24.6
1
106
VIIIe: Unspecified malignant bone tumours
IX: Soft tissue and other extraosseous sarcomas
-
3
5.5
-
-
5.5
VIIId: Other specified malignant bone tumours
42
VIIIc: Ewing tumours and related sarcomas of bone
VIIIa: Osteosarcomas
4
50
VIII: Malignant bone tumours
VIIIb: Chondrosarcomas
Tot
100
Belgium: Boys 2004-2009
247.6
-
-
-
-
-
2.8
-
-
-
2.8
-
-
2.8
-
-
2.8
-
-
-
2.8
19.3
22.0
-
-
-
-
-
-
1
291.0
-
-
-
-
-
-
-
-
-
-
-
-
-
2.8
-
2.8
-
5.5
-
-
8.3
13.9
-
-
2.8
-
-
2.8
2
256.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2.8
-
-
13.9
16.7
-
-
-
-
-
-
3
Belgium: Boys, age-specific incidence rates of cancer in children and adolescents, by tumour type in 2004-2009 (N/1,000,000 person years)
4
181.8
-
-
-
-
-
2.8
-
-
-
2.8
-
-
-
-
-
-
-
2.8
-
-
2.8
5.6
-
2.8
-
-
-
2.8
5
139.8
-
-
-
2.8
-
-
-
-
-
2.8
-
-
-
-
-
-
-
-
-
-
2.8
2.8
-
-
5.6
-
-
5.6
141.7
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2.8
2.8
-
-
-
-
2.8
2.8
-
-
-
-
-
-
6
7
157.2
-
-
-
-
2.8
2.8
-
-
-
5.5
-
-
-
-
-
-
2.8
5.5
-
-
-
8.3
2.8
-
8.3
-
-
11.0
8
162.0
-
-
-
11.0
2.7
5.5
-
2.7
-
22.0
-
-
-
-
-
-
-
2.7
-
-
2.7
5.5
-
-
2.7
-
-
2.7
9
136.8
-
-
-
8.2
2.7
2.7
-
-
-
13.7
-
-
-
-
5.5
5.5
-
-
-
-
2.7
2.7
-
-
5.5
-
8.2
13.7
10
159.7
-
-
-
2.7
2.7
2.7
2.7
-
-
10.8
-
-
-
-
-
-
2.7
-
-
-
5.4
8.1
-
2.7
8.1
-
5.4
16.2
11
159.8
-
-
-
2.7
-
-
-
-
-
2.7
-
-
-
-
5.3
5.3
2.7
5.3
-
5.3
2.7
16.0
-
-
5.3
-
13.3
18.6
12
125.9
-
-
-
2.6
-
2.6
2.6
-
2.6
10.5
-
-
2.6
-
2.6
5.2
-
18.4
-
-
2.6
21.0
-
-
7.9
-
-
7.9
13
207.1
-
-
-
20.7
2.6
2.6
2.6
10.4
-
38.8
-
-
-
-
2.6
2.6
-
2.6
2.6
2.6
2.6
10.4
-
-
10.4
-
18.1
28.5
14
202.3
-
-
-
12.8
2.6
10.2
2.6
2.6
-
30.7
-
-
-
2.6
5.1
7.7
-
5.1
-
5.1
7.7
17.9
-
-
10.2
-
15.4
25.6
15
16
17
appendix
-
-
-
28.1
5.1
7.7
-
10.2
-
51.1
-
-
46.0
-
2.6
48.6
5.1
23.0
-
-
5.1
33.2
-
-
-
-
5.1
5.1
291.5
2.5
-
2.5
7.6
10.2
10.2
-
7.6
-
35.6
-
-
33.1
-
5.1
38.1
2.5
7.6
-
2.5
7.6
20.3
-
-
15.3
2.5
22.9
40.7
289.9
246.6
-
-
-
12.7
-
12.7
-
2.5
-
28.0
-
-
12.7
-
12.7
25.4
2.5
2.5
-
-
7.6
12.7
-
-
-
2.5
17.8
20.3
71
-
358.5
292.7
belgian cancer registry
-
-
13.1
28.8
5.2
20.7
2.6
23.5
5.2
10.5
38.8
7.8
78.5
-
2.6
-
2.6
65.4
51.8
10.5
-
2.6
81.1
2.6
51.8
10.5
-
12.9
2.6
2.6
2.6
-
7.8
2.6
15.5
18.3
5.2
-
-
10.5
12.9
18.1
19
26.2
18
28.5
5
10
Id: Myelodysplastic syndromes and other myeloproliferative diseases
-
16
11
3
IIc: Burkitt lymphomas
IId: Miscellaneous lymphoreticular neoplasms
33
38
12
IIIe: Other specified intracranial and intraspinal neoplasms
IIIf: Unspecified intracranial and intraspinal neoplasms
IVa: Neuroblastomas and ganglioneuroblastomas
53
1
-
VIIc: Unspecified malignant hepatic tumours
-
-
3
5
VIIa: Hepatoblastomas
VIIb: Hepatic carcinomas
1
3
1
-
7
8
9
1
22
23
-
3
2
2
4
10
21
-
6
VIc: Unspecified malignant renal tumours
VII: Hepatic tumours
2
VIb: Renal carcinomas
50
VI: Renal Tumours
VIa: Nephroblastomas and other nonepithelial renal tumours
25
1
55
V: Retinoblastomas
IVb: Other peripheral nervous cell tumours
56
34
IIIc: Intracranial and intraspinal embryonal tumours
IIId: Other gliomas
IV: Neuroblastomas and other peripheral nervous cell tumours
36
136
IIIa: Ependymomas and choroid plexus tumours
IIIb: Astrocytomas
III: CNS and miscellaneous intracranial and intraspinal neoplasms
289
3
60
IIe: Unspecified lymphomas
-
120
IIa: Hodgkin lymphomas
IIb: Non-Hodgkin lymphomas
1
4
-
-
-
210
II: Lymphomas and reticuloendothelial neoplasms
-
11
Ic: Chronic myeloproliferative diseases
Ie: Unspecified and other specified leukaemias
53
5
189
Ib: Acute myeloid leukaemias
Ia: Lymphoid leukaemias
I: Leukaemias, myeloproliferative and myelodysplastic diseases
0
10
Tot
263
Belgium: Girls 2004-2009
Belgium: Girls, number of invasive tumours in children and adolescents by tumour type and age in 2004-2009
1
-
-
2
2
-
-
7
7
8
-
9
9
2
-
2
6
3
8
21
-
3
-
1
-
4
-
3
-
5
12
20
2
-
-
-
-
-
-
9
9
4
-
10
10
-
-
2
1
9
2
14
-
1
-
-
1
2
-
2
-
1
34
37
3
-
1
-
1
-
-
9
9
4
-
2
2
-
1
3
2
6
6
18
-
-
2
1
-
3
-
-
-
5
19
24
4
-
-
-
-
-
-
4
4
-
-
4
4
-
1
3
2
6
-
12
-
1
1
2
1
5
-
-
-
-
16
16
5
-
-
-
-
-
-
5
5
-
-
1
1
-
-
1
1
13
1
16
-
1
1
1
1
4
-
1
-
4
17
22
6
-
-
-
-
-
-
-
-
-
-
2
2
-
1
2
3
6
-
12
-
-
3
2
1
6
-
-
-
1
9
10
7
-
-
-
-
-
-
1
1
-
-
1
1
-
-
2
-
9
-
11
-
-
3
2
1
6
-
-
-
4
5
9
-
-
-
-
-
-
2
2
-
-
1
1
-
5
2
2
8
-
17
-
-
1
1
-
2
-
-
-
-
4
4
8
-
-
-
-
-
-
-
-
-
-
1
1
-
2
1
2
4
1
10
-
-
1
2
5
8
-
1
-
3
4
8
9
10
-
-
-
-
-
-
2
2
-
-
-
-
1
2
-
4
6
-
13
1
1
-
3
3
8
-
-
1
2
7
10
-
-
-
-
-
-
1
1
-
-
-
-
1
1
2
-
7
2
13
1
1
-
1
2
5
-
1
-
4
3
8
11
-
-
-
-
-
1
1
2
-
-
1
1
-
4
-
1
10
1
16
-
-
-
3
-
3
-
-
1
1
10
12
12
13
-
-
-
-
-
-
2
2
-
-
-
-
2
1
2
3
11
1
20
-
-
1
3
10
14
-
-
1
1
8
10
14
-
-
-
-
-
-
-
-
-
-
-
-
1
-
3
-
5
1
10
-
-
2
3
9
14
-
-
-
1
9
10
15
-
-
-
-
-
-
-
-
-
-
-
-
-
5
1
1
12
-
19
-
-
1
8
10
19
-
-
-
6
6
12
-
-
-
-
-
-
-
-
-
-
-
-
2
3
-
1
6
1
13
-
-
-
4
15
19
-
-
2
-
7
9
16
-
-
-
-
-
-
-
-
-
-
-
-
2
1
1
-
5
-
9
-
-
-
6
18
24
-
-
1
3
3
7
17
-
-
-
-
-
-
-
-
-
-
-
-
1
3
2
3
1
2
12
1
-
-
9
17
27
-
1
4
5
5
15
18
19
-
-
-
-
-
1
-
1
-
-
1
1
-
5
2
-
5
-
12
-
-
-
7
26
33
-
1
1
2
6
10
-
2
82
24
VIIIe: Unspecified malignant bone tumours
IX: Soft tissue and other extraosseous sarcomas
-
2
1,345
3
I-XII: All tumours
XIIb: Other unspecified malignant tumours
7
4
XIIa: Other specified malignant tumours
XII: Other and unspecified malignant neoplasms
93
1
-
1
1
-
38
85
XIe: Skin carcinomas
XIf: Other and unspecified carcinomas
-
-
-
-
1
-
54
3
XId: Malignant melanomas
XIc: Nasopharyngeal carcinomas
1
41
XIb: Thyroid carcinomas
XIa: Adrenocortical carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
222
4
Xe: Other and unspecified malignant gonadal tumours
-
24
Xc: Malignant gonadal germ cell tumours
Xd: Gonadal carcinomas
9
5
21
Xa: Intracranial and intraspinal germ cell tumours
Xb: Malignant extracranial and extragonadal germ cell tumours
-
9
-
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads
56
3
51
IXc: Kaposi sarcomas
IXd: Other specified soft tissue sarcomas
IXe: Unspecified soft tissue sarcomas
1
-
-
7
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms
IXa: Rhabdomyosarcomas
4
2
-
33
VIIIc: Ewing tumours and related sarcomas of bone
-
-
VIIId: Other specified malignant bone tumours
36
VIIIa: Osteosarcomas
-
0
3
76
VIII: Malignant bone tumours
VIIIb: Chondrosarcomas
Tot
Belgium: Girls 2004-2009
Belgium: Girls, number of invasive tumours in children and adolescents by tumour type and age in 2004-2009
1
81
-
-
-
-
-
-
-
-
-
-
-
-
-
6
-
6
-
-
-
-
2
2
-
-
2
-
-
2
82
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
3
-
1
-
-
2
3
-
-
-
-
-
-
2
69
-
-
-
-
1
1
-
-
-
2
-
-
-
1
-
1
-
-
-
-
4
4
-
-
1
-
-
1
3
44
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
2
2
-
-
-
-
-
-
4
55
-
-
-
1
1
-
-
-
-
2
-
-
-
-
-
-
-
1
-
-
3
4
-
-
1
-
-
1
5
36
-
-
-
-
1
1
-
-
-
2
-
-
1
1
-
2
-
-
-
-
2
2
-
-
-
-
-
-
6
34
-
-
-
-
-
-
1
1
-
2
-
-
1
-
1
2
-
1
-
-
-
1
-
-
-
-
1
1
7
36
-
-
-
1
1
-
-
-
-
2
-
-
1
-
1
2
-
1
-
-
2
3
-
-
3
-
-
3
8
38
1
-
1
2
1
1
-
1
-
5
-
-
-
-
-
-
-
-
-
-
2
2
-
-
1
-
2
3
9
48
-
-
-
1
2
3
-
1
-
7
-
-
2
-
1
3
-
1
-
-
1
2
-
-
1
-
2
3
10
11
50
-
-
-
5
2
1
1
-
-
9
1
-
1
-
-
2
-
1
-
-
1
2
-
-
4
-
6
10
54
-
-
-
6
2
1
-
1
-
10
-
-
2
-
-
2
-
1
-
-
-
1
-
-
3
-
4
7
12
70
-
-
-
4
3
-
-
7
-
14
-
-
2
-
-
2
-
3
-
-
-
3
-
1
1
-
3
5
13
14
70
1
-
1
6
6
3
-
1
-
16
-
-
4
-
1
5
-
4
-
-
-
4
-
-
6
-
4
10
appendix
-
2
2
14
2
8
-
4
-
28
1
1
2
-
-
4
-
8
-
2
-
10
-
-
1
1
1
3
17
87
-
-
-
7
3
5
-
2
1
18
-
1
4
-
1
6
-
3
-
2
1
6
1
1
1
-
2
5
16
76
97
-
-
-
12
5
3
1
8
-
29
-
-
2
-
-
2
-
2
-
-
1
3
-
-
6
1
6
13
15
73
115
110
belgian cancer registry
1
1
1
1
3
12
5
13
12
14
11
4
38
-
1
1
1
1
36
1
-
3
2
11
10
1
1
1
1
13
-
11
-
2
1
1
-
3
6
4
19
18
14.3
10
Id: Myelodysplastic syndromes and other myeloproliferative diseases
-
16
11
3
IIc: Burkitt lymphomas
IId: Miscellaneous lymphoreticular neoplasms
33
38
12
IIIe: Other specified intracranial and intraspinal neoplasms
IIIf: Unspecified intracranial and intraspinal neoplasms
IVa: Neuroblastomas and ganglioneuroblastomas
53
1
-
VIIc: Unspecified malignant hepatic tumours
-
-
8.6
5
VIIa: Hepatoblastomas
VIIb: Hepatic carcinomas
2.9
8.6
1
-
20.0
22.9
25.8
2.9
63.0
65.8
-
8.6
5.7
5.7
11.5
28.6
60.1
-
6
VIc: Unspecified malignant renal tumours
VII: Hepatic tumours
2
VIb: Renal carcinomas
50
VI: Renal Tumours
VIa: Nephroblastomas and other nonepithelial renal tumours
25
1
55
V: Retinoblastomas
IVb: Other peripheral nervous cell tumours
56
34
IIIc: Intracranial and intraspinal embryonal tumours
IIId: Other gliomas
IV: Neuroblastomas and other peripheral nervous cell tumours
36
136
IIIa: Ependymomas and choroid plexus tumours
IIIb: Astrocytomas
III: CNS and miscellaneous intracranial and intraspinal neoplasms
289
8.6
60
IIe: Unspecified lymphomas
-
120
IIa: Hodgkin lymphomas
IIb: Non-Hodgkin lymphomas
2.9
11.5
-
-
-
210
II: Lymphomas and reticuloendothelial neoplasms
-
11
Ic: Chronic myeloproliferative diseases
Ie: Unspecified and other specified leukaemias
53
14.3
189
Ib: Acute myeloid leukaemias
Ia: Lymphoid leukaemias
I: Leukaemias, myeloproliferative and myelodysplastic diseases
0
28.6
Tot
263
Belgium: Girls 2004-2009
-
-
5.8
5.8
-
-
20.2
20.2
23.0
-
25.9
25.9
5.8
-
5.8
17.3
8.6
23.0
60.5
-
8.6
-
2.9
-
11.5
-
8.6
-
14.4
34.6
57.6
1
-
-
-
-
-
-
26.1
26.1
11.6
-
29.0
29.0
-
-
5.8
2.9
26.1
5.8
40.6
-
2.9
-
-
2.9
5.8
-
5.8
-
2.9
98.5
107.2
2
-
2.9
-
2.9
-
-
26.2
26.2
11.7
-
5.8
5.8
-
2.9
8.7
5.8
17.5
17.5
52.4
-
-
5.8
2.9
-
8.7
-
-
-
14.6
55.3
69.9
3
Belgium: Girls, age-specific incidence rates of cancer in children and adolescents, by tumour type in 2004-2009 (N/1,000,000 person years)
4
-
-
-
-
-
-
11.7
11.7
-
-
11.7
11.7
-
2.9
8.8
5.8
17.5
-
35.0
-
2.9
2.9
5.8
2.9
14.6
-
-
-
-
46.7
46.7
5
-
-
-
-
-
-
14.6
14.6
-
-
2.9
2.9
-
-
2.9
2.9
37.9
2.9
46.7
-
2.9
2.9
2.9
2.9
11.7
-
2.9
-
11.7
49.6
64.2
6
-
-
-
-
-
-
-
-
-
-
5.8
5.8
-
2.9
5.8
8.7
17.4
-
34.8
-
-
8.7
5.8
2.9
17.4
-
-
-
2.9
26.1
29.0
7
-
-
-
-
-
-
2.9
2.9
-
-
2.9
2.9
-
-
5.7
-
25.9
-
31.6
-
-
8.6
5.7
2.9
17.2
-
-
-
11.5
14.4
25.9
8
-
-
-
-
-
-
5.7
5.7
-
-
2.9
2.9
-
14.3
5.7
5.7
22.9
-
48.7
-
-
2.9
2.9
-
5.7
-
-
-
-
11.5
11.5
9
-
-
-
-
-
-
-
-
-
-
2.9
2.9
-
5.7
2.9
5.7
11.4
2.9
28.6
-
-
2.9
5.7
14.3
22.9
-
2.9
-
8.6
11.4
22.9
10
-
-
-
-
-
-
5.7
5.7
-
-
-
-
2.8
5.7
-
11.3
17.0
-
36.8
2.8
2.8
-
8.5
8.5
22.6
-
-
2.8
5.7
19.8
28.3
11
-
-
-
-
-
-
2.8
2.8
-
-
-
-
2.8
2.8
5.6
-
19.5
5.6
36.2
2.8
2.8
-
2.8
5.6
13.9
-
2.8
-
11.1
8.4
22.3
12
-
-
-
-
-
2.7
2.7
5.5
-
-
2.7
2.7
-
11.0
-
2.7
27.4
2.7
43.9
-
-
-
8.2
-
8.2
-
-
2.7
2.7
27.4
32.9
13
-
-
-
-
-
-
5.4
5.4
-
-
-
-
5.4
2.7
5.4
8.1
29.8
2.7
54.2
-
-
2.7
8.1
27.1
37.9
-
-
2.7
2.7
21.7
27.1
14
-
-
-
-
-
-
-
-
-
-
-
-
2.7
-
8.0
-
13.4
2.7
26.8
-
-
5.4
8.0
24.1
37.5
-
-
-
2.7
24.1
26.8
15
-
-
-
-
-
-
-
-
-
-
-
-
-
13.3
2.7
2.7
31.9
-
50.5
-
-
2.7
21.3
26.6
50.5
-
-
-
15.9
15.9
31.9
16
-
-
-
-
-
-
-
-
-
-
-
-
5.3
8.0
-
2.7
16.0
2.7
34.6
-
-
-
10.6
39.9
50.6
-
-
5.3
-
18.6
24.0
17
-
-
-
-
-
-
-
-
-
-
-
-
5.4
2.7
2.7
-
13.4
-
24.1
-
-
-
16.1
48.2
64.2
-
-
2.7
8.0
8.0
18.7
18
-
-
-
-
-
-
-
-
-
-
-
-
2.7
8.1
5.4
8.1
2.7
5.4
32.4
2.7
-
-
24.3
45.8
72.8
-
2.7
10.8
13.5
13.5
40.4
19
-
-
-
-
-
2.7
-
2.7
-
-
2.7
2.7
-
13.5
5.4
-
13.5
-
32.4
-
-
-
18.9
70.2
89.2
-
2.7
2.7
5.4
16.2
27.0
-
-
2
2
82
24
VIIIe: Unspecified malignant bone tumours
IX: Soft tissue and other extraosseous sarcomas
-
2
1,345
3
I-XII: All tumours
XIIb: Other unspecified malignant tumours
7
4
XIIa: Other specified malignant tumours
XII: Other and unspecified malignant neoplasms
266.2
2.9
-
2.9
2.9
-
38
85
XIe: Skin carcinomas
XIf: Other and unspecified carcinomas
-
-
-
-
2.9
-
54
3
XId: Malignant melanomas
XIc: Nasopharyngeal carcinomas
1
41
XIb: Thyroid carcinomas
XIa: Adrenocortical carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
222
4
Xe: Other and unspecified malignant gonadal tumours
-
24
Xc: Malignant gonadal germ cell tumours
Xd: Gonadal carcinomas
25.8
5
21
Xa: Intracranial and intraspinal germ cell tumours
Xb: Malignant extracranial and extragonadal germ cell tumours
-
25.8
-
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads
56
8.6
51
IXc: Kaposi sarcomas
IXd: Other specified soft tissue sarcomas
IXe: Unspecified soft tissue sarcomas
2.9
-
-
7
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms
IXa: Rhabdomyosarcomas
11.5
33
VIIIc: Ewing tumours and related sarcomas of bone
VIIId: Other specified malignant bone tumours
-
3
-
36
VIIIb: Chondrosarcomas
VIIIa: Osteosarcomas
-
76
VIII: Malignant bone tumours
0
Tot
Belgium: Girls 2004-2009
233.3
-
-
-
-
-
-
-
-
-
-
-
-
-
17.3
-
17.3
-
-
-
-
5.8
5.8
-
-
5.8
-
-
5.8
1
237.7
-
-
-
-
-
-
-
-
-
-
-
-
-
8.7
-
8.7
-
2.9
-
-
5.8
8.7
-
-
-
-
-
-
2
201.0
-
-
-
-
2.9
2.9
-
-
-
5.8
-
-
-
2.9
-
2.9
-
-
-
-
11.7
11.7
-
-
2.9
-
-
2.9
3
Belgium: Girls, age-specific incidence rates of cancer in children and adolescents, by tumour type in 2004-2009 (N/1,000,000 person years)
128.5
-
-
-
-
-
2.9
-
-
-
2.9
-
-
-
-
-
-
-
-
-
-
5.8
5.8
-
-
-
-
-
-
4
5
160.5
-
-
-
2.9
2.9
-
-
-
-
5.8
-
-
-
-
-
-
-
2.9
-
-
8.8
11.7
-
-
2.9
-
-
2.9
104.4
-
-
-
-
2.9
2.9
-
-
-
5.8
-
-
2.9
2.9
-
5.8
-
-
-
-
5.8
5.8
-
-
-
-
-
-
6
7
97.7
-
-
-
-
-
-
2.9
2.9
-
5.7
-
-
2.9
-
2.9
5.7
-
2.9
-
-
-
2.9
-
-
-
-
2.9
2.9
8
103.1
-
-
-
2.9
2.9
-
-
-
-
5.7
-
-
2.9
-
2.9
5.7
-
2.9
-
-
5.7
8.6
-
-
8.6
-
-
8.6
9
108.7
2.9
-
2.9
5.7
2.9
2.9
-
2.9
-
14.3
-
-
-
-
-
-
-
-
-
-
5.7
5.7
-
-
2.9
-
5.7
8.6
10
135.8
-
-
-
2.8
5.7
8.5
-
2.8
-
19.8
-
-
5.7
-
2.8
8.5
-
2.8
-
-
2.8
5.7
-
-
2.8
-
5.7
8.5
11
139.3
-
-
-
13.9
5.6
2.8
2.8
-
-
25.1
2.8
-
2.8
-
-
5.6
-
2.8
-
-
2.8
5.6
-
-
11.1
-
16.7
27.9
12
148.1
-
-
-
16.5
5.5
2.7
-
2.7
-
27.4
-
-
5.5
-
-
5.5
-
2.7
-
-
-
2.7
-
-
8.2
-
11.0
19.2
13
189.6
-
-
-
10.8
8.1
-
-
19.0
-
37.9
-
-
5.4
-
-
5.4
-
8.1
-
-
-
8.1
-
2.7
2.7
-
8.1
13.5
14
187.7
2.7
-
2.7
16.1
16.1
8.0
-
2.7
-
42.9
-
-
10.7
-
2.7
13.4
-
10.7
-
-
-
10.7
-
-
16.1
-
10.7
26.8
15
16
17
appendix
-
5.4
5.4
37.5
5.4
21.4
-
10.7
-
75.0
2.7
2.7
5.4
-
-
10.7
-
21.4
-
5.4
-
26.8
-
-
2.7
2.7
2.7
8.0
232.9
-
-
-
18.6
8.0
13.3
-
5.3
2.7
47.9
-
2.7
10.6
-
2.7
16.0
-
8.0
-
5.3
2.7
16.0
2.7
2.7
2.7
-
5.3
13.3
202.3
257.9
-
-
-
31.9
13.3
8.0
2.7
21.3
-
77.1
-
-
5.3
-
-
5.3
-
5.3
-
-
2.7
8.0
-
-
15.9
2.7
15.9
34.6
75
310.7
296.6
belgian cancer registry
2.7
2.7
2.7
2.7
8.1
32.4
13.5
35.0
32.4
37.7
29.7
10.8
102.7
-
2.7
2.7
2.7
2.7
97.1
2.7
-
8.1
5.4
29.7
27.0
2.7
2.7
2.7
2.7
-
35.1
5.4
-
-
-
29.7
2.7
2.7
10.8
19
8.1
18
16.2
16
2
Id: Myelodysplastic syndromes and other myeloproliferative diseases
Ie: Unspecified and other specified leukaemias
38
12
3
IIc: Burkitt lymphomas
IId: Miscellaneous lymphoreticular neoplasms
IIe: Unspecified lymphomas
11
IIIf: Unspecified intracranial and intraspinal neoplasms
5
-
VIIa: Hepatoblastomas
VIIb: Hepatic carcinomas
VIIc: Unspecified malignant hepatic tumours
5
1
VII: Hepatic tumours
0.4
2
VIb: Renal carcinomas
VIc: Unspecified malignant renal tumours
-
-
0.9
0.9
0.2
8.5
9.1
7.1
0.4
12.9
13.2
2.0
7.4
6.0
47
VIa: Nephroblastomas and other nonepithelial renal tumours
50
VI: Renal Tumours
2
39
IVb: Other peripheral nervous cell tumours
V: Retinoblastomas
71
IVa: Neuroblastomas and ganglioneuroblastomas
73
41
IIIe: Other specified intracranial and intraspinal neoplasms
IV: Neuroblastomas and other peripheral nervous cell tumours
33
IIId: Other gliomas
8.0
17.6
97
44
IIIb: Astrocytomas
4.5
45.5
0.5
2.2
6.9
7.4
10.1
27.2
0.4
2.9
0.9
25
IIIc: Intracranial and intraspinal embryonal tumours
IIIa: Ependymomas and choroid plexus tumours
251
41
IIb: Non-Hodgkin lymphomas
III: CNS and miscellaneous intracranial and intraspinal neoplasms
56
IIa: Hodgkin lymphomas
150
5
Ic: Chronic myeloproliferative diseases
II: Lymphomas and reticuloendothelial neoplasms
31
5.6
42.7
236
Ib: Acute myeloid leukaemias
Ia: Lymphoid leukaemias
52.5
290
I: Leukaemias, myeloproliferative and myelodysplastic diseases
CR
Tot
Belgium: 2004-2009
-
-
1.0
1.0
0.2
0.3
9.1
9.7
7.8
0.3
14.1
14.4
2.1
7.5
5.9
8.2
17.7
4.8
46.1
0.5
2.3
6.7
7.2
9.5
26.2
0.4
2.9
0.9
5.8
44.2
54.2
ESR
-
-
1.0
1.0
0.2
0.3
9.6
10.1
8.3
0.3
14.9
15.3
2.1
7.5
5.8
8.3
17.9
4.9
46.5
0.5
2.4
6.6
7.1
9.0
25.5
0.4
2.9
0.8
6.0
45.4
55.5
WSR
Boys (0-14 years)
-
-
0.001
0.001
0.000
0.001
0.013
0.014
0.011
0.001
0.020
0.020
0.003
0.011
0.009
0.012
0.026
0.007
0.068
0.001
0.003
0.010
0.011
0.015
0.040
0.001
0.004
0.001
0.008
0.065
0.079
CRi
-
1
5
6
1
1
50
52
25
1
54
55
7
21
27
29
107
33
224
2
11
15
26
34
88
-
8
3
37
162
210
Tot
Belgium: age-standardised incidence rates of cancer in children and adolescents, by tumour type and sex in 2004-2009 (N/1,000,000 person years)
-
0.2
0.9
1.1
0.2
0.2
9.5
9.8
4.7
0.2
10.2
10.4
1.3
4.0
5.1
5.5
20.3
6.2
42.4
0.4
2.1
2.8
4.9
6.4
16.7
-
1.5
0.6
7.0
30.7
39.8
CR
-
0.2
1.1
1.3
0.2
0.2
10.1
10.5
5.3
0.2
11.2
11.4
1.3
3.9
5.2
5.6
20.1
6.7
42.8
0.3
2.2
2.8
4.8
6.1
16.3
-
1.6
0.5
7.1
31.7
41.0
ESR
-
0.2
1.1
1.3
0.2
0.2
10.5
10.9
5.6
0.2
11.8
12.0
1.2
3.9
5.3
5.7
19.9
7.0
43.0
0.3
2.3
2.8
4.7
5.8
15.9
-
1.7
0.5
7.3
32.4
41.8
WSR
Girls (0-14 years)
-
0.000
0.001
0.002
0.000
0.000
0.014
0.015
0.007
0.000
0.016
0.016
0.002
0.006
0.008
0.008
0.030
0.009
0.064
0.001
0.003
0.004
0.007
0.009
0.025
-
0.002
0.001
0.011
0.046
0.060
CRi
-
1
5
6
1
3
51
55
39
2
72
74
16
69
36
49
129
33
332
3
15
47
84
143
292
3
21
14
51
273
362
Tot
-
0.1
0.7
0.8
0.1
0.4
6.8
7.4
5.2
0.3
9.6
9.9
2.1
9.2
4.8
6.6
17.3
4.4
44.5
0.4
2.0
6.3
11.2
19.2
39.1
0.4
2.8
1.9
6.8
36.6
48.5
CR
-
0.1
0.7
0.9
0.2
0.4
7.4
8.0
5.9
0.3
10.8
11.1
2.2
9.1
4.8
6.8
17.4
4.6
45.0
0.4
2.1
6.2
10.8
18.0
37.5
0.4
2.8
1.8
6.9
38.1
50.1
ESR
-
0.1
0.8
0.9
0.2
0.4
7.9
8.4
6.4
0.3
11.7
11.9
2.2
9.1
4.8
7.0
17.6
4.7
45.4
0.4
2.2
6.1
10.5
17.0
36.2
0.4
2.8
1.7
6.9
39.4
51.3
WSR
Boys (0-19 years)
-
0.000
0.001
0.002
0.000
0.001
0.014
0.015
0.011
0.001
0.020
0.020
0.004
0.018
0.010
0.013
0.035
0.009
0.089
0.001
0.004
0.013
0.022
0.037
0.077
0.001
0.006
0.004
0.014
0.074
0.098
CRi
-
1
5
6
1
2
50
53
25
1
55
56
12
38
33
34
136
36
289
3
11
16
60
120
210
-
10
11
53
189
263
Tot
-
0.1
0.7
0.8
0.1
0.3
7.0
7.4
3.5
0.1
7.7
7.8
1.7
5.3
4.6
4.8
19.0
5.0
40.4
0.4
1.5
2.2
8.4
16.8
29.4
-
1.4
1.5
7.4
26.4
36.8
CR
-
0.2
0.8
1.0
0.2
0.3
7.7
8.1
4.0
0.2
8.6
8.8
1.6
5.2
4.7
4.9
19.0
5.5
40.9
0.4
1.7
2.3
8.0
15.7
28.1
-
1.5
1.4
7.5
27.6
38.0
ESR
-
0.2
0.9
1.0
0.2
0.2
8.1
8.6
4.3
0.2
9.3
9.4
1.6
5.1
4.8
5.0
18.9
5.8
41.2
0.4
1.8
2.3
7.7
14.8
27.0
-
1.5
1.3
7.6
28.4
38.8
WSR
Girls (0-19 years)
CRi
-
0.000
0.001
0.002
0.000
0.001
0.014
0.015
0.007
0.000
0.016
0.016
0.003
0.011
0.009
0.010
0.038
0.010
0.081
0.001
0.003
0.005
0.016
0.033
0.057
-
0.003
0.003
0.015
0.054
0.074
-
Xe: Other and unspecified malignant gonadal tumours
0.2
6
24
2
1
1
XIf: Other and unspecified carcinomas
XII: Other and unspecified malignant neoplasms
XIIa: Other specified malignant tumours
XIIb: Other unspecified malignant tumours
190.7
0.2
2.4
0.7
194.0
0.2
0.2
0.4
4.1
1.0
2.3
0.7
1.0
0.2
9.2
-
-
1.0
1.0
1.7
3.7
0.5
3.5
0.2
1.4
6.5
12.1
0.2
0.4
4.7
-
3.9
9.1
ESR
CR: crude incidence rate (N/1,000,000 person years)
ESR and WSR: age standardised incidence using the European or World standard population (N/1,000,000 person years)
CRi: Cumulative Risk, 0-14 year or 0-19 year (%)
1,053
4.3
0.4
13
XId: Malignant melanomas
XIe: Skin carcinomas
I-XII: All tumours
1.1
4
XIc: Nasopharyngeal carcinomas
1.1
0.2
1
6
XIa: Adrenocortical carcinomas
9.8
-
-
0.9
XIb: Thyroid carcinomas
54
5
Xc: Malignant gonadal germ cell tumours
Xd: Gonadal carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
1.8
5
0.9
10
Xa: Intracranial and intraspinal germ cell tumours
Xb: Malignant extracranial and extragonadal germ cell tumours
0.5
3
3.6
3.6
0.2
1.4
6.2
12.0
0.2
20
IXe: Unspecified soft tissue sarcomas
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads
4.9
0.4
20
1
IXd: Other specified soft tissue sarcomas
8
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms
66
IX: Soft tissue and other extraosseous sarcomas
IXc: Kaposi sarcomas
1
VIIIe: Unspecified malignant bone tumours
34
2
VIIId: Other specified malignant bone tumours
IXa: Rhabdomyosarcomas
27
VIIIc: Ewing tumours and related sarcomas of bone
-
4.2
-
23
VIIIb: Chondrosarcomas
VIIIa: Osteosarcomas
9.6
53
VIII: Malignant bone tumours
CR
Tot
Belgium: 2004-2009
195.8
0.2
0.2
0.4
3.9
1.0
2.2
0.6
0.9
0.2
8.8
-
-
1.0
1.0
1.7
3.7
0.5
3.4
0.2
1.4
6.6
12.1
0.2
0.4
4.5
-
3.6
8.6
WSR
Boys (0-14 years)
0.286
0.000
0.000
0.001
0.006
0.002
0.003
0.001
0.002
0.000
0.014
-
-
0.001
0.001
0.003
0.005
0.001
0.005
0.000
0.002
0.009
0.018
0.000
0.001
0.007
-
0.006
0.014
CRi
860
3
-
3
27
20
12
2
12
-
73
1
-
14
20
4
39
-
17
-
1
21
39
-
1
23
-
22
46
Tot
Belgium: age-standardised incidence rates of cancer in children and adolescents, by tumour type and sex in 2004-2009 (N/1,000,000 person years)
162.9
0.6
-
0.6
5.1
3.8
2.3
0.4
2.3
-
13.8
0.2
-
2.7
3.8
0.8
7.4
-
3.2
-
0.2
4.0
7.4
-
0.2
4.4
-
4.2
8.7
CR
165.3
0.6
-
0.6
4.8
3.6
2.2
0.4
2.1
-
13.0
0.2
-
2.5
4.2
0.7
7.5
-
3.1
-
0.2
4.1
7.5
-
0.2
4.2
-
3.9
8.2
ESR
166.3
0.6
-
0.6
4.5
3.4
2.1
0.3
2.0
-
12.3
0.2
-
2.3
4.4
0.7
7.6
-
3.1
-
0.2
4.2
7.5
-
0.2
4.0
-
3.6
7.7
WSR
Girls (0-14 years)
0.244
0.001
-
0.001
0.007
0.006
0.003
0.001
0.003
-
0.020
0.000
-
0.004
0.006
0.001
0.011
-
0.005
-
0.000
0.006
0.011
-
0.000
0.006
-
0.006
0.013
CRi
1,628
2
1
3
62
19
36
5
21
1
144
1
-
86
6
22
115
9
42
1
10
44
106
1
3
42
4
50
100
Tot
218.0
0.3
0.1
0.4
8.3
2.5
4.8
0.7
2.8
0.1
19.3
0.1
-
11.5
0.8
2.9
15.4
1.2
5.6
0.1
1.3
5.9
14.2
0.1
0.4
5.6
0.5
6.7
13.4
CR
218.5
0.3
0.2
0.4
7.8
2.4
4.6
0.6
2.6
0.1
18.2
0.1
-
10.8
0.9
2.8
14.6
1.1
5.4
0.1
1.3
6.1
14.2
0.1
0.4
5.4
0.5
6.3
12.7
ESR
218.2
0.3
0.2
0.4
7.4
2.3
4.4
0.6
2.5
0.1
17.2
0.1
-
10.1
0.9
2.7
13.8
1.1
5.2
0.1
1.3
6.3
14.0
0.1
0.4
5.2
0.5
5.9
12.1
WSR
Boys (0-19 years)
0.433
0.001
0.000
0.001
0.016
0.005
0.009
0.001
0.005
0.000
0.038
0.000
-
0.022
0.002
0.006
0.030
0.002
0.011
0.000
0.003
0.012
0.028
0.000
0.001
0.011
0.001
0.013
0.026
CRi
1,345
3
4
7
85
38
54
3
41
1
222
2
4
24
21
5
56
-
51
-
7
24
82
2
2
33
3
36
76
Tot
188.1
0.4
0.5
0.9
11.1
5.0
7.1
0.4
5.4
0.1
29.1
0.3
0.5
3.2
3.3
0.7
7.9
-
6.8
-
0.9
3.5
11.2
0.3
0.3
4.5
0.4
4.7
10.1
ESR
appendix
188.2
0.4
0.6
1.0
11.9
5.3
7.6
0.4
5.7
0.1
31.1
0.3
0.6
3.4
2.9
0.7
7.8
-
7.1
-
1.0
3.4
11.5
0.3
0.3
4.6
0.4
5.0
10.6
CR
187.4
0.4
0.5
0.9
10.5
4.8
6.7
0.4
5.0
0.1
27.5
0.2
0.5
3.0
3.6
0.7
7.9
-
6.5
-
0.9
3.6
11.0
0.2
0.2
4.3
0.4
4.5
9.6
WSR
Girls (0-19 years)
77
CRi
belgian cancer registry
0.374
0.001
0.001
0.002
0.023
0.010
0.015
0.001
0.011
0.000
0.060
0.001
0.001
0.007
0.006
0.001
0.016
-
0.014
-
0.002
0.007
0.023
0.001
0.001
0.009
0.001
0.010
0.021
-
22
5
IId: Miscellaneous lymphoreticular neoplasms
IVa: Neuroblastomas and ganglioneuroblastomas
2
VIc: Unspecified malignant renal tumours
-
1
0
VIIb: Hepatic carcinomas
VIIc: Unspecified malignant hepatic tumours
-
100.0
100.0
-
-
96.7
95.8
100.0
-
95.2
95.2
93.8
93.4
91.1
79.2
88.9
89.3
88.5
94.2
10
VIIa: Hepatoblastomas
11
3
VII: Hepatic tumours
91
VIa: Nephroblastomas and other nonepithelial renal tumours
96
VI: Renal Tumours
VIb: Renal carcinomas
57
2
124
V: Retinoblastomas
IVb: Other peripheral nervous cell tumours
126
61
16
IIIe: Other specified intracranial and intraspinal neoplasms
IIIf: Unspecified intracranial and intraspinal neoplasms
IV: Neuroblastomas and other peripheral nervous cell tumours
72
56
IIIc: Intracranial and intraspinal embryonal tumours
IIId: Other gliomas
56
199
IIIa: Ependymomas and choroid plexus tumours
IIIb: Astrocytomas
III: CNS and miscellaneous intracranial and intraspinal neoplasms
460
52
IIc: Burkitt lymphomas
IIe: Unspecified lymphomas
90.9
64
96.9
100.0
90
IIa: Hodgkin lymphomas
IIb: Non-Hodgkin lymphomas
96.6
2
Ie: Unspecified and other specified leukaemias
95.2
-
79.4
94.6
92.3
-
-
-
-
-
-
95.6
94.7
98.2
-
79.2
79.5
-
93.4
80.2
66.2
83.4
82.1
81.8
-
85.9
94.2
92.1
98.9
94.3
-
90.5
-
61.5
90.2
86.1
3 yr OS
-
-
-
-
-
-
94.2
93.5
98.2
-
74.2
74.7
-
93.4
80.2
59.9
81.1
80.0
79.5
-
-
94.2
90.3
98.9
93.8
-
-
-
55.1
89.2
84.0
5 yr OS
Boys & Girls (0-14 years)
1 yr OS
233
21
Id: Myelodysplastic syndromes and other myeloproliferative diseases
II: Lymphomas and reticuloendothelial neoplasms
8
68
Ib: Acute myeloid leukaemias
Ic: Chronic myeloproliferative diseases
392
491
N at risk
Ia: Lymphoid leukaemias
I: Leukaemias, myeloproliferative and myelodysplastic diseases
Belgium: 2004-2009
Belgium: observed survival rates of cancer in children, by tumour type and sex in 2004-2009
-
-
-
-
-
-
[87.2:97.5]
[86.5:97.0]
[90.7:99.7]
-
[65.2:81.6]
[65.8:82.0]
-
[84.3:97.4]
[68.0:88.6]
[47.6:71.1]
[74.9:86.1]
[67.6:88.5]
[75.4:83.1]
-
-
[84.4:98.0]
[80.3:95.5]
[93.9:99.8]
[89.9:96.3]
-
-
-
[42.7:66.9]
[85.6:91.9]
[80.4:87.1]
95% CI (5 yr OS)
0
0
5
5
1
2
42
45
36
1
71
72
10
40
32
44
96
24
246
3
11
37
40
56
147
2
14
5
31
231
283
N at risk
-
-
-
-
-
-
97.6
95.5
100.0
-
94.4
94.4
-
97.5
90.6
81.8
89.6
91.7
89.8
-
90.9
94.6
97.5
100.0
97.3
-
92.9
-
77.4
94.8
92.2
1 yr OS
-
-
-
-
-
-
97.6
95.5
97.2
-
75.4
75.7
-
97.5
81.3
70.1
85.4
79.2
83.6
-
-
94.6
92.4
100.0
95.2
-
92.9
-
54.4
89.9
85.7
3 yr OS
-
-
-
-
-
-
94.6
92.7
97.2
-
65.8
66.4
-
97.5
81.3
60.6
82.6
79.2
80.6
-
-
94.6
89.5
100.0
94.3
-
-
-
-
88.7
83.1
5 yr OS
Boys (0-14 years)
-
-
-
-
-
-
[82.2:98.5]
[80.6:97.5]
[85.8:99.5]
-
[52.5:76.9]
[53.3:77.3]
-
[87.1:99.6]
[64.7:91.1]
[44.8:74.4]
[73.5:89.0]
[59.5:90.8]
[75.0:85.3]
-
-
[82.3:98.5]
[75.8:95.8]
[100.0:100.0]
[89.2:97.1]
-
-
-
-
[83.8:92.3]
[78.1:87.2]
95% CI (5 yr OS)
0
1
5
6
1
1
49
51
21
1
53
54
6
21
24
28
103
32
214
2
11
15
24
34
86
0
7
3
37
161
208
N at risk
-
-
-
-
-
-
95.9
96.1
100.0
-
96.2
96.3
-
85.7
91.7
75.0
88.3
87.5
86.9
-
90.9
93.3
95.8
100.0
95.3
-
-
-
81.1
94.4
92.3
1 yr OS
-
-
-
-
-
-
93.9
94.1
100.0
-
84.4
84.7
-
85.7
78.7
60.0
81.5
84.4
79.7
-
-
93.3
91.7
97.0
92.9
-
-
-
67.3
90.7
86.5
3 yr OS
-
-
-
-
-
-
93.9
94.1
-
-
84.4
84.7
-
85.7
-
-
79.8
80.4
78.2
-
-
-
91.7
97.0
92.9
-
-
-
63.6
89.8
85.2
5 yr OS
Girls (0-14 years)
-
-
-
-
-
-
[83.5:97.9]
[84.1:98.0]
-
-
[72.0:91.9]
[72.5:92.0]
-
[65.4:95.0]
-
-
[70.6:86.6]
[63.1:90.7]
[72.1:83.4]
-
-
-
[74.2:97.7]
[84.7:99.5]
[85.4:96.7]
-
-
-
[47.0:77.5]
[84.1:93.7]
[79.6:89.4]
95% CI (5 yr OS)
0
VIIIb: Chondrosarcomas
IXe: Unspecified soft tissue sarcomas
-
1
1
1,3,5 yr OS: one, three and five-year observed survival rates (%)
95% CI (5 yr OS): 95% confidence interval of the five-year observed survival rates (%)
Survival data are not presented when the number of patients at risk is less than 10 cases.
I-XII: All tumours
1,853
4
5
XII: Other and unspecified malignant neoplasms
XIIb: Other unspecified malignant tumours
47
XIf: Other and unspecified carcinomas
1
22
XIe: Skin carcinomas
XIIa: Other specified malignant tumours
6
24
XIc: Nasopharyngeal carcinomas
XId: Malignant melanomas
18
XIb: Thyroid carcinomas
XIa: Adrenocortical carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
118
0
Xe: Other and unspecified malignant gonadal tumours
-
19
Xc: Malignant gonadal germ cell tumours
Xd: Gonadal carcinomas
93.4
-
-
-
95.7
100.0
100.0
-
100.0
-
98.3
100.0
100.0
13
24
Xa: Intracranial and intraspinal germ cell tumours
100.0
100.0
57
Xb: Malignant extracranial and extragonadal germ cell tumours
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads
2
97.2
36
1
IXd: Other specified soft tissue sarcomas
IXc: Kaposi sarcomas
-
9
95.1
94.4
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms
103
IX: Soft tissue and other extraosseous sarcomas
-
55
0
VIIIe: Unspecified malignant bone tumours
-
93.9
-
95.5
94.8
86.9
-
-
-
93.6
100.0
95.8
-
100.0
-
95.7
-
-
94.7
100.0
100.0
98.2
-
82.4
-
-
85.2
83.1
-
-
77.0
-
79.4
78.9
3 yr OS
84.8
-
-
-
89.9
100.0
95.8
-
-
-
94.4
-
-
-
100.0
-
92.3
-
74.9
-
-
85.2
80.8
-
-
74.8
-
73.1
74.9
5 yr OS
Boys & Girls (0-14 years)
1 yr OS
IXa: Rhabdomyosarcomas
3
VIIId: Other specified malignant bone tumours
49
44
VIIIa: Osteosarcomas
VIIIc: Ewing tumours and related sarcomas of bone
96
N at risk
VIII: Malignant bone tumours
Belgium: 2004-2009
Belgium: observed survival rates of cancer in children, by tumour type and sex in 2004-2009
[83.0:86.4]
-
-
-
[75.9:96.1]
[100.0:100.0]
[79.8:99.3]
-
-
-
[88.0:97.4]
-
-
-
[100.0:100.0]
-
[79.3:97.4]
-
[53.8:88.4]
-
-
[73.4:92.3]
[71.1:87.8]
-
-
[60.9:85.0]
-
[57.6:84.5]
[64.9:82.7]
95% CI (5 yr OS)
1,023
1
1
2
21
5
13
4
6
1
50
0
0
5
5
10
20
2
20
1
8
34
65
0
2
27
0
23
52
N at risk
93.5
-
-
-
90.5
-
100.0
-
-
-
96.0
-
-
-
-
-
100.0
-
100.0
-
-
93.9
95.3
-
-
96.3
-
91.3
94.2
1 yr OS
86.9
-
-
-
90.5
-
92.3
-
-
-
91.9
-
-
-
-
-
100.0
-
83.6
-
-
87.9
84.1
-
-
84.7
-
73.4
80.2
3 yr OS
83.9
-
-
-
82.9
-
-
-
-
-
88.6
-
-
-
-
-
-
-
-
-
-
87.9
80.1
-
-
80.4
-
-
75.5
5 yr OS
Boys (0-14 years)
[81.4:86.1]
-
-
-
[59.1:94.2]
-
-
-
-
-
[75.4:95.1]
-
-
-
-
-
-
-
-
-
-
[72.7:95.2]
[66.4:89.1]
-
-
[61.4:91.4]
-
-
[61.7:85.4]
95% CI (5 yr OS)
830
3
0
3
26
17
11
2
12
0
68
1
0
14
19
3
37
0
16
0
1
21
38
0
1
22
0
21
44
N at risk
93.2
-
-
-
100.0
100.0
100.0
-
100.0
-
100.0
-
-
100.0
100.0
-
100.0
-
93.8
-
-
95.2
94.7
-
-
90.9
-
100.0
95.5
1 yr OS
appendix
87.0
-
-
-
96.2
100.0
100.0
-
-
-
98.5
-
-
92.9
100.0
-
97.3
-
-
-
-
81.0
81.6
-
-
67.9
-
85.7
77.2
3 yr OS
85.9
-
-
-
96.2
100.0
-
-
-
-
98.5
-
-
-
100.0
-
92.7
-
-
-
-
-
81.6
-
-
67.9
-
-
73.8
5 yr OS
Girls (0-14 years)
79
belgian cancer registry
[83.3:88.2]
-
-
-
[81.1:99.3]
[100.0:100.0]
-
-
-
-
[92.1:99.7]
-
-
-
[100.0:100.0]
-
[76.0:98.1]
-
-
-
-
-
[66.6:90.8]
-
-
[46.9:83.5]
-
-
[58.7:84.9]
95% CI (5 yr OS)
27
3
Id: Myelodysplastic syndromes and other myeloproliferative diseases
Ie: Unspecified and other specified leukaemias
93.3
88.0
-
60
25
6
IIc: Burkitt lymphomas
IId: Miscellaneous lymphoreticular neoplasms
64
102
26
IIId: Other gliomas
IIIe: Other specified intracranial and intraspinal neoplasms
IIIf: Unspecified intracranial and intraspinal neoplasms
IVa: Neuroblastomas and ganglioneuroblastomas
-
2
0
VIIb: Hepatic carcinomas
VIIc: Unspecified malignant hepatic tumours
-
100.0
100.0
-
-
96.8
96.0
100.0
-
94.4
94.5
96.2
95.1
90.6
81.7
89.3
90.8
10
VIIa: Hepatoblastomas
12
2
VIc: Unspecified malignant renal tumours
VII: Hepatic tumours
5
VIb: Renal carcinomas
95
102
VI: Renal Tumours
VIa: Nephroblastomas and other nonepithelial renal tumours
57
2
126
V: Retinoblastomas
IVb: Other peripheral nervous cell tumours
128
82
IIIc: Intracranial and intraspinal embryonal tumours
IV: Neuroblastomas and other peripheral nervous cell tumours
65
253
IIIa: Ependymomas and choroid plexus tumours
IIIb: Astrocytomas
III: CNS and miscellaneous intracranial and intraspinal neoplasms
89.9
95.0
592
99.6
254
140
IIa: Hodgkin lymphomas
IIb: Non-Hodgkin lymphomas
IIe: Unspecified lymphomas
96.7
-
96.3
485
II: Lymphomas and reticuloendothelial neoplasms
77.5
25
96.0
102
Ib: Acute myeloid leukaemias
Ic: Chronic myeloproliferative diseases
91.3
-
-
-
-
-
-
94.7
94.1
98.2
-
78.7
79.1
96.2
95.1
79.6
67.5
82.6
84.6
83.1
-
83.4
93.3
89.9
97.5
93.7
-
92.6
96.0
61.3
87.5
83.5
3 yr OS
-
-
-
-
-
-
93.4
92.9
98.2
-
73.9
74.4
-
95.1
79.6
61.4
80.8
82.8
81.3
-
83.4
93.3
88.1
97.5
93.2
-
-
85.3
56.9
86.3
81.2
5 yr OS
Boys & Girls (0-19 years)
1 yr OS
94.1
611
N at risk
454
Ia: Lymphoid leukaemias
I: Leukaemias, myeloproliferative and myelodysplastic diseases
Belgium: 2004-2009
Belgium: observed survival rates of cancer in children and adolescents, by tumour type and sex in 2004-2009
-
-
-
-
-
-
[86.4:97.0]
[86.0:96.5]
[90.7:99.7]
-
[64.9:81.2]
[65.5:81.6]
-
[89.0:97.9]
[68.1:87.7]
[49.6:72.0]
[75.4:85.3]
[71.7:90.1]
[77.8:84.3]
-
[64.1:93.4]
[84.1:97.4]
[81.6:92.6]
[94.7:98.9]
[90.5:95.1]
-
-
[64.3:94.9]
[46.8:66.5]
[82.7:89.2]
[77.7:84.2]
95% CI (5 yr OS)
0
1
5
6
1
3
46
50
36
1
72
73
15
67
35
49
124
30
320
3
14
45
83
140
285
3
18
14
49
267
351
N at risk
-
-
-
-
-
-
97.8
95.9
100.0
-
93.1
93.2
93.3
98.5
88.6
83.7
89.5
93.3
90.9
-
85.7
93.3
94.0
99.3
96.1
-
94.4
92.9
75.5
94.0
91.2
1 yr OS
-
-
-
-
-
-
95.6
93.9
97.2
-
74.3
74.7
-
98.5
77.1
68.5
83.0
83.3
83.9
-
-
93.3
87.8
98.4
93.6
-
94.4
92.9
56.5
87.1
83.0
3 yr OS
-
-
-
-
-
-
92.9
91.4
97.2
-
64.8
65.5
-
98.5
77.1
59.1
80.9
83.3
81.5
-
-
93.3
86.4
98.4
93.1
-
-
-
51.0
86.0
80.1
5 yr OS
Boys (0-19 years)
-
-
-
-
-
-
[81.0:97.6]
[79.8:96.6]
[85.8:99.5]
-
[51.7:76.1]
[52.5:76.5]
-
[92.0:99.7]
[61.0:87.9]
[43.9:72.8]
[72.9:87.0]
[66.4:92.7]
[76.7:85.6]
-
-
[82.1:97.7]
[77.2:92.2]
[94.4:99.6]
[89.5:95.6]
-
-
-
[36.9:64.9]
[81.1:89.7]
[75.3:84.1]
95% CI (5 yr OS)
0
1
5
6
1
2
49
52
21
1
54
55
11
35
29
33
129
35
272
3
11
15
57
114
200
0
9
11
53
187
260
N at risk
-
-
-
-
-
-
95.9
96.2
100.0
-
96.3
96.4
100.0
88.6
93.1
78.8
89.1
88.6
88.6
-
90.9
93.3
96.5
100.0
97.5
-
-
100.0
79.2
94.1
91.5
1 yr OS
-
-
-
-
-
-
93.9
94.2
100.0
-
84.7
85.0
-
88.6
82.5
66.0
82.1
85.7
82.2
-
-
93.3
93.0
96.4
93.9
-
-
-
65.6
88.2
84.1
3 yr OS
-
-
-
-
-
-
93.9
94.2
-
-
84.7
85.0
-
88.6
82.5
-
80.8
82.1
81.0
-
-
-
90.8
96.4
93.2
-
-
-
63.0
86.8
82.6
5 yr OS
Girls (0-19 years)
-
-
-
-
-
-
[83.5:97.9]
[84.4:98.0]
-
-
[72.5:92.0]
[73.0:92.2]
-
[74.0:95.5]
[64.9:92.3]
-
[72.8:86.8]
[66.0:91.6]
[75.8:85.3]
-
-
-
[80.0:96.0]
[91.1:98.6]
[88.7:96.0]
-
-
-
[49.2:75.0]
[81.0:91.0]
[77.3:86.8]
95% CI (5 yr OS)
Xe: Other and unspecified malignant gonadal tumours
-
2
1,3,5 yr OS: one, three and five-year observed survival rates (%)
95% CI (5 yr OS): 95% confidence interval of the five-year observed survival rates (%)
Survival data are not presented when the number of patients at risk is less than 10 cases.
2,856
5
I-XII: All tumours
XIIb: Other unspecified malignant tumours
XII: Other and unspecified malignant neoplasms
5
10
XIf: Other and unspecified carcinomas
XIIa: Other specified malignant tumours
47
139
XIe: Skin carcinomas
8
87
XIc: Nasopharyngeal carcinomas
XId: Malignant melanomas
59
94.1
-
-
-
96.4
100.0
100.0
-
100.0
-
98.2
3
342
XIb: Thyroid carcinomas
XIa: Adrenocortical carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
100.0
-
106
Xc: Malignant gonadal germ cell tumours
100.0
4
26
26
Xa: Intracranial and intraspinal germ cell tumours
100.0
-
95.6
-
94.1
93.8
94.5
99.4
Xb: Malignant extracranial and extragonadal germ cell tumours
Xd: Gonadal carcinomas
-
165
8
X: Germ cell tumours. trophoblastic tumours and neoplasms of gonads
91
1
IXd: Other specified soft tissue sarcomas
17
IXb: Fibrosarcomas. peripheral nerve sheath tumours. and other fibromatous neoplasms
IXc: Kaposi sarcomas
IXe: Unspecified soft tissue sarcomas
66
183
IX: Soft tissue and other extraosseous sarcomas
IXa: Rhabdomyosarcomas
5
2
VIIId: Other specified malignant bone tumours
VIIIe: Unspecified malignant bone tumours
94.5
-
7
73
VIIIb: Chondrosarcomas
VIIIc: Ewing tumours and related sarcomas of bone
93.9
82
VIIIa: Osteosarcomas
94.7
87.5
-
-
-
95.7
100.0
97.7
-
100.0
-
97.0
-
-
96.2
100.0
96.0
95.7
-
83.0
-
70.1
81.5
81.0
-
-
73.4
-
79.2
77.8
3 yr OS
85.4
-
-
-
92.3
100.0
97.7
-
100.0
-
95.6
-
-
94.9
100.0
88.6
93.9
-
80.7
-
-
81.5
78.2
-
-
70.1
-
71.2
71.6
5 yr OS
Boys & Girls (0-19 years)
1 yr OS
169
N at risk
VIII: Malignant bone tumours
Belgium: 2004-2009
Belgium: observed survival rates of cancer in children and adolescents. by tumour type and sex in 2004-2009
[84.0:86.7]
-
-
-
[85.8:96.0]
[100.0:100.0]
[92.0:99.4]
-
[100.0:100.0]
-
[92.5:97.5]
-
-
[88.5:97.8]
[100.0:100.0]
[65.2:97.0]
[88.7:96.8]
-
[70.5:88.0]
-
-
[70.4:89.1]
[71.2:83.9]
-
-
[58.5:79.6]
-
[60.0:80.3]
[64.0:78.1]
95% CI (5 yr OS)
1,568
2
1
3
57
15
35
5
19
1
132
1
0
82
6
22
111
8
42
1
10
42
103
0
3
42
4
49
98
N at risk
93.9
-
-
-
93.0
100.0
100.0
-
100.0
-
97.0
-
-
100.0
-
100.0
100.0
-
95.2
-
-
92.7
93.1
-
-
95.2
-
91.8
93.9
1 yr OS
86.6
-
-
-
93.0
100.0
97.1
-
100.0
-
95.4
-
-
97.6
-
95.2
97.3
-
77.5
-
-
82.9
79.1
-
-
70.4
-
75.4
73.8
3 yr OS
83.9
-
-
-
87.5
-
97.1
-
-
-
93.1
-
-
97.6
-
87.3
95.9
-
72.4
-
-
82.9
73.8
-
-
64.6
-
67.2
67.1
5 yr OS
Boys (0-19 years)
[81.9:85.7]
-
-
-
[74.8:94.3]
-
[85.5:99.5]
-
-
-
[86.8:96.5]
-
-
[91.5:99.3]
-
[62.5:96.6]
[89.8:98.4]
-
[55.0:84.9]
-
-
[68.7:91.5]
[63.4:82.1]
-
-
[48.9:77.7]
-
[52.3:79.2]
[56.7:76.1]
95% CI (5 yr OS)
1,288
3
4
7
82
32
52
3
40
1
210
2
4
24
20
4
54
0
49
0
7
24
80
2
2
31
3
33
71
N at risk
94.3
-
-
-
98.8
100.0
100.0
-
100.0
-
99.0
-
-
100.0
100.0
-
98.1
-
95.9
-
-
95.8
96.3
-
-
93.5
-
97.0
95.8
1 yr OS
appendix
88.5
-
-
-
97.6
100.0
98.1
-
100.0
-
98.1
-
-
91.7
100.0
-
92.6
-
87.4
-
-
79.2
83.4
-
-
77.3
-
84.8
83.1
3 yr OS
87.2
-
-
-
95.5
100.0
98.1
-
100.0
-
97.2
-
-
-
100.0
-
89.9
-
87.4
-
-
79.2
83.4
-
-
77.3
-
77.1
77.4
5 yr OS
Girls (0-19 years)
81
belgian cancer registry
[85.2:89.0]
-
-
-
[87.1:98.5]
[100.0:100.0]
[89.9:99.7]
-
[100.0:100.0]
-
[93.4:98.8]
-
-
-
[100.0:100.0]
-
[78.1:95.7]
-
[75.1:94.1]
-
-
[59.5:90.8]
[73.7:90.1]
-
-
[60.0:88.5]
-
[59.4:88.6]
[65.9:85.9]
95% CI (5 yr OS)
2
-
Id: Myelodysplastic syndromes and other myeloproliferative diseases
Ie: Unspecified and other specified leukaemias
9
2
-
8
3
4
IIc: Burkitt lymphomas
IId: Miscellaneous lymphoreticular neoplasms
8
-
-
VIIb: Hepatic carcinomas
VIIc: Unspecified malignant hepatic tumours
1
1
2
VIIa: Hepatoblastomas
2
-
VII: Hepatic tumours
1
1
VIb: Renal carcinomas
VIc: Unspecified malignant renal tumours
1
21
23
16
1
24
25
-
14
7
14
32
19
20
VIa: Nephroblastomas and other nonepithelial renal tumours
VI: Renal Tumours
8
V: Retinoblastomas
IVb: Other peripheral nervous cell tumours
21
12
IIIe: Other specified intracranial and intraspinal neoplasms
IIIf: Unspecified intracranial and intraspinal neoplasms
21
7
IVa: Neuroblastomas and ganglioneuroblastomas
10
IIIc: Intracranial and intraspinal embryonal tumours
IIId: Other gliomas
IV: Neuroblastomas and other peripheral nervous cell tumours
13
37
IIIa: Ependymomas and choroid plexus tumours
IIIb: Astrocytomas
III: CNS and miscellaneous intracranial and intraspinal neoplasms
75
9
13
79
24
15
IIa: Hodgkin lymphomas
IIb: Non-Hodgkin lymphomas
IIe: Unspecified lymphomas
44
-
3
43
II: Lymphomas and reticuloendothelial neoplasms
2
1
20
8
Ib: Acute myeloid leukaemias
Ic: Chronic myeloproliferative diseases
97
-
1
1
2
1
1
16
18
7
-
19
19
2
10
9
17
24
10
72
1
7
11
12
16
47
1
2
1
11
65
80
2006
-
-
-
-
-
-
14
14
9
1
22
23
1
10
7
6
34
10
68
-
1
3
12
9
25
-
6
-
12
59
77
2007
Boys & Girls (0-14 years)
2005
73
85
2004
73
Ia: Lymphoid leukaemias
I: Leukaemias, myeloproliferative and myelodysplastic diseases
Belgium: 2004-2009
Belgium: number of new diagnoses of cancer in children, by tumour type, incidence year and sex in 2004-2009
-
-
3
3
-
-
11
11
8
-
14
14
3
5
11
12
40
9
80
-
6
16
11
13
46
-
5
2
9
63
79
2008
-
-
3
3
-
-
16
16
16
1
25
26
12
11
19
14
37
8
101
-
4
6
10
13
33
1
6
2
8
65
82
2009
-
-
1
1
-
-
13
13
4
-
10
10
-
10
3
7
20
4
44
2
2
6
8
9
27
-
1
1
3
40
45
2004
-
-
-
-
-
1
12
13
9
-
11
11
-
10
4
10
11
4
39
-
1
8
6
17
32
-
3
1
10
47
61
2005
-
-
-
-
1
1
6
8
6
-
9
9
-
4
5
9
10
7
35
1
5
9
7
10
32
1
2
1
6
34
44
2006
-
-
-
-
-
-
5
5
5
1
14
15
-
6
3
4
19
4
36
-
1
2
6
4
13
-
3
-
5
34
42
2007
Boys (0-14 years)
-
-
2
2
-
-
2
2
3
-
10
10
3
5
7
5
16
4
40
-
2
10
9
6
27
-
3
1
4
39
47
2008
-
-
2
2
-
-
9
9
12
1
17
18
8
6
11
9
21
2
57
-
1
3
5
10
19
1
4
1
3
42
51
2009
-
-
1
1
-
1
6
7
4
-
11
11
-
2
4
3
17
9
35
2
1
2
5
6
16
-
1
1
5
33
40
2004
-
-
1
1
1
-
9
10
7
1
13
14
-
4
3
4
21
4
36
-
1
1
3
7
12
-
-
-
10
26
36
2005
-
1
1
2
-
-
10
10
1
-
10
10
2
6
4
8
14
3
37
-
2
2
5
6
15
-
-
-
5
31
36
2006
-
-
-
-
-
-
9
9
4
-
8
8
1
4
4
2
15
6
32
-
-
1
6
5
12
-
3
-
7
25
35
2007
Girls (0-14 years)
-
-
1
1
-
-
9
9
5
-
4
4
-
-
4
7
24
5
40
-
4
6
2
7
19
-
2
1
5
24
32
2008
-
-
1
1
-
-
7
7
4
-
8
8
4
5
8
5
16
6
44
-
3
3
5
3
14
-
2
1
5
23
31
2009
13
IX: Soft tissue and other extraosseous sarcomas
-
Xe: Other and unspecified malignant gonadal tumours
2
314
XIIb: Other unspecified malignant tumours
I-XII: All tumours
-
2
XIIa: Other specified malignant tumours
XII: Other and unspecified malignant neoplasms
4
3
8
XIe: Skin carcinomas
5
XIf: Other and unspecified carcinomas
3
2
XIc: Nasopharyngeal carcinomas
XId: Malignant melanomas
350
1
-
1
10
-
2
2
XIb: Thyroid carcinomas
-
1
19
-
-
3
XIa: Adrenocortical carcinomas
21
1
Xc: Malignant gonadal germ cell tumours
Xd: Gonadal carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
1
3
6
5
Xa: Intracranial and intraspinal germ cell tumours
Xb: Malignant extracranial and extragonadal germ cell tumours
2
6
-
1
6
15
10
-
-
9
5
IXd: Other specified soft tissue sarcomas
IXe: Unspecified soft tissue sarcomas
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads
-
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms
IXc: Kaposi sarcomas
8
-
IXa: Rhabdomyosarcomas
1
VIIId: Other specified malignant bone tumours
VIIIe: Unspecified malignant bone tumours
14
-
6
VIIIb: Chondrosarcomas
VIIIc: Ewing tumours and related sarcomas of bone
10
4
VIIIa: Osteosarcomas
24
318
1
-
1
10
7
7
2
5
-
31
-
-
2
5
1
8
1
3
-
2
10
16
-
-
9
-
8
17
2006
285
-
-
-
11
4
4
-
4
-
23
-
-
7
2
-
9
-
6
-
1
13
20
-
-
9
-
8
17
2007
Boys & Girls (0-14 years)
2005
11
2004
VIII: Malignant bone tumours
Belgium: 2004-2009
Belgium: number of new diagnoses of cancer in children, by tumour type, incidence year and sex in 2004-2009
312
-
1
1
6
5
3
2
2
-
18
-
-
2
7
5
14
-
7
-
4
10
21
1
1
8
-
7
17
2008
334
-
-
-
6
3
3
-
3
-
15
1
-
4
2
2
9
-
10
1
1
8
20
-
1
4
-
8
13
2009
181
1
-
1
7
-
3
1
-
1
12
-
-
-
-
5
5
-
3
-
-
6
9
-
1
5
-
4
10
2004
191
-
-
-
5
1
1
-
1
-
8
-
-
-
1
1
2
2
2
-
1
2
7
-
-
5
-
4
9
2005
164
-
-
-
4
2
3
2
1
-
12
-
-
2
1
-
3
1
-
-
2
6
9
-
-
4
-
2
6
2006
151
-
-
-
4
-
3
-
2
-
9
-
-
1
1
-
2
-
4
-
1
7
12
-
-
7
-
5
12
2007
Boys (0-14 years)
168
-
1
1
2
2
1
1
2
-
8
-
-
1
2
3
6
-
5
-
3
8
16
1
-
3
-
2
6
2008
198
-
-
-
2
1
2
-
-
-
5
-
-
1
-
1
2
-
6
1
1
5
13
-
1
3
-
6
10
2009
133
1
-
1
1
3
2
1
2
-
9
-
-
1
3
-
4
-
2
-
-
2
4
-
-
1
-
-
1
2004
159
1
-
1
5
3
2
-
1
-
11
-
-
3
5
-
8
-
4
-
-
4
8
-
-
9
-
6
15
2005
134
-
-
-
7
4
1
-
2
-
14
-
-
6
1
-
7
-
2
-
-
6
8
-
-
2
-
3
5
2007
appendix
154
1
-
1
6
5
4
-
4
-
19
-
-
-
4
1
5
-
3
-
-
4
7
-
-
5
-
6
11
2006
Girls (0-14 years)
83
136
144
belgian cancer registry
-
-
2
4
3
4
1
1
2
3
-
10
10
-
1
1
-
3
5
-
1
2
2
7
2
8
4
-
-
1
7
3
5
2
-
1
1
5
3
2
5
2009
11
2008
-
13
3
4
IIc: Burkitt lymphomas
IId: Miscellaneous lymphoreticular neoplasms
1
8
17
3
IIIe: Other specified intracranial and intraspinal neoplasms
-
-
VIIb: Hepatic carcinomas
VIIc: Unspecified malignant hepatic tumours
1
1
2
VIIa: Hepatoblastomas
2
-
VII: Hepatic tumours
1
1
VIb: Renal carcinomas
VIc: Unspecified malignant renal tumours
1
22
24
16
1
24
25
11
14
19
20
VIa: Nephroblastomas and other nonepithelial renal tumours
VI: Renal Tumours
8
21
IVa: Neuroblastomas and ganglioneuroblastomas
IVb: Other peripheral nervous cell tumours
V: Retinoblastomas
21
IV: Neuroblastomas and other peripheral nervous cell tumours
IIIf: Unspecified intracranial and intraspinal neoplasms
18
10
IIIc: Intracranial and intraspinal embryonal tumours
IIId: Other gliomas
12
46
15
45
IIIa: Ependymomas and choroid plexus tumours
102
10
IIIb: Astrocytomas
III: CNS and miscellaneous intracranial and intraspinal neoplasms
98
2
23
IIe: Unspecified lymphomas
53
43
IIa: Hodgkin lymphomas
IIb: Non-Hodgkin lymphomas
24
89
1
3
86
-
II: Lymphomas and reticuloendothelial neoplasms
3
Id: Myelodysplastic syndromes and other myeloproliferative diseases
Ie: Unspecified and other specified leukaemias
5
29
9
6
Ib: Acute myeloid leukaemias
81
119
-
1
1
2
1
1
17
19
7
-
19
19
2
12
10
17
34
11
86
1
8
12
28
44
93
1
3
2
15
77
98
2006
-
1
-
1
-
-
15
15
9
1
24
25
4
22
9
8
41
12
96
-
2
3
25
39
69
-
8
-
21
69
98
2007
Boys & Girls (0-19 years)
2005
86
104
2004
Ic: Chronic myeloproliferative diseases
Ia: Lymphoid leukaemias
I: Leukaemias, myeloproliferative and myelodysplastic diseases
Belgium: 2004-2009
Belgium: number of new diagnoses of cancer in children and adolescents, by tumour type, incidence year and sex in 2004-2009
-
-
3
3
-
1
12
13
8
-
14
14
4
15
12
18
51
10
110
-
6
18
24
38
86
-
6
7
16
72
101
2008
-
-
3
3
-
1
16
17
16
1
25
26
14
23
19
16
48
9
129
1
5
7
20
46
79
1
8
5
14
77
105
2009
-
-
1
1
-
-
13
13
4
-
10
10
2
13
3
7
24
6
55
2
2
10
13
21
48
-
1
4
4
49
58
2004
-
-
-
-
-
1
13
14
9
-
11
11
1
12
5
10
19
8
55
-
1
9
15
29
54
1
3
2
17
49
72
2005
-
-
-
-
1
1
7
9
6
-
9
9
-
5
6
9
15
8
43
1
6
10
15
26
58
1
2
2
9
40
54
2006
-
1
-
1
-
-
6
6
5
1
15
16
1
14
3
5
22
4
49
-
2
2
14
20
38
-
5
-
8
38
51
2007
Boys (0-19 years)
-
-
2
2
-
-
3
3
3
-
10
10
3
11
8
8
23
4
57
-
2
12
16
21
51
-
4
5
6
46
61
2008
-
-
2
2
-
1
9
10
12
1
17
18
9
14
11
10
26
3
73
-
2
4
11
26
43
1
6
1
7
51
66
2009
-
-
1
1
-
1
6
7
4
-
11
11
1
4
5
3
21
9
43
2
1
3
10
22
38
-
2
2
5
37
46
2004
-
-
1
1
1
-
9
10
7
1
13
14
-
6
6
4
27
4
47
-
1
1
9
24
35
-
-
3
12
32
47
2005
-
1
1
2
-
-
10
10
1
-
10
10
2
7
4
8
19
3
43
-
2
2
13
18
35
-
1
-
6
37
44
2006
-
-
-
-
-
-
9
9
4
-
9
9
3
8
6
3
19
8
47
-
-
1
11
19
31
-
3
-
13
31
47
2007
Girls (0-19 years)
-
-
1
1
-
1
9
10
5
-
4
4
1
4
4
10
28
6
53
-
4
6
8
17
35
-
2
2
10
26
40
2008
-
-
1
1
-
-
7
7
4
-
8
8
5
9
8
6
22
6
56
1
3
3
9
20
36
-
2
4
7
26
39
2009
4
1
3
477
XIIb: Other unspecified malignant tumours
I-XII: All tumours
-
3
XIIa: Other specified malignant tumours
XII: Other and unspecified malignant neoplasms
9
7
27
XIe: Skin carcinomas
XIf: Other and unspecified carcinomas
12
2
14
XIc: Nasopharyngeal carcinomas
XId: Malignant melanomas
524
1
2
3
24
-
7
6
XIb: Thyroid carcinomas
-
52
2
58
-
-
16
XIa: Adrenocortical carcinomas
XI: Other malignant epithelial neoplasms and malignant melanomas
-
Xe: Other and unspecified malignant gonadal tumours
14
Xc: Malignant gonadal germ cell tumours
-
3
Xd: Gonadal carcinomas
4
6
Xa: Intracranial and intraspinal germ cell tumours
Xb: Malignant extracranial and extragonadal germ cell tumours
6
26
23
X: Germ cell tumours, trophoblastic tumours and neoplasms of gonads
IXe: Unspecified soft tissue sarcomas
16
15
-
2
8
30
IXd: Other specified soft tissue sarcomas
25
IX: Soft tissue and other extraosseous sarcomas
-
-
-
IXc: Kaposi sarcomas
1
VIIId: Other specified malignant bone tumours
VIIIe: Unspecified malignant bone tumours
17
-
11
VIIIc: Ewing tumours and related sarcomas of bone
1
IXb: Fibrosarcomas, peripheral nerve sheath tumours, and other fibromatous neoplasms
3
VIIIb: Chondrosarcomas
19
9
14
VIIIa: Osteosarcomas
37
495
1
-
1
31
11
17
3
11
-
73
1
2
22
5
3
33
2
16
-
3
10
31
-
1
13
1
18
33
2006
471
-
-
-
22
10
19
-
13
-
64
-
2
26
3
2
33
2
11
-
3
18
34
-
-
14
1
12
27
2007
Boys & Girls (0-19 years)
2005
IXa: Rhabdomyosarcomas
29
2004
VIII: Malignant bone tumours
Belgium: 2004-2009
Belgium: number of new diagnoses of cancer in children and adolescents, by tumour type, incidence year and sex in 2004-2009
490
-
2
2
21
10
12
2
11
-
56
-
-
14
7
8
29
-
18
-
7
12
37
2
2
13
-
14
31
2008
516
-
1
1
22
10
16
1
14
-
63
2
-
18
3
4
27
-
17
1
2
11
31
1
1
7
1
9
19
2009
268
2
-
2
12
2
7
1
-
1
23
-
-
12
-
6
18
1
8
-
-
6
15
-
1
9
1
10
21
2004
279
-
-
-
11
3
3
-
3
-
20
-
-
10
1
4
15
4
3
-
1
3
11
-
-
7
-
11
18
2005
262
-
-
-
11
5
8
3
2
-
29
-
-
19
1
2
22
2
8
-
2
6
18
-
-
6
1
7
14
2006
251
-
-
-
7
3
11
-
6
-
27
-
-
18
1
1
20
2
4
-
3
11
20
-
-
10
1
7
18
2007
Boys (0-19 years)
269
-
1
1
9
4
4
1
5
-
23
-
-
12
2
6
20
-
9
-
3
10
22
1
1
6
-
8
16
2008
299
-
-
-
12
2
3
-
5
-
22
1
-
15
1
3
20
-
10
1
1
8
20
-
1
4
1
7
13
2009
209
1
-
1
15
5
7
1
6
1
35
-
-
2
3
-
5
-
7
-
-
3
10
-
-
2
2
4
8
2004
245
1
2
3
13
6
9
-
4
-
32
-
-
6
5
-
11
-
13
-
1
5
19
-
-
10
1
8
19
2005
220
-
-
-
15
7
8
-
7
-
37
-
2
8
2
1
13
-
7
-
-
7
14
-
-
4
-
5
9
2007
appendix
233
1
-
1
20
6
9
-
9
-
44
1
2
3
4
1
11
-
8
-
1
4
13
-
1
7
-
11
19
2006
Girls (0-19 years)
85
217
221
belgian cancer registry
1
1
1
1
8
10
6
12
1
13
1
8
9
6
41
33
-
1
2
-
3
5
-
1
2
2
7
9
-
1
4
7
3
2
9
11
15
-
1
1
1
3
2
6
7
6
15
-
2009
2008
Cancer in Belgium, 2010
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Belgium: Males 2010
2,531
871
43
36
3
24
21
5,616
10
541
63
30
22
785
145
36
479
56
1,411
178
2,967
139
854
680
18
57
125
43
134
135
15
60
61
59
157
31
148
90
50
Tot
Belgium: Males, number of invasive tumours by primary site and age group in 2010
-
-
1
-
-
-
-
-
-
-
1
2
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
1
2
6
-
-
1
-
-
-
-
-
-
-
-
-
1
-
-
-
3
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
10-
-
5
4
7
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
6
-
-
-
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
15-
2
13
-
3
-
-
-
1
-
-
1
-
-
2
-
-
-
-
3
-
4
-
-
-
-
-
-
1
-
-
-
-
-
-
-
1
1
-
-
20-
5
31
4
1
-
2
-
4
-
-
-
-
-
3
-
1
4
-
4
-
8
-
3
-
-
-
-
-
-
-
-
1
-
-
-
-
2
-
-
25-
7
32
5
2
-
-
-
7
-
-
-
-
-
3
-
-
2
1
3
-
8
-
4
2
-
1
-
3
-
-
-
3
-
-
1
-
1
-
-
30-
10
54
1
3
-
2
-
10
-
-
1
-
-
9
-
-
8
-
12
-
23
1
8
2
-
-
-
2
-
-
-
-
-
-
1
1
4
1
-
35-
18
62
2
-
-
2
1
47
-
8
2
-
-
7
3
1
3
1
20
-
33
3
12
2
-
-
-
3
2
4
-
1
2
1
2
-
8
1
2
40-
29
75
2
4
-
-
1
124
-
28
4
-
-
26
6
2
15
4
54
4
62
7
38
25
-
4
8
5
16
15
-
5
5
4
13
2
9
8
1
45-
68
67
1
2
-
1
4
320
2
47
6
2
-
40
5
1
32
5
92
8
147
7
46
81
-
14
20
8
18
17
-
5
9
8
38
3
19
10
2
50-
87
94
5
-
-
4
3
576
3
83
9
1
3
66
12
2
52
6
161
15
226
18
74
88
5
9
28
7
26
27
1
3
5
24
39
6
27
19
1
55-
166
96
4
2
1
2
3
809
1
88
11
7
2
107
16
1
71
6
211
21
300
25
93
99
4
11
29
2
28
26
3
9
15
7
27
6
28
16
4
60-
217
73
3
1
-
3
1
811
2
88
6
4
3
122
20
4
82
14
204
29
399
16
109
94
2
8
17
4
18
22
3
5
7
5
14
4
16
14
6
65-
356
93
3
2
1
2
3
1,011
-
69
5
6
-
122
23
8
83
8
207
29
486
19
128
100
3
1
12
4
14
13
3
5
6
7
7
2
14
9
6
70-
522
88
4
1
1
3
3
964
1
70
11
2
11
131
20
4
77
5
188
31
540
18
136
83
2
3
4
1
6
8
2
10
4
1
11
3
7
6
13
75-
536
55
1
1
-
3
1
643
-
45
3
3
2
96
17
9
35
2
164
27
461
18
122
61
2
4
6
1
4
2
2
5
3
-
3
2
8
4
12
80-
507
32
-
1
-
-
-
289
1
15
3
3
1
51
23
3
12
4
88
14
259
7
81
43
-
1
1
2
2
1
-
7
5
2
1
1
4
2
3
85+
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Penis
Prostate
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C46
C47,C49
C48
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Mesothelioma
32,671
33,267
35,798
339
257
462
2
25
31
55
329
481
424
103
1,021
154
7
29
204
14
453
8
61
50
1,755
101
145
981
14
318
8,663
85
83
23
162
31
Tot
204
Belgium: Males 2010
C45
72
75
75
2
1
1
-
5
-
1
4
15
-
-
2
-
-
6
-
2
11
-
7
-
-
-
-
4
-
3
-
-
-
-
5
-
-
00-
42
44
45
2
-
2
-
4
-
-
1
8
-
-
6
2
-
2
1
1
6
-
3
-
-
-
-
1
-
-
-
-
-
-
2
-
-
05-
46
49
49
3
-
-
-
-
-
-
1
9
-
-
10
2
-
1
-
-
6
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
84
88
88
1
3
-
-
2
-
1
6
6
-
-
8
12
-
-
1
1
7
-
-
-
-
-
-
-
-
12
-
-
-
1
2
-
1
15-
105
106
108
1
-
1
-
1
-
-
3
4
-
-
5
11
1
-
5
-
8
-
-
-
-
-
-
-
-
34
-
-
-
-
2
-
-
20-
197
203
208
2
4
2
-
1
-
-
8
4
1
-
10
14
1
1
5
-
10
-
-
-
-
-
-
3
-
61
-
-
-
1
4
2
1
25-
229
234
241
2
3
1
-
1
-
1
5
4
1
-
18
14
-
-
6
1
19
-
-
-
3
-
-
1
-
73
-
-
-
-
2
1
-
30-
327
332
342
1
4
3
-
1
-
1
13
5
5
2
21
17
1
-
15
-
17
-
1
-
4
-
1
24
-
37
1
2
-
-
6
5
2
35-
483
495
513
5
7
6
-
1
1
1
12
7
4
2
41
10
-
-
22
-
31
1
3
-
10
-
1
24
1
37
17
2
4
-
9
-
1
40-
997
1,018
1,047
7
14
22
-
2
1
1
13
19
11
6
66
11
-
2
26
3
28
1
1
-
27
4
5
51
-
18
76
2
5
1
9
7
3
45-
1,956
1,978
2,046
6
16
29
1
-
4
-
20
30
20
3
71
10
-
2
21
1
44
1
4
1
52
2
5
83
2
10
416
5
9
2
8
6
7
50-
3,212
3,243
3,330
17
14
40
-
2
1
2
30
57
37
11
89
12
-
3
27
-
46
-
5
-
109
5
10
105
1
15
830
5
11
4
16
1
10
55-
4,486
4,531
4,697
20
25
57
-
2
3
8
25
55
44
8
109
9
-
6
20
1
53
-
7
6
196
16
28
158
4
7
1,395
14
14
3
18
1
28
60-
4,695
4,769
4,986
39
35
53
-
-
4
7
19
57
63
17
117
6
1
-
18
2
44
1
7
5
221
13
13
152
1
4
1,562
12
5
2
21
1
34
65-
5,133
5,257
5,779
79
45
79
-
2
6
11
53
50
82
22
131
13
1
2
14
-
35
-
9
18
340
26
30
135
1
2
1,498
17
14
2
18
2
47
75-
appendix
5,197
5,293
5,649
61
35
54
-
1
4
11
42
79
81
10
139
7
1
2
15
1
59
1
5
7
319
18
28
116
1
2
1,597
10
13
6
21
1
32
70-
2,007
1,952
3,545
3,458
belgian cancer registry
33
2,514
29
4,081
22
69
58
43
1
-
5
2
5
-
29
5
49
29
5
26
17
43
72
106
45
1
2
2
-
2
10
19
-
3
3
1
6
7
4
8
6
208
266
6
18
11
46
78
-
3
3
5
457
11
3
1
5
814
4
12
7
10
28
-
85+
80-
89
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Belgium: Males 2010
2,531
871
43
36
3
24
21
5,616
10
541
63
30
22
785
145
36
479
56
1,411
178
2,967
139
854
680
18
57
125
43
134
135
15
60
61
59
157
31
148
90
50
Tot
-
-
0.3
-
-
-
-
-
-
-
0.3
0.6
-
-
-
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
0.3
-
0.3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.7
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
0.3
0.6
1.9
-
-
0.3
-
-
-
-
-
-
-
-
-
0.3
-
-
-
1.0
-
-
-
-
-
-
-
-
-
-
0.3
-
-
-
-
-
-
-
10-
-
1.5
1.2
2.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1.8
-
-
-
-
0.3
-
-
-
-
0.3
-
-
-
-
-
-
-
-
15-
0.6
3.9
-
0.9
-
-
-
0.3
-
-
0.3
-
-
0.6
-
-
-
-
0.9
-
1.2
-
-
-
-
-
-
0.3
-
-
-
-
-
-
-
0.3
0.3
-
-
20-
1.4
9.0
1.2
0.3
-
0.6
-
1.2
-
-
-
-
-
0.9
-
0.3
1.2
-
1.2
-
2.3
-
0.9
-
-
-
-
-
-
-
-
0.3
-
-
-
-
0.6
-
-
25-
2.0
9.1
1.4
0.6
-
-
-
2.0
-
-
-
-
-
0.9
-
-
0.6
0.3
0.9
-
2.3
-
1.1
0.6
-
0.3
-
0.9
-
-
-
0.9
-
-
0.3
-
0.3
-
-
30-
Belgium: Males, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)
2.6
14.3
0.3
0.8
-
0.5
-
2.6
-
-
0.3
-
-
2.4
-
-
2.1
-
3.2
-
6.1
0.3
2.1
0.5
-
-
-
0.5
-
-
-
-
-
-
0.3
0.3
1.1
0.3
-
35-
4.5
15.5
0.5
-
-
0.5
0.2
11.7
-
2.0
0.5
-
-
1.7
0.7
0.2
0.7
0.2
5.0
-
8.2
0.7
3.0
0.5
-
-
-
0.7
0.5
1.0
-
0.2
0.5
0.2
0.5
-
2.0
0.2
0.5
40-
7.0
18.1
0.5
1.0
-
-
0.2
30.0
-
6.8
1.0
-
-
6.3
1.4
0.5
3.6
1.0
13.0
1.0
15.0
1.7
9.2
6.0
-
1.0
1.9
1.2
3.9
3.6
-
1.2
1.2
1.0
3.1
0.5
2.2
1.9
0.2
45-
17.7
17.4
0.3
0.5
-
0.3
1.0
83.3
0.5
12.2
1.6
0.5
-
10.4
1.3
0.3
8.3
1.3
23.9
2.1
38.3
1.8
12.0
21.1
-
3.6
5.2
2.1
4.7
4.4
-
1.3
2.3
2.1
9.9
0.8
4.9
2.6
0.5
50-
25.3
27.4
1.5
-
-
1.2
0.9
167.7
0.9
24.2
2.6
0.3
0.9
19.2
3.5
0.6
15.1
1.7
46.9
4.4
65.8
5.2
21.5
25.6
1.5
2.6
8.2
2.0
7.6
7.9
0.3
0.9
1.5
7.0
11.4
1.7
7.9
5.5
0.3
55-
53.4
30.9
1.3
0.6
0.3
0.6
1.0
260.1
0.3
28.3
3.5
2.3
0.6
34.4
5.1
0.3
22.8
1.9
67.8
6.8
96.4
8.0
29.9
31.8
1.3
3.5
9.3
0.6
9.0
8.4
1.0
2.9
4.8
2.3
8.7
1.9
9.0
5.1
1.3
60-
97.3
32.7
1.3
0.4
-
1.3
0.4
363.6
0.9
39.5
2.7
1.8
1.3
54.7
9.0
1.8
36.8
6.3
91.5
13.0
178.9
7.2
48.9
42.1
0.9
3.6
7.6
1.8
8.1
9.9
1.3
2.2
3.1
2.2
6.3
1.8
7.2
6.3
2.7
65-
171.9
44.9
1.4
1.0
0.5
1.0
1.4
488.1
-
33.3
2.4
2.9
-
58.9
11.1
3.9
40.1
3.9
99.9
14.0
234.6
9.2
61.8
48.3
1.4
0.5
5.8
1.9
6.8
6.3
1.4
2.4
2.9
3.4
3.4
1.0
6.8
4.3
2.9
70-
302.2
50.9
2.3
0.6
0.6
1.7
1.7
558.0
0.6
40.5
6.4
1.2
6.4
75.8
11.6
2.3
44.6
2.9
108.8
17.9
312.6
10.4
78.7
48.0
1.2
1.7
2.3
0.6
3.5
4.6
1.2
5.8
2.3
0.6
6.4
1.7
4.1
3.5
7.5
75-
479.3
49.2
0.9
0.9
-
2.7
0.9
574.9
-
40.2
2.7
2.7
1.8
85.8
15.2
8.0
31.3
1.8
146.6
24.1
412.2
16.1
109.1
54.5
1.8
3.6
5.4
0.9
3.6
1.8
1.8
4.5
2.7
-
2.7
1.8
7.2
3.6
10.7
80-
730.1
46.1
-
1.4
-
-
-
416.1
1.4
21.6
4.3
4.3
1.4
73.4
33.1
4.3
17.3
5.8
126.7
20.2
372.9
10.1
116.6
61.9
-
1.4
1.4
2.9
2.9
1.4
-
10.1
7.2
2.9
1.4
1.4
5.8
2.9
4.3
85+
CR
47.6
16.4
0.8
0.7
0.1
0.5
0.4
105.7
0.2
10.2
1.2
0.6
0.4
14.8
2.7
0.7
9.0
1.1
26.6
3.4
55.9
2.6
16.1
12.8
0.3
1.1
2.4
0.8
2.5
2.5
0.3
1.1
1.1
1.1
3.0
0.6
2.8
1.7
0.9
33.9
14.1
0.8
0.7
0.0
0.4
0.3
82.5
0.2
8.3
1.0
0.5
0.3
11.6
2.1
0.5
7.3
0.9
21.1
2.6
42.4
2.1
12.4
10.4
0.3
0.9
2.0
0.7
2.2
2.2
0.2
0.9
1.0
1.0
2.6
0.5
2.4
1.5
0.7
ESR
20.6
10.7
0.7
0.7
0.0
0.3
0.2
55.4
0.1
5.8
0.7
0.4
0.2
7.8
1.4
0.3
5.1
0.6
14.5
1.7
28.0
1.4
8.3
7.1
0.2
0.7
1.5
0.6
1.6
1.6
0.2
0.7
0.7
0.7
1.9
0.4
1.8
1.0
0.4
WSR
1.9
1.1
0.1
0.1
0.0
0.0
0.0
6.8
0.0
0.7
0.1
0.0
0.0
0.9
0.2
0.0
0.7
0.1
1.8
0.2
3.2
0.2
0.9
0.9
0.0
0.1
0.2
0.1
0.2
0.2
0.0
0.1
0.1
0.1
0.2
0.0
0.2
0.1
0.0
CRi
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Penis
Prostate
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
C46
C47,C49
C48
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
Myeloproliferative Disorders
Myelodysplastic syndromes
MPD
MDS
32,671
33,267
35,798
339
257
462
22.4
23.3
23.3
0.6
0.3
0.3
-
1.6
-
0.3
1.2
4.7
-
-
0.6
-
-
1.9
-
0.6
3.4
-
2.2
-
-
-
-
1.2
-
0.9
-
-
-
-
1.6
-
-
00-
13.8
14.4
14.8
0.7
-
0.7
-
1.3
-
-
0.3
2.6
-
-
2.0
0.7
-
0.7
0.3
0.3
2.0
-
1.0
-
-
-
-
0.3
-
-
-
-
-
-
0.7
-
-
05-
14.8
15.8
15.8
1.0
-
-
-
-
-
-
0.3
2.9
-
-
3.2
0.6
-
0.3
-
-
1.9
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
25.3
26.5
26.5
0.3
0.9
-
-
0.6
-
0.3
1.8
1.8
-
-
2.4
3.6
-
-
0.3
0.3
2.1
-
-
-
-
-
-
-
-
3.6
-
-
-
0.3
0.6
-
0.3
15-
CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRi: Cumulative Risk (0-74 years)
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Unknown primary site
C80
2
25
Other and ill-defined sites
55
329
Lymphoid, haematopoietic and related tissue, NOS
Monocytic leukaemia
C93
C76
Myeloid leukaemia
C92
481
424
C96
Lymphoid leukaemia
C91
31
Multiple myeloma
C90
103
1,021
154
7
29
204
14
453
8
61
50
1,755
101
145
981
14
318
8,663
85
83
23
162
C94-C95 Leukaemia other
Malignant immunoproliferative diseases
C88
C82-C86 Non-Hodgkin-lymphoma
Mesothelioma
31
Tot
204
Belgium: Males 2010
C45
31.7
32.0
32.6
0.3
-
0.3
-
0.3
-
-
0.9
1.2
-
-
1.5
3.3
0.3
-
1.5
-
2.4
-
-
-
-
-
-
-
-
10.3
-
-
-
-
0.6
-
-
20-
57.1
58.8
60.2
0.6
1.2
0.6
-
0.3
-
-
2.3
1.2
0.3
-
2.9
4.1
0.3
0.3
1.4
-
2.9
-
-
-
-
-
-
0.9
-
17.7
-
-
-
0.3
1.2
0.6
0.3
25-
65.2
66.6
68.6
0.6
0.9
0.3
-
0.3
-
0.3
1.4
1.1
0.3
-
5.1
4.0
-
-
1.7
0.3
5.4
-
-
-
0.9
-
-
0.3
-
20.8
-
-
-
-
0.6
0.3
-
30-
86.5
87.8
90.5
0.3
1.1
0.8
-
0.3
-
0.3
3.4
1.3
1.3
0.5
5.6
4.5
0.3
-
4.0
-
4.5
-
0.3
-
1.1
-
0.3
6.3
-
9.8
0.3
0.5
-
-
1.6
1.3
0.5
35-
120.5
123.5
128.0
1.2
1.7
1.5
-
0.2
0.2
0.2
3.0
1.7
1.0
0.5
10.2
2.5
-
-
5.5
-
7.7
0.2
0.7
-
2.5
-
0.2
6.0
0.2
9.2
4.2
0.5
1.0
-
2.2
-
0.2
40-
240.9
246.0
253.0
1.7
3.4
5.3
-
0.5
0.2
0.2
3.1
4.6
2.7
1.4
15.9
2.7
-
0.5
6.3
0.7
6.8
0.2
0.2
-
6.5
1.0
1.2
12.3
-
4.3
18.4
0.5
1.2
0.2
2.2
1.7
0.7
45-
509.2
514.9
532.6
1.6
4.2
7.5
0.3
-
1.0
-
5.2
7.8
5.2
0.8
18.5
2.6
-
0.5
5.5
0.3
11.5
0.3
1.0
0.3
13.5
0.5
1.3
21.6
0.5
2.6
108.3
1.3
2.3
0.5
2.1
1.6
1.8
50-
935.1
944.2
969.5
4.9
4.1
11.6
-
0.6
0.3
0.6
8.7
16.6
10.8
3.2
25.9
3.5
-
0.9
7.9
-
13.4
-
1.5
-
31.7
1.5
2.9
30.6
0.3
4.4
241.6
1.5
3.2
1.2
4.7
0.3
2.9
55-
2,138.1
2,235.3
17.5
15.7
23.8
-
-
1.8
3.1
8.5
25.6
28.2
7.6
52.5
2.7
0.4
-
8.1
0.9
19.7
0.4
3.1
2.2
99.1
5.8
5.8
68.1
0.4
1.8
700.3
5.4
2.2
0.9
9.4
0.4
15.2
65-
1,442.1 2,104.9
1,456.6
1,510.0
6.4
8.0
18.3
-
0.6
1.0
2.6
8.0
17.7
14.1
2.6
35.0
2.9
-
1.9
6.4
0.3
17.0
-
2.3
1.9
63.0
5.1
9.0
50.8
1.3
2.3
448.5
4.5
4.5
1.0
5.8
0.3
9.0
60-
2,509.1
2,555.5
2,727.3
29.5
16.9
26.1
-
0.5
1.9
5.3
20.3
38.1
39.1
4.8
67.1
3.4
0.5
1.0
7.2
0.5
28.5
0.5
2.4
3.4
154.0
8.7
13.5
56.0
0.5
1.0
771.0
4.8
6.3
2.9
10.1
0.5
15.4
70-
75-
2,971.3
3,043.1
3,345.3
45.7
26.0
45.7
-
1.2
3.5
6.4
30.7
28.9
47.5
12.7
75.8
7.5
0.6
1.2
8.1
-
20.3
-
5.2
10.4
196.8
15.1
17.4
78.1
0.6
1.2
867.1
9.8
8.1
1.2
10.4
1.2
27.2
80-
3,620.0
47.5
31.7
61.9
-
-
2.9
7.2
41.8
41.8
37.4
7.2
103.7
2.9
1.4
-
-
-
14.4
-
4.3
8.6
299.5
8.6
8.6
66.2
-
-
658.1
7.2
4.3
-
17.3
5.8
14.4
85+
3,091.9
appendix
2,810.8
3,169.7 2,890.0
3,649.0
51.9
25.9
61.7
0.9
-
4.5
4.5
40.2
38.4
43.8
15.2
94.8
1.8
-
1.8
7.2
0.9
17.0
2.7
3.6
6.3
237.8
9.8
16.1
69.7
2.7
2.7
727.8
9.8
4.5
0.9
6.3
-
25.0
615.0
626.2
673.9
6.4
4.8
8.7
0.0
0.5
0.6
1.0
6.2
9.1
8.0
1.9
19.2
2.9
0.1
0.5
3.8
0.3
8.5
0.2
1.1
0.9
33.0
1.9
2.7
18.5
0.3
6.0
163.1
1.6
1.6
0.4
3.0
0.6
3.8
CR
91
0.2
0.4
0.5
10.8
0.4
0.2
0.1
0.9
0.8
86.4
5.8
0.1
10.7
1.4
1.3
1.2
128.4
6.1
0.2
15.1
2.1
0.0
0.3
0.4
33.6
34.0
0.3
0.5
belgian cancer registry
338.7
489.5
35.2
365.1
344.5
3.2
4.7
531.9
2.7
3.8
498.0
0.3
4.5
6.7
0.0
0.6
0.0
0.5
0.0
0.1
0.0
3.6
0.6
0.8
0.3
0.6
0.5
0.1
1.2
0.2
0.3
0.0
0.1
0.0
4.9
4.1
5.9
7.6
1.0
1.5
6.2
11.4
2.7
0.5
3.4
0.5
15.7
0.0
0.3
0.1
6.2
7.6
0.3
2.5
0.0
0.1
0.1
0.1
0.6
0.9
1.0
2.8
0.0
0.4
0.7
1.8
0.9
15.8
1.4
24.7
1.3
0.0
0.1
0.1
0.0
2.1
0.3
2.6
0.4
0.2
0.0
1.9
2.9
CRi
WSR
ESR
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Belgium: Females 2010
Belgium: Females, number of invasive tumours by primary site and age group in 2010
1,783
1,239
26
25
-
13
17
2,215
3
83
16
12
14
738
120
94
192
102
981
129
2,628
113
547
242
2
12
25
15
38
68
19
41
51
26
48
25
76
38
11
Tot
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
00-
-
1
-
1
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
2
3
2
5
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
3
14
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
8
-
-
-
-
-
-
1
-
-
1
1
-
-
-
-
1
-
-
15-
2
29
-
-
-
-
-
2
-
-
1
-
-
1
-
-
2
-
1
-
9
1
1
-
-
-
-
1
-
-
1
3
-
2
-
-
1
1
-
20-
4
69
2
1
-
-
-
2
-
-
-
-
-
-
-
-
1
-
-
-
11
-
1
-
-
-
-
-
-
-
1
1
-
-
-
-
-
1
-
25-
10
72
-
3
-
1
-
7
-
-
-
-
-
3
-
-
2
-
4
-
9
-
1
-
-
-
-
1
-
-
1
1
-
-
1
1
3
1
-
30-
10
98
1
3
-
1
1
17
-
-
-
-
-
5
-
-
3
2
11
2
18
2
5
2
-
1
-
-
-
-
-
2
-
1
-
-
-
-
-
35-
27
116
3
2
-
-
1
44
-
4
-
1
1
11
1
1
3
6
23
3
20
5
6
2
-
-
-
1
-
2
1
-
-
-
1
1
3
-
1
40-
37
127
2
1
-
-
2
115
-
4
-
-
2
18
4
-
3
7
40
5
64
4
18
7
-
-
-
2
2
4
1
2
3
2
2
1
4
1
1
45-
58
94
-
4
-
-
1
210
1
11
2
-
-
40
3
8
15
9
50
6
94
9
23
14
1
1
6
1
4
13
6
3
7
6
5
2
14
4
-
50-
75
111
2
-
-
2
2
326
-
16
-
2
2
54
6
2
14
12
95
6
167
7
37
26
-
2
7
-
11
14
1
4
7
2
12
1
8
6
-
55-
94
117
3
2
-
1
3
350
1
17
5
-
1
81
13
7
21
20
113
13
237
15
43
31
-
3
5
1
6
9
-
4
5
4
11
3
12
12
1
60-
117
82
5
1
-
2
2
295
-
17
2
1
2
82
14
10
27
7
105
14
272
10
57
31
-
1
2
2
7
8
2
6
1
-
4
2
8
4
-
65-
191
87
3
-
-
1
1
291
1
6
1
3
-
135
14
10
28
10
134
19
352
19
59
30
-
-
3
-
3
4
1
2
7
6
5
4
7
1
1
70-
283
86
1
-
-
-
2
274
-
4
1
1
3
127
26
22
34
16
147
19
422
15
82
34
-
2
2
-
4
7
2
1
6
1
3
6
5
2
1
75-
329
68
1
-
-
1
2
177
-
2
1
1
1
106
18
17
21
5
140
22
493
13
91
37
-
2
-
4
1
4
-
7
10
1
3
1
6
5
3
80-
541
64
1
-
-
2
-
105
-
2
3
2
2
75
21
17
18
8
116
20
444
13
123
28
1
-
-
-
-
3
1
4
5
1
1
3
4
-
3
85+
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Vulva
Vagina
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C46
C47,C49
C48
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Mesothelioma
Belgium: Females 2010
C45
28,291
28,750
30,533
212
247
408
3
28
30
40
292
343
327
111
926
149
6
29
651
18
322
10
56
11
477
39
79
551
3
46
865
9
1,415
593
43
216
9,908
33
152
7
51
Tot
76
78
78
2
-
-
-
9
2
-
5
14
-
1
3
-
-
5
-
3
9
-
8
-
1
-
-
5
-
-
1
-
-
-
2
-
-
2
3
-
-
00-
38
39
39
1
-
-
-
2
-
-
1
8
-
-
3
1
1
1
1
3
9
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
1
-
-
05-
41
42
44
-
1
-
-
1
-
1
3
6
-
-
1
3
-
-
3
1
3
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
1
-
-
10-
79
80
83
-
1
1
-
1
-
-
1
5
-
-
2
16
-
1
10
1
5
-
-
-
-
-
-
1
-
-
2
-
-
1
-
-
-
-
3
-
-
15-
134
137
139
-
3
1
-
-
-
-
6
-
-
-
8
22
-
1
16
1
4
-
-
-
-
-
-
1
1
-
6
-
-
3
-
-
7
-
1
-
-
20-
242
246
250
2
2
1
-
-
-
1
4
1
-
1
9
22
-
1
27
1
11
-
3
-
-
-
-
3
1
-
4
-
1
17
-
2
37
-
4
1
-
25-
410
413
423
3
-
1
-
2
-
1
6
2
3
-
20
9
-
1
48
-
13
1
-
-
-
-
-
5
-
1
6
1
-
36
-
3
133
1
6
-
-
30-
728
732
742
-
4
4
-
-
1
-
8
3
2
5
22
14
-
-
62
1
7
-
3
-
2
-
1
9
-
-
13
-
7
59
-
2
322
-
6
-
-
35-
1,198
1,206
1,233
1
7
2
-
4
1
2
17
8
3
2
25
9
-
3
53
2
9
1
1
-
5
-
1
16
-
1
25
-
18
77
-
8
634
1
7
-
-
40-
1,896
1,913
1,950
4
13
17
-
2
3
4
20
12
11
7
49
6
1
1
69
-
15
-
2
-
9
-
1
16
-
1
37
-
46
84
3
15
1,005
2
9
-
1
45-
2,429
2,450
2,508
5
16
22
-
1
1
-
16
23
16
5
50
7
1
3
78
2
24
-
5
-
13
2
1
35
1
2
77
-
78
61
4
22
1,192
3
14
-
3
50-
2,829
2,853
2,928
10
14
26
-
-
3
2
19
23
27
10
57
9
-
3
85
-
27
-
3
-
28
2
5
42
-
3
93
1
135
54
5
15
1,173
1
8
-
6
55-
3,372
3,410
3,504
15
23
35
-
2
1
2
22
40
36
6
84
7
1
3
52
-
30
1
4
1
40
2
4
66
-
9
123
1
208
46
4
13
1,334
3
15
2
5
60-
3,190
3,257
3,448
27
40
59
-
2
3
6
38
43
47
16
116
2
-
2
35
1
38
1
7
2
73
4
13
89
-
10
117
-
212
31
1
15
927
3
15
1
13
70-
appendix
2,972
3,006
3,123
16
18
33
-
2
-
7
27
32
38
13
107
10
1
2
45
-
32
2
3
1
47
6
8
64
-
4
95
-
225
33
4
19
1,005
6
9
-
7
65-
95
2
16
2
699
37
5
32
148
1
93
8
61
13
8
83
1
15
2
882
33
6
30
236
108
5
102
18
10
81
-
28
36
5
128
16
57
36
32
4
6
2
62
36
47
3,299
2,970
2,887
5
148
18
59
51
36
5
6
1
68
46
42
3,745
3,462
3,374
belgian cancer registry
2,396
2,456
2,997
37
23
76
-
-
3
5
31
11
94
2
-
-
2
15
1
-
29
2
25
46
23
15
-
3
5
1
4
4
8
5
14
35
-
2
64
5
101
29
9
32
558
7
19
2
3
10
3
85+
80-
75-
1
93
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Belgium: Females 2010
1,783
1,239
26
25
-
13
17
2,215
3
83
16
12
14
738
120
94
192
102
981
129
2,628
113
547
242
2
12
25
15
38
68
19
41
51
26
48
25
76
38
11
Tot
-
0.3
-
-
-
0.3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.3
-
-
-
-
-
-
-
-
-
-
-
00-
-
0.3
-
0.3
-
-
-
-
-
-
-
0.3
-
-
-
-
-
-
0.3
-
0.7
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
0.7
1.0
0.7
1.7
-
0.3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
0.9
4.4
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.3
-
2.5
-
-
-
-
-
-
0.3
-
-
0.3
0.3
-
-
-
-
0.3
-
-
15-
0.6
8.8
-
-
-
-
-
0.6
-
-
0.3
-
-
0.3
-
-
0.6
-
0.3
-
2.7
0.3
0.3
-
-
-
-
0.3
-
-
0.3
0.9
-
0.6
-
-
0.3
0.3
-
20-
1.2
19.9
0.6
0.3
-
-
-
0.6
-
-
-
-
-
-
-
-
0.3
-
-
-
3.2
-
0.3
-
-
-
-
-
-
-
0.3
0.3
-
-
-
-
-
0.3
-
25-
2.9
20.8
-
0.9
-
0.3
-
2.0
-
-
-
-
-
0.9
-
-
0.6
-
1.2
-
2.6
-
0.3
-
-
-
-
0.3
-
-
0.3
0.3
-
-
0.3
0.3
0.9
0.3
-
30-
Belgium: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)
2.7
26.5
0.3
0.8
-
0.3
0.3
4.6
-
-
-
-
-
1.4
-
-
0.8
0.5
3.0
0.5
4.9
0.5
1.4
0.5
-
0.3
-
-
-
-
-
0.5
-
0.3
-
-
-
-
-
35-
6.9
29.8
0.8
0.5
-
-
0.3
11.3
-
1.0
-
0.3
0.3
2.8
0.3
0.3
0.8
1.5
5.9
0.8
5.1
1.3
1.5
0.5
-
-
-
0.3
-
0.5
0.3
-
-
-
0.3
0.3
0.8
-
0.3
40-
9.1
31.3
0.5
0.2
-
-
0.5
28.3
-
1.0
-
-
0.5
4.4
1.0
-
0.7
1.7
9.8
1.2
15.8
1.0
4.4
1.7
-
-
-
0.5
0.5
1.0
0.2
0.5
0.7
0.5
0.5
0.2
1.0
0.2
0.2
45-
15.1
24.5
-
1.0
-
-
0.3
54.8
0.3
2.9
0.5
-
-
10.4
0.8
2.1
3.9
2.3
13.0
1.6
24.5
2.3
6.0
3.7
0.3
0.3
1.6
0.3
1.0
3.4
1.6
0.8
1.8
1.6
1.3
0.5
3.7
1.0
-
50-
21.7
32.1
0.6
-
-
0.6
0.6
94.2
-
4.6
-
0.6
0.6
15.6
1.7
0.6
4.0
3.5
27.5
1.7
48.3
2.0
10.7
7.5
-
0.6
2.0
-
3.2
4.0
0.3
1.2
2.0
0.6
3.5
0.3
2.3
1.7
-
55-
29.3
36.5
0.9
0.6
-
0.3
0.9
109.1
0.3
5.3
1.6
-
0.3
25.2
4.1
2.2
6.5
6.2
35.2
4.1
73.9
4.7
13.4
9.7
-
0.9
1.6
0.3
1.9
2.8
-
1.2
1.6
1.2
3.4
0.9
3.7
3.7
0.3
60-
48.1
33.7
2.1
0.4
-
0.8
0.8
121.4
-
7.0
0.8
0.4
0.8
33.7
5.8
4.1
11.1
2.9
43.2
5.8
111.9
4.1
23.4
12.8
-
0.4
0.8
0.8
2.9
3.3
0.8
2.5
0.4
-
1.6
0.8
3.3
1.6
-
65-
77.6
35.3
1.2
-
-
0.4
0.4
118.2
0.4
2.4
0.4
1.2
-
54.8
5.7
4.1
11.4
4.1
54.4
7.7
143.0
7.7
24.0
12.2
-
-
1.2
-
1.2
1.6
0.4
0.8
2.8
2.4
2.0
1.6
2.8
0.4
0.4
70-
120.5
36.6
0.4
-
-
-
0.9
116.7
-
1.7
0.4
0.4
1.3
54.1
11.1
9.4
14.5
6.8
62.6
8.1
179.7
6.4
34.9
14.5
-
0.9
0.9
-
1.7
3.0
0.9
0.4
2.6
0.4
1.3
2.6
2.1
0.9
0.4
75-
177.0
36.6
0.5
-
-
0.5
1.1
95.2
-
1.1
0.5
0.5
0.5
57.0
9.7
9.1
11.3
2.7
75.3
11.8
265.2
7.0
49.0
19.9
-
1.1
-
2.2
0.5
2.2
-
3.8
5.4
0.5
1.6
0.5
3.2
2.7
1.6
80-
326.0
38.6
0.6
-
-
1.2
-
63.3
-
1.2
1.8
1.2
1.2
45.2
12.7
10.2
10.8
4.8
69.9
12.1
267.5
7.8
74.1
16.9
0.6
-
-
-
-
1.8
0.6
2.4
3.0
0.6
0.6
1.8
2.4
-
1.8
85+
32.3
22.4
0.5
0.5
-
0.2
0.3
40.1
0.1
1.5
0.3
0.2
0.3
13.4
2.2
1.7
3.5
1.8
17.7
2.3
47.5
2.0
9.9
4.4
0.0
0.2
0.5
0.3
0.7
1.2
0.3
0.7
0.9
0.5
0.9
0.5
1.4
0.7
0.2
CR
17.3
19.4
0.4
0.5
-
0.2
0.2
30.6
0.0
1.3
0.2
0.2
0.2
8.7
1.3
1.0
2.4
1.4
11.8
1.5
28.8
1.4
5.9
2.9
0.0
0.2
0.4
0.2
0.6
1.0
0.3
0.6
0.6
0.4
0.7
0.3
1.1
0.6
0.1
ESR
11.1
15.8
0.4
0.5
-
0.2
0.2
21.7
0.0
0.9
0.2
0.1
0.1
5.9
0.9
0.6
1.7
1.0
8.2
1.0
19.4
1.0
3.9
2.0
0.0
0.1
0.3
0.2
0.4
0.7
0.3
0.5
0.4
0.3
0.5
0.2
0.8
0.4
0.1
WSR
1.1
1.5
0.0
0.0
-
0.0
0.0
2.7
0.0
0.1
0.0
0.0
0.0
0.7
0.1
0.1
0.2
0.1
1.0
0.1
2.2
0.1
0.4
0.2
0.0
0.0
0.0
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.1
0.0
0.1
0.0
0.0
CRi
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Vulva
Vagina
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
C46
C47,C49
C48
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
Myeloproliferative Disorders
Myelodysplastic syndromes
MPD
MDS
28,291
28,750
30,533
212
247
408
24.8
25.4
25.4
0.7
-
-
-
2.9
0.7
-
1.6
4.6
-
0.3
1.0
-
-
1.6
-
1.0
2.9
-
2.6
-
0.3
-
-
1.6
-
-
0.3
-
-
-
0.7
-
-
0.7
1.0
-
-
00-
13.0
13.4
13.4
0.3
-
-
-
0.7
-
-
0.3
2.7
-
-
1.0
0.3
0.3
0.3
0.3
1.0
3.1
-
-
-
-
-
-
0.3
-
-
-
-
-
-
-
-
-
-
0.3
-
-
05-
13.8
14.1
14.8
-
0.3
-
-
0.3
-
0.3
1.0
2.0
-
-
0.3
1.0
-
-
1.0
0.3
1.0
-
-
-
-
-
-
-
-
-
0.3
-
-
-
-
-
-
-
0.3
-
-
10-
24.8
25.1
26.1
-
0.3
0.3
-
0.3
-
-
0.3
1.6
-
-
0.6
5.0
-
0.3
3.1
0.3
1.6
-
-
-
-
-
-
0.3
-
-
0.6
-
-
0.3
-
-
-
-
0.9
-
-
15-
CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRi: Cumulative Risk (0-74 years)
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Unknown primary site
C80
3
Other and ill-defined sites
C76
40
28
Monocytic leukaemia
C93
343
292
30
Myeloid leukaemia
C92
Lymphoid, haematopoietic and related tissue, NOS
Lymphoid leukaemia
C91
111
327
C96
Multiple myeloma
C90
926
149
6
29
651
18
322
10
56
11
477
39
79
551
3
46
865
9
1,415
593
43
216
9,908
33
152
7
51
Tot
C94-C95 Leukaemia other
Malignant immunoproliferative diseases
C88
C82-C86 Non-Hodgkin-lymphoma
Mesothelioma
Belgium: Females 2010
C45
40.7
41.6
42.2
-
0.9
0.3
-
-
-
-
1.8
-
-
-
2.4
6.7
-
0.3
4.9
0.3
1.2
-
-
-
-
-
-
0.3
0.3
-
1.8
-
-
0.9
-
-
2.1
-
0.3
-
-
20-
69.9
71.0
72.2
0.6
0.6
0.3
-
-
-
0.3
1.2
0.3
-
0.3
2.6
6.4
-
0.3
7.8
0.3
3.2
-
0.9
-
-
-
-
0.9
0.3
-
1.2
-
0.3
4.9
-
0.6
10.7
-
1.2
0.3
-
25-
118.2
119.1
122.0
0.9
-
0.3
-
0.6
-
0.3
1.7
0.6
0.9
-
5.8
2.6
-
0.3
13.8
-
3.7
0.3
-
-
-
-
-
1.4
-
0.3
1.7
0.3
-
10.4
-
0.9
38.3
0.3
1.7
-
-
30-
196.9
198.0
200.7
-
1.1
1.1
-
-
0.3
-
2.2
0.8
0.5
1.4
6.0
3.8
-
-
16.8
0.3
1.9
-
0.8
-
0.5
-
0.3
2.4
-
-
3.5
-
1.9
16.0
-
0.5
87.1
-
1.6
-
-
35-
308.0
310.1
317.0
0.3
1.8
0.5
-
1.0
0.3
0.5
4.4
2.1
0.8
0.5
6.4
2.3
-
0.8
13.6
0.5
2.3
0.3
0.3
-
1.3
-
0.3
4.1
-
0.3
6.4
-
4.6
19.8
-
2.1
163.0
0.3
1.8
-
-
40-
466.7
470.9
480.0
1.0
3.2
4.2
-
0.5
0.7
1.0
4.9
3.0
2.7
1.7
12.1
1.5
0.2
0.2
17.0
-
3.7
-
0.5
-
2.2
-
0.2
3.9
-
0.2
9.1
-
11.3
20.7
0.7
3.7
247.4
0.5
2.2
-
0.2
45-
633.6
639.1
654.2
1.3
4.2
5.7
-
0.3
0.3
-
4.2
6.0
4.2
1.3
13.0
1.8
0.3
0.8
20.3
0.5
6.3
-
1.3
-
3.4
0.5
0.3
9.1
0.3
0.5
20.1
-
20.3
15.9
1.0
5.7
310.9
0.8
3.7
-
0.8
50-
1,092.2
4.7
7.2
10.9
-
0.6
0.3
0.6
6.9
12.5
11.2
1.9
26.2
2.2
0.3
0.9
16.2
-
9.4
0.3
1.2
0.3
12.5
0.6
1.2
20.6
-
2.8
38.3
0.3
64.8
14.3
1.2
4.1
415.8
0.9
4.7
0.6
1.6
60-
817.7
1,051.1
824.6 1,062.9
846.3
2.9
4.0
7.5
-
-
0.9
0.6
5.5
6.6
7.8
2.9
16.5
2.6
-
0.9
24.6
-
7.8
-
0.9
-
8.1
0.6
1.4
12.1
-
0.9
26.9
0.3
39.0
15.6
1.4
4.3
339.0
0.3
2.3
-
1.7
55-
1,222.6
1,236.6
1,284.7
6.6
7.4
13.6
-
0.8
-
2.9
11.1
13.2
15.6
5.3
44.0
4.1
0.4
0.8
18.5
-
13.2
0.8
1.2
0.4
19.3
2.5
3.3
26.3
-
1.6
39.1
-
92.6
13.6
1.6
7.8
413.4
2.5
3.7
-
2.9
65-
1,295.9
1,323.1
1,400.7
11.0
16.2
24.0
-
0.8
1.2
2.4
15.4
17.5
19.1
6.5
47.1
0.8
-
0.8
14.2
0.4
15.4
0.4
2.8
0.8
29.7
1.6
5.3
36.2
-
4.1
47.5
-
86.1
12.6
0.4
6.1
376.6
1.2
6.1
0.4
5.3
70-
1,436.8
1,474.3
1,594.8
17.9
19.6
29.0
0.4
-
2.6
2.1
15.3
21.7
25.1
7.7
63.0
2.1
0.4
-
9.8
0.9
19.6
1.3
3.4
1.7
34.5
4.3
7.7
43.4
-
2.1
46.0
-
100.5
12.8
2.6
14.1
375.6
0.9
6.4
0.4
1.3
75-
1,553.1
1,597.7
1,774.7
25.3
19.4
33.4
1.1
-
3.2
2.2
17.2
19.4
30.7
8.6
68.9
2.7
-
-
15.6
-
13.4
-
2.2
0.5
44.7
4.3
7.0
32.8
-
4.3
50.0
0.5
79.6
17.2
2.7
19.9
376.0
1.1
8.6
-
5.4
80-
CR
511.8
520.1
552.4
3.8
4.5
7.4
0.1
0.5
0.5
0.7
5.3
6.2
5.9
2.0
16.8
2.7
0.1
0.5
11.8
0.3
5.8
0.2
1.0
0.2
8.6
0.7
1.4
10.0
0.1
0.8
15.6
0.2
25.6
10.7
0.8
3.9
179.2
0.6
2.7
0.1
0.9
appendix
1,443.6
1,479.7
1,805.7
22.3
13.9
45.8
-
-
1.8
3.0
18.7
21.7
16.9
6.6
56.6
1.2
-
1.2
9.0
-
9.0
0.6
3.0
1.2
57.2
3.0
8.4
21.1
-
1.2
38.6
3.0
60.9
17.5
5.4
19.3
336.2
4.2
11.4
1.2
1.8
85+
0.1
0.0
0.7
106.2
1.8
0.4
143.8
2.6
0.5
1.0
0.1
0.1
0.6
0.0
0.0
0.1
5.0
0.5
0.3
3.3
0.1
0.8
0.1
4.0
0.4
8.8
0.5
0.1
7.0
0.8
0.4
5.0
0.1
0.8
0.1
4.7
0.4
10.8
0.5
3.1
0.4
0.3
0.7
0.0
3.0
2.1
1.5
295.1
284.0
280.4
3.9
0.5
0.4
0.6
0.0
4.5
3.0
2.2
404.5
387.2
382.1
27.0
27.3
28.1
0.2
0.2
0.3
-
0.0
0.0
0.0
0.3
0.4
0.3
belgian cancer registry
3.8
4.6
0.1
1.0
2.6
1.4
3.8
8.4
11.6
0.2
0.9
0.1
2.7
0.1
2.7
0.9
0.0
0.4
0.0
0.1
0.0
0.4
0.0
0.1
0.1
0.0
8.2
0.4
11.5
0.6
1.6
0.0
7.5
12.5
9.4
18.0
0.2
11.3
0.0
1.7
0.2
0.0
0.4
0.1
0.1
CRi
2.1
0.4
0.6
0.4
WSR
ESR
95
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Flemish Region: Males 2010
1,597
468
26
22
-
17
6
3,348
5
310
43
20
9
446
83
22
250
30
916
104
1,874
94
549
408
6
29
55
22
74
69
8
32
31
28
79
17
76
51
41
Tot
-
-
1
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
Flemish Region: Males, number of invasive tumours by primary site and age group in 2010
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
-
1
2
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
3
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
10-
-
2
1
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
15-
1
4
-
2
-
-
-
-
-
-
-
-
-
1
-
-
-
-
3
-
3
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
20-
4
16
1
1
-
2
-
-
-
-
-
-
-
2
-
-
1
-
2
-
5
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
-
25-
2
13
2
2
-
-
-
4
-
-
-
-
-
2
-
-
1
-
2
-
5
-
2
2
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
30-
6
27
1
2
-
2
-
8
-
-
-
-
-
5
-
-
5
-
5
-
13
-
4
2
-
-
-
2
-
-
-
-
-
-
-
-
2
1
-
35-
12
32
1
-
-
1
-
23
-
6
-
-
-
4
2
1
1
1
11
-
18
2
7
2
-
-
-
-
1
2
-
1
2
-
1
-
3
1
2
40-
19
45
2
2
-
-
1
67
-
9
3
-
-
10
2
1
9
2
35
2
36
5
24
16
-
2
2
3
10
8
-
3
2
1
6
2
6
5
-
45-
42
35
1
1
-
-
-
152
1
26
3
1
-
30
2
1
16
2
56
7
76
3
24
40
-
8
5
4
8
10
-
3
2
6
27
3
9
5
1
50-
45
52
3
-
-
3
-
301
-
39
6
1
1
38
5
1
23
2
103
9
133
9
50
44
1
4
16
3
12
14
1
1
3
14
15
3
16
11
1
55-
94
50
2
-
-
2
2
431
-
42
10
4
1
51
8
1
36
4
131
11
182
18
57
53
2
5
9
-
14
14
1
5
6
2
14
3
11
10
3
60-
139
39
2
1
-
2
-
493
2
58
3
2
-
66
14
3
48
9
135
14
268
11
72
66
1
5
11
3
12
10
3
2
5
1
3
2
9
6
6
65-
215
50
3
2
-
1
3
641
-
40
4
4
-
79
11
3
47
4
137
20
295
14
83
69
-
1
7
4
8
8
1
1
3
3
4
-
8
4
3
70-
348
51
4
1
-
2
-
621
1
44
9
2
5
75
14
3
36
2
131
18
365
11
90
52
1
1
1
-
4
3
1
7
4
-
7
3
3
3
11
75-
359
33
-
1
-
2
-
410
-
36
3
1
2
53
11
6
21
2
110
16
298
14
79
35
1
3
3
-
3
-
-
3
1
-
2
1
4
3
11
80-
310
19
-
1
-
-
-
197
1
10
2
3
-
30
14
2
5
2
55
7
170
7
55
27
-
-
1
1
2
-
-
4
3
1
-
-
3
2
3
85+
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Penis
Prostate
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C46
C47,C49
C48
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
148
Mesothelioma
20,073
20,458
22,055
204
181
266
2
16
22
28
208
310
252
59
608
81
7
20
92
11
262
3
33
35
1,079
70
92
651
10
165
5,651
51
47
13
101
12
Tot
Flemish Region: Males 2010
C45
43
44
44
-
1
-
-
3
-
-
2
10
-
-
2
-
-
3
-
2
5
-
5
-
-
-
-
2
-
3
-
-
-
-
3
-
-
00-
22
23
24
1
-
1
-
2
-
-
-
5
-
-
5
-
-
2
-
1
2
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
05-
25
26
26
1
-
-
-
-
-
-
1
6
-
-
5
-
-
1
-
-
3
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
47
50
50
-
3
-
-
2
-
-
2
4
-
-
5
7
-
-
-
1
5
-
-
-
-
-
-
-
-
7
-
-
-
1
1
-
1
15-
61
62
63
1
-
1
-
-
-
-
1
3
-
-
3
7
1
-
3
-
3
-
-
-
-
-
-
-
-
24
-
-
-
-
-
-
-
20-
97
103
107
2
4
1
-
1
-
-
2
3
1
-
5
9
1
1
3
-
4
-
-
-
-
-
-
2
-
26
-
-
-
-
2
1
1
25-
121
124
126
1
2
-
-
1
-
-
4
1
1
-
8
8
-
-
4
-
14
-
-
-
1
-
-
1
-
39
-
-
-
-
2
1
-
30-
163
167
173
-
4
-
-
1
-
-
6
2
5
1
12
5
1
-
7
-
8
-
-
-
-
-
1
9
-
20
-
-
-
-
2
2
2
35-
257
264
276
3
4
2
-
1
-
1
8
4
4
1
22
5
-
-
8
-
13
-
2
-
5
-
-
17
-
17
11
1
3
-
7
-
-
40-
566
578
597
3
9
11
-
1
-
1
11
13
5
1
35
5
-
1
13
2
12
-
-
-
21
4
4
34
-
10
47
1
1
1
7
3
1
45-
1,108
1,126
1,168
5
13
18
1
-
4
-
14
24
11
3
35
4
-
2
9
1
27
1
-
1
34
2
3
51
-
2
269
3
6
1
7
2
5
50-
1,787
1,807
1,852
9
11
19
-
1
1
1
14
31
19
6
49
8
-
1
6
-
24
-
1
-
55
3
4
62
1
7
511
1
7
3
6
1
7
55-
2,617
2,644
2,738
13
14
24
-
2
1
4
17
37
22
6
62
5
-
4
10
-
33
-
4
4
110
9
18
105
4
6
880
12
10
2
7
-
24
60-
2,969
3,014
3,153
22
23
38
-
-
3
5
15
36
48
7
72
4
1
-
10
2
27
-
5
2
132
8
8
103
1
2
1,008
5
3
1
13
-
23
65-
3,355
3,434
3,782
47
32
52
-
1
4
5
35
40
47
14
84
8
1
2
9
-
24
-
4
13
219
16
19
100
1
1
998
11
7
1
16
-
37
75-
appendix
3,303
3,371
3,586
44
24
32
-
-
3
5
27
50
53
5
88
3
1
2
7
1
39
-
5
4
200
15
18
71
1
-
1,060
6
7
2
12
-
21
702
10
6
1,313
1,275
2,257
belgian cancer registry
1,623
17
21
31
2,667
31
36
20
2,308
-
2
1
4
2
4
-
18
19
23
4
10
11
26
30
1
47
1
2
1
69
-
1
5
14
3
2
170
2
4
132
9
4
4
13
7
41
52
3
-
569
2
298
8
1
3
3
-
6
20
1
85+
80-
97
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Parotid gland
C07
C10
8
Mouth, NOS
C06
Salivary glands, NOS
Palate
C05
Tonsil
Floor of mouth
C04
C08
Gum
C03
C09
32
Tongue
C02
1,597
468
26
22
-
17
6
3,348
5
310
43
20
9
446
83
22
250
30
916
104
1,874
94
549
408
6
29
55
22
74
69
31
28
79
17
76
51
Base of tongue
C01
41
Tot
Lip
C00
Flemish Region: Males 2010
-
-
0.6
-
-
-
-
-
-
-
-
1.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
0.6
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
-
0.6
1.2
-
-
-
-
-
-
-
-
-
-
-
-
0.6
-
-
-
1.7
-
-
-
-
-
-
-
-
-
-
0.6
-
-
-
-
-
-
-
10-
-
1.1
0.5
2.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1.6
-
-
-
-
-
-
-
-
-
0.5
-
-
-
-
-
-
-
-
15-
0.5
2.2
-
1.1
-
-
-
-
-
-
-
-
-
0.5
-
-
-
-
1.6
-
1.6
-
-
-
-
-
-
0.5
-
-
-
-
-
-
-
-
0.5
-
-
20-
2.1
8.2
0.5
0.5
-
1.0
-
-
-
-
-
-
-
1.0
-
-
0.5
-
1.0
-
2.6
-
1.0
-
-
-
-
-
-
-
-
0.5
-
-
-
-
0.5
-
-
25-
1.0
6.6
1.0
1.0
-
-
-
2.0
-
-
-
-
-
1.0
-
-
0.5
-
1.0
-
2.6
-
1.0
1.0
-
-
-
0.5
-
-
-
-
-
-
-
-
-
-
-
30-
2.8
12.8
0.5
0.9
-
0.9
-
3.8
-
-
-
-
-
2.4
-
-
2.4
-
2.4
-
6.2
-
1.9
0.9
-
-
-
0.9
-
-
-
-
-
-
-
-
0.9
0.5
-
35-
Flemish Region: Males, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)
5.1
13.6
0.4
-
-
0.4
-
9.8
-
2.6
-
-
-
1.7
0.9
0.4
0.4
0.4
4.7
-
7.7
0.9
3.0
0.9
-
-
-
-
0.4
0.9
-
0.4
0.9
-
0.4
-
1.3
0.4
0.9
40-
7.7
18.1
0.8
0.8
-
-
0.4
27.0
-
3.6
1.2
-
-
4.0
0.8
0.4
3.6
0.8
14.1
0.8
14.5
2.0
9.7
6.4
-
0.8
0.8
1.2
4.0
3.2
-
1.2
0.8
0.4
2.4
0.8
2.4
2.0
-
45-
18.2
15.2
0.4
0.4
-
-
-
65.9
0.4
11.3
1.3
0.4
-
13.0
0.9
0.4
6.9
0.9
24.3
3.0
33.0
1.3
10.4
17.4
-
3.5
2.2
1.7
3.5
4.3
-
1.3
0.9
2.6
11.7
1.3
3.9
2.2
0.4
50-
22.1
25.5
1.5
-
-
1.5
-
147.7
-
19.1
2.9
0.5
0.5
18.6
2.5
0.5
11.3
1.0
50.5
4.4
65.3
4.4
24.5
21.6
0.5
2.0
7.8
1.5
5.9
6.9
0.5
0.5
1.5
6.9
7.4
1.5
7.8
5.4
0.5
55-
50.6
26.9
1.1
-
-
1.1
1.1
232.0
-
22.6
5.4
2.2
0.5
27.4
4.3
0.5
19.4
2.2
70.5
5.9
98.0
9.7
30.7
28.5
1.1
2.7
4.8
-
7.5
7.5
0.5
2.7
3.2
1.1
7.5
1.6
5.9
5.4
1.6
60-
98.8
27.7
1.4
0.7
-
1.4
-
350.5
1.4
41.2
2.1
1.4
-
46.9
10.0
2.1
34.1
6.4
96.0
10.0
190.5
7.8
51.2
46.9
0.7
3.6
7.8
2.1
8.5
7.1
2.1
1.4
3.6
0.7
2.1
1.4
6.4
4.3
4.3
65-
162.3
37.7
2.3
1.5
-
0.8
2.3
483.8
-
30.2
3.0
3.0
-
59.6
8.3
2.3
35.5
3.0
103.4
15.1
222.7
10.6
62.6
52.1
-
0.8
5.3
3.0
6.0
6.0
0.8
0.8
2.3
2.3
3.0
-
6.0
3.0
2.3
70-
75-
318.9
46.7
3.7
0.9
-
1.8
-
569.0
0.9
40.3
8.2
1.8
4.6
68.7
12.8
2.7
33.0
1.8
120.0
16.5
334.5
10.1
82.5
47.6
0.9
0.9
0.9
-
3.7
2.7
0.9
6.4
3.7
-
6.4
2.7
2.7
2.7
10.1
522.0
48.0
-
1.5
-
2.9
-
596.2
-
52.3
4.4
1.5
2.9
77.1
16.0
8.7
30.5
2.9
160.0
23.3
433.3
20.4
114.9
50.9
1.5
4.4
4.4
-
4.4
-
-
4.4
1.5
-
2.9
1.5
5.8
4.4
16.0
80-
735.2
45.1
-
2.4
-
-
-
467.2
2.4
23.7
4.7
7.1
-
71.2
33.2
4.7
11.9
4.7
130.4
16.6
403.2
16.6
130.4
64.0
-
-
2.4
2.4
4.7
-
-
9.5
7.1
2.4
-
-
7.1
4.7
7.1
85+
51.8
15.2
0.8
0.7
-
0.6
0.2
108.5
0.2
10.0
1.4
0.6
0.3
14.5
2.7
0.7
8.1
1.0
29.7
3.4
60.7
3.0
17.8
13.2
0.2
0.9
1.8
0.7
2.4
2.2
0.3
1.0
1.0
0.9
2.6
0.6
2.5
1.7
1.3
CR
34.3
12.4
0.8
0.7
-
0.5
0.1
78.6
0.1
7.6
1.1
0.5
0.2
10.7
1.9
0.5
6.2
0.8
22.2
2.4
43.2
2.2
12.9
10.1
0.1
0.8
1.5
0.6
2.0
1.9
0.2
0.8
0.8
0.8
2.2
0.4
2.1
1.4
0.9
ESR
20.8
9.4
0.7
0.7
-
0.4
0.1
52.2
0.1
5.2
0.7
0.4
0.1
7.2
1.3
0.3
4.4
0.6
15.2
1.6
28.4
1.5
8.6
6.9
0.1
0.6
1.0
0.5
1.4
1.4
0.2
0.6
0.6
0.6
1.6
0.3
1.5
1.0
0.5
WSR
1.8
1.0
0.1
0.1
-
0.0
0.0
6.4
0.0
0.7
0.1
0.0
0.0
0.9
0.1
0.0
0.6
0.1
1.8
0.2
3.2
0.2
1.0
0.9
0.0
0.1
0.1
0.1
0.2
0.2
0.0
0.0
0.1
0.1
0.2
0.0
0.2
0.1
0.0
CRi
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Penis
Prostate
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
C46
C47,C49
C48
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
Myeloproliferative Disorders
Myelodysplastic syndromes
MPD
MDS
20,073
20,458
22,055
204
181
266
24.5
25.0
25.0
-
0.6
-
-
1.7
-
-
1.1
5.7
-
-
1.1
-
-
1.7
-
1.1
2.8
-
2.8
-
-
-
-
1.1
-
1.7
-
-
-
-
1.7
-
-
00-
13.2
13.9
14.5
0.6
-
0.6
-
1.2
-
-
-
3.0
-
-
3.0
-
-
1.2
-
0.6
1.2
-
0.6
-
-
-
-
0.6
-
-
-
-
-
-
-
-
-
05-
14.4
15.0
15.0
0.6
-
-
-
-
-
-
0.6
3.5
-
-
2.9
-
-
0.6
-
-
1.7
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
25.0
26.6
26.6
-
1.6
-
-
1.1
-
-
1.1
2.1
-
-
2.7
3.7
-
-
-
0.5
2.7
-
-
-
-
-
-
-
-
3.7
-
-
-
0.5
0.5
-
0.5
15-
CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRi: Cumulative Risk (0-74 years)
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Unknown primary site
C80
2
16
Other and ill-defined sites
28
Lymphoid, haematopoietic and related tissue, NOS
Monocytic leukaemia
C93
208
C76
Myeloid leukaemia
C92
310
252
C96
Lymphoid leukaemia
C91
22
Multiple myeloma
C90
59
608
81
7
20
92
11
262
3
33
35
1,079
70
92
651
10
165
5,651
51
47
13
101
C94-C95 Leukaemia other
Malignant immunoproliferative diseases
C88
C82-C86 Non-Hodgkin-lymphoma
148
Mesothelioma
12
Tot
Flemish Region: Males 2010
C45
33.1
33.7
34.2
0.5
-
0.5
-
-
-
-
0.5
1.6
-
-
1.6
3.8
0.5
-
1.6
-
1.6
-
-
-
-
-
-
-
-
13.0
-
-
-
-
-
-
-
20-
49.9
53.0
55.0
1.0
2.1
0.5
-
0.5
-
-
1.0
1.5
0.5
-
2.6
4.6
0.5
0.5
1.5
-
2.1
-
-
-
-
-
-
1.0
-
13.4
-
-
-
-
1.0
0.5
0.5
25-
61.9
63.4
64.4
0.5
1.0
-
-
0.5
-
-
2.0
0.5
0.5
-
4.1
4.1
-
-
2.0
-
7.2
-
-
-
0.5
-
-
0.5
-
19.9
-
-
-
-
1.0
0.5
-
30-
77.3
79.2
82.0
-
1.9
-
-
0.5
-
-
2.8
0.9
2.4
0.5
5.7
2.4
0.5
-
3.3
-
3.8
-
-
-
-
-
0.5
4.3
-
9.5
-
-
-
-
0.9
0.9
0.9
35-
109.3
112.3
117.4
1.3
1.7
0.9
-
0.4
-
0.4
3.4
1.7
1.7
0.4
9.4
2.1
-
-
3.4
-
5.5
-
0.9
-
2.1
-
-
7.2
-
7.2
4.7
0.4
1.3
-
3.0
-
-
40-
228.0
232.8
240.4
1.2
3.6
4.4
-
0.4
-
0.4
4.4
5.2
2.0
0.4
14.1
2.0
-
0.4
5.2
0.8
4.8
-
-
-
8.5
1.6
1.6
13.7
-
4.0
18.9
0.4
0.4
0.4
2.8
1.2
0.4
45-
480.6
488.4
506.6
2.2
5.6
7.8
0.4
-
1.7
-
6.1
10.4
4.8
1.3
15.2
1.7
-
0.9
3.9
0.4
11.7
0.4
-
0.4
14.7
0.9
1.3
22.1
-
0.9
116.7
1.3
2.6
0.4
3.0
0.9
2.2
50-
876.7
886.5
908.6
4.4
5.4
9.3
-
0.5
0.5
0.5
6.9
15.2
9.3
2.9
24.0
3.9
-
0.5
2.9
-
11.8
-
0.5
-
27.0
1.5
2.0
30.4
0.5
3.4
250.7
0.5
3.4
1.5
2.9
0.5
3.4
55-
1,408.5
1,423.1
1,473.7
7.0
7.5
12.9
-
1.1
0.5
2.2
9.1
19.9
11.8
3.2
33.4
2.7
-
2.2
5.4
-
17.8
-
2.2
2.2
59.2
4.8
9.7
56.5
2.2
3.2
473.6
6.5
5.4
1.1
3.8
-
12.9
60-
65-
2,110.9
2,142.9
2,241.8
15.6
16.4
27.0
-
-
2.1
3.6
10.7
25.6
34.1
5.0
51.2
2.8
0.7
-
7.1
1.4
19.2
-
3.6
1.4
93.9
5.7
5.7
73.2
0.7
1.4
716.7
3.6
2.1
0.7
9.2
-
16.4
2,492.9
2,544.3
2,706.5
33.2
18.1
24.2
-
-
2.3
3.8
20.4
37.7
40.0
3.8
66.4
2.3
0.8
1.5
5.3
0.8
29.4
-
3.8
3.0
151.0
11.3
13.6
53.6
0.8
-
800.0
4.5
5.3
1.5
9.1
-
15.8
70-
75-
3,074.3
3,146.7
3,465.6
43.1
29.3
47.6
-
0.9
3.7
4.6
32.1
36.7
43.1
12.8
77.0
7.3
0.9
1.8
8.2
-
22.0
-
3.7
11.9
200.7
14.7
17.4
91.6
0.9
0.9
914.5
10.1
6.4
0.9
14.7
-
33.9
3,282.0
3,356.1
3,878.1
45.1
29.1
52.3
1.5
-
5.8
2.9
43.6
33.4
37.8
16.0
100.3
2.9
-
1.5
4.4
1.5
20.4
2.9
4.4
10.2
247.2
13.1
18.9
75.6
2.9
1.5
827.4
11.6
4.4
1.5
8.7
-
29.1
80-
CR
663.1
714.8
6.6
5.9
8.6
0.1
0.5
0.7
0.9
6.7
10.0
8.2
1.9
19.7
2.6
0.2
0.6
3.0
0.4
8.5
0.1
1.1
1.1
35.0
2.3
3.0
21.1
0.3
5.3
183.2
1.7
1.5
0.4
3.3
0.4
4.8
650.6
appendix
3,023.9
3,114.0
3,849.3
49.8
40.3
73.5
-
-
4.7
9.5
45.1
42.7
23.7
9.5
111.5
2.4
2.4
-
-
-
11.9
-
4.7
9.5
313.1
9.5
9.5
97.2
-
-
706.8
7.1
-
-
23.7
4.7
14.2
85+
99
11.2
3.0
360.9
340.1
333.9
4.6
528.6
494.3
485.2
33.0
33.4
34.7
0.3
0.3
0.4
0.0
0.0
0.0
belgian cancer registry
4.1
3.2
6.3
4.5
0.6
0.0
0.6
0.3
0.0
0.1
0.4
0.7
0.5
0.7
0.4
3.6
0.5
0.1
1.2
0.2
0.0
5.1
0.9
1.3
0.2
0.0
4.1
11.0
15.2
0.6
0.0
6.4
2.2
2.5
0.1
0.0
8.2
0.2
0.2
1.8
0.0
6.0
2.0
0.6
2.6
0.6
5.7
0.4
7.2
0.1
0.4
0.9
0.0
0.9
0.4
0.7
0.1
1.0
15.5
1.6
24.3
1.4
2.1
1.3
0.2
0.2
11.5
0.0
0.4
0.2
5.5
5.6
0.1
0.1
0.0
0.2
0.0
0.3
CRi
16.3
90.5
134.8
0.3
0.3
0.8
2.0
2.6
0.8
0.3
0.4
1.2
2.3
3.4
1.2
WSR
ESR
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Flemish Region: Females 2010
1,116
678
14
18
-
10
6
1,195
1
37
11
6
8
422
57
52
100
47
615
63
1,676
75
334
126
1
6
7
8
21
35
16
22
31
11
21
10
34
23
7
Tot
Flemish Region: Females, number of invasive tumours by primary site and age group in 2010
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
00-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
2
-
2
5
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
2
8
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
7
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
15-
-
10
-
-
-
-
-
1
-
-
-
-
-
-
-
-
2
-
1
-
6
-
-
-
-
-
-
1
-
-
1
3
-
-
-
-
-
-
-
20-
1
28
-
-
-
-
-
2
-
-
-
-
-
-
-
-
1
-
-
-
7
-
1
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
25-
7
35
-
2
-
-
-
5
-
-
-
-
-
1
-
-
1
-
2
-
4
-
-
-
-
-
-
-
-
-
-
1
-
-
1
-
1
-
-
30-
5
49
1
1
-
1
-
10
-
-
-
-
-
3
-
-
2
-
7
1
10
1
2
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
35-
15
64
2
1
-
-
-
23
-
2
-
-
-
5
-
1
2
3
13
2
12
2
3
-
-
-
-
1
-
1
1
-
-
-
1
-
2
-
-
40-
24
78
-
1
-
-
-
53
-
1
-
-
2
13
2
-
1
2
24
3
39
4
14
3
-
-
-
2
1
1
1
2
1
1
-
1
4
-
-
45-
32
47
-
3
-
-
-
121
-
3
2
-
-
22
2
3
11
4
27
-
49
5
16
7
-
1
2
1
2
8
5
2
3
3
1
1
6
3
-
50-
43
57
1
-
-
2
-
178
-
6
-
1
2
40
3
2
8
7
59
1
107
5
16
8
-
-
3
-
7
5
1
1
2
1
5
1
3
3
-
55-
59
72
1
1
-
1
1
176
-
7
3
-
-
41
6
4
7
9
72
8
151
10
30
14
-
3
1
-
3
3
-
2
4
1
2
2
3
8
1
60-
84
51
4
1
-
1
2
152
-
10
2
1
2
46
6
4
9
2
64
7
187
7
30
18
-
-
-
-
4
6
1
3
-
-
4
1
4
4
-
65-
126
49
1
-
-
1
1
162
1
3
1
-
-
78
10
3
18
5
96
10
247
14
36
17
-
-
-
-
2
4
1
1
6
2
3
2
4
-
1
70-
171
55
1
-
-
-
2
150
-
3
-
1
-
70
13
14
17
8
91
8
274
9
53
19
-
1
1
-
1
3
2
-
4
-
3
1
3
1
1
75-
214
39
-
-
-
-
-
97
-
1
1
1
-
59
10
10
9
3
92
11
302
9
60
22
-
1
-
2
1
2
-
3
8
1
1
-
-
3
2
80-
331
35
1
-
-
2
-
65
-
1
2
2
2
44
5
11
12
4
67
12
269
9
73
18
1
-
-
-
-
2
1
4
3
1
-
1
3
-
2
85+
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Vulva
Vagina
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C46
C47,C49
C48
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Mesothelioma
Flemish Region: Females 2010
C45
16,383
16,674
17,790
120
171
219
1
19
23
22
176
187
206
62
545
83
4
20
286
14
192
6
35
5
292
25
52
368
3
26
510
4
826
330
28
128
5,731
18
96
2
35
Tot
44
45
45
1
-
-
-
6
2
-
3
6
-
1
2
-
-
3
-
2
2
-
5
-
1
-
-
4
-
-
-
-
-
-
1
-
-
1
2
-
-
00-
21
21
21
-
-
-
-
2
-
-
1
5
-
-
1
1
1
1
1
2
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
26
26
28
-
-
-
-
1
-
1
2
3
-
-
1
2
-
-
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
10-
41
42
44
-
1
1
-
-
-
-
-
2
-
-
1
8
-
-
5
1
1
-
-
-
-
-
-
1
-
-
1
-
-
1
-
-
-
-
-
-
-
15-
68
71
71
-
3
1
-
-
-
-
4
-
-
-
4
13
-
-
7
1
3
-
-
-
-
-
-
1
1
-
4
-
-
-
-
-
3
-
1
-
-
20-
127
128
129
-
1
-
-
-
-
1
2
1
-
-
6
11
-
-
12
1
7
-
2
-
-
-
-
3
1
-
3
-
-
10
-
1
24
-
1
-
-
25-
203
205
212
2
-
1
-
1
-
-
3
2
2
-
7
5
-
1
17
-
7
-
-
-
-
-
-
2
-
-
4
1
-
22
-
1
71
-
3
-
-
30-
406
410
415
-
4
1
-
-
-
-
4
2
2
2
11
7
-
-
26
1
4
-
3
-
1
-
1
4
-
-
11
-
5
33
-
1
196
-
2
-
-
35-
677
682
697
1
4
1
-
3
-
1
11
5
2
2
18
5
-
3
20
2
6
-
1
-
3
-
1
9
-
1
12
-
12
38
-
5
369
-
6
-
-
40-
1,065
1,074
1,098
3
6
7
-
1
3
2
10
4
7
4
26
4
1
1
31
-
4
-
1
-
8
-
-
10
-
-
19
-
23
49
2
7
578
2
6
-
1
45-
1,382
1,391
1,423
-
9
12
-
1
-
-
12
12
9
4
32
4
-
2
28
1
14
-
2
-
8
1
-
19
1
1
52
-
51
35
2
11
692
2
11
-
3
50-
1,551
1,570
1,613
7
12
13
-
-
1
-
13
11
19
7
30
6
-
3
29
-
15
-
1
-
17
-
3
25
-
2
55
-
81
31
4
9
632
-
5
-
4
55-
1,867
1,896
1,955
10
19
13
-
1
1
2
14
23
28
3
48
5
1
2
26
-
17
1
1
-
21
2
2
44
-
6
66
-
117
24
3
7
726
3
11
-
2
60-
1,972
2,015
2,141
17
26
39
-
2
1
2
25
27
26
8
79
1
-
1
18
1
29
-
4
1
52
2
10
56
-
6
64
-
137
20
1
12
547
1
12
-
9
70-
appendix
1,776
1,799
1,883
9
14
18
-
1
-
4
12
15
19
8
69
5
-
2
24
-
22
1
2
1
30
4
6
46
-
4
59
-
135
18
2
7
617
2
5
-
5
65-
9
3
11
1
10
20
55
4
46
11
5
44
2
22
17
5
69
9
38
18
18
2
6
1
36
22
25
64
71
9
8
50
2
6
3
26
2
14
1
1
88
9
37
31
24
3
6
35
33
27
1,413
1,448
1,779
18
17
41
-
-
3
4
18
5
53
-
-
1
57
3
9
27
-
2
41
2
50
17
7
19
belgian cancer registry
1,713
17
1
-
2,031
1
76
139
1,974
10
19
13
1,760
1
7
2
4
2,091
5
23
25
326
2
415
2
535
1
2
6
3
85+
80-
75-
2,262
101
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Flemish Region: Females 2010
1,116
678
14
18
-
10
6
1,195
1
37
11
6
8
422
57
52
100
47
615
63
1,676
75
334
126
1
6
7
8
21
35
16
22
31
11
21
10
34
23
7
Tot
-
0.6
-
-
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.6
-
-
-
-
-
-
-
-
-
-
-
00-
-
-
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
1.2
-
1.2
3.0
-
0.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2.4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
1.1
4.4
-
1.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3.9
-
-
-
-
-
-
-
-
-
0.6
-
-
-
-
-
0.6
-
-
15-
-
5.5
-
-
-
-
-
0.6
-
-
-
-
-
-
-
-
1.1
-
0.6
-
3.3
-
-
-
-
-
-
0.6
-
-
0.6
1.7
-
-
-
-
-
-
-
20-
0.5
14.6
-
-
-
-
-
1.0
-
-
-
-
-
-
-
-
0.5
-
-
-
3.7
-
0.5
-
-
-
-
-
-
-
0.5
-
-
-
-
-
-
0.5
-
25-
3.6
18.2
-
1.0
-
-
-
2.6
-
-
-
-
-
0.5
-
-
0.5
-
1.0
-
2.1
-
-
-
-
-
-
-
-
-
-
0.5
-
-
0.5
-
0.5
-
-
30-
2.4
23.7
0.5
0.5
-
0.5
-
4.8
-
-
-
-
-
1.4
-
-
1.0
-
3.4
0.5
4.8
0.5
1.0
-
-
-
-
-
-
-
-
-
-
0.5
-
-
-
-
-
35-
Flemish Region: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)
6.6
28.2
0.9
0.4
-
-
-
10.1
-
0.9
-
-
-
2.2
-
0.4
0.9
1.3
5.7
0.9
5.3
0.9
1.3
-
-
-
-
0.4
-
0.4
0.4
-
-
-
0.4
-
0.9
-
-
40-
9.9
32.3
-
0.4
-
-
-
22.0
-
0.4
-
-
0.8
5.4
0.8
-
0.4
0.8
9.9
1.2
16.2
1.7
5.8
1.2
-
-
-
0.8
0.4
0.4
0.4
0.8
0.4
0.4
-
0.4
1.7
-
-
45-
14.2
20.9
-
1.3
-
-
-
53.7
-
1.3
0.9
-
-
9.8
0.9
1.3
4.9
1.8
12.0
-
21.7
2.2
7.1
3.1
-
0.4
0.9
0.4
0.9
3.5
2.2
0.9
1.3
1.3
0.4
0.4
2.7
1.3
-
50-
21.5
28.5
0.5
-
-
1.0
-
88.9
-
3.0
-
0.5
1.0
20.0
1.5
1.0
4.0
3.5
29.5
0.5
53.5
2.5
8.0
4.0
-
-
1.5
-
3.5
2.5
0.5
0.5
1.0
0.5
2.5
0.5
1.5
1.5
-
55-
31.7
38.6
0.5
0.5
-
0.5
0.5
94.4
-
3.8
1.6
-
-
22.0
3.2
2.1
3.8
4.8
38.6
4.3
81.0
5.4
16.1
7.5
-
1.6
0.5
-
1.6
1.6
-
1.1
2.1
0.5
1.1
1.1
1.6
4.3
0.5
60-
56.5
34.3
2.7
0.7
-
0.7
1.3
102.2
-
6.7
1.3
0.7
1.3
30.9
4.0
2.7
6.1
1.3
43.0
4.7
125.8
4.7
20.2
12.1
-
-
-
-
2.7
4.0
0.7
2.0
-
-
2.7
0.7
2.7
2.7
-
65-
83.3
32.4
0.7
-
-
0.7
0.7
107.1
0.7
2.0
0.7
-
-
51.6
6.6
2.0
11.9
3.3
63.5
6.6
163.3
9.3
23.8
11.2
-
-
-
-
1.3
2.6
0.7
0.7
4.0
1.3
2.0
1.3
2.6
-
0.7
70-
120.8
38.9
0.7
-
-
-
1.4
106.0
-
2.1
-
0.7
-
49.5
9.2
9.9
12.0
5.7
64.3
5.7
193.6
6.4
37.4
13.4
-
0.7
0.7
-
0.7
2.1
1.4
-
2.8
-
2.1
0.7
2.1
0.7
0.7
75-
199.0
36.3
-
-
-
-
-
90.2
-
0.9
0.9
0.9
-
54.9
9.3
9.3
8.4
2.8
85.6
10.2
280.9
8.4
55.8
20.5
-
0.9
-
1.9
0.9
1.9
-
2.8
7.4
0.9
0.9
-
-
2.8
1.9
80-
356.6
37.7
1.1
-
-
2.2
-
70.0
-
1.1
2.2
2.2
2.2
47.4
5.4
11.9
12.9
4.3
72.2
12.9
289.8
9.7
78.6
19.4
1.1
-
-
-
-
2.2
1.1
4.3
3.2
1.1
-
1.1
3.2
-
2.2
85+
35.2
21.4
0.4
0.6
-
0.3
0.2
37.7
0.0
1.2
0.3
0.2
0.3
13.3
1.8
1.6
3.2
1.5
19.4
2.0
52.9
2.4
10.5
4.0
0.0
0.2
0.2
0.3
0.7
1.1
0.5
0.7
1.0
0.3
0.7
0.3
1.1
0.7
0.2
CR
18.4
17.9
0.4
0.6
-
0.3
0.1
27.7
0.0
0.9
0.2
0.1
0.2
8.4
1.1
0.9
2.1
1.1
12.5
1.2
31.2
1.6
6.0
2.4
0.0
0.1
0.2
0.2
0.6
0.9
0.4
0.5
0.6
0.3
0.5
0.2
0.9
0.6
0.1
ESR
11.8
14.4
0.3
0.7
-
0.3
0.1
19.6
0.0
0.7
0.2
0.1
0.1
5.7
0.7
0.5
1.5
0.7
8.6
0.8
21.2
1.1
4.0
1.6
0.0
0.1
0.1
0.2
0.4
0.6
0.4
0.4
0.4
0.2
0.4
0.2
0.7
0.4
0.1
WSR
1.2
1.4
0.0
0.0
-
0.0
0.0
2.4
0.0
0.1
0.0
0.0
0.0
0.7
0.1
0.0
0.2
0.1
1.0
0.1
2.4
0.1
0.4
0.2
-
0.0
0.0
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.1
0.0
CRi
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
83
4
20
286
14
192
6
35
5
292
25
52
368
3
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C76
C80
MPD
MDS
16,383
16,674
17,790
120
171
219
26.3
26.9
26.9
0.6
-
-
-
3.6
1.2
-
1.8
3.6
-
0.6
1.2
-
-
1.8
-
1.2
1.2
-
3.0
-
0.6
-
-
2.4
-
-
-
-
-
-
0.6
-
-
0.6
1.2
-
-
00-
13.2
13.2
13.2
-
-
-
-
1.3
-
-
0.6
3.2
-
-
0.6
0.6
0.6
0.6
0.6
1.3
2.5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
15.6
15.6
16.8
-
-
-
-
0.6
-
0.6
1.2
1.8
-
-
0.6
1.2
-
-
0.6
-
1.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.6
-
-
10-
22.8
23.3
24.4
-
0.6
0.6
-
-
-
-
-
1.1
-
-
0.6
4.4
-
-
2.8
0.6
0.6
-
-
-
-
-
-
0.6
-
-
0.6
-
-
0.6
-
-
-
-
-
-
-
15-
CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRi: Cumulative Risk (0-74 years)
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
19
Lymphoid, haematopoietic and related tissue, NOS
C96
1
23
C94-C95 Leukaemia other
22
176
187
206
Monocytic leukaemia
Placenta
C58
26
510
C93
Female genital organs, NOS
C57
Myeloid leukaemia
Ovary
C56
4
Lymphoid leukaemia
Uterus
C55
330
826
C92
Corpus uteri
C54
C91
Cervix uteri
C53
28
128
62
Vagina
C52
Multiple myeloma
Vulva
C51
18
5,731
Malignant immunoproliferative diseases
Breast
C50
C90
Retroperitoneum and peritoneum
C48
96
C88
Soft tissues
C47,C49
2
545
Kaposi's sarcoma
C46
35
Tot
C82-C86 Non-Hodgkin-lymphoma
Mesothelioma
Flemish Region: Females 2010
C45
37.7
39.4
39.4
-
1.7
0.6
-
-
-
-
2.2
-
-
-
2.2
7.2
-
-
3.9
0.6
1.7
-
-
-
-
-
-
0.6
0.6
-
2.2
-
-
-
-
-
1.7
-
0.6
-
-
20-
66.2
66.8
67.3
-
0.5
-
-
-
-
0.5
1.0
0.5
-
-
3.1
5.7
-
-
6.3
0.5
3.7
-
1.0
-
-
-
-
1.6
0.5
-
1.6
-
-
5.2
-
0.5
12.5
-
0.5
-
-
25-
105.6
106.6
110.3
1.0
-
0.5
-
0.5
-
-
1.6
1.0
1.0
-
3.6
2.6
-
0.5
8.8
-
3.6
-
-
-
-
-
-
1.0
-
-
2.1
0.5
-
11.4
-
0.5
36.9
-
1.6
-
-
30-
196.0
197.9
200.4
-
1.9
0.5
-
-
-
-
1.9
1.0
1.0
1.0
5.3
3.4
-
-
12.6
0.5
1.9
-
1.4
-
0.5
-
0.5
1.9
-
-
5.3
-
2.4
15.9
-
0.5
94.6
-
1.0
-
-
35-
297.9
300.1
306.7
0.4
1.8
0.4
-
1.3
-
0.4
4.8
2.2
0.9
0.9
7.9
2.2
-
1.3
8.8
0.9
2.6
-
0.4
-
1.3
-
0.4
4.0
-
0.4
5.3
-
5.3
16.7
-
2.2
162.3
-
2.6
-
-
40-
441.4
445.1
455.0
1.2
2.5
2.9
-
0.4
1.2
0.8
4.1
1.7
2.9
1.7
10.8
1.7
0.4
0.4
12.8
-
1.7
-
0.4
-
3.3
-
-
4.1
-
-
7.9
-
9.5
20.3
0.8
2.9
239.5
0.8
2.5
-
0.4
45-
613.1
617.1
631.3
-
4.0
5.3
-
0.4
-
-
5.3
5.3
4.0
1.8
14.2
1.8
-
0.9
12.4
0.4
6.2
-
0.9
-
3.5
0.4
-
8.4
0.4
0.4
23.1
-
22.6
15.5
0.9
4.9
307.0
0.9
4.9
-
1.3
50-
5.4
10.2
7.0
-
0.5
0.5
1.1
7.5
12.3
15.0
1.6
25.8
2.7
0.5
1.1
14.0
-
9.1
0.5
0.5
-
11.3
1.1
1.1
23.6
-
3.2
35.4
-
62.8
12.9
1.6
3.8
389.5
1.6
5.9
-
1.1
60-
6.1
9.4
12.1
-
0.7
-
2.7
8.1
10.1
12.8
5.4
46.4
3.4
-
1.3
16.1
-
14.8
0.7
1.3
0.7
20.2
2.7
4.0
30.9
-
2.7
39.7
-
90.8
12.1
1.3
4.7
415.0
1.3
3.4
-
3.4
65-
774.9
784.4
1,001.7
1,194.4
1,017.3 1,209.9
805.9 1,049.0 1,266.4
3.5
6.0
6.5
-
-
0.5
-
6.5
5.5
9.5
3.5
15.0
3.0
-
1.5
14.5
-
7.5
-
0.5
-
8.5
-
1.5
12.5
-
1.0
27.5
-
40.5
15.5
2.0
4.5
315.8
-
2.5
-
2.0
55-
1,303.7
1,332.1
1,415.4
11.2
17.2
25.8
-
1.3
0.7
1.3
16.5
17.8
17.2
5.3
52.2
0.7
-
0.7
11.9
0.7
19.2
-
2.6
0.7
34.4
1.3
6.6
37.0
-
4.0
42.3
-
90.6
13.2
0.7
7.9
361.6
0.7
7.9
-
5.9
70-
1,434.8
1,477.2
1,598.0
19.1
23.3
24.7
-
-
4.2
2.1
17.0
21.9
26.1
6.4
62.2
0.7
0.7
-
9.9
1.4
18.4
2.1
4.2
1.4
35.3
5.7
6.4
50.2
-
-
45.2
-
98.2
9.2
2.8
17.7
378.0
1.4
7.1
0.7
2.1
75-
1,593.3
1,637.0
1,836.1
23.3
20.5
33.5
0.9
-
5.6
1.9
16.7
16.7
35.3
8.4
64.2
4.7
-
-
15.8
-
20.5
-
1.9
-
40.9
4.7
10.2
42.8
-
3.7
51.2
0.9
70.7
17.7
1.9
21.4
386.0
1.9
10.2
-
5.6
80-
0.6
3.0
0.1
1.1
CR
517.4
526.6
561.8
3.8
5.4
6.9
0.0
0.6
0.7
0.7
5.6
5.9
6.5
2.0
17.2
2.6
0.1
0.6
9.0
0.4
6.1
0.2
1.1
0.2
9.2
0.8
1.6
11.6
0.1
0.8
16.1
0.1
26.1
10.4
0.9
4.0
181.0
appendix
1,522.4
1,560.1
1,916.7
19.4
18.3
44.2
-
-
3.2
4.3
19.4
21.5
18.3
5.4
57.1
-
-
1.1
10.8
-
7.5
1.1
5.4
1.1
61.4
3.2
9.7
29.1
-
2.2
44.2
2.2
53.9
18.3
7.5
20.5
351.2
3.2
9.7
1.1
2.2
85+
-
0.8
0.1
0.9
0.1
0.9
0.1
0.1
2.7
8.4
0.1
2.7
11.6
0.3
0.0
3.5
3.1
0.4
0.4
0.8
0.0
2.7
2.5
1.4
287.9
276.1
272.2
4.2
4.0
0.5
0.4
0.7
0.0
4.0
3.5
2.1
396.1
377.7
372.1
belgian cancer registry
26.3
26.6
27.5
0.1
0.3
0.3
-
0.1
0.0
0.3
0.3
1.0
2.8
1.3
4.1
0.2
0.0
0.1
6.5
0.6
7.9
0.6
0.0
0.4
0.0
0.1
0.0
0.4
0.0
0.1
0.6
0.0
0.1
1.0
0.0
1.6
0.2
0.6
3.7
0.1
0.1
0.5
3.5
5.3
0.5
0.3
0.4
4.6
5.6
0.6
7.7
0.1
0.1
0.9
8.2
0.4
11.5
0.6
0.0
0.1
0.7
7.1
12.4
9.0
17.9
0.0
1.7
0.4
2.5
11.0
0.6
0.0
0.2
0.3
1.8
2.2
0.1
103.8
0.0
0.0
CRi
0.4
0.5
0.7
140.6
WSR
ESR
103
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Brussels Capital Region: Males 2010
242
80
6
8
-
2
3
450
1
36
6
4
4
65
15
4
56
7
91
24
239
11
71
41
2
5
11
8
13
12
2
2
6
6
12
2
17
8
3
Tot
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
Brussels Capital Region: Males, number of invasive tumours by primary site and age group in 2010
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
-
-
2
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
15-
-
1
-
1
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
20-
1
2
1
-
-
-
-
2
-
-
-
-
-
-
-
1
1
-
1
-
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
25-
2
6
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30-
2
6
-
1
-
-
-
1
-
-
-
-
-
1
-
-
1
-
3
-
5
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
35-
-
5
-
-
-
-
1
7
-
-
-
-
-
1
-
-
2
-
-
-
1
-
2
-
-
-
-
2
1
-
-
-
-
-
-
-
-
-
-
40-
3
3
-
2
-
-
-
11
-
1
1
-
-
4
2
-
5
1
4
-
9
-
6
-
-
-
3
1
2
1
-
-
-
1
1
-
1
1
1
45-
8
5
-
-
-
1
-
37
-
3
1
-
-
3
2
-
4
-
9
1
10
1
3
6
-
1
1
1
4
1
-
1
1
1
1
-
4
1
1
50-
4
10
1
-
-
-
-
50
1
4
-
-
-
6
2
-
6
-
10
2
13
2
3
9
1
1
1
1
2
1
-
-
1
1
5
-
1
1
-
55-
17
14
-
2
-
-
1
72
-
9
-
1
1
7
2
-
4
1
14
2
34
1
8
5
-
1
1
1
2
2
-
-
1
2
2
1
3
-
-
60-
7
6
1
-
-
1
-
68
-
7
1
1
1
11
1
-
6
1
16
5
26
1
7
3
-
1
1
-
1
3
-
1
1
-
2
-
3
2
-
65-
28
7
-
-
-
-
-
72
-
4
-
1
-
6
3
3
8
2
15
3
36
-
9
4
-
-
1
-
1
1
1
-
1
-
-
-
2
1
1
70-
52
8
-
-
-
-
1
66
-
6
1
-
2
11
1
-
12
1
6
4
38
3
11
5
1
-
2
1
-
1
-
-
-
1
1
-
1
1
-
75-
52
5
-
-
-
-
-
40
-
2
-
1
-
7
-
-
3
-
5
4
39
2
12
5
-
-
1
1
-
2
1
-
1
-
-
-
1
1
-
80-
66
2
-
-
-
-
-
24
-
-
-
-
-
8
2
-
3
-
7
3
24
-
8
4
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
85+
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Penis
Prostate
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C46
C47,C49
C48
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Mesothelioma
Brussels Capital Region: Males 2010
C45
2,553
2,588
2,830
19
16
57
-
2
1
3
24
37
41
8
89
27
-
3
30
2
44
2
8
1
140
6
10
75
3
32
526
7
9
4
12
13
4
Tot
13
14
14
1
-
-
-
-
-
1
1
2
-
-
-
-
-
2
-
-
2
-
2
-
-
-
-
1
-
-
-
-
-
-
-
-
-
00-
5
6
6
1
-
-
-
1
-
-
1
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
4
5
5
1
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
13
13
13
-
-
-
-
-
-
-
2
-
-
-
-
1
-
-
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
15-
11
11
11
-
-
-
-
-
-
-
2
-
-
-
1
-
-
-
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
-
20-
30
30
31
-
-
1
-
-
-
-
1
-
-
-
2
2
-
-
1
-
-
-
-
-
-
-
-
1
-
9
-
-
-
1
1
1
-
25-
29
29
31
-
-
1
-
-
-
-
-
2
-
-
2
4
-
-
2
1
1
-
-
-
-
-
-
-
-
6
-
-
-
-
-
-
-
30-
56
57
59
1
-
1
-
-
-
-
4
-
-
-
2
8
-
-
3
-
4
-
-
-
3
-
-
4
-
4
-
-
-
-
-
2
-
35-
47
49
49
2
-
1
-
-
-
-
-
-
-
-
6
2
-
-
2
-
3
1
-
-
1
-
1
1
1
4
1
1
-
-
-
-
-
40-
112
113
116
-
1
2
-
-
-
-
1
1
3
1
11
1
-
1
4
1
3
1
-
-
1
-
-
6
-
1
7
-
2
-
1
3
-
45-
176
178
186
-
2
4
-
-
-
-
-
2
2
-
6
2
-
-
2
-
6
-
1
-
2
-
-
9
1
3
28
-
-
1
1
2
-
50-
257
258
262
1
-
5
-
-
-
-
1
8
4
3
9
2
-
-
6
-
3
-
-
-
12
-
2
12
-
1
48
1
2
-
3
-
-
55-
330
334
351
2
2
7
-
-
-
-
1
5
6
-
4
-
-
-
2
-
4
-
1
1
15
2
1
12
-
-
72
-
1
-
2
-
-
60-
333
337
344
3
1
6
-
-
-
-
-
2
4
1
11
2
-
-
2
-
2
-
1
-
21
1
-
8
-
1
86
2
1
-
1
1
2
65-
379
385
437
3
3
9
-
-
1
1
5
2
9
1
11
1
-
-
1
-
2
-
1
-
28
2
1
12
-
-
101
1
2
-
2
1
-
75-
appendix
357
361
389
1
3
8
-
1
-
1
3
2
7
2
8
1
-
-
2
-
5
-
-
-
27
-
2
4
-
1
95
1
-
2
-
1
2
70-
178
176
230
225
belgian cancer registry
244
282
2
3
2
-
-
-
-
-
4
-
-
8
2
-
-
4
5
8
-
7
-
3
-
-
-
-
-
3
-
-
1
1
3
-
-
12
-
18
1
-
2
1
1
1
4
1
-
-
-
43
1
1
-
-
45
2
-
85+
-
80-
105
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
2
Gum
Floor of mouth
C03
C04
17
Tongue
C02
242
80
6
8
-
2
3
450
1
36
6
4
4
65
15
4
56
7
91
24
239
11
71
41
2
5
11
8
13
12
2
2
6
6
12
8
Base of tongue
C01
3
Tot
Lip
C00
Brussels Capital Region: Males 2010
-
-
-
-
-
-
-
-
-
-
2.4
-
-
-
-
-
2.4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
-
-
6.6
6.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3.3
-
-
-
-
3.3
-
-
-
-
-
-
-
-
-
-
-
-
-
15-
-
2.9
-
2.9
-
-
-
-
-
-
2.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
20-
2.2
4.4
2.2
-
-
-
-
4.4
-
-
-
-
-
-
-
2.2
2.2
-
2.2
-
2.2
-
2.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
25-
4.1
12.4
2.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2.1
2.1
-
2.1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30-
4.4
13.1
-
2.2
-
-
-
2.2
-
-
-
-
-
2.2
-
-
2.2
-
6.6
-
10.9
2.2
2.2
-
-
-
-
-
-
-
-
-
-
-
-
-
2.2
-
-
35-
-
12.1
-
-
-
-
2.4
16.9
-
-
-
-
-
2.4
-
-
4.8
-
-
-
2.4
-
4.8
-
-
-
-
4.8
2.4
-
-
-
-
-
-
-
-
-
-
40-
Brussels Capital Region: Males, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)
8.3
8.3
-
5.5
-
-
-
30.3
-
2.8
2.8
-
-
11.0
5.5
-
13.8
2.8
11.0
-
24.8
-
16.5
-
-
-
8.3
2.8
5.5
2.8
-
-
-
2.8
2.8
-
2.8
2.8
2.8
45-
25.7
16.1
-
-
-
3.2
-
119.0
-
9.7
3.2
-
-
9.7
6.4
-
12.9
-
29.0
3.2
32.2
3.2
9.7
19.3
-
3.2
3.2
3.2
12.9
3.2
-
3.2
3.2
3.2
3.2
-
12.9
3.2
3.2
50-
14.9
37.2
3.7
-
-
-
-
186.1
3.7
14.9
-
-
-
22.3
7.4
-
22.3
-
37.2
7.4
48.4
7.4
11.2
33.5
3.7
3.7
3.7
3.7
7.4
3.7
-
-
3.7
3.7
18.6
-
3.7
3.7
-
55-
74.6
61.5
-
8.8
-
-
4.4
316.1
-
39.5
-
4.4
4.4
30.7
8.8
-
17.6
4.4
61.5
8.8
149.2
4.4
35.1
21.9
-
4.4
4.4
4.4
8.8
8.8
-
-
4.4
8.8
8.8
4.4
13.2
-
-
60-
41.4
35.5
5.9
-
-
5.9
-
402.6
-
41.4
5.9
5.9
5.9
65.1
5.9
-
35.5
5.9
94.7
29.6
153.9
5.9
41.4
17.8
-
5.9
5.9
-
5.9
17.8
-
5.9
5.9
-
11.8
-
17.8
11.8
-
65-
192.5
48.1
-
-
-
-
-
495.0
-
27.5
-
6.9
-
41.2
20.6
20.6
55.0
13.7
103.1
20.6
247.5
-
61.9
27.5
-
-
6.9
-
6.9
6.9
6.9
-
6.9
-
-
-
13.7
6.9
6.9
70-
422.9
65.1
-
-
-
-
8.1
536.7
-
48.8
8.1
-
16.3
89.5
8.1
-
97.6
8.1
48.8
32.5
309.0
24.4
89.5
40.7
8.1
-
16.3
8.1
-
8.1
-
-
-
8.1
8.1
-
8.1
8.1
-
75-
592.1
56.9
-
-
-
-
-
455.4
-
22.8
-
11.4
-
79.7
-
-
34.2
-
56.9
45.5
444.0
22.8
136.6
56.9
-
-
11.4
11.4
-
22.8
11.4
-
11.4
-
-
-
11.4
11.4
-
80-
984.0
29.8
-
-
-
-
-
357.8
-
-
-
-
-
119.3
29.8
-
44.7
-
104.4
44.7
357.8
-
119.3
59.6
-
-
-
-
-
-
-
-
-
-
-
14.9
-
-
-
85+
CR
45.9
15.2
1.1
1.5
-
0.4
0.6
85.4
0.2
6.8
1.1
0.8
0.8
12.3
2.8
0.8
10.6
1.3
17.3
4.6
45.4
2.1
13.5
7.8
0.4
0.9
2.1
1.5
2.5
2.3
0.4
0.4
1.1
1.1
2.3
0.4
3.2
1.5
0.6
39.4
15.2
1.2
1.6
-
0.5
0.6
88.9
0.2
7.4
1.2
0.8
0.8
12.3
3.0
0.8
10.7
1.4
18.3
4.5
43.8
2.0
12.8
8.0
0.4
1.1
2.1
1.5
2.8
2.4
0.3
0.5
1.2
1.2
2.6
0.4
3.5
1.6
0.6
ESR
23.3
11.2
1.2
1.6
-
0.3
0.4
60.8
0.1
5.2
1.1
0.5
0.5
8.2
2.1
0.6
7.5
1.0
12.9
2.9
29.4
1.3
8.6
5.3
0.2
1.0
1.5
1.1
2.1
1.7
0.2
0.3
0.9
0.9
1.9
0.3
2.6
1.1
0.5
WSR
1.8
1.3
0.1
0.1
-
0.0
0.0
7.6
0.0
0.7
0.1
0.1
0.1
0.9
0.3
0.1
0.8
0.1
1.7
0.3
3.3
0.1
0.9
0.6
0.0
0.1
0.2
0.1
0.2
0.2
0.0
0.0
0.1
0.1
0.2
0.0
0.3
0.1
0.1
CRi
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Penis
Prostate
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
C46
C47,C49
C48
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
Myeloproliferative Disorders
Myelodysplastic syndromes
MPD
MDS
2,553
2,588
2,830
19
16
57
31.2
33.6
33.6
2.4
-
-
-
-
-
2.4
2.4
4.8
-
-
-
-
-
4.8
-
-
4.8
-
4.8
-
-
-
-
2.4
-
-
-
-
-
-
-
-
-
00-
14.9
17.9
17.9
3.0
-
-
-
3.0
-
-
3.0
3.0
-
-
-
3.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
13.3
16.7
16.7
3.3
-
-
-
-
-
-
-
3.3
-
-
3.3
-
-
-
-
-
3.3
-
3.3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
43.2
43.2
43.2
-
-
-
-
-
-
-
6.6
-
-
-
-
3.3
-
-
3.3
-
6.6
-
-
-
-
-
-
-
-
3.3
-
-
-
-
-
-
-
15-
CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRi: Cumulative Risk (0-74 years)
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Unknown primary site
C80
-
Other and ill-defined sites
C76
3
1
Monocytic leukaemia
C93
24
2
Myeloid leukaemia
C92
41
37
Lymphoid, haematopoietic and related tissue, NOS
Lymphoid leukaemia
C91
C96
Multiple myeloma
C90
8
89
27
-
3
30
2
44
2
8
1
140
6
10
75
3
32
526
7
9
4
12
13
4
Tot
C94-C95 Leukaemia other
Malignant immunoproliferative diseases
C88
C82-C86 Non-Hodgkin-lymphoma
Mesothelioma
Brussels Capital Region: Males 2010
C45
31.9
31.9
31.9
-
-
-
-
-
-
-
5.8
-
-
-
2.9
-
-
-
2.9
-
5.8
-
-
-
-
-
-
-
-
2.9
-
-
-
-
2.9
-
-
20-
66.6
66.6
68.8
-
-
2.2
-
-
-
-
2.2
-
-
-
4.4
4.4
-
-
2.2
-
-
-
-
-
-
-
-
2.2
-
20.0
-
-
-
2.2
2.2
2.2
-
25-
59.8
59.8
63.9
-
-
2.1
-
-
-
-
-
4.1
-
-
4.1
8.2
-
-
4.1
2.1
2.1
-
-
-
-
-
-
-
-
12.4
-
-
-
-
-
-
-
30-
122.6
124.8
129.1
2.2
-
2.2
-
-
-
-
8.8
-
-
-
4.4
17.5
-
-
6.6
-
8.8
-
-
-
6.6
-
-
8.8
-
8.8
-
-
-
-
-
4.4
-
35-
113.5
118.3
118.3
4.8
-
2.4
-
-
-
-
-
-
-
-
14.5
4.8
-
-
4.8
-
7.2
2.4
-
-
2.4
-
2.4
2.4
2.4
9.7
2.4
2.4
-
-
-
-
-
40-
308.1
310.9
319.1
-
2.8
5.5
-
-
-
-
2.8
2.8
8.3
2.8
30.3
2.8
-
2.8
11.0
2.8
8.3
2.8
-
-
2.8
-
-
16.5
-
2.8
19.3
-
5.5
-
2.8
8.3
-
45-
566.2
572.6
598.3
-
6.4
12.9
-
-
-
-
-
6.4
6.4
-
19.3
6.4
-
-
6.4
-
19.3
-
3.2
-
6.4
-
-
29.0
3.2
9.7
90.1
-
-
3.2
3.2
6.4
-
50-
17.8
5.9
35.5
-
-
-
-
-
11.8
23.7
5.9
65.1
11.8
-
-
11.8
-
11.8
-
5.9
-
124.3
5.9
-
47.4
-
5.9
509.2
11.8
5.9
-
5.9
5.9
11.8
65-
1,466.1
1,971.6
1,995.3
1,540.8 2,036.7
8.8
8.8
30.7
-
-
-
-
4.4
21.9
26.3
-
17.6
-
-
-
8.8
-
17.6
-
4.4
4.4
65.8
8.8
4.4
52.7
-
-
316.1
-
4.4
-
8.8
-
-
60-
956.5 1,448.6
960.3
975.1
3.7
-
18.6
-
-
-
-
3.7
29.8
14.9
11.2
33.5
7.4
-
-
22.3
-
11.2
-
-
-
44.7
-
7.4
44.7
-
3.7
178.7
3.7
7.4
-
11.2
-
-
55-
2,454.3
2,481.8
2,674.3
6.9
20.6
55.0
-
6.9
-
6.9
20.6
13.7
48.1
13.7
55.0
6.9
-
-
13.7
-
34.4
-
-
-
185.6
-
13.7
27.5
-
6.9
653.1
6.9
-
13.7
-
6.9
13.7
70-
3,082.1
3,130.8
3,553.7
24.4
24.4
73.2
-
-
8.1
8.1
40.7
16.3
73.2
8.1
89.5
8.1
-
-
8.1
-
16.3
-
8.1
-
227.7
16.3
8.1
97.6
-
-
821.3
8.1
16.3
-
16.3
8.1
-
75-
2,561.8
2,618.7
3,210.7
34.2
22.8
91.1
-
-
-
-
-
56.9
34.2
-
91.1
-
-
-
11.4
-
11.4
-
11.4
-
136.6
11.4
11.4
45.5
11.4
-
512.4
11.4
-
-
-
-
-
80-
CR
491.3
537.2
3.6
3.0
10.8
-
0.4
0.2
0.6
4.6
7.0
7.8
1.5
16.9
5.1
-
0.6
5.7
0.4
8.4
0.4
1.5
0.2
26.6
1.1
1.9
14.2
0.6
6.1
99.9
1.3
1.7
0.8
2.3
2.5
0.8
484.6
appendix
2,624.1
2,653.9
3,638.0
-
29.8
59.6
-
-
-
-
29.8
59.6
44.7
-
104.4
-
-
-
-
-
44.7
-
-
-
268.4
-
29.8
14.9
-
-
641.1
-
14.9
-
-
29.8
-
85+
107
0.1
0.5
0.2
0.6
12.0
1.1
16.7
1.7
-
372.0
348.8
343.9
3.5
538.0
498.6
492.1
0.3
33.6
34.0
35.2
0.3
0.2
0.8
-
0.0
belgian cancer registry
1.9
2.9
3.0
7.2
0.1
0.4
0.2
0.4
-
0.5
0.6
10.6
0.0
3.8
4.4
0.5
5.3
5.4
7.9
7.0
1.3
0.4
-
-
0.0
4.1
0.7
0.0
0.7
0.0
0.1
0.0
2.2
0.1
0.1
1.2
8.5
-
4.6
5.8
0.6
0.1
0.1
4.8
7.1
0.3
0.4
0.3
1.5
1.6
0.3
0.2
0.2
8.6
0.7
17.2
1.1
26.4
1.2
1.8
0.0
0.4
5.1
5.5
10.7
67.9
102.3
0.5
0.9
1.3
14.9
0.4
1.2
1.8
0.1
1.9
0.2
0.2
0.6
1.8
2.4
CRi
2.4
0.6
0.9
0.8
WSR
ESR
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Brussels Capital Region: Females 2010
189
102
5
-
-
2
2
206
-
12
3
2
-
68
17
9
21
15
65
16
236
4
48
25
-
3
3
3
4
5
2
1
4
3
6
-
8
4
-
Tot
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
Brussels Capital Region: Females, number of invasive tumours by primary site and age group in 2010
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
15-
1
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
1
-
20-
1
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
25-
2
9
-
-
-
1
-
2
-
-
-
-
-
-
-
-
1
-
1
-
1
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
1
-
-
30-
2
10
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
2
-
-
3
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
35-
3
3
1
-
-
-
-
6
-
1
-
-
-
-
1
-
-
-
4
1
3
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
40-
2
3
1
-
-
-
1
14
-
-
-
-
-
1
1
-
-
2
4
1
3
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
1
-
45-
4
15
-
-
-
-
1
12
-
4
-
-
-
2
-
1
1
4
2
1
10
1
3
1
-
-
1
-
-
1
-
-
1
-
1
-
1
-
-
50-
5
11
-
-
-
-
-
30
-
3
-
1
-
3
2
-
1
1
6
2
17
-
4
4
-
2
-
-
1
1
-
-
-
-
2
-
2
-
-
55-
2
9
2
-
-
-
-
30
-
1
1
-
-
11
1
1
2
2
10
-
22
-
4
3
-
-
1
1
1
-
-
1
1
2
1
-
2
1
-
60-
8
5
1
-
-
-
-
30
-
2
-
-
-
7
2
2
5
1
10
2
22
1
4
6
-
-
-
2
-
1
1
-
-
-
-
-
1
-
-
65-
17
11
-
-
-
-
-
22
-
1
-
1
-
16
-
3
4
1
2
1
19
1
5
1
-
-
-
-
1
-
-
-
-
-
2
-
-
-
-
70-
37
6
-
-
-
-
-
24
-
-
1
-
-
11
3
1
3
-
10
2
32
-
9
4
-
-
1
-
1
1
-
-
1
-
-
-
-
1
-
75-
32
8
-
-
-
1
-
24
-
-
-
-
-
11
2
-
2
2
8
4
51
-
8
2
-
1
-
-
-
-
-
-
-
-
-
-
1
-
-
80-
72
6
-
-
-
-
-
11
-
-
-
-
-
6
5
1
2
-
7
2
49
-
9
3
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
85+
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Vulva
Vagina
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C46
C47,C49
C48
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Mesothelioma
Brussels Capital Region: Females 2010
C45
2,624
2,648
2,837
9
15
42
-
5
1
3
34
29
29
13
95
13
-
3
88
1
28
2
7
2
43
1
4
39
-
5
83
1
115
57
3
19
927
3
15
4
6
Tot
11
11
11
-
-
-
-
3
-
-
-
2
-
-
1
-
-
1
-
-
1
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
1
-
-
00-
5
5
5
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
05-
6
6
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
1
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
10-
6
6
7
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
15-
12
12
13
-
-
-
-
-
-
-
1
-
-
-
1
2
-
1
2
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
20-
21
21
22
-
-
-
-
-
-
-
1
-
-
-
2
2
-
-
1
-
1
-
1
-
-
-
-
-
-
-
-
-
-
1
-
-
5
-
1
1
-
25-
70
70
72
-
-
-
-
-
-
-
1
-
-
-
4
-
-
-
11
-
-
-
-
-
-
-
-
1
-
1
-
-
-
5
-
1
26
1
2
-
-
30-
81
81
83
-
-
-
-
-
1
-
1
1
-
-
4
2
-
-
8
-
2
-
-
-
-
-
-
1
-
-
-
-
1
3
-
1
38
-
1
-
-
35-
119
119
122
-
-
-
-
-
-
-
2
1
-
-
-
-
-
-
10
-
2
-
-
-
-
-
-
-
-
-
3
-
1
15
-
1
62
-
-
-
-
40-
173
176
178
-
3
1
-
1
-
-
2
1
2
-
6
-
-
-
7
-
4
-
-
-
-
-
-
-
-
-
5
-
9
4
-
3
94
-
-
-
-
45-
213
214
218
-
1
2
-
-
-
-
1
1
6
-
5
1
-
-
15
-
1
-
1
-
-
-
-
1
-
-
6
-
7
3
-
2
98
-
-
-
-
50-
247
247
252
-
-
1
-
-
-
1
1
3
-
2
10
1
-
-
13
-
-
-
1
-
1
-
-
3
-
-
11
1
6
4
1
1
92
-
1
-
-
55-
309
309
311
-
-
6
-
-
-
-
5
2
-
2
9
1
-
-
3
-
2
-
2
1
2
-
-
6
-
-
10
-
13
7
-
-
124
-
1
1
2
60-
262
266
283
-
4
4
-
-
-
-
3
3
7
3
9
-
-
-
7
-
2
1
-
-
8
-
1
9
-
1
13
-
12
2
-
-
84
-
1
1
-
70-
appendix
268
268
276
-
-
2
-
1
-
1
5
2
2
2
9
2
-
-
2
-
2
1
-
-
6
-
-
1
-
-
5
-
19
2
-
2
94
2
-
-
1
65-
109
-
5
4
5
4
5
2
3
1
11
2
2
240
243
315
2
1
10
-
-
-
-
4
5
5
2
10
1
-
1
1
-
-
-
7
belgian cancer registry
298
6
1
283
2
-
339
14
10
307
-
1
324
-
-
287
-
-
-
-
1
3
4
-
1
-
-
1
2
3
10
9
-
1
-
3
-
6
7
-
9
1
1
3
57
-
2
1
3
-
15
21
2
5
5
-
1
-
1
-
4
1
-
72
81
12
-
-
-
2
1
7
11
-
-
1
2
-
85+
80-
75-
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Brussels Capital Region: Females 2010
189
102
5
-
-
2
2
206
-
12
3
2
-
68
17
9
21
15
65
16
236
4
48
25
-
3
3
3
4
5
2
1
4
3
6
-
8
4
-
Tot
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
3.5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3.5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
3.4
3.4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3.4
-
3.4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
15-
2.6
-
-
-
-
-
-
-
-
-
2.6
-
-
-
-
-
-
-
-
-
2.6
-
-
-
-
-
-
-
-
-
-
-
-
2.6
-
-
-
2.6
-
20-
2.0
8.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
25-
4.2
18.7
-
-
-
2.1
-
4.2
-
-
-
-
-
-
-
-
2.1
-
2.1
-
2.1
-
-
-
-
-
-
-
-
-
2.1
-
-
-
-
-
2.1
-
-
30-
4.7
23.6
-
-
-
-
-
2.4
-
-
-
-
-
-
-
-
-
4.7
-
-
7.1
2.4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
35-
8.0
8.0
2.7
-
-
-
-
16.0
-
2.7
-
-
-
-
2.7
-
-
-
10.7
2.7
8.0
-
5.3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
40-
Brussels Capital Region: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)
5.7
8.5
2.8
-
-
-
2.8
39.8
-
-
-
-
-
2.8
2.8
-
-
5.7
11.4
2.8
8.5
-
-
2.8
-
-
-
-
-
2.8
-
-
-
-
-
-
-
2.8
-
45-
12.3
46.2
-
-
-
-
3.1
37.0
-
12.3
-
-
-
6.2
-
3.1
3.1
12.3
6.2
3.1
30.8
3.1
9.2
3.1
-
-
3.1
-
-
3.1
-
-
3.1
-
3.1
-
3.1
-
-
50-
17.0
37.3
-
-
-
-
-
101.9
-
10.2
-
3.4
-
10.2
6.8
-
3.4
3.4
20.4
6.8
57.7
-
13.6
13.6
-
6.8
-
-
3.4
3.4
-
-
-
-
6.8
-
6.8
-
-
55-
7.7
34.5
7.7
-
-
-
-
115.1
-
3.8
3.8
-
-
42.2
3.8
3.8
7.7
7.7
38.4
-
84.4
-
15.3
11.5
-
-
3.8
3.8
3.8
-
-
3.8
3.8
7.7
3.8
-
7.7
3.8
-
60-
39.3
24.6
4.9
-
-
-
-
147.6
-
9.8
-
-
-
34.4
9.8
9.8
24.6
4.9
49.2
9.8
108.2
4.9
19.7
29.5
-
-
-
9.8
-
4.9
4.9
-
-
-
-
-
4.9
-
-
65-
88.0
56.9
-
-
-
-
-
113.8
-
5.2
-
5.2
-
82.8
-
15.5
20.7
5.2
10.3
5.2
98.3
5.2
25.9
5.2
-
-
-
-
5.2
-
-
-
-
-
10.3
-
-
-
-
70-
196.9
31.9
-
-
-
-
-
127.7
-
-
5.3
-
-
58.5
16.0
5.3
16.0
-
53.2
10.6
170.3
-
47.9
21.3
-
-
5.3
-
5.3
5.3
-
-
5.3
-
-
-
-
5.3
-
75-
194.0
48.5
-
-
-
6.1
-
145.5
-
-
-
-
-
66.7
12.1
-
12.1
12.1
48.5
24.2
309.1
-
48.5
12.1
-
6.1
-
-
-
-
-
-
-
-
-
-
6.1
-
-
80-
402.1
33.5
-
-
-
-
-
61.4
-
-
-
-
-
33.5
27.9
5.6
11.2
-
39.1
11.2
273.6
-
50.3
16.8
-
-
-
-
-
-
-
-
5.6
-
-
-
-
-
-
85+
33.6
18.1
0.9
-
-
0.4
0.4
36.6
-
2.1
0.5
0.4
-
12.1
3.0
1.6
3.7
2.7
11.6
2.8
41.9
0.7
8.5
4.4
-
0.5
0.5
0.5
0.7
0.9
0.4
0.2
0.7
0.5
1.1
-
1.4
0.7
-
CR
18.5
16.5
1.0
-
-
0.2
0.4
32.8
-
2.4
0.5
0.4
-
9.4
2.1
1.4
3.1
2.7
9.7
2.1
29.0
0.7
6.1
3.9
-
0.5
0.5
0.6
0.7
0.9
0.3
0.2
0.6
0.6
1.1
-
1.4
0.7
-
ESR
11.5
12.6
0.8
-
-
0.2
0.3
23.3
-
1.7
0.4
0.2
-
6.3
1.4
1.0
2.1
2.0
7.1
1.4
19.6
0.5
4.0
2.7
-
0.3
0.4
0.4
0.4
0.7
0.3
0.2
0.4
0.5
0.8
-
1.0
0.6
-
WSR
1.0
1.4
0.1
-
-
0.0
0.0
2.8
-
0.2
0.0
0.0
-
0.9
0.1
0.2
0.3
0.2
0.8
0.2
2.1
0.1
0.4
0.3
-
0.0
0.0
0.1
0.1
0.1
0.0
0.0
0.0
0.1
0.1
-
0.1
0.0
-
CRi
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
-
13
-
3
88
1
28
2
7
2
43
1
4
39
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C76
C80
MPD
MDS
2,624
2,648
2,837
9
15
42
27.6
27.6
27.6
-
-
-
-
7.5
-
-
-
5.0
-
-
2.5
-
-
2.5
-
-
2.5
-
2.5
-
-
-
-
2.5
-
-
-
-
-
-
-
-
-
-
2.5
-
-
00-
15.4
15.4
15.4
-
-
-
-
-
-
-
-
3.1
-
-
3.1
-
-
-
-
-
6.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3.1
-
-
05-
20.9
20.9
20.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
7.0
3.5
-
-
-
-
-
-
-
-
-
-
3.5
-
-
-
-
-
-
-
-
-
-
10-
20.6
20.6
24.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
6.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3.4
-
-
15-
CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRi: Cumulative Risk (0-74 years)
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
5
Lymphoid, haematopoietic and related tissue, NOS
C96
-
1
C94-C95 Leukaemia other
3
34
29
29
Monocytic leukaemia
Placenta
C58
5
83
C93
Female genital organs, NOS
C57
Myeloid leukaemia
Ovary
C56
1
C92
Uterus
C55
57
115
Lymphoid leukaemia
Corpus uteri
C54
Multiple myeloma
Cervix uteri
C53
3
C91
Vagina
C52
19
927
C90
Vulva
C51
13
Breast
C50
3
15
95
Retroperitoneum and peritoneum
C48
Malignant immunoproliferative diseases
Soft tissues
C47,C49
4
C88
Kaposi's sarcoma
C46
6
Tot
C82-C86 Non-Hodgkin-lymphoma
Mesothelioma
Brussels Capital Region: Females 2010
C45
31.2
31.2
33.8
-
-
-
-
-
-
-
2.6
-
-
-
2.6
5.2
-
2.6
5.2
-
-
-
-
-
-
-
-
-
-
-
2.6
-
-
-
-
-
-
-
-
-
-
20-
42.0
42.0
44.0
-
-
-
-
-
-
-
2.0
-
-
-
4.0
4.0
-
-
2.0
-
2.0
-
2.0
-
-
-
-
-
-
-
-
-
-
2.0
-
-
10.0
-
2.0
2.0
-
25-
145.5
145.5
149.6
-
-
-
-
-
-
-
2.1
-
-
-
8.3
-
-
-
22.9
-
-
-
-
-
-
-
-
2.1
-
2.1
-
-
-
10.4
-
2.1
54.0
2.1
4.2
-
-
30-
191.1
191.1
195.8
-
-
-
-
-
2.4
-
2.4
2.4
-
-
9.4
4.7
-
-
18.9
-
4.7
-
-
-
-
-
-
2.4
-
-
-
-
2.4
7.1
-
2.4
89.7
-
2.4
-
-
35-
316.9
316.9
324.9
-
-
-
-
-
-
-
5.3
2.7
-
-
-
-
-
-
26.6
-
5.3
-
-
-
-
-
-
-
-
-
8.0
-
2.7
39.9
-
2.7
165.1
-
-
-
-
40-
491.3
499.8
505.5
-
8.5
2.8
-
2.8
-
-
5.7
2.8
5.7
-
17.0
-
-
-
19.9
-
11.4
-
-
-
-
-
-
-
-
-
14.2
-
25.6
11.4
-
8.5
266.9
-
-
-
-
45-
656.6
659.7
672.1
-
3.1
6.2
-
-
-
-
3.1
3.1
18.5
-
15.4
3.1
-
-
46.2
-
3.1
-
3.1
-
-
-
-
3.1
-
-
18.5
-
21.6
9.2
-
6.2
302.1
-
-
-
-
50-
838.7
838.7
855.6
-
-
3.4
-
-
-
3.4
3.4
10.2
-
6.8
34.0
3.4
-
-
44.1
-
-
-
3.4
-
3.4
-
-
10.2
-
-
37.3
3.4
20.4
13.6
3.4
3.4
312.4
-
3.4
-
-
55-
1,185.5
1,185.5
1,193.2
-
-
23.0
-
-
-
-
19.2
7.7
-
7.7
34.5
3.8
-
-
11.5
-
7.7
-
7.7
3.8
7.7
-
-
23.0
-
-
38.4
-
49.9
26.9
-
-
475.8
-
3.8
3.8
7.7
60-
-
20.7
20.7
-
-
-
-
15.5
15.5
36.2
15.5
46.6
-
-
-
36.2
-
10.3
5.2
-
-
41.4
-
5.2
46.6
-
5.2
67.3
-
62.1
10.3
-
-
434.7
-
5.2
5.2
-
70-
1,318.1
1,318.1
1,355.8
1,376.5
1,357.5 1,464.4
-
-
9.8
-
4.9
-
4.9
24.6
9.8
9.8
9.8
44.3
9.8
-
-
9.8
-
9.8
4.9
-
-
29.5
-
-
4.9
-
-
24.6
-
93.4
9.8
-
9.8
462.3
9.8
-
-
4.9
65-
30.3
24.2
30.3
-
-
-
-
24.2
30.3
36.4
12.1
84.9
-
-
-
24.2
-
6.1
-
-
-
60.6
6.1
-
36.4
-
12.1
72.7
-
90.9
30.3
6.1
24.2
436.4
-
12.1
-
12.1
80-
1,860.7
1,505.9 1,806.2
1,527.2
1,724.0 2,054.7
10.6
10.6
58.5
-
-
-
5.3
16.0
10.6
5.3
-
53.2
5.3
-
-
10.6
-
16.0
-
5.3
5.3
47.9
-
16.0
37.2
-
5.3
37.2
-
111.7
26.6
-
5.3
431.0
-
5.3
-
-
75-
0.5
2.7
0.7
1.1
CR
466.3
470.5
504.1
1.6
2.7
7.5
-
0.9
0.2
0.5
6.0
5.2
5.2
2.3
16.9
2.3
-
0.5
15.6
0.2
5.0
0.4
1.2
0.4
7.6
0.2
0.7
6.9
-
0.9
14.7
0.2
20.4
10.1
0.5
3.4
164.7
appendix
1,340.3
1,357.0
1,759.1
11.2
5.6
55.8
-
-
-
-
22.3
27.9
27.9
11.2
55.8
5.6
-
5.6
5.6
-
16.8
-
-
-
39.1
-
-
16.8
-
-
50.3
-
61.4
5.6
5.6
16.8
318.3
-
11.2
5.6
5.6
85+
0.2
-
1.2
294.4
402.0
28.3
28.4
29.1
-
-
0.1
0.0
0.3
0.4
belgian cancer registry
296.0
404.6
3.3
5.0
307.5
-
-
423.1
0.2
1.2
1.0
1.3
0.1
0.3
0.3
0.3
0.5
0.2
1.9
0.0
3.8
5.0
0.6
0.4
3.3
0.2
1.1
0.2
2.7
-
0.0
3.9
0.4
4.0
0.5
15.6
0.3
0.0
1.3
12.3
0.2
10.2
0.3
4.6
0.1
0.1
1.9
4.2
0.4
0.0
13.8
0.3
1.3
-
1.1
0.3
0.4
1.8
0.2
5.0
0.0
-
3.1
0.1
0.5
1.1
2.1
0.3
0.0
0.5
3.8
-
0.3
0.5
5.4
0.0
8.9
12.4
0.0
1.4
0.1
0.2
0.7
0.0
7.3
0.2
0.3
12.1
11.6
1.9
2.6
9.4
112.6
152.4
0.1
0.1
0.1
0.1
CRi
16.7
2.0
0.4
0.4
0.5
2.1
0.5
0.8
0.5
WSR
ESR
111
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Walloon Region: Males 2010
692
323
11
6
3
5
12
1,818
4
195
14
6
9
274
47
10
173
19
404
50
854
34
234
231
10
23
59
13
47
54
5
26
24
25
66
12
55
31
6
Tot
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
Walloon Region: Males, number of invasive tumours by primary site and age group in 2010
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
1
1
4
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
-
3
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
15-
1
8
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
20-
-
13
2
-
-
-
-
2
-
-
-
-
-
1
-
-
2
-
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
25-
3
13
2
-
-
-
-
3
-
-
-
-
-
1
-
-
1
-
-
-
2
-
2
-
-
1
-
2
-
-
-
3
-
-
1
-
1
-
-
30-
2
21
-
-
-
-
-
1
-
-
1
-
-
3
-
-
2
-
4
-
5
-
3
-
-
-
-
-
-
-
-
-
-
-
1
1
1
-
-
35-
6
25
1
-
-
1
-
17
-
2
2
-
-
2
1
-
-
-
9
-
14
1
3
-
-
-
-
1
-
2
-
-
-
1
1
-
5
-
-
40-
7
27
-
-
-
-
-
46
-
18
-
-
-
12
2
1
1
1
15
2
17
2
8
9
-
2
3
1
4
6
-
2
3
2
6
-
2
2
-
45-
18
27
-
1
-
-
4
131
1
18
2
1
-
7
1
-
12
3
27
-
61
3
19
35
-
5
14
3
6
6
-
1
6
1
10
-
6
4
-
50-
38
32
1
-
-
1
3
225
2
40
3
-
2
22
5
1
23
4
48
4
80
7
21
35
3
4
11
3
12
12
-
2
1
9
19
3
10
7
-
55-
55
32
2
-
1
-
-
306
1
37
1
2
-
49
6
-
31
1
66
8
84
6
28
41
2
5
19
1
12
10
2
4
8
3
11
2
14
6
1
60-
71
28
-
-
-
-
1
250
-
23
2
1
2
45
5
1
28
4
53
10
105
4
30
25
1
2
5
1
5
9
-
2
1
4
9
2
4
6
-
65-
113
36
-
-
1
1
-
298
-
25
1
1
-
37
9
2
28
2
55
6
155
5
36
27
3
-
4
-
5
4
1
4
2
4
3
2
4
4
2
70-
122
29
-
-
1
1
2
277
-
20
1
-
4
45
5
1
29
2
51
9
137
4
35
26
-
2
1
-
2
4
1
3
-
-
3
-
3
2
2
75-
125
17
1
-
-
1
1
193
-
7
-
1
-
36
6
3
11
-
49
7
124
2
31
21
1
1
2
-
1
-
1
2
1
-
1
1
3
-
1
80-
131
11
-
-
-
-
-
68
-
5
1
-
1
13
7
1
4
2
26
4
65
-
18
12
-
1
-
1
-
1
-
3
2
1
1
-
1
-
-
85+
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Penis
Prostate
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C46
C47,C49
C48
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Mesothelioma
Walloon Region: Males 2010
C45
10,045
10,221
10,913
116
60
139
-
7
8
24
97
134
131
36
324
46
-
6
82
1
147
3
20
14
536
25
43
255
1
121
2,486
27
27
6
49
6
52
Tot
16
17
17
1
-
1
-
2
-
-
1
3
-
-
-
-
-
1
-
-
4
-
-
-
-
-
-
1
-
-
-
-
-
-
2
-
-
00-
15
15
15
-
-
1
-
1
-
-
-
2
-
-
1
1
-
-
1
-
4
-
2
-
-
-
-
-
-
-
-
-
-
-
2
-
-
05-
17
18
18
1
-
-
-
-
-
-
-
2
-
-
4
2
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
24
25
25
1
-
-
-
-
-
1
2
2
-
-
3
4
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
1
-
-
15-
33
33
34
-
-
-
-
1
-
-
-
1
-
-
1
4
-
-
1
-
3
-
-
-
-
-
-
-
-
9
-
-
-
-
1
-
-
20-
70
70
70
-
-
-
-
-
-
-
5
1
-
-
3
3
-
-
1
-
6
-
-
-
-
-
-
-
-
26
-
-
-
-
1
-
-
25-
79
81
84
1
1
-
-
-
-
1
1
1
-
-
8
2
-
-
-
-
4
-
-
-
2
-
-
-
-
28
-
-
-
-
-
-
-
30-
108
108
110
-
-
2
-
-
-
1
3
3
-
1
7
4
-
-
5
-
5
-
1
-
1
-
-
11
-
13
1
2
-
-
4
1
-
35-
179
182
188
-
3
3
-
-
1
-
4
3
-
1
13
3
-
-
12
-
15
-
1
-
4
-
-
6
-
16
5
-
1
-
2
-
1
40-
319
327
334
4
4
9
-
1
1
-
1
5
3
4
20
5
-
-
9
-
13
-
1
-
5
-
1
11
-
7
22
1
2
-
1
1
2
45-
672
674
692
1
1
7
-
-
-
-
6
4
7
-
30
4
-
-
10
-
11
-
3
-
16
-
2
23
1
5
119
2
3
-
-
2
2
50-
1,168
1,178
1,216
7
3
16
-
1
-
1
15
18
14
2
31
2
-
2
15
-
19
-
4
-
42
2
4
31
-
7
271
3
2
1
7
-
3
55-
1,539
1,553
1,608
5
9
26
-
-
2
4
7
13
16
2
43
4
-
2
8
1
16
-
2
1
71
5
9
41
-
1
443
2
3
1
9
1
4
60-
1,393
1,418
1,489
14
11
9
-
-
1
2
4
19
11
9
34
-
-
-
6
-
15
1
1
3
68
4
5
41
-
1
468
5
1
1
7
-
9
65-
1,399
1,438
1,560
29
10
18
-
1
1
5
13
8
26
7
36
4
-
-
4
-
9
-
4
5
93
8
10
23
-
1
399
5
5
1
-
1
10
75-
appendix
1,537
1,561
1,674
16
8
14
-
-
1
5
12
27
21
3
43
3
-
-
6
-
15
1
-
3
92
3
8
41
-
1
442
3
6
2
9
-
9
70-
8
25
516
501
976
belgian cancer registry
647
1,132
1,007
3
-
1
12
-
3
7
1
15
24
7
8
15
1
13
20
18
29
6
1
-
-
1
-
-
4
-
1
-
2
2
-
4
58
84
1
2
22
1
4
4
-
2
2
116
2
200
-
1
2
2
-
4
8
2
85+
80-
113
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Walloon Region: Males 2010
692
323
11
6
3
5
12
1,818
4
195
14
6
9
274
47
10
173
19
404
50
854
34
234
231
10
23
59
13
47
54
5
26
24
25
66
12
55
31
6
Tot
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
0.9
0.9
3.8
-
-
0.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
-
2.6
0.9
0.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1.8
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
15-
0.9
7.1
-
-
-
-
-
0.9
-
-
-
-
-
0.9
-
-
-
-
-
-
0.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.9
-
-
-
20-
-
12.3
1.9
-
-
-
-
1.9
-
-
-
-
-
0.9
-
-
1.9
-
0.9
-
1.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.9
-
-
25-
2.8
12.1
1.9
-
-
-
-
2.8
-
-
-
-
-
0.9
-
-
0.9
-
-
-
1.9
-
1.9
-
-
0.9
-
1.9
-
-
-
2.8
-
-
0.9
-
0.9
-
-
30-
1.6
17.3
-
-
-
-
-
0.8
-
-
0.8
-
-
2.5
-
-
1.6
-
3.3
-
4.1
-
2.5
-
-
-
-
-
-
-
-
-
-
-
0.8
0.8
0.8
-
-
35-
Walloon Region: Males, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)
4.8
20.1
0.8
-
-
0.8
-
13.7
-
1.6
1.6
-
-
1.6
0.8
-
-
-
7.2
-
11.3
0.8
2.4
-
-
-
-
0.8
-
1.6
-
-
-
0.8
0.8
-
4.0
-
-
40-
5.4
20.9
-
-
-
-
-
35.6
-
13.9
-
-
-
9.3
1.5
0.8
0.8
0.8
11.6
1.5
13.2
1.5
6.2
7.0
-
1.5
2.3
0.8
3.1
4.6
-
1.5
2.3
1.5
4.6
-
1.5
1.5
-
45-
14.7
22.0
-
0.8
-
-
3.3
106.9
0.8
14.7
1.6
0.8
-
5.7
0.8
-
9.8
2.4
22.0
-
49.8
2.4
15.5
28.6
-
4.1
11.4
2.4
4.9
4.9
-
0.8
4.9
0.8
8.2
-
4.9
3.3
-
50-
33.7
28.4
0.9
-
-
0.9
2.7
199.5
1.8
35.5
2.7
-
1.8
19.5
4.4
0.9
20.4
3.5
42.6
3.5
70.9
6.2
18.6
31.0
2.7
3.5
9.8
2.7
10.6
10.6
-
1.8
0.9
8.0
16.8
2.7
8.9
6.2
-
55-
53.7
31.2
2.0
-
1.0
-
-
298.6
1.0
36.1
1.0
2.0
-
47.8
5.9
-
30.2
1.0
64.4
7.8
82.0
5.9
27.3
40.0
2.0
4.9
18.5
1.0
11.7
9.8
2.0
3.9
7.8
2.9
10.7
2.0
13.7
5.9
1.0
60-
108.4
42.7
-
-
-
-
1.5
381.6
-
35.1
3.1
1.5
3.1
68.7
7.6
1.5
42.7
6.1
80.9
15.3
160.3
6.1
45.8
38.2
1.5
3.1
7.6
1.5
7.6
13.7
-
3.1
1.5
6.1
13.7
3.1
6.1
9.2
-
65-
188.1
59.9
-
-
1.7
1.7
-
496.0
-
41.6
1.7
1.7
-
61.6
15.0
3.3
46.6
3.3
91.5
10.0
258.0
8.3
59.9
44.9
5.0
-
6.7
-
8.3
6.7
1.7
6.7
3.3
6.7
5.0
3.3
6.7
6.7
3.3
70-
237.7
56.5
-
-
1.9
1.9
3.9
539.7
-
39.0
1.9
-
7.8
87.7
9.7
1.9
56.5
3.9
99.4
17.5
266.9
7.8
68.2
50.7
-
3.9
1.9
-
3.9
7.8
1.9
5.8
-
-
5.8
-
5.8
3.9
3.9
75-
364.6
49.6
2.9
-
-
2.9
2.9
562.9
-
20.4
-
2.9
-
105.0
17.5
8.7
32.1
-
142.9
20.4
361.7
5.8
90.4
61.2
2.9
2.9
5.8
-
2.9
-
2.9
5.8
2.9
-
2.9
2.9
8.7
-
2.9
80-
636.7
53.5
-
-
-
-
-
330.5
-
24.3
4.9
-
4.9
63.2
34.0
4.9
19.4
9.7
126.4
19.4
315.9
-
87.5
58.3
-
4.9
-
4.9
-
4.9
-
14.6
9.7
4.9
4.9
-
4.9
-
-
85+
CR
40.7
19.0
0.6
0.4
0.2
0.3
0.7
106.9
0.2
11.5
0.8
0.4
0.5
16.1
2.8
0.6
10.2
1.1
23.8
2.9
50.2
2.0
13.8
13.6
0.6
1.4
3.5
0.8
2.8
3.2
0.3
1.5
1.4
1.5
3.9
0.7
3.2
1.8
0.4
31.6
17.0
0.6
0.4
0.1
0.2
0.6
88.2
0.2
9.9
0.8
0.3
0.4
13.1
2.2
0.4
8.6
1.0
19.6
2.4
40.5
1.7
11.2
11.4
0.5
1.2
3.1
0.7
2.4
2.9
0.2
1.3
1.2
1.3
3.5
0.6
2.8
1.6
0.3
ESR
19.6
13.1
0.6
0.5
0.1
0.2
0.5
59.9
0.2
7.0
0.5
0.2
0.3
9.0
1.5
0.3
6.0
0.7
13.4
1.6
26.8
1.2
7.5
7.8
0.3
0.9
2.3
0.5
1.8
2.1
0.1
0.9
0.9
1.0
2.6
0.5
2.1
1.2
0.2
WSR
2.0
1.4
0.0
0.0
0.0
0.0
0.0
7.4
0.0
0.9
0.1
0.0
0.0
1.1
0.2
0.0
0.8
0.1
1.6
0.2
3.2
0.2
0.9
0.9
0.1
0.1
0.3
0.1
0.2
0.3
0.0
0.1
0.1
0.1
0.3
0.1
0.2
0.2
0.0
CRi
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
C68
C69
C70
C71
C72
C73
C74
C75
C81
25
46
-
6
82
1
147
3
20
14
536
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C76
C80
MPD
MDS
10,045
10,221
10,913
116
60
139
15.4
16.3
16.3
1.0
-
1.0
-
1.9
-
-
1.0
2.9
-
-
-
-
-
1.0
-
-
3.8
-
-
-
-
-
-
1.0
-
-
-
-
-
-
1.9
-
-
00-
14.3
14.3
14.3
-
-
1.0
-
1.0
-
-
-
1.9
-
-
1.0
1.0
-
-
1.0
-
3.8
-
1.9
-
-
-
-
-
-
-
-
-
-
-
1.9
-
-
05-
16.0
16.9
16.9
0.9
-
-
-
-
-
-
-
1.9
-
-
3.8
1.9
-
-
-
-
1.9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
21.1
22.0
22.0
0.9
-
-
-
-
-
0.9
1.8
1.8
-
-
2.6
3.5
-
-
-
-
-
-
-
-
-
-
-
-
-
3.5
-
-
-
-
0.9
-
-
15-
CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRi: Cumulative Risk (0-74 years)
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
7
Lymphoid, haematopoietic and related tissue, NOS
C96
-
8
C94-C95 Leukaemia other
24
97
134
131
Monocytic leukaemia
Bladder
C67
C93
Ureter
C66
43
255
Myeloid leukaemia
Renal pelvis
C65
C92
Kidney
C64
1
121
Lymphoid leukaemia
Male genital organs, NOS
C63
Multiple myeloma
Testis
C62
2,486
C91
Prostate
C61
27
27
C90
Penis
C60
36
Breast
C50
6
49
324
Retroperitoneum and peritoneum
C48
Malignant immunoproliferative diseases
Soft tissues
C47,C49
6
C88
Kaposi's sarcoma
C46
52
Tot
C82-C86 Non-Hodgkin-lymphoma
Mesothelioma
Walloon Region: Males 2010
C45
29.2
29.2
30.1
-
-
-
-
0.9
-
-
-
0.9
-
-
0.9
3.5
-
-
0.9
-
2.7
-
-
-
-
-
-
-
-
8.0
-
-
-
-
0.9
-
-
20-
66.1
66.1
66.1
-
-
-
-
-
-
-
4.7
0.9
-
-
2.8
2.8
-
-
0.9
-
5.7
-
-
-
-
-
-
-
-
24.6
-
-
-
-
0.9
-
-
25-
73.7
75.6
78.4
0.9
0.9
-
-
-
-
0.9
0.9
0.9
-
-
7.5
1.9
-
-
-
-
3.7
-
-
-
1.9
-
-
-
-
26.1
-
-
-
-
-
-
-
30-
89.0
89.0
90.6
-
-
1.6
-
-
-
0.8
2.5
2.5
-
0.8
5.8
3.3
-
-
4.1
-
4.1
-
0.8
-
0.8
-
-
9.1
-
10.7
0.8
1.6
-
-
3.3
0.8
-
35-
143.9
146.3
151.1
-
2.4
2.4
-
-
0.8
-
3.2
2.4
-
0.8
10.5
2.4
-
-
9.6
-
12.1
-
0.8
-
3.2
-
-
4.8
-
12.9
4.0
-
0.8
-
1.6
-
0.8
40-
246.9
253.1
258.5
3.1
3.1
7.0
-
0.8
0.8
-
0.8
3.9
2.3
3.1
15.5
3.9
-
-
7.0
-
10.1
-
0.8
-
3.9
-
0.8
8.5
-
5.4
17.0
0.8
1.5
-
0.8
0.8
1.5
45-
548.4
550.0
564.7
0.8
0.8
5.7
-
-
-
-
4.9
3.3
5.7
-
24.5
3.3
-
-
8.2
-
9.0
-
2.4
-
13.1
-
1.6
18.8
0.8
4.1
97.1
1.6
2.4
-
-
1.6
1.6
50-
4.9
8.8
25.4
-
-
2.0
3.9
6.8
12.7
15.6
2.0
42.0
3.9
-
2.0
7.8
1.0
15.6
-
2.0
1.0
69.3
4.9
8.8
40.0
-
1.0
432.2
2.0
2.9
1.0
8.8
1.0
3.9
60-
1,035.6
1,044.5
1,501.6
1,515.3
1,078.2 1,569.0
6.2
2.7
14.2
-
0.9
-
0.9
13.3
16.0
12.4
1.8
27.5
1.8
-
1.8
13.3
-
16.8
-
3.5
-
37.2
1.8
3.5
27.5
-
6.2
240.3
2.7
1.8
0.9
6.2
-
2.7
55-
2,126.3
2,164.4
2,272.8
21.4
16.8
13.7
-
-
1.5
3.1
6.1
29.0
16.8
13.7
51.9
-
-
-
9.2
-
22.9
1.5
1.5
4.6
103.8
6.1
7.6
62.6
-
1.5
714.4
7.6
1.5
1.5
10.7
-
13.7
65-
70-
2,558.0
2,598.0
2,786.1
26.6
13.3
23.3
-
-
1.7
8.3
20.0
44.9
35.0
5.0
71.6
5.0
-
-
10.0
-
25.0
1.7
-
5.0
153.1
5.0
13.3
68.2
-
1.7
735.6
5.0
10.0
3.3
15.0
-
15.0
75-
2,725.9
2,801.9
3,039.6
56.5
19.5
35.1
-
1.9
1.9
9.7
25.3
15.6
50.7
13.6
70.1
7.8
-
-
7.8
-
17.5
-
7.8
9.7
181.2
15.6
19.5
44.8
-
1.9
777.4
9.7
9.7
1.9
-
1.9
19.5
2,846.6
2,937.0
3,301.5
70.0
20.4
72.9
-
-
2.9
8.7
43.7
43.7
58.3
17.5
84.6
-
-
2.9
11.7
-
11.7
2.9
-
-
245.0
2.9
11.7
64.2
-
5.8
583.3
5.8
5.8
-
2.9
-
23.3
80-
601.2
641.9
6.8
3.5
8.2
-
0.4
0.5
1.4
5.7
7.9
7.7
2.1
19.1
2.7
-
0.4
4.8
0.1
8.6
0.2
1.2
0.8
31.5
1.5
2.5
15.0
0.1
7.1
146.2
1.6
1.6
0.4
2.9
0.4
3.1
CR
590.8
appendix
2,434.9
2,507.8
3,144.4
58.3
14.6
38.9
-
-
-
4.9
38.9
34.0
63.2
4.9
87.5
4.9
-
-
-
-
9.7
-
4.9
9.7
281.9
9.7
-
19.4
-
-
563.8
9.7
9.7
-
9.7
-
19.4
85+
115
0.3
0.2
0.3
1.2
0.0
0.4
0.0
-
0.4
0.8
0.1
6.7
0.0
3.3
0.3
0.7
1.0
0.1
8.0
0.0
4.3
0.3
36.3
35.0
11.9
1.2
3.9
5.2
3.4
0.8
0.3
0.5
4.5
2.0
3.4
370.0
350.4
345.0
16.3
1.7
6.0
6.8
4.7
1.1
0.4
0.4
6.5
2.9
5.2
534.7
503.1
495.0
belgian cancer registry
34.6
0.3
0.2
0.5
-
0.0
0.0
0.1
0.3
0.6
0.4
0.1
1.3
0.2
2.4
2.6
0.7
0.0
0.1
0.1
1.9
0.8
16.1
0.1
0.2
1.2
1.4
2.0
0.0
0.1
0.1
24.9
9.2
12.9
0.5
6.8
0.0
82.7
122.0
7.3
0.9
1.3
0.1
10.6
0.9
1.3
0.0
2.3
0.2
2.7
0.3
0.2
0.0
1.6
2.4
CRi
WSR
ESR
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Walloon Region: Females 2010
478
459
7
7
-
1
9
814
2
34
2
4
6
248
46
33
71
40
301
50
716
34
165
91
1
3
15
4
13
28
1
18
16
12
21
15
34
11
4
Tot
Walloon Region: Females, number of invasive tumours by primary site and age group in 2010
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
-
1
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
-
5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
-
-
15-
1
19
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
2
1
1
-
-
-
-
-
-
-
-
-
-
1
-
-
1
-
-
20-
2
37
2
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
25-
1
28
-
1
-
-
-
-
-
-
-
-
-
2
-
-
-
-
1
-
4
-
1
-
-
-
-
1
-
-
-
-
-
-
-
1
1
1
-
30-
3
39
-
2
-
-
1
6
-
-
-
-
-
2
-
-
1
-
4
1
5
-
3
2
-
1
-
-
-
-
-
2
-
-
-
-
-
-
-
35-
9
49
-
1
-
-
1
15
-
1
-
1
1
6
-
-
1
3
6
-
5
3
1
2
-
-
-
-
-
1
-
-
-
-
-
1
1
-
1
40-
11
46
1
-
-
-
1
48
-
3
-
-
-
4
1
-
2
3
12
1
22
-
4
3
-
-
-
-
1
2
-
-
2
1
2
-
-
-
1
45-
22
32
-
1
-
-
-
77
1
4
-
-
-
16
1
4
3
1
21
5
35
3
4
6
1
-
3
-
2
4
1
1
3
3
3
1
7
1
-
50-
27
43
1
-
-
-
2
118
-
7
-
-
-
11
1
-
5
4
30
3
43
2
17
14
-
-
4
-
3
8
-
3
5
1
5
-
3
3
-
55-
33
36
-
1
-
-
2
144
1
9
1
-
1
29
6
2
12
9
31
5
64
5
9
14
-
-
3
-
2
6
-
1
-
1
8
1
7
3
-
60-
25
26
-
-
-
1
-
113
-
5
-
-
-
29
6
4
13
4
31
5
63
2
23
7
-
1
2
-
3
1
-
3
1
-
-
1
3
-
-
65-
48
27
2
-
-
-
-
107
-
2
-
2
-
41
4
4
6
4
36
8
86
4
18
12
-
-
3
-
-
-
-
1
1
4
-
2
3
1
-
70-
75
25
-
-
-
-
-
100
-
1
-
-
3
46
10
7
14
8
46
9
116
6
20
11
-
1
-
-
2
3
-
1
1
1
-
5
2
-
-
75-
83
21
1
-
-
-
2
56
-
1
-
-
1
36
6
7
10
-
40
7
140
4
23
13
-
-
-
2
-
2
-
4
2
-
2
1
5
2
1
80-
138
23
-
-
-
-
-
29
-
1
1
-
-
25
11
5
4
4
42
6
126
4
41
7
-
-
-
-
-
1
-
-
1
-
1
2
1
-
1
85+
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Vulva
Vagina
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C46
C47,C49
C48
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Mesothelioma
Walloon Region: Females 2010
C45
9,284
9,428
9,906
83
61
147
2
4
6
15
82
127
92
36
286
53
2
6
277
3
102
2
14
4
142
13
23
144
-
15
272
4
474
206
12
69
3,250
12
41
1
10
Tot
21
22
22
1
-
-
-
-
-
-
2
6
-
-
-
-
-
1
-
1
6
-
2
-
-
-
-
-
-
-
1
-
-
-
1
-
-
1
-
-
-
00-
12
13
13
1
-
-
-
-
-
-
-
2
-
-
1
-
-
-
-
1
3
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
9
10
10
-
1
-
-
-
-
-
1
3
-
-
-
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
32
32
32
-
-
-
-
1
-
-
1
3
-
-
1
8
-
1
5
-
2
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
2
-
-
15-
54
54
55
-
-
-
-
-
-
-
1
-
-
-
3
7
-
-
7
-
1
-
-
-
-
-
-
-
-
-
1
-
-
3
-
-
4
-
-
-
-
20-
94
97
99
2
1
1
-
-
-
-
1
-
-
1
1
9
-
1
14
-
3
-
-
-
-
-
-
-
-
-
1
-
1
6
-
1
8
-
2
-
-
25-
137
138
139
1
-
-
-
1
-
1
2
-
1
-
9
4
-
-
20
-
6
1
-
-
-
-
-
2
-
-
2
-
-
9
-
1
36
-
1
-
-
30-
241
241
244
-
-
3
-
-
-
-
3
-
-
3
7
5
-
-
28
-
1
-
-
-
1
-
-
4
-
-
2
-
1
23
-
-
88
-
3
-
-
35-
402
405
414
-
3
1
-
1
1
1
4
2
1
-
7
4
-
-
23
-
1
1
-
-
2
-
-
7
-
-
10
-
5
24
-
2
203
1
1
-
-
40-
658
663
674
1
4
9
-
-
-
2
8
7
2
3
17
2
-
-
31
-
7
-
1
-
1
-
1
6
-
1
13
-
14
31
1
5
333
-
3
-
-
45-
834
845
867
5
6
8
-
-
1
-
3
10
1
1
13
2
1
1
35
1
9
-
2
-
5
1
1
15
-
1
19
-
20
23
2
9
402
1
3
-
-
50-
1,031
1,036
1,063
3
2
12
-
-
2
1
5
9
8
1
17
2
-
-
43
-
12
-
1
-
10
2
2
14
-
1
27
-
48
19
-
5
449
1
2
-
2
55-
1,196
1,205
1,238
5
4
16
-
1
-
-
3
15
8
1
27
1
-
1
23
-
11
-
1
-
17
-
2
16
-
3
47
1
78
15
1
6
484
-
3
1
1
60-
956
976
1,024
10
10
16
-
-
2
4
10
13
14
5
28
1
-
1
10
-
7
-
3
1
13
2
2
24
-
3
40
-
63
9
-
3
296
2
2
-
4
70-
appendix
928
939
964
7
4
13
-
-
-
2
10
15
17
3
29
3
1
-
19
-
8
-
1
-
11
2
2
17
-
-
31
-
71
13
2
10
294
2
4
-
1
65-
5
-
3
212
10
2
8
57
26
2
9
2
2
29
1
2
2
4
266
7
2
12
76
37
4
24
6
2
22
1
1
17
4
25
5
17
903
2
1
21
10
17
986
903
876
1
1
22
11
13
1,159
1,084
1,060
belgian cancer registry
743
765
-
1
9
13
10
11
6
-
9
5
13
9
1
31
45
3
50
21
-
-
-
4
8
7
-
-
1
31
2
5
5
-
-
14
3
40
11
1
10
175
4
8
-
-
2
-
85+
80-
75-
18
117
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
Walloon Region: Females 2010
478
459
7
7
-
1
9
814
2
34
2
4
6
248
46
33
71
40
301
50
716
34
165
91
1
3
15
4
13
28
1
18
16
12
21
15
34
11
4
Tot
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
00-
-
1.0
-
-
-
-
-
-
-
-
-
1.0
-
-
-
-
-
-
1.0
-
1.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
-
2.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
-
4.6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
0.9
-
-
-
0.9
-
-
-
-
-
-
-
15-
0.9
17.2
-
-
-
-
-
0.9
-
-
-
-
-
0.9
-
-
-
-
-
-
1.8
0.9
0.9
-
-
-
-
-
-
-
-
-
-
0.9
-
-
0.9
-
-
20-
1.9
35.3
1.9
1.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2.9
-
-
-
-
-
-
-
-
-
-
1.0
-
-
-
-
-
-
-
25-
0.9
26.3
-
0.9
-
-
-
-
-
-
-
-
-
1.9
-
-
-
-
0.9
-
3.8
-
0.9
-
-
-
-
0.9
-
-
-
-
-
-
-
0.9
0.9
0.9
-
30-
2.5
32.4
-
1.7
-
-
0.8
5.0
-
-
-
-
-
1.7
-
-
0.8
-
3.3
0.8
4.2
-
2.5
1.7
-
0.8
-
-
-
-
-
1.7
-
-
-
-
-
-
-
35-
Walloon Region: Females, age-specific and age-standardised incidence rates of cancer, by primary site in 2010 (n/100,000 person years)
7.3
39.5
-
0.8
-
-
0.8
12.1
-
0.8
-
0.8
0.8
4.8
-
-
0.8
2.4
4.8
-
4.0
2.4
0.8
1.6
-
-
-
-
-
0.8
-
-
-
-
-
0.8
0.8
-
0.8
40-
8.5
35.5
0.8
-
-
-
0.8
37.0
-
2.3
-
-
-
3.1
0.8
-
1.5
2.3
9.3
0.8
17.0
-
3.1
2.3
-
-
-
-
0.8
1.5
-
-
1.5
0.8
1.5
-
-
-
0.8
45-
17.5
25.5
-
0.8
-
-
-
61.3
0.8
3.2
-
-
-
12.7
0.8
3.2
2.4
0.8
16.7
4.0
27.9
2.4
3.2
4.8
0.8
-
2.4
-
1.6
3.2
0.8
0.8
2.4
2.4
2.4
0.8
5.6
0.8
-
50-
23.2
37.0
0.9
-
-
-
1.7
101.4
-
6.0
-
-
-
9.5
0.9
-
4.3
3.4
25.8
2.6
37.0
1.7
14.6
12.0
-
-
3.4
-
2.6
6.9
-
2.6
4.3
0.9
4.3
-
2.6
2.6
-
55-
30.5
33.2
-
0.9
-
-
1.8
132.9
0.9
8.3
0.9
-
0.9
26.8
5.5
1.8
11.1
8.3
28.6
4.6
59.1
4.6
8.3
12.9
-
-
2.8
-
1.8
5.5
-
0.9
-
0.9
7.4
0.9
6.5
2.8
-
60-
33.8
35.1
-
-
-
1.4
-
152.6
-
6.8
-
-
-
39.2
8.1
5.4
17.6
5.4
41.9
6.8
85.1
2.7
31.1
9.5
-
1.4
2.7
-
4.1
1.4
-
4.1
1.4
-
-
1.4
4.1
-
-
65-
63.5
35.7
2.6
-
-
-
-
141.6
-
2.6
-
2.6
-
54.3
5.3
5.3
7.9
5.3
47.6
10.6
113.8
5.3
23.8
15.9
-
-
4.0
-
-
-
-
1.3
1.3
5.3
-
2.6
4.0
1.3
-
70-
100.7
33.6
-
-
-
-
-
134.3
-
1.3
-
-
4.0
61.8
13.4
9.4
18.8
10.7
61.8
12.1
155.7
8.1
26.9
14.8
-
1.3
-
-
2.7
4.0
-
1.3
1.3
1.3
-
6.7
2.7
-
-
75-
134.1
33.9
1.6
-
-
-
3.2
90.5
-
1.6
-
-
1.6
58.2
9.7
11.3
16.2
-
64.6
11.3
226.3
6.5
37.2
21.0
-
-
-
3.2
-
3.2
-
6.5
3.2
-
3.2
1.6
8.1
3.2
1.6
80-
249.8
41.6
-
-
-
-
-
52.5
-
1.8
1.8
-
-
45.2
19.9
9.0
7.2
7.2
76.0
10.9
228.1
7.2
74.2
12.7
-
-
-
-
-
1.8
-
-
1.8
-
1.8
3.6
1.8
-
1.8
85+
26.6
25.5
0.4
0.4
-
0.1
0.5
45.3
0.1
1.9
0.1
0.2
0.3
13.8
2.6
1.8
3.9
2.2
16.7
2.8
39.8
1.9
9.2
5.1
0.1
0.2
0.8
0.2
0.7
1.6
0.1
1.0
0.9
0.7
1.2
0.8
1.9
0.6
0.2
CR
14.8
23.1
0.3
0.4
-
0.1
0.4
35.3
0.1
1.6
0.1
0.2
0.2
9.1
1.5
1.1
2.8
1.7
11.2
1.8
24.1
1.3
5.7
3.6
0.1
0.1
0.7
0.2
0.6
1.3
0.1
0.8
0.7
0.6
1.0
0.5
1.5
0.5
0.1
ESR
9.6
19.5
0.3
0.4
-
0.0
0.3
25.2
0.1
1.2
0.0
0.2
0.1
6.2
1.0
0.7
1.9
1.2
7.7
1.2
16.2
0.9
3.8
2.5
0.0
0.1
0.5
0.2
0.5
0.9
0.0
0.6
0.5
0.4
0.7
0.4
1.1
0.4
0.1
WSR
0.9
1.8
0.0
0.0
-
0.0
0.0
3.2
0.0
0.2
0.0
0.0
0.0
0.8
0.1
0.1
0.2
0.1
0.9
0.2
1.8
0.1
0.4
0.3
0.0
0.0
0.1
0.0
0.1
0.1
0.0
0.1
0.1
0.1
0.1
0.0
0.1
0.0
0.0
CRi
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Vulva
Vagina
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
C46
C47,C49
C48
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
Myeloproliferative Disorders
Myelodysplastic syndromes
MPD
MDS
9,284
9,428
9,906
83
61
147
21.1
22.1
22.1
1.0
-
-
-
-
-
-
2.0
6.0
-
-
-
-
-
1.0
-
1.0
6.0
-
2.0
-
-
-
-
-
-
-
1.0
-
-
-
1.0
-
-
1.0
-
-
-
00-
11.9
12.9
12.9
1.0
-
-
-
-
-
-
-
2.0
-
-
1.0
-
-
-
-
1.0
3.0
-
-
-
-
-
-
1.0
-
-
-
-
-
-
-
-
-
-
-
-
-
05-
8.8
9.8
9.8
-
1.0
-
-
-
-
-
1.0
2.9
-
-
-
1.0
-
-
-
-
1.0
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
10-
29.3
29.3
29.3
-
-
-
-
0.9
-
-
0.9
2.7
-
-
0.9
7.3
-
0.9
4.6
-
1.8
-
-
-
-
-
-
-
-
-
0.9
-
-
-
-
-
-
-
1.8
-
-
15-
CR: crude (all ages) incidence rate (N/100,000 person years)
ESR and WSR: age standardised incidence rate, using the European or World Standard Population (N/100,000 person years)
CRi: Cumulative Risk (0-74 years)
Total excl. non-melanoma and MDS, MPD
Total excl. non-melanoma
Total
Unknown primary site
C80
2
4
Other and ill-defined sites
15
Lymphoid, haematopoietic and related tissue, NOS
Monocytic leukaemia
C93
82
127
C76
Myeloid leukaemia
C92
C96
Lymphoid leukaemia
C91
36
92
6
Multiple myeloma
C90
286
53
2
6
277
3
102
2
14
4
142
13
23
144
-
15
272
4
474
206
12
69
3,250
12
41
1
10
Tot
C94-C95 Leukaemia other
Malignant immunoproliferative diseases
C88
C82-C86 Non-Hodgkin-lymphoma
Mesothelioma
Walloon Region: Females 2010
C45
49.0
49.0
49.9
-
-
-
-
-
-
-
0.9
-
-
-
2.7
6.3
-
-
6.3
-
0.9
-
-
-
-
-
-
-
-
-
0.9
-
-
2.7
-
-
3.6
-
-
-
-
20-
89.8
92.6
94.5
1.9
1.0
1.0
-
-
-
-
1.0
-
-
1.0
1.0
8.6
-
1.0
13.4
-
2.9
-
-
-
-
-
-
-
-
-
1.0
-
1.0
5.7
-
1.0
7.6
-
1.9
-
-
25-
128.7
129.6
130.6
0.9
-
-
-
0.9
-
0.9
1.9
-
0.9
-
8.5
3.8
-
-
18.8
-
5.6
0.9
-
-
-
-
-
1.9
-
-
1.9
-
-
8.5
-
0.9
33.8
-
0.9
-
-
30-
200.5
200.5
203.0
-
-
2.5
-
-
-
-
2.5
-
-
2.5
5.8
4.2
-
-
23.3
-
0.8
-
-
-
0.8
-
-
3.3
-
-
1.7
-
0.8
19.1
-
-
73.2
-
2.5
-
-
35-
324.0
326.4
333.6
-
2.4
0.8
-
0.8
0.8
0.8
3.2
1.6
0.8
-
5.6
3.2
-
-
18.5
-
0.8
0.8
-
-
1.6
-
-
5.6
-
-
8.1
-
4.0
19.3
-
1.6
163.6
0.8
0.8
-
-
40-
507.2
511.1
519.5
0.8
3.1
6.9
-
-
-
1.5
6.2
5.4
1.5
2.3
13.1
1.5
-
-
23.9
-
5.4
-
0.8
-
0.8
-
0.8
4.6
-
0.8
10.0
-
10.8
23.9
0.8
3.9
256.7
-
2.3
-
-
45-
664.5
673.2
690.8
4.0
4.8
6.4
-
-
0.8
-
2.4
8.0
0.8
0.8
10.4
1.6
0.8
0.8
27.9
0.8
7.2
-
1.6
-
4.0
0.8
0.8
12.0
-
0.8
15.1
-
15.9
18.3
1.6
7.2
320.3
0.8
2.4
-
-
50-
886.0
890.3
913.5
2.6
1.7
10.3
-
-
1.7
0.9
4.3
7.7
6.9
0.9
14.6
1.7
-
-
37.0
-
10.3
-
0.9
-
8.6
1.7
1.7
12.0
-
0.9
23.2
-
41.2
16.3
-
4.3
385.9
0.9
1.7
-
1.7
55-
1,103.7
1,112.0
1,142.4
4.6
3.7
14.8
-
0.9
-
-
2.8
13.8
7.4
0.9
24.9
0.9
-
0.9
21.2
-
10.2
-
0.9
-
15.7
-
1.8
14.8
-
2.8
43.4
0.9
72.0
13.8
0.9
5.5
446.6
-
2.8
0.9
0.9
60-
1,252.9
1,267.7
1,301.5
9.5
5.4
17.6
-
-
-
2.7
13.5
20.3
23.0
4.1
39.2
4.1
1.4
-
25.7
-
10.8
-
1.4
-
14.9
2.7
2.7
23.0
-
-
41.9
-
95.9
17.6
2.7
13.5
396.9
2.7
5.4
-
1.4
65-
1,265.0
1,291.5
1,355.0
13.2
13.2
21.2
-
-
2.6
5.3
13.2
17.2
18.5
6.6
37.1
1.3
-
1.3
13.2
-
9.3
-
4.0
1.3
17.2
2.6
2.6
31.8
-
4.0
52.9
-
83.4
11.9
-
4.0
391.7
2.6
2.6
-
5.3
70-
1,423.1
1,455.4
1,556.1
17.5
14.8
29.5
1.3
-
-
1.3
12.1
24.2
28.2
12.1
67.1
4.0
-
-
9.4
-
22.8
-
1.3
1.3
29.5
2.7
8.1
32.2
-
5.4
49.7
-
102.0
16.1
2.7
9.4
357.1
-
5.4
-
-
75-
1,415.7
1,459.3
1,593.5
27.5
16.2
33.9
1.6
-
-
3.2
16.2
21.0
21.0
8.1
72.7
-
-
-
12.9
-
3.2
-
3.2
1.6
46.9
3.2
3.2
14.5
-
3.2
42.0
-
92.1
12.9
3.2
16.2
342.6
-
4.8
-
3.2
80-
CR
516.3
524.3
550.9
4.6
3.4
8.2
0.1
0.2
0.3
0.8
4.6
7.1
5.1
2.0
15.9
2.9
0.1
0.3
15.4
0.2
5.7
0.1
0.8
0.2
7.9
0.7
1.3
8.0
-
0.8
15.1
0.2
26.4
11.5
0.7
3.8
180.7
0.7
2.3
0.1
0.6
appendix
1,344.8
1,384.6
1,634.4
30.8
9.0
45.2
-
-
-
1.8
16.3
19.9
10.9
7.2
56.1
1.8
-
-
7.2
-
9.0
-
-
1.8
56.1
3.6
9.0
9.0
-
-
25.3
5.4
72.4
19.9
1.8
18.1
316.7
7.2
14.5
-
-
85+
0.1
0.0
0.0
0.0
0.8
108.5
2.0
0.4
147.0
2.7
0.5
0.1
0.0
0.0
0.4
0.1
3.1
7.8
0.9
2.3
4.5
2.7
0.5
0.2
0.1
3.1
10.9
1.3
3.4
5.4
3.5
0.6
0.3
0.2
28.9
3.7
1.7
2.0
304.8
295.2
291.6
5.3
2.3
2.8
415.0
400.2
395.1
belgian cancer registry
27.9
28.2
0.2
0.4
-
0.2
0.0
0.2
0.0
0.1
0.3
0.4
0.3
0.1
0.8
0.2
0.0
0.0
1.2
0.0
12.0
0.4
0.0
0.4
0.1
0.1
14.7
0.6
0.7
0.3
0.0
4.3
0.1
0.1
0.3
3.0
4.5
0.1
0.0
0.2
0.3
0.5
0.5
1.0
0.0
5.0
0.5
0.8
-
4.5
-
8.2
0.4
11.3
0.6
6.2
0.0
0.1
0.1
1.6
8.1
12.7
10.2
18.4
0.2
11.7
0.0
1.4
0.4
1.7
0.5
0.0
0.0
0.3
0.4
CRi
WSR
ESR
119
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
Primary site
Males
256
20
24
-
11
6
3,066
3
352
283
22
19
-
6
8
3,008
10
341
10
40
9
1
310
49
16
106
24
749
159
43
2
266
50
13
122
21
721
167
1,437
54
49
1,410
525
366
16
21
50
533
384
21
23
49
15
30
39
21
72
8
37
38
26
76
7
24
41
23
77
10
6
72
81
27
48
2002
77
36
39
2001
340
23
21
1
7
5
3,047
8
369
34
13
6
337
61
9
119
27
816
149
1,512
76
513
350
10
31
45
23
34
85
12
30
41
19
75
11
65
32
49
2003
370
25
28
-
5
18
3,263
8
348
36
10
3
347
74
20
141
27
831
205
1,582
62
533
362
9
39
76
21
44
84
8
38
42
26
92
11
95
37
44
2004
377
23
23
1
7
10
3,190
5
315
46
16
3
327
62
18
167
29
832
118
1,697
56
523
397
16
30
55
15
35
79
14
30
44
27
84
8
98
21
45
2005
N
385
20
21
-
8
10
3,255
4
319
34
15
1
361
84
23
168
20
905
100
1,743
73
512
422
8
41
55
21
40
92
5
24
51
29
74
14
79
29
39
2006
446
22
22
-
12
8
3,350
9
342
40
14
3
352
83
21
185
24
906
88
1,701
44
523
435
10
45
68
18
52
88
10
31
32
30
72
9
71
58
20
2007
423
23
17
-
9
7
3,283
1
313
47
20
6
360
83
17
228
31
947
104
1,890
70
537
387
14
35
42
22
63
97
8
29
26
32
89
16
86
59
22
2008
Flemish Region: Males, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2001-2010
404
14
14
-
9
12
3,256
7
307
31
17
7
395
98
19
206
40
963
101
1,930
61
545
410
9
43
65
22
52
90
13
35
32
32
92
15
85
68
36
2009
468
26
22
-
17
6
3,348
5
310
43
20
9
446
83
22
250
30
916
104
1,874
94
549
408
6
29
55
22
74
69
8
32
31
28
79
17
76
51
41
2010
5.9
0.5
0.8
-
0.3
0.1
58.1
0.1
7.2
1.0
0.2
0.0
5.2
1.0
0.2
2.4
0.4
13.9
3.1
25.9
0.9
9.8
8.0
0.5
0.6
1.1
0.6
0.9
1.7
0.2
0.6
1.0
0.6
1.7
0.1
1.7
0.8
0.7
2001
6.1
0.7
0.6
-
0.1
0.2
55.7
0.2
7.1
0.8
0.2
0.0
6.0
0.9
0.3
2.1
0.4
14.1
2.9
25.8
1.1
9.6
7.5
0.4
0.5
1.2
0.4
0.6
1.6
0.2
0.7
0.8
0.6
1.8
0.2
1.9
0.6
0.8
2002
7.8
0.7
0.7
0.0
0.1
0.1
55.2
0.2
7.5
0.7
0.3
0.1
6.1
1.0
0.2
2.6
0.6
15.0
2.6
26.6
1.4
9.1
7.0
0.3
0.7
1.0
0.5
0.7
1.9
0.3
0.6
0.9
0.4
1.7
0.3
1.4
0.7
0.9
2003
8.2
0.8
1.0
-
0.1
0.4
58.0
0.1
7.0
0.7
0.2
0.1
6.5
1.3
0.3
2.7
0.6
15.2
3.5
26.7
1.2
9.2
7.1
0.2
0.8
1.6
0.5
1.0
1.7
0.1
0.8
0.9
0.5
2.0
0.2
2.1
0.8
0.7
2004
8.3
0.6
0.8
0.0
0.2
0.2
56.0
0.1
6.0
0.9
0.3
0.1
5.9
1.1
0.3
3.2
0.6
15.0
2.1
28.6
1.1
9.0
7.6
0.4
0.6
1.2
0.4
0.8
1.7
0.2
0.6
0.8
0.6
1.8
0.2
2.1
0.5
0.8
2005
8.3
0.6
0.8
-
0.2
0.2
55.9
0.1
6.0
0.7
0.3
0.0
6.2
1.4
0.4
3.2
0.4
15.8
1.7
28.8
1.4
8.4
7.8
0.2
0.9
1.1
0.5
0.9
1.9
0.1
0.5
1.0
0.6
1.6
0.2
1.6
0.6
0.7
2006
WSR
9.5
0.5
0.8
-
0.3
0.2
56.6
0.1
6.6
0.8
0.3
0.1
6.2
1.4
0.4
3.3
0.4
15.5
1.4
27.2
0.8
8.5
8.1
0.2
0.9
1.5
0.4
1.1
1.8
0.2
0.6
0.6
0.6
1.6
0.2
1.4
1.2
0.3
2007
8.7
0.6
0.5
-
0.2
0.1
54.7
0.0
5.7
0.9
0.3
0.1
6.2
1.4
0.2
4.2
0.5
16.1
1.7
29.7
1.2
8.5
7.0
0.3
0.7
0.9
0.5
1.2
2.0
0.1
0.5
0.5
0.7
1.8
0.3
1.8
1.2
0.4
2008
8.0
0.4
0.5
-
0.2
0.2
52.4
0.1
5.5
0.6
0.3
0.1
6.5
1.6
0.3
3.6
0.7
15.8
1.6
29.8
1.0
8.5
7.1
0.2
0.8
1.2
0.5
1.1
1.8
0.2
0.6
0.6
0.7
1.8
0.2
1.8
1.3
0.5
2009
9.4
0.7
0.7
-
0.4
0.1
52.2
0.1
5.2
0.7
0.4
0.1
7.2
1.3
0.3
4.4
0.6
15.2
1.6
28.4
1.5
8.6
6.9
0.1
0.6
1.0
0.5
1.4
1.4
0.2
0.6
0.6
0.6
1.6
0.3
1.5
1.0
0.5
2010
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
8
WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)
17.920
77
73
9
365
10
24
3
19
15
547
15
11
21
23
147
235
263
181
202
36
472
79
6
11
54
7
250
198
20
495
74
3
12
49
7
221
4
12
37
12
928
40
57
458
33
1,005
47
61
472
-
129
134
6
5,012
5,438
31
50
Total excl. non-melanoma and MDS, MPD
Prostate
C61
54
30
17.148
Penis
C60
11
16.998
Breast
C50
17
9
94
17.765
Retroperitoneum and peritoneum
C48
7
94
17.784
Soft tissues
C47,C49
Total excl. non-melanoma
Kaposi's sarcoma
C46
98
18.525
Mesothelioma
C45
772
741
129
Total
Malignant neoplasms of skin
C44
18.108
18.279
19.166
81
90
353
13
5
17
22
158
248
250
43
516
94
6
10
57
7
270
7
25
11
885
37
77
521
6
129
5,575
36
54
13
120
19
119
887
19.109
19.402
20.363
165
128
327
12
2
21
23
147
282
227
66
560
81
8
10
63
11
255
7
29
14
954
51
57
502
6
128
5,927
38
57
16
118
8
138
961
19.236
19.530
20.593
165
129
303
10
3
16
22
170
269
229
59
556
107
5
7
69
9
263
3
19
9
977
40
73
520
5
158
6,133
37
50
18
102
10
142
1,063
19.457
19.773
20.964
188
128
310
8
9
15
23
156
255
243
64
645
91
9
11
79
8
256
4
31
11
1,021
57
62
538
10
149
5,941
53
37
17
100
10
150
1,191
19.757
20.079
21.419
178
144
308
-
8
13
32
194
266
259
63
592
86
3
8
76
6
277
1
38
14
1,043
49
72
573
8
171
5,969
44
53
14
122
15
136
1,340
19.944
20.297
21.653
206
147
308
1
8
15
40
185
309
274
68
588
102
7
13
91
7
270
3
42
17
1,046
66
68
585
10
175
5,818
41
51
13
118
14
148
1,356
19.972
20.319
21.858
200
147
289
1
3
12
23
185
282
263
70
597
96
8
12
110
10
288
3
39
11
1,062
69
85
601
5
181
5,742
49
54
13
123
16
135
1,539
20.073
20.458
22.055
204
181
266
2
16
22
28
208
310
252
59
608
81
7
20
92
11
262
3
33
35
1,079
70
92
651
10
165
5,651
51
47
13
101
12
148
1,597
346.6
347.0
359.9
0.2
0.2
10.3
0.4
0.5
0.4
0.6
4.1
6.4
3.7
0.4
10.8
2.4
0.1
0.6
1.1
0.2
5.7
0.1
0.9
0.2
17.7
0.8
1.2
9.7
0.1
4.5
99.5
0.5
1.0
0.3
2.2
0.1
2.5
12.9
327.1
329.8
342.9
1.3
1.4
6.9
0.6
0.1
0.4
0.3
3.2
5.7
3.7
0.7
9.9
2.6
0.2
0.3
1.2
0.3
6.2
0.2
1.0
0.2
16.0
0.7
1.0
9.5
-
4.3
91.5
0.6
0.9
0.3
2.1
0.2
1.9
13.1
344.0
347.1
362.0
1.4
1.7
6.3
0.3
0.3
0.3
0.5
3.4
6.1
4.6
0.8
10.6
2.8
0.2
0.3
1.4
0.2
6.8
0.1
1.0
0.2
15.1
0.7
1.4
10.7
0.1
4.2
100.5
0.6
1.0
0.3
2.8
0.4
2.2
14.9
354.5
359.7
375.4
2.6
2.5
5.8
0.2
0.1
0.4
0.4
2.9
6.3
4.0
1.3
11.3
2.4
0.3
0.4
1.4
0.5
6.0
0.1
0.7
0.3
15.9
0.8
0.9
10.1
0.1
4.2
105.2
0.7
1.0
0.3
2.7
0.2
2.5
15.7
353.2
358.4
374.9
2.8
2.4
5.2
0.3
0.1
0.4
0.4
3.7
6.2
3.9
1.2
11.0
3.5
0.2
0.3
1.6
0.3
6.5
0.0
0.5
0.2
15.8
0.7
1.1
10.2
0.2
5.0
107.5
0.6
1.0
0.4
2.2
0.3
2.5
16.6
351.5
356.7
375.0
2.9
2.3
5.2
0.2
0.4
0.3
0.4
3.0
5.7
4.2
1.1
12.6
2.6
0.3
0.5
1.8
0.3
5.9
0.1
0.8
0.2
16.2
0.9
1.0
10.2
0.2
5.3
104.1
1.0
0.6
0.3
2.4
0.3
2.6
18.3
appendix
350.8
356.0
375.8
2.8
2.5
5.2
-
0.2
0.2
0.5
3.7
5.8
4.5
1.2
11.6
2.6
0.1
0.3
1.8
0.3
6.3
0.0
0.9
0.2
16.1
0.8
1.2
10.5
0.2
5.7
102.1
0.8
1.0
0.3
2.5
0.4
2.3
19.8
346.3
351.9
370.9
3.0
2.6
5.0
0.0
0.2
0.3
0.6
3.5
6.6
4.6
1.2
11.1
3.0
0.2
0.4
2.0
0.2
5.7
0.0
0.7
0.3
15.3
1.0
1.0
10.8
0.2
5.9
97.6
0.6
0.9
0.3
2.5
0.3
2.5
19.0
121
0.9
4.1
6.4
1.2
4.3
6.0
340.1
333.9
345.7
340.1
belgian cancer registry
3.0
360.9
2.6
3.0
4.1
3.2
4.6
366.4
0.6
0.0
0.1
0.0
0.3
11.0
10.8
0.2
2.2
2.9
3.6
0.2
0.3
0.4
0.6
0.5
3.5
2.0
2.2
0.4
5.7
0.4
0.1
0.4
0.0
1.0
6.7
0.4
0.9
0.2
1.0
15.5
1.0
1.4
1.3
15.3
0.2
11.5
5.5
6.1
0.1
90.5
94.8
10.8
0.8
0.8
0.8
0.3
0.3
0.9
0.3
2.0
2.7
2.3
2.2
0.4
20.8
20.7
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
Mesothelioma
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
C45
Primary site
Females
21
504
446
17
20
-
13
8
656
2
39
9
4
2
251
35
49
90
21
518
114
21
522
438
21
18
-
4
8
681
1
38
7
3
4
310
46
42
76
35
489
114
42
1,363
40
354
89
1,383
326
93
4
3
5
5
8
7
3
7
5
7
17
7
20
18
8
20
17
27
6
29
8
10
2002
23
14
17
17
5
26
6
12
2001
14
582
480
31
20
1
-
6
692
3
53
12
8
3
298
64
39
71
48
540
125
1,415
49
306
116
3
5
5
5
4
22
8
22
15
8
14
14
36
9
16
2003
19
690
497
14
21
-
3
9
831
1
45
8
7
2
286
77
39
75
28
526
141
1,388
45
328
122
2
6
8
4
14
21
5
17
21
17
29
12
30
10
14
2004
34
701
561
21
30
-
5
5
868
3
34
11
14
3
312
64
43
92
33
508
107
1,396
47
339
130
-
5
7
3
4
21
20
24
29
16
29
10
43
6
14
2005
N
24
747
598
23
20
-
3
8
886
5
29
8
8
2
305
74
43
89
32
582
80
1,473
58
336
128
6
3
7
5
5
33
10
18
15
13
20
8
35
10
11
2006
32
860
573
21
22
-
4
4
998
3
45
6
13
3
319
69
46
82
40
598
65
1,556
71
274
136
2
13
7
10
12
19
11
20
20
16
30
15
20
10
6
2007
37
949
684
15
17
-
7
8
971
1
38
20
5
10
318
77
46
106
35
613
75
1,610
47
288
114
4
3
11
6
15
30
5
25
16
17
14
16
42
15
12
2008
Flemish Region: Females, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2001-2010
28
955
717
20
11
-
4
8
1,084
1
46
9
6
5
378
85
53
106
45
583
81
1,675
63
337
137
3
10
14
9
24
31
11
19
13
8
19
11
42
14
15
2009
35
1,116
678
14
18
-
10
6
1,195
1
37
11
6
8
422
57
52
100
47
615
63
1,676
75
334
126
1
6
7
8
21
35
16
22
31
11
21
10
34
23
7
2010
0.4
6.5
10.3
0.4
0.6
-
0.3
0.2
11.9
0.0
0.8
0.2
0.1
0.0
3.7
0.5
0.7
1.4
0.4
8.2
1.9
19.4
0.7
4.1
1.5
0.1
0.1
0.1
0.1
0.2
0.5
0.1
0.4
0.2
0.4
0.4
0.1
0.5
0.1
0.1
2001
0.3
6.4
9.5
0.7
0.5
-
0.1
0.2
12.7
0.0
0.7
0.2
0.1
0.0
4.2
0.6
0.5
1.2
0.6
7.3
1.6
18.5
0.8
4.6
1.3
0.1
0.1
0.2
0.2
0.1
0.3
0.2
0.3
0.3
0.4
0.6
0.1
0.5
0.2
0.2
2002
0.3
7.3
10.8
0.8
0.5
0.0
-
0.1
12.7
0.1
0.9
0.2
0.2
0.0
4.0
0.9
0.5
1.0
0.9
8.1
1.8
19.8
0.8
3.7
1.8
0.1
0.1
0.1
0.1
0.1
0.5
0.1
0.4
0.2
0.2
0.3
0.2
0.6
0.2
0.2
2003
0.3
8.5
11.2
0.4
0.6
-
0.1
0.2
14.8
0.0
0.9
0.2
0.1
0.0
4.0
1.1
0.5
1.3
0.5
7.7
2.0
18.5
0.7
4.1
1.7
0.0
0.1
0.1
0.1
0.3
0.4
0.1
0.3
0.4
0.4
0.6
0.2
0.7
0.2
0.1
2004
0.6
8.4
12.4
0.5
1.0
-
0.1
0.1
14.9
0.0
0.6
0.2
0.3
0.0
4.6
0.8
0.5
1.4
0.5
7.6
1.5
18.7
0.7
4.3
1.9
-
0.1
0.2
0.1
0.1
0.4
0.4
0.4
0.4
0.3
0.6
0.2
0.9
0.1
0.2
0.4
8.9
13.1
0.6
0.7
-
0.1
0.1
15.3
0.1
0.6
0.1
0.2
0.0
4.4
0.9
0.6
1.4
0.5
8.7
1.1
20.0
0.9
4.4
1.9
0.1
0.1
0.2
0.2
0.1
0.7
0.2
0.4
0.2
0.2
0.4
0.1
0.7
0.2
0.2
2006
WSR
2005
0.4
10.0
12.0
0.5
0.6
-
0.1
0.1
16.7
0.0
0.8
0.1
0.2
0.0
4.6
1.0
0.5
1.3
0.6
8.6
0.9
20.1
1.1
3.6
1.9
0.0
0.3
0.1
0.2
0.3
0.4
0.3
0.3
0.3
0.3
0.6
0.2
0.4
0.2
0.1
2007
0.5
10.9
14.8
0.4
0.5
-
0.2
0.1
16.3
0.0
0.7
0.3
0.1
0.2
4.5
0.9
0.5
1.7
0.5
8.9
1.0
21.2
0.7
3.5
1.5
0.1
0.1
0.2
0.1
0.3
0.5
0.1
0.5
0.2
0.3
0.3
0.2
0.7
0.2
0.2
2008
0.3
10.2
14.9
0.4
0.3
-
0.1
0.1
17.9
0.0
0.7
0.1
0.1
0.1
5.0
1.1
0.6
1.6
0.7
8.1
1.1
21.4
0.9
4.3
1.9
0.1
0.2
0.2
0.3
0.5
0.6
0.2
0.4
0.2
0.1
0.4
0.2
0.8
0.2
0.2
2009
0.5
11.8
14.4
0.3
0.7
-
0.3
0.1
19.6
0.0
0.7
0.2
0.1
0.1
5.7
0.7
0.5
1.5
0.7
8.6
0.8
21.2
1.1
4.0
1.6
0.0
0.1
0.1
0.2
0.4
0.6
0.4
0.4
0.4
0.2
0.4
0.2
0.7
0.4
0.1
2010
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
72
4
12
9
483
16
12
25
WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)
13,940
14,075
14,597
57
78
296
10
1
18
9
117
11
191
171
185
34
397
143
197
9
430
2
71
5
7
165
5
214
10
20
1
225
26
36
287
5
14
568
39
768
363
25
88
5,245
23
83
87
13
134
5
181
6
27
3
249
23
30
273
1
10
597
26
810
391
23
14,212
Vagina
C52
14,233
Vulva
C51
5,300
Total excl. non-melanoma and MDS, MPD
Breast
C50
26
Total excl. non-melanoma
Retroperitoneum and peritoneum
C48
1
88
14,737
Soft tissues
C47,C49
Total
Kaposi's sarcoma
C46
7
14,505
14,681
15,263
79
97
314
24
4
17
10
134
177
166
36
420
55
2
7
158
2
175
18
29
2
218
25
37
330
3
13
607
49
796
354
22
88
5,521
21
84
4
14,698
14,928
15,618
121
109
271
15
3
10
13
154
217
220
47
462
74
4
12
166
11
205
11
28
4
246
17
44
353
2
16
566
20
858
372
27
85
5,312
27
100
2
14,955
15,215
15,916
137
123
256
3
5
11
16
150
188
200
56
440
77
3
8
228
7
163
7
21
4
270
12
44
337
3
19
563
28
827
403
28
102
5,466
25
92
4
14,956
15,187
15,934
93
138
209
7
3
8
16
125
169
190
45
482
68
7
11
220
10
158
6
16
-
254
18
43
337
1
14
583
16
834
360
27
102
5,495
21
84
3
15,523
15,814
16,674
131
160
272
2
6
5
22
162
190
211
42
489
57
2
11
209
7
190
10
30
4
255
27
45
349
6
22
547
4
856
401
26
80
5,676
18
96
4
15,620
15,912
16,861
154
138
276
2
5
10
35
131
162
223
47
499
71
4
12
223
6
195
6
27
6
292
27
47
352
2
24
535
6
919
357
20
113
5,475
33
101
2
15,923
16,214
17,169
138
153
197
1
9
11
21
120
207
202
42
509
71
2
10
263
8
207
9
39
4
273
26
51
339
3
30
482
4
890
355
26
115
5,540
30
100
2
16,383
16,674
17,790
120
171
219
1
19
23
22
176
187
206
62
545
83
4
20
286
14
192
6
35
5
292
25
52
368
3
26
510
4
826
330
28
128
5,731
18
96
267.5
267.8
274.3
0.2
0.2
7.9
0.4
0.5
0.4
0.3
2.7
3.8
3.0
0.1
7.4
2.8
0.1
0.4
3.1
0.2
4.4
0.1
0.5
0.1
3.0
0.3
0.4
5.1
0.0
0.2
11.3
0.5
14.5
8.9
0.3
1.1
110.1
0.5
2.1
0.0
0.1
257.0
259.0
265.4
0.7
1.3
4.2
0.2
0.0
0.3
0.2
2.3
3.7
2.6
0.7
7.2
2.4
0.0
0.1
3.8
0.2
4.9
0.2
0.5
0.0
2.8
0.3
0.5
5.2
0.2
0.3
10.5
0.6
13.5
8.4
0.4
1.3
107.2
0.5
1.9
0.1
265.3
267.7
275.0
1.0
1.5
4.3
0.5
0.2
0.2
0.2
2.6
3.7
2.6
0.5
7.2
1.7
0.1
0.3
4.0
0.1
4.1
0.4
0.5
0.0
2.8
0.4
0.4
5.5
0.1
0.3
10.9
0.9
13.5
8.0
0.3
1.4
112.0
0.4
2.0
0.1
264.8
267.8
276.3
1.5
1.5
3.8
0.4
0.2
0.2
0.3
2.8
4.5
3.2
0.7
7.9
2.4
0.1
0.6
4.2
0.6
4.3
0.3
0.7
0.1
3.0
0.2
0.6
5.9
0.1
0.3
10.1
0.3
14.4
8.4
0.5
1.3
105.4
0.5
2.0
267.3
271.1
279.5
1.7
2.0
3.5
0.1
0.2
0.3
0.3
3.0
3.8
2.9
0.9
7.2
2.5
0.1
0.4
5.3
0.3
3.7
0.2
0.5
0.0
3.3
0.1
0.6
5.5
0.1
0.3
9.8
0.5
13.4
9.3
0.4
1.5
106.4
0.5
2.3
0.0
265.9
269.2
278.0
1.2
2.1
2.8
0.2
0.1
0.1
0.2
2.4
3.8
3.0
0.7
8.1
2.3
0.2
0.3
5.4
0.5
4.2
0.1
0.3
-
3.0
0.2
0.5
5.7
0.0
0.3
10.1
0.3
13.9
8.1
0.4
1.5
105.3
0.4
1.7
0.0
appendix
270.3
274.3
284.3
1.6
2.3
3.8
0.1
0.1
0.1
0.6
3.0
4.1
3.2
0.7
8.1
1.9
0.0
0.3
4.9
0.2
4.2
0.2
0.7
0.0
3.1
0.3
0.5
5.9
0.2
0.4
9.8
0.1
13.9
9.1
0.3
1.2
107.2
0.4
2.0
0.0
265.5
269.5
280.4
1.9
2.1
3.6
0.1
0.2
0.1
0.7
2.3
3.1
3.2
0.7
7.8
1.9
0.1
0.4
5.2
0.3
4.2
0.1
0.7
0.1
3.4
0.3
0.6
5.5
0.1
0.4
8.8
0.1
14.2
7.8
0.2
1.6
102.3
0.6
1.8
0.1
123
276.1
272.2
270.7
266.6
belgian cancer registry
1.4
287.9
2.5
2.4
280.9
2.7
2.4
1.7
0.8
0.0
0.0
0.4
0.3
0.4
3.1
2.4
0.3
3.5
4.0
0.2
1.0
2.8
2.7
8.4
7.9
0.6
0.1
2.7
0.1
2.3
6.5
0.6
6.3
0.4
3.7
0.5
4.3
0.1
0.2
0.3
0.1
3.5
3.1
0.8
0.3
0.2
0.7
0.6
0.5
0.0
0.1
5.6
8.2
0.4
7.9
0.5
0.1
0.0
0.0
5.5
7.1
12.4
1.7
0.4
1.5
0.4
7.8
103.8
101.3
13.8
1.8
0.3
0.4
0.0
1.8
0.0
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
35
634
42
48
1
8
23
5,519
12
627
638
37
34
1
9
17
5,426
11
560
21
72
23
10
545
108
27
300
49
1,262
203
2,704
100
874
666
46
51
127
47
13
588
122
36
259
45
1,259
303
2,554
95
884
626
42
58
146
43
160
100
99
26
48
67
67
164
19
54
81
53
159
32
29
167
177
55
62
2005
187
64
59
2004
628
33
34
-
12
18
5,389
7
538
51
21
9
616
126
30
346
44
1,385
156
2,722
109
862
691
25
66
132
45
92
157
8
49
67
61
133
35
166
69
54
2006
737
37
39
-
20
15
5,524
14
623
57
27
7
648
145
27
375
47
1,378
145
2,737
82
872
691
19
77
158
38
107
196
22
57
60
61
163
32
151
97
35
2007
Lip
Primary site
C00
N
Males
761
33
33
-
11
12
5,488
3
592
66
30
16
595
132
31
429
51
1,450
159
2,912
116
821
660
23
70
122
39
138
193
11
50
55
63
157
34
167
108
42
2008
Belgium: Males, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2004-2010
732
25
30
1
16
20
5,519
10
558
43
34
16
702
151
22
409
66
1,456
147
2,931
107
848
681
21
81
145
46
115
174
21
54
56
59
169
30
177
118
56
2009
871
43
36
3
24
21
5,616
10
541
63
30
22
785
145
36
479
56
1,411
178
2,967
139
854
680
18
57
125
43
134
135
15
60
61
59
157
31
148
90
50
2010
8.5
0.7
1.0
0.0
0.1
0.3
60.7
0.1
7.9
0.6
0.3
0.1
6.6
1.4
0.3
3.0
0.5
14.1
3.2
26.7
1.1
9.4
7.5
0.6
0.8
2.0
0.6
1.4
2.1
0.2
0.7
1.0
0.7
2.2
0.4
2.5
0.9
0.6
2004
8.1
0.7
0.7
0.0
0.1
0.2
59.1
0.1
6.7
0.8
0.3
0.1
5.9
1.1
0.3
3.4
0.6
13.6
2.2
27.9
1.2
9.4
7.9
0.6
0.7
1.6
0.5
1.3
2.1
0.3
0.6
0.8
0.9
2.1
0.4
2.3
0.7
0.7
2005
8.1
0.5
0.7
-
0.2
0.2
57.8
0.1
6.3
0.6
0.2
0.1
6.6
1.3
0.3
4.0
0.5
14.8
1.6
27.6
1.2
8.8
8.0
0.3
0.9
1.7
0.6
1.2
2.0
0.1
0.6
0.8
0.8
1.7
0.4
2.1
0.9
0.6
2006
9.5
0.6
0.8
-
0.3
0.2
58.4
0.1
7.3
0.7
0.3
0.1
7.0
1.5
0.3
4.3
0.5
14.6
1.4
26.9
0.9
8.9
7.9
0.3
0.9
2.1
0.5
1.4
2.5
0.3
0.6
0.7
0.8
2.1
0.4
1.9
1.2
0.4
2007
WSR
9.3
0.6
0.6
-
0.1
0.1
57.1
0.0
6.8
0.8
0.3
0.2
6.3
1.4
0.3
4.8
0.5
15.1
1.7
28.4
1.3
8.1
7.3
0.3
0.9
1.6
0.5
1.7
2.4
0.1
0.6
0.6
0.8
2.0
0.4
2.1
1.3
0.4
2008
8.9
0.4
0.6
0.0
0.2
0.2
56.1
0.1
6.2
0.5
0.4
0.2
7.3
1.5
0.2
4.5
0.7
14.9
1.4
28.4
1.1
8.2
7.5
0.3
0.9
1.8
0.6
1.4
2.1
0.3
0.6
0.7
0.7
2.0
0.3
2.2
1.4
0.5
2009
10.7
0.7
0.7
0.0
0.3
0.2
55.4
0.1
5.8
0.7
0.4
0.2
7.8
1.4
0.3
5.1
0.6
14.5
1.7
28.0
1.4
8.3
7.1
0.2
0.7
1.5
0.6
1.6
1.6
0.2
0.7
0.7
0.7
1.9
0.4
1.8
1.0
0.4
2010
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)
34,047
247
173
270
577
178
18
5
31
32
644
16
9
29
37
290
439
434
255
369
89
981
179
6
13
368
106
970
158
9
17
11
170
29
435
156
422
7
38
11
28
18
1,632
69
114
845
11
284
9,725
39
1,664
89
96
816
10
251
9,738
83
68
Total excl. non-melanoma and MDS, MPD
Prostate
C61
88
66
31,872
Penis
C60
32,292
Breast
C50
32,016
Retroperitoneum and peritoneum
C48
22
24
24
180
22
182
32,464
Soft tissues
C47,C49
Total excl. non-melanoma
Kaposi's sarcoma
C46
211
210
34,137
Mesothelioma
C45
1,755
1,673
Total
Malignant neoplasms of skin
C44
31,472
31,897
33,790
252
173
584
19
16
25
37
254
392
397
98
1,009
177
13
15
175
14
418
4
53
23
1,606
81
98
854
13
274
9,279
76
65
24
169
18
206
1,893
31,997
32,422
34,640
230
195
557
2
11
24
60
318
404
416
107
993
162
4
18
186
14
434
1
58
27
1,680
84
123
893
13
304
8,983
74
81
20
193
35
198
2,218
32,264
32,787
34,978
306
217
579
1
14
23
61
300
474
392
116
1,005
181
10
21
211
10
437
5
62
26
1,700
92
117
954
13
322
8,844
72
85
28
193
35
208
2,191
32,314
32,862
35,245
330
218
512
2
7
17
50
323
470
407
105
1,000
173
10
25
259
13
464
4
54
22
1,730
117
119
957
8
314
8,698
80
99
14
181
40
194
2,383
32,671
33,267
35,798
339
257
462
2
25
31
55
329
481
424
103
1,021
154
7
29
204
14
453
8
61
50
1,755
101
145
981
14
318
8,663
85
83
23
162
31
204
2,531
364.5
369.3
385.6
2.7
2.2
7.0
0.2
0.2
0.3
0.4
3.2
6.2
4.0
1.3
11.9
2.8
0.2
0.4
2.1
0.5
6.1
0.1
0.6
0.2
16.9
0.9
0.9
10.0
0.1
4.7
105.5
0.7
1.0
0.3
2.4
0.3
2.3
16.3
358.9
363.2
380.0
2.4
1.9
6.2
0.3
0.1
0.4
0.4
3.9
6.3
3.9
1.1
11.7
3.4
0.1
0.3
2.4
0.2
6.4
0.1
0.7
0.3
16.2
0.7
1.1
10.0
0.2
5.2
104.3
0.8
0.9
0.3
2.3
0.3
2.3
16.7
350.6
354.9
372.7
2.4
1.9
6.1
0.3
0.4
0.3
0.4
3.1
5.3
4.2
1.1
12.0
3.0
0.2
0.3
2.4
0.4
5.9
0.1
0.7
0.2
15.7
0.8
1.0
10.1
0.2
5.3
100.1
0.8
0.7
0.3
2.4
0.2
2.1
17.7
352.0
356.3
376.2
2.2
2.0
5.9
0.0
0.2
0.2
0.6
3.9
5.5
4.5
1.3
11.8
2.8
0.1
0.4
2.6
0.4
5.9
0.0
0.8
0.2
16.2
0.8
1.2
10.1
0.2
5.8
95.1
0.8
0.9
0.3
2.5
0.5
2.0
19.9
appendix
347.7
352.7
371.7
2.7
2.3
5.9
0.0
0.2
0.3
0.6
3.4
6.2
4.0
1.3
11.8
3.1
0.2
0.5
2.8
0.2
5.8
0.1
0.7
0.3
15.7
0.9
1.1
10.8
0.2
6.1
91.8
0.7
0.9
0.4
2.5
0.4
2.2
18.9
0.4
2.1
0.3
0.6
2.4
0.2
belgian cancer registry
338.7
3.2
365.1
3.0
368.7
344.5
2.7
2.4
348.7
4.5
5.0
343.4
0.6
0.0
0.1
0.0
0.3
0.2
6.3
3.6
4.1
5.9
4.1
0.6
1.0
1.1
3.7
11.4
11.0
0.6
0.1
2.5
0.5
0.6
3.0
2.7
0.2
0.3
0.1
6.2
0.1
6.6
0.3
0.9
3.4
0.4
0.2
0.9
0.9
15.8
1.1
1.4
1.1
15.7
0.1
10.7
5.8
0.1
5.8
89.0
10.8
0.8
86.4
0.9
0.9
1.9
1.9
1.1
20.6
20.0
125
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
Mesothelioma
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
C45
26
1,167
893
29
47
1,228
975
36
41
-
34
11
9
1,602
4
84
21
17
12
534
102
60
169
71
886
4
18
1,567
3
100
17
12
10
503
118
63
116
69
880
171
2,425
2,396
238
87
526
231
86
512
233
12
16
13
9
15
9
21
16
10
27
54
25
56
44
14
45
29
40
24
70
13
23
34
40
32
46
30
69
17
18
41
1,225
970
42
34
-
6
11
1,715
5
82
14
14
8
580
100
70
156
74
937
136
2,514
105
530
217
13
8
24
9
22
62
18
34
25
32
30
22
74
23
20
48
1,473
984
34
37
-
7
12
1,889
7
72
15
18
9
544
116
67
144
78
979
102
2,571
114
455
251
5
18
16
17
31
66
14
46
32
27
58
30
52
23
12
2007
2006
N
2005
Primary site
2004
Females
51
1,563
1,161
31
34
-
14
15
1,813
2
85
24
14
16
585
117
70
196
76
975
121
2,623
86
503
227
9
17
23
14
35
74
9
40
29
36
30
32
72
28
15
2008
Belgium: Females, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2004-2010
40
1,576
1,192
27
21
-
9
13
2,093
6
104
14
17
12
655
142
71
199
84
923
140
2,672
107
518
237
8
16
35
20
44
64
16
37
30
19
46
32
75
37
15
2009
51
1,783
1,239
26
25
-
13
17
2,215
3
83
16
12
14
738
120
94
192
102
981
129
2,628
113
547
242
2
12
25
15
38
68
19
41
51
26
48
25
76
38
11
2010
0.2
8.1
11.8
0.5
0.6
-
0.1
0.2
16.6
0.0
1.1
0.2
0.1
0.1
4.3
1.0
0.4
1.1
0.7
7.5
2.0
18.4
0.8
3.9
2.0
0.1
0.2
0.2
0.2
0.3
0.7
0.2
0.4
0.4
0.4
0.5
0.3
0.8
0.2
0.1
2004
0.5
8.6
12.7
0.5
0.8
-
0.1
0.1
16.7
0.0
0.9
0.2
0.2
0.1
4.7
0.8
0.4
1.7
0.7
7.9
1.4
19.0
0.8
4.0
2.1
0.1
0.2
0.2
0.1
0.3
0.7
0.3
0.4
0.4
0.4
0.5
0.2
0.8
0.2
0.2
2005
0.4
8.3
12.3
0.7
0.7
-
0.1
0.1
17.7
0.1
0.9
0.2
0.2
0.1
4.9
0.7
0.6
1.4
0.7
8.0
1.1
19.6
1.0
4.1
2.0
0.2
0.1
0.3
0.2
0.2
0.8
0.2
0.4
0.2
0.4
0.4
0.2
0.9
0.2
0.2
2006
0.4
9.9
12.3
0.5
0.6
-
0.1
0.1
19.2
0.0
0.8
0.2
0.2
0.1
4.7
0.9
0.5
1.2
0.7
8.3
0.8
19.5
1.0
3.6
2.1
0.0
0.2
0.2
0.2
0.4
0.8
0.2
0.5
0.3
0.3
0.7
0.3
0.6
0.3
0.1
2007
WSR
0.4
10.3
14.6
0.5
0.7
-
0.2
0.2
18.4
0.0
1.0
0.2
0.2
0.1
4.9
0.8
0.5
1.8
0.7
8.2
0.9
20.0
0.8
3.9
1.9
0.1
0.2
0.3
0.2
0.4
0.8
0.1
0.4
0.2
0.4
0.3
0.3
0.7
0.3
0.1
2008
0.3
9.8
14.6
0.3
0.4
-
0.1
0.1
21.1
0.1
1.1
0.1
0.1
0.1
5.3
1.0
0.5
1.8
0.8
7.7
1.2
19.9
0.9
3.9
2.0
0.1
0.2
0.4
0.3
0.5
0.8
0.2
0.4
0.3
0.2
0.5
0.3
0.9
0.4
0.1
2009
0.4
11.1
15.8
0.4
0.5
-
0.2
0.2
21.7
0.0
0.9
0.2
0.1
0.1
5.9
0.9
0.6
1.7
1.0
8.2
1.0
19.4
1.0
3.9
2.0
0.0
0.1
0.3
0.2
0.4
0.7
0.3
0.5
0.4
0.3
0.5
0.2
0.8
0.4
0.1
2010
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
8
197
158
529
24
7
20
22
WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)
25,757
26,141
27,369
207
177
483
10
7
17
24
277
249
335
313
83
256
380
82
780
122
128
834
3
20
503
12
294
11
38
6
453
22
71
538
5
33
936
55
1,371
655
47
170
9,403
40
137
4
18
475
21
325
19
50
6
398
32
70
531
3
28
915
59
1,418
653
53
149
25,837
Vagina
C52
26,192
Vulva
C51
9,420
Total excl. non-melanoma and MDS, MPD
Breast
C50
38
Total excl. non-melanoma
Retroperitoneum and peritoneum
C48
9
168
27,359
Soft tissues
C47,C49
Total
Kaposi's sarcoma
C46
12
25,871
26,237
27,462
171
195
432
11
8
13
26
220
254
317
95
809
114
10
24
511
13
294
10
37
1
392
33
73
534
1
33
928
24
1,344
611
49
170
9,506
42
143
4
26,718
27,123
28,596
188
217
516
2
11
11
34
275
298
333
97
866
109
5
22
515
12
309
13
46
6
416
34
80
523
8
28
925
11
1,392
702
47
172
9,695
38
163
10
27,091
27,546
29,109
237
218
541
5
15
15
53
239
270
336
83
876
128
8
16
551
7
328
10
44
8
481
41
80
548
4
52
885
7
1,473
640
36
190
9,590
53
166
11
27,448
27,899
29,475
216
235
384
3
17
19
35
223
344
348
76
887
125
6
15
639
10
359
11
63
7
467
45
83
523
4
48
791
10
1,456
605
45
192
9,604
47
156
7
28,291
28,750
30,533
212
247
408
3
28
30
40
292
343
327
111
926
149
6
29
651
18
322
10
56
11
477
39
79
551
3
46
865
9
1,415
593
43
216
9,908
33
152
0.1
274.6
277.4
285.4
1.4
1.3
4.2
0.3
0.1
0.2
0.2
2.9
4.2
3.3
0.8
8.3
2.3
0.1
0.4
6.9
0.5
4.2
0.2
0.7
0.1
2.9
0.2
0.6
5.5
0.0
0.3
9.7
0.6
13.8
8.5
0.5
1.3
109.9
0.4
2.0
0.1
272.1
275.4
284.0
1.6
1.7
4.0
0.2
0.2
0.2
0.2
3.0
3.5
2.7
0.8
7.6
2.4
0.0
0.6
7.0
0.3
4.1
0.1
0.7
0.0
3.3
0.1
0.5
5.5
0.1
0.3
9.5
0.5
13.1
8.7
0.4
1.4
107.2
0.5
1.9
270.7
274.0
282.3
1.4
1.9
3.5
0.1
0.2
0.1
0.2
2.4
3.4
2.9
0.9
7.8
2.0
0.1
0.4
7.3
0.3
4.1
0.1
0.5
0.0
2.9
0.3
0.5
5.3
0.0
0.4
9.5
0.3
13.1
7.9
0.4
1.5
107.7
0.5
1.7
0.1
275.2
278.5
288.4
1.4
1.9
4.3
0.0
0.1
0.1
0.4
3.1
3.6
2.9
0.9
8.3
2.1
0.1
0.3
7.3
0.2
4.0
0.1
0.6
0.0
2.8
0.2
0.6
5.1
0.2
0.3
9.6
0.1
13.1
9.2
0.4
1.5
108.0
0.4
2.0
0.0
appendix
273.6
277.1
287.5
1.7
1.9
4.2
0.1
0.4
0.1
0.6
2.5
3.1
2.8
0.8
8.2
2.2
0.2
0.3
7.6
0.2
4.4
0.1
0.6
0.1
3.3
0.3
0.5
5.3
0.1
0.5
8.7
0.0
13.4
8.2
0.3
1.6
104.9
0.6
1.8
0.1
287.4
belgian cancer registry
280.4
1.5
295.1
1.5
284.0
2.1
2.2
277.6
3.0
2.8
273.9
0.7
0.0
0.0
0.3
0.3
0.4
0.3
3.1
0.2
3.8
3.9
1.0
2.6
2.7
2.4
8.4
8.1
0.6
0.5
0.3
0.1
8.8
9.0
2.7
0.4
0.2
2.4
4.0
4.8
0.1
0.1
0.1
3.1
0.1
3.3
0.3
0.8
0.3
0.5
0.7
0.5
5.1
0.0
0.1
5.0
0.1
8.2
0.4
7.6
0.1
0.1
0.5
7.5
12.5
1.8
0.4
1.6
0.4
7.7
106.2
103.8
13.2
1.7
0.4
0.4
0.1
0.1
1.6
127
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip. oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart. mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
59
6
7
-
1
1
410
-
63
65
5
3
-
1
2
393
1
47
3
1
1
38
11
1
28
7
77
18
228
10
66
1
-
51
4
2
19
5
70
22
204
6
76
44
3
48
5
5
16
5
13
8
12
9
18
9
3
3
4
6
5
4
16
7
-
2005
13
3
3
6
4
17
2
14
6
-
2004
57
3
2
-
1
2
363
1
51
6
-
1
40
11
3
35
8
85
16
207
7
75
51
1
7
6
14
9
20
3
5
3
2
13
5
16
10
-
2006
72
5
3
-
1
1
364
2
62
3
3
-
61
11
2
35
6
94
13
239
8
80
46
1
5
13
7
10
25
2
3
8
5
23
2
17
7
4
2007
Lip
Primary site
C00
N
Males
77
4
5
-
-
1
375
-
53
-
2
3
64
6
5
36
8
94
15
228
12
64
46
2
10
16
5
15
18
-
3
4
3
11
2
13
6
5
2008
83
2
4
-
2
6
386
1
51
3
3
1
62
7
-
52
6
85
9
187
4
66
53
-
3
6
8
16
15
3
7
8
3
8
1
11
12
4
2009
Brussels Capital Region: Males. number of invasive tumours and age-standardised incidence by primary site and incidence year. 2004-2010
80
6
8
-
2
3
450
1
36
6
4
4
65
15
4
56
7
91
24
239
11
71
41
2
5
11
8
13
12
2
2
6
6
12
2
17
8
3
2010
8.8
0.8
1.4
-
0.2
0.2
58.2
-
10.4
0.2
0.1
-
6.9
0.5
0.2
2.8
0.7
9.7
2.9
26.6
0.9
10.4
7.2
0.7
0.8
2.4
1.5
1.5
2.1
0.5
0.4
0.8
0.8
2.8
0.4
2.4
0.9
-
2004
8.7
1.0
0.8
-
0.1
0.2
57.3
0.2
7.3
0.4
-
0.2
4.8
1.4
0.2
3.7
0.8
9.8
2.8
29.4
1.3
8.2
6.4
0.5
0.9
2.7
1.4
1.9
2.7
0.4
0.5
0.4
1.0
0.8
0.7
2.5
1.3
-
2005
7.8
0.6
0.4
-
0.1
0.3
49.9
0.2
7.6
0.7
-
0.2
5.3
1.6
0.4
4.8
0.9
11.4
2.1
24.0
1.0
9.7
7.6
0.1
1.2
0.9
2.6
1.4
2.8
0.2
0.7
0.4
0.4
2.2
0.7
2.5
1.7
-
2006
10.5
1.0
0.4
-
0.1
0.2
51.1
0.3
9.2
0.4
0.4
-
8.3
1.2
0.4
5.4
1.0
12.0
1.6
29.4
1.1
11.0
6.8
0.1
0.7
2.0
1.2
1.7
3.6
0.2
0.2
1.3
0.9
3.6
0.2
2.7
1.2
0.5
2007
WSR
10.6
0.8
1.1
-
-
0.2
52.7
-
7.9
-
0.3
0.5
8.3
0.7
0.6
5.0
0.9
12.2
2.1
28.4
1.7
8.6
6.4
0.3
1.3
2.4
0.8
2.4
2.9
-
0.4
0.4
0.4
1.6
0.3
2.2
1.1
0.5
2008
11.9
0.5
0.8
-
0.5
1.0
51.3
0.2
7.6
0.4
0.5
0.2
9.0
0.8
-
7.4
0.8
11.3
1.1
23.3
0.6
8.9
7.8
-
0.3
0.9
1.3
2.5
2.1
0.5
0.9
1.2
0.5
1.0
0.2
1.7
1.7
0.6
2009
11.2
1.2
1.6
-
0.3
0.4
60.8
0.1
5.2
1.1
0.5
0.5
8.2
2.1
0.6
7.5
1.0
12.9
2.9
29.4
1.3
8.6
5.3
0.2
1.0
1.5
1.1
2.1
1.7
0.2
0.3
0.9
0.9
1.9
0.3
2.6
1.1
0.5
2010
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord. cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid. haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
8
26
13
85
1
1
1
5
25
31
36
8
86
20
1
3
23
6
24
-
WSR: age standardised incidence rate. using the World Standard Population (n/100.000 person years)
EAPC: Estimated annual percentage change (%)
2,686
22
8
54
1
-
3
3
22
50
39
4
90
21
-
1
15
2
36
1
6
6
-
140
5
8
69
3
137
5
7
55
2
24
18
1
666
605
11
Total excl. non-melanoma and MDS. MPD
Prostate
C61
7
6
2,520
Penis
C60
1
2,490
Breast
C50
1
9
24
2,397
Retroperitoneum and peritoneum
C48
9
16
2,436
Soft tissues
C47.C49
Total excl. non-melanoma
Kaposi's sarcoma
C46
9
6
2,600
Mesothelioma
C45
166
164
Total
Malignant neoplasms of skin
C44
2,312
2,332
2,486
11
9
54
1
2
2
2
27
26
30
9
71
26
-
1
21
2
29
-
5
1
123
6
7
42
-
24
604
7
8
4
26
3
9
154
2,407
2,424
2,648
11
6
55
-
1
2
3
26
31
34
8
81
18
1
1
27
4
27
-
2
3
129
6
12
54
1
24
552
7
8
-
19
13
13
224
2,491
2,530
2,728
21
18
63
-
2
-
9
19
34
27
10
83
15
2
2
33
-
38
-
6
2
130
1
14
76
1
32
627
11
5
3
14
13
6
198
2,418
2,456
2,647
22
16
37
1
1
1
8
32
43
36
8
82
26
-
4
28
2
48
1
3
4
131
8
9
57
1
26
579
6
7
-
20
21
7
191
2,553
2,588
2,830
19
16
57
-
2
1
3
24
37
41
8
86
27
-
3
30
2
44
2
8
1
140
6
10
75
3
32
526
7
9
4
12
13
4
242
335.7
340.4
357.7
2.9
1.8
11.4
0.1
0.3
0.2
0.7
3.8
5.5
4.3
0.9
13.3
3.4
0.3
1.0
3.5
0.9
3.9
-
0.6
-
16.1
0.7
1.0
7.9
0.1
3.3
79.0
0.6
1.1
0.1
2.5
1.4
0.7
17.3
343.9
347.6
366.0
2.7
1.1
7.1
0.2
-
0.6
0.4
3.4
9.7
5.3
0.7
12.5
3.8
-
0.2
2.5
0.3
6.1
0.1
1.1
0.7
15.8
0.6
1.1
9.9
0.5
4.2
85.4
1.5
1.0
0.1
3.8
1.4
1.1
18.4
319.0
321.8
338.5
1.6
1.3
7.0
0.1
0.5
0.5
0.3
4.0
4.7
4.4
1.3
10.0
4.8
-
0.2
3.4
0.5
5.0
-
0.5
0.1
14.8
0.7
1.2
6.5
-
4.4
81.6
0.9
1.2
0.6
3.7
0.5
1.2
16.7
335.5
337.9
362.7
1.5
0.8
7.3
-
0.2
0.2
0.3
4.2
4.9
4.6
1.1
10.6
3.5
0.2
0.1
4.1
0.9
4.2
-
0.3
0.3
16.5
0.8
2.0
8.2
0.1
4.4
75.8
0.9
1.1
-
2.9
2.0
1.4
24.8
appendix
340.6
345.1
365.3
2.1
2.3
8.1
-
0.6
-
1.0
2.5
5.5
3.5
1.3
11.7
2.7
0.5
0.4
4.9
-
6.0
-
0.9
0.3
15.2
0.1
1.9
10.9
0.2
5.6
83.0
1.5
0.5
0.3
2.2
2.1
1.0
20.2
348.8
343.9
335.0
330.4
belgian cancer registry
2.9
372.0
2.7
1.9
1.9
355.4
7.2
0.4
0.1
4.4
0.1
0.1
0.2
3.8
0.5
1.3
5.4
7.2
4.5
1.1
5.3
4.6
11.5
11.3
1.0
4.1
0.7
0.9
4.7
4.6
4.3
-
7.1
0.3
0.1
0.3
1.5
0.4
0.2
0.5
0.6
7.5
0.7
17.2
1.2
1.2
0.9
15.2
0.4
10.7
5.1
4.4
0.1
67.9
76.2
7.8
1.2
0.9
1.0
0.6
-
0.9
1.8
1.9
3.3
0.6
1.0
3.2
23.3
20.4
129
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
Mesothelioma
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
C45
1
92
84
2
4
-
1
3
182
1
3
117
87
6
4
-
-
1
167
-
1
11
2
-
1
35
10
4
23
11
64
11
-
2
42
8
4
13
14
75
9
260
230
21
7
40
21
6
34
26
3
2
1
2
3
2
3
11
2
3
2
6
5
2
1
5
5
1
3
5
1
-
4
4
2
5
3
11
1
-
2
121
90
3
5
-
-
-
188
-
14
1
-
-
68
12
6
17
13
86
11
254
10
29
16
-
1
5
3
2
6
1
1
1
7
3
6
13
5
2
5
154
100
4
8
-
2
3
192
1
5
2
3
-
40
7
6
12
12
70
5
218
7
40
32
-
-
1
3
3
10
1
2
-
3
5
2
9
-
1
2007
2006
N
2005
Primary site
2004
Females
-
134
96
5
5
-
-
2
175
-
7
-
2
-
64
7
2
21
15
59
17
230
9
60
32
3
2
2
3
6
7
-
1
7
4
-
2
9
1
2
2008
3
153
113
2
2
-
2
2
204
2
8
-
3
2
60
12
4
26
12
81
10
195
3
55
15
1
1
3
3
3
12
1
2
3
3
6
1
9
5
-
2009
Brussels Capital Region: Females, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2004-2010
6
189
102
5
-
-
2
2
206
-
12
3
2
-
68
17
9
21
15
65
16
236
4
48
25
-
3
3
3
4
5
2
1
4
3
6
-
8
4
-
2010
0.1
6.9
10.8
0.2
0.5
-
0.4
0.3
20.5
0.1
1.3
0.4
-
0.2
4.2
1.0
0.4
1.0
1.5
6.4
2.4
17.7
0.5
2.5
3.1
0.2
0.0
0.3
0.5
0.1
0.6
0.0
0.4
0.5
0.3
0.7
0.3
1.5
0.2
-
2004
0.4
9.3
11.3
0.9
1.0
-
-
0.1
20.4
-
1.4
0.0
-
0.0
3.5
0.7
0.4
2.6
1.1
6.0
0.9
21.0
0.8
4.0
2.2
0.3
0.2
0.3
0.2
0.4
1.6
0.2
0.6
0.5
0.6
0.2
0.3
0.5
0.1
-
2005
0.3
8.4
11.5
0.6
1.1
-
-
-
22.1
-
1.4
0.1
-
-
7.4
0.8
0.7
1.7
1.2
9.2
1.3
20.2
1.2
2.2
1.9
-
0.2
0.7
0.5
0.3
0.8
0.1
0.1
0.2
0.9
0.5
0.7
1.9
0.5
0.2
2006
0.5
11.0
12.7
0.7
1.3
-
0.2
0.2
21.7
0.0
0.8
0.3
0.4
-
3.8
0.8
0.4
1.1
1.3
6.3
0.3
19.0
0.4
3.5
3.2
-
-
0.2
0.5
0.2
1.3
0.0
0.2
-
0.4
0.8
0.3
1.4
-
0.1
2007
WSR
-
8.8
11.6
0.7
1.0
-
-
0.3
20.8
-
1.0
-
0.2
-
6.1
0.6
0.3
2.1
1.8
5.4
1.5
19.0
0.9
6.6
2.9
0.4
0.3
0.3
0.5
0.9
1.0
-
0.1
0.5
0.6
-
0.3
0.9
0.1
0.1
2008
0.1
11.4
13.3
0.3
0.3
-
0.2
0.2
23.4
0.3
1.0
-
0.3
0.1
5.6
0.9
0.5
2.6
1.5
8.0
1.1
14.5
0.5
4.0
1.3
0.1
0.1
0.3
0.5
0.4
1.6
0.1
0.3
0.5
0.5
0.9
0.0
0.9
0.7
-
2009
0.5
11.5
12.6
0.8
-
-
0.2
0.3
23.3
-
1.7
0.4
0.2
-
6.3
1.4
1.0
2.1
2.0
7.1
1.4
19.6
0.5
4.0
2.7
-
0.3
0.4
0.4
0.4
0.7
0.3
0.2
0.4
0.5
0.8
-
1.0
0.6
-
2010
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
2
15
WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)
2,402
2,435
2,552
17
16
44
63
9
2
-
2
2
2
1
-
31
1
23
31
31
9
30
46
3
92
7
18
84
-
2
54
1
-
1
80
1
22
-
27
8
2
1
47
3
6
33
-
2
85
2
103
62
5
13
876
1
17
6
-
36
3
5
28
-
2
73
4
109
62
5
15
2,501
Vagina
C52
Total excl. non-melanoma and MDS, MPD
Vulva
C51
929
2,617
Breast
C50
4
2,525
Retroperitoneum and peritoneum
C48
2
13
Total excl. non-melanoma
Soft tissues
C47,C49
Total
Kaposi's sarcoma
C46
4
2,518
2,539
2,660
10
11
60
1
1
2
2
20
18
28
12
71
9
1
4
62
-
34
-
1
-
39
1
8
36
-
3
65
1
104
85
3
13
932
3
14
-
2,498
2,529
2,683
17
14
53
-
-
2
5
30
33
29
15
88
10
-
3
86
-
18
-
4
2
37
3
9
27
-
2
74
1
106
72
5
26
921
6
17
3
2,525
2,561
2,695
17
19
62
1
5
-
8
28
26
23
11
86
15
2
2
66
1
33
2
3
2
32
6
10
34
2
9
80
-
117
72
5
25
882
3
12
5
2,562
2,582
2,735
10
10
47
1
3
1
4
23
21
32
4
98
12
-
-
97
-
35
-
4
-
38
5
8
37
-
2
63
2
121
81
7
17
908
2
15
4
2,624
2,648
2,837
9
15
42
-
5
1
3
34
29
29
13
95
13
-
3
88
1
28
2
7
2
43
1
4
39
-
5
83
1
115
57
3
19
927
3
15
293.5
295.7
302.6
1.4
0.8
5.1
0.2
0.2
0.0
0.0
4.2
4.2
4.6
0.3
9.3
2.8
-
0.2
12.7
0.1
4.0
0.2
0.8
-
2.9
0.1
0.8
3.5
-
0.3
9.5
0.5
11.2
8.3
0.3
1.2
122.1
0.4
1.6
0.3
0.3
280.6
283.4
292.8
1.1
1.6
4.0
0.2
-
0.1
-
4.6
3.7
3.4
0.8
9.6
1.3
-
0.5
8.1
0.1
3.8
-
2.0
0.2
4.0
0.1
0.5
4.3
-
0.2
9.5
0.2
10.6
8.6
0.5
1.2
110.7
0.2
2.6
297.6
299.7
308.1
0.7
1.5
5.0
0.1
0.3
0.2
0.2
2.2
2.9
3.2
1.4
8.6
1.6
0.2
0.9
9.6
-
5.6
-
0.3
-
3.3
0.1
0.7
3.9
-
0.3
7.7
0.1
10.6
11.7
0.5
1.3
119.7
0.4
2.1
0.7
-
288.7
291.6
302.6
1.3
1.6
4.4
-
-
0.1
0.3
3.7
4.7
2.8
1.9
8.6
2.0
-
0.4
13.3
-
2.4
-
0.5
0.1
2.5
0.3
0.7
3.2
-
0.1
8.2
0.1
11.1
10.4
0.6
2.4
116.1
0.7
2.3
appendix
286.2
288.7
297.6
1.2
1.4
5.3
0.2
1.0
-
1.1
3.3
2.9
1.8
1.5
7.6
3.0
0.5
0.3
10.3
0.2
4.5
0.1
0.6
0.2
2.6
0.5
0.9
4.2
0.3
0.9
8.9
-
11.6
9.5
0.5
2.2
108.6
0.3
1.5
0.3
294.4
290.0
belgian cancer registry
307.5
296.0
303.4
1.3
0.3
1.1
0.9
292.0
-
1.2
0.8
3.3
0.1
0.1
4.2
0.3
0.5
0.2
3.3
3.8
1.3
2.7
3.2
2.5
10.2
9.8
0.4
2.8
1.8
1.9
0.5
-
0.3
12.3
5.4
14.5
4.2
-
-
1.1
0.3
0.5
3.1
0.2
0.0
0.4
-
0.3
0.8
2.9
3.8
4.2
0.3
-
8.9
0.1
7.7
0.1
12.8
0.3
7.3
11.6
10.4
1.9
0.2
1.7
112.6
111.8
0.7
2.0
0.4
0.2
0.4
0.6
1.6
131
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
205
11
13
1
196
9
8
-
1
5
2
1,843
4
5
198
23
5
6
180
35
8
105
13
353
67
1,846
4
216
10
12
10
190
44
14
99
13
358
76
779
34
27
768
285
225
27
16
56
275
216
28
14
57
12
53
46
13
63
9
15
19
34
67
8
13
33
23
70
20
16
58
63
27
17
2005
78
21
15
2004
186
10
11
-
3
6
1,771
2
168
11
6
7
215
31
4
143
16
395
40
772
29
275
218
16
18
71
10
43
45
-
20
13
30
46
16
71
30
15
2006
219
10
14
-
7
6
1,810
3
219
14
10
4
235
51
4
155
17
378
44
797
30
269
210
8
27
77
13
45
83
10
23
20
26
68
21
63
32
11
2007
Lip
Primary site
C00
N
Males
261
6
11
-
2
4
1,830
2
226
19
8
7
171
43
9
165
12
409
40
794
34
220
227
7
25
64
12
60
78
3
18
25
28
57
16
68
43
15
2008
Walloon Region: Males, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2004-2010
245
9
12
1
5
2
1,877
2
200
9
14
8
245
46
3
151
20
408
37
814
42
237
218
12
35
74
16
47
69
5
12
16
24
69
14
81
38
16
2009
323
11
6
3
5
12
1,818
4
195
14
6
9
274
47
10
173
19
404
50
854
34
234
231
10
23
59
13
47
54
5
26
24
25
66
12
55
31
6
2010
8.8
0.6
0.8
0.0
0.1
0.2
66.6
0.1
8.9
0.4
0.5
0.3
6.7
1.8
0.3
3.5
0.4
12.9
2.6
26.5
1.0
9.7
8.4
1.2
0.6
2.5
0.6
2.0
2.9
0.3
0.5
1.3
1.0
2.4
0.7
3.2
0.9
0.6
2004
7.9
0.7
0.5
-
0.0
0.2
65.9
0.1
7.8
0.8
0.2
0.2
6.4
1.2
0.3
3.8
0.5
11.9
2.3
26.0
1.3
10.2
8.6
1.1
0.7
2.2
0.5
2.2
2.6
0.4
0.6
0.8
1.4
3.0
0.9
2.5
1.1
0.6
2005
7.8
0.4
0.6
-
0.2
0.2
63.5
0.1
6.6
0.5
0.2
0.3
7.6
1.0
0.1
5.5
0.6
13.6
1.3
26.2
1.1
9.3
8.4
0.7
0.8
2.9
0.4
1.8
1.9
-
0.8
0.5
1.3
1.8
0.6
3.0
1.2
0.6
2006
9.2
0.5
0.9
-
0.3
0.3
63.8
0.1
8.2
0.5
0.4
0.1
8.3
1.8
0.1
5.9
0.6
13.4
1.5
25.7
1.1
9.0
7.9
0.4
1.1
3.2
0.5
1.8
3.4
0.4
0.8
0.8
1.1
2.8
0.8
2.6
1.3
0.4
2007
WSR
10.4
0.4
0.6
-
0.0
0.1
62.8
0.1
8.6
0.7
0.3
0.2
5.9
1.6
0.2
6.1
0.4
13.7
1.4
25.8
1.2
7.3
8.2
0.3
1.0
2.6
0.6
2.4
3.2
0.1
0.7
0.9
1.0
2.3
0.6
2.6
1.7
0.5
2008
9.8
0.5
0.7
0.0
0.2
0.1
64.2
0.1
7.4
0.3
0.5
0.3
8.4
1.5
0.1
5.5
0.8
14.0
1.2
26.8
1.5
7.7
7.9
0.5
1.2
3.0
0.7
1.8
2.7
0.2
0.4
0.6
1.0
2.7
0.4
3.1
1.4
0.5
2009
13.1
0.6
0.5
0.1
0.2
0.5
59.9
0.2
7.0
0.5
0.2
0.3
9.0
1.5
0.3
6.0
0.7
13.4
1.6
26.8
1.2
7.5
7.8
0.3
0.9
2.3
0.5
1.8
2.1
0.1
0.9
0.9
1.0
2.6
0.5
2.1
1.2
0.2
2010
Mesothelioma
Kaposi's sarcoma
Soft tissues
Retroperitoneum and peritoneum
Breast
Penis
Prostate
Testis
Male genital organs, NOS
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C45
C46
C47,C49
C48
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
3
10,146
Total excl. non-melanoma and MDS, MPD
WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)
10,242
10,510
10,768
60
36
220
7
2
12
7
98
120
101
26
91
51
1
5
10,626
11,174
79
37
232
3
6
7
9
83
121
105
32
86
57
-
4
86
12
136
70
143
4
13
13
7
515
24
33
256
4
573
33
32
259
4
102
3
2,926
105
20
3,206
22
25
3
7
24
54
48
5
60
66
5
526
548
Total excl. non-melanoma
Total
Malignant neoplasms of skin
C44
9,703
9,792
10,340
53
36
220
10
5
8
12
71
111
124
25
72
60
4
3
75
4
133
-
17
11
462
18
29
274
3
101
2,734
16
20
3
43
5
47
548
9,833
9,919
10,573
41
45
194
2
2
9
25
98
107
123
36
83
58
-
9
83
4
130
-
18
10
508
29
39
266
4
109
2,462
23
20
6
52
7
49
654
9,829
9,960
10,597
79
52
208
-
4
8
12
96
131
91
38
85
64
1
6
87
3
129
2
14
7
524
25
35
293
2
115
2,399
20
29
12
61
8
54
637
9,924
10,087
10,740
108
55
186
-
3
4
19
106
145
108
27
85
51
2
9
121
1
128
-
12
7
537
40
25
299
2
107
2,377
25
38
1
38
3
52
653
10,045
10,221
10,913
116
60
139
-
7
8
24
97
134
131
36
89
46
-
6
82
1
147
3
20
14
536
25
43
255
1
121
2,486
27
27
6
49
6
52
692
390.6
394.9
412.0
2.8
1.6
8.3
0.1
0.4
0.2
0.3
3.5
6.1
3.6
1.3
13.3
3.2
-
0.3
3.1
0.6
7.0
0.2
0.4
0.1
19.1
1.2
1.0
10.4
0.1
6.2
113.1
0.8
1.0
0.3
1.8
0.2
2.4
17.1
372.9
375.9
392.4
1.8
1.3
7.9
0.3
0.2
0.5
0.3
4.3
5.5
3.5
1.0
12.6
3.0
0.1
0.4
4.1
-
6.4
0.2
1.0
0.4
17.2
0.9
1.1
9.8
0.2
5.9
102.8
0.8
0.8
0.1
2.2
0.2
2.0
16.5
356.0
359.0
375.9
1.6
1.4
7.5
0.5
0.4
0.3
0.5
3.1
4.7
4.2
1.0
10.2
3.2
0.2
0.1
3.3
0.3
6.1
-
0.7
0.4
15.0
0.6
0.9
10.8
0.1
5.8
96.7
0.6
0.7
0.1
1.9
0.1
1.4
16.9
357.6
360.3
379.1
1.2
1.5
6.8
0.0
0.2
0.3
0.8
4.0
4.8
4.4
1.4
10.9
3.0
-
0.8
3.7
0.3
5.7
-
0.8
0.3
16.3
0.8
1.2
9.8
0.2
6.6
86.1
0.9
0.7
0.3
2.3
0.2
1.6
18.8
appendix
351.3
355.3
373.7
2.2
1.8
7.2
-
0.2
0.3
0.4
3.5
5.6
3.0
1.3
12.0
3.2
0.0
0.5
3.7
0.2
6.1
0.1
0.7
0.2
16.3
0.7
1.2
10.8
0.1
6.6
82.5
0.7
1.0
0.5
2.7
0.3
1.8
18.3
350.4
345.0
355.8
350.8
belgian cancer registry
3.4
370.0
3.0
2.0
2.0
374.2
4.5
0.5
0.1
6.2
0.3
0.2
-
3.4
0.8
0.6
5.2
6.6
4.0
1.2
3.9
3.5
12.0
11.7
1.0
-
0.3
0.6
2.4
3.3
5.4
2.8
0.0
0.0
0.2
0.1
6.7
0.8
-
0.4
0.2
0.9
6.1
0.8
16.1
1.4
1.2
9.2
0.7
16.5
0.0
6.8
5.9
0.1
82.7
80.3
11.3
0.9
2.3
0.2
0.0
0.9
0.2
0.1
1.6
1.3
1.6
1.6
0.9
19.6
18.4
133
Lip
Base of tongue
Tongue
Gum
Floor of mouth
Palate
Mouth, NOS
Parotid gland
Salivary glands, NOS
Tonsil
Oropharynx
Nasopharynx
Pyriform sinus
Hypopharynx
Lip, oral cavity and pharynx, NOS
Oesophagus
Stomach
Small intestine
Colon
Rectosigmoid junction
Rectum
Anus and anal canal
Liver and intrahepatic bile ducts
Gallbladder
Biliary tract, NOS
Pancreas
Other ill-defined digestive organs
Nasal cavity and middle ear
Accessory sinuses
Larynx
Trachea
Bronchus and lung
Thymus
Heart, mediastinum and pleura
Respiratory system and intrathoracic organs, NOS
Bone and articular cartilage of limbs
Bone and articular cartilage, NOS
Malignant melanoma of skin
Malignant neoplasms of skin
Mesothelioma
C00
C01
C02
C03
C04
C05
C06
C07
C08
C09
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
C20
C21
C22
C23
C24
C25
C26
C30
C31
C32
C33
C34
C37
C38
C39
C40
C41
C43
C44
C45
9
55
6
385
312
13
9
-
-
6
554
1
10
410
327
9
7
-
6
3
567
1
9
39
7
3
8
187
44
5
6
175
13
28
33
54
27
314
20
28
27
279
76
33
769
35
147
80
778
150
85
5
5
9
6
4
14
22
3
15
11
8
10
11
22
6
9
6
3
11
29
8
13
15
13
12
15
28
6
4
15
357
282
16
9
-
3
3
641
-
39
5
6
6
207
14
21
50
29
269
45
787
37
165
73
7
4
12
1
15
23
7
15
9
12
7
8
26
8
7
11
459
311
9
7
-
1
5
699
3
22
7
2
6
185
40
15
50
26
311
32
797
36
141
83
3
5
8
4
16
37
2
24
12
8
23
13
23
13
5
2007
2006
N
2005
Primary site
2004
Females
14
480
381
11
12
-
7
5
667
1
40
4
7
6
203
33
22
69
26
303
29
783
30
155
81
2
12
10
5
14
37
4
14
6
15
16
14
21
12
1
2008
9
468
362
5
8
-
3
3
805
3
50
5
8
5
217
45
14
67
27
259
49
802
41
126
85
4
5
18
8
17
21
4
16
14
8
21
20
24
18
-
2009
Walloon Region: Females, number of invasive tumours and age-standardised incidence by primary site and incidence year, 2004-2010
10
478
459
7
7
-
1
9
814
2
34
2
4
6
248
46
33
71
40
301
50
716
34
165
91
1
3
15
4
13
28
1
18
16
12
21
15
34
11
4
2010
0.2
7.6
13.2
0.7
0.5
-
-
0.2
18.8
0.0
1.5
0.2
0.1
0.2
4.8
0.8
0.4
0.8
0.9
7.4
2.0
18.5
1.0
3.9
2.3
0.2
0.2
0.2
0.1
0.3
1.1
0.3
0.4
0.4
0.6
0.4
0.5
1.0
0.3
0.1
2004
0.3
9.0
13.5
0.5
0.4
-
0.3
0.1
19.2
0.0
1.4
0.3
0.1
0.2
5.3
0.7
0.3
1.8
0.8
8.8
1.4
18.9
0.9
3.5
2.3
0.3
0.3
0.2
0.1
0.5
0.9
0.2
0.4
0.4
0.4
0.4
0.3
0.8
0.3
0.2
2005
0.4
7.1
11.5
0.8
0.5
-
0.1
0.1
21.0
-
1.3
0.3
0.3
0.1
5.2
0.4
0.5
1.3
0.8
6.5
1.0
18.8
1.3
4.1
2.2
0.3
0.2
0.5
0.0
0.5
0.9
0.2
0.5
0.3
0.4
0.3
0.3
1.0
0.3
0.2
2006
0.3
9.2
12.7
0.4
0.3
-
0.0
0.1
23.1
0.1
0.8
0.3
0.0
0.1
5.1
0.9
0.4
1.3
0.7
8.2
0.9
18.5
1.0
3.6
2.3
0.1
0.2
0.3
0.2
0.6
1.3
0.1
0.9
0.4
0.3
0.9
0.4
0.9
0.5
0.1
2007
WSR
0.4
9.6
15.3
0.6
0.8
-
0.3
0.2
21.6
0.0
1.5
0.2
0.2
0.2
5.2
0.7
0.5
1.8
0.9
7.8
0.7
17.8
0.8
3.7
2.3
0.1
0.5
0.3
0.2
0.5
1.3
0.1
0.5
0.2
0.5
0.5
0.5
0.6
0.5
0.0
2008
0.2
8.6
14.7
0.2
0.5
-
0.2
0.1
26.2
0.1
1.9
0.1
0.2
0.1
5.9
1.1
0.3
1.8
0.8
6.9
1.3
18.5
1.1
3.1
2.2
0.1
0.2
0.6
0.4
0.6
0.8
0.2
0.6
0.4
0.3
0.8
0.5
0.9
0.6
-
2009
0.3
9.6
19.5
0.3
0.4
-
0.0
0.3
25.2
0.1
1.2
0.0
0.2
0.1
6.2
1.0
0.7
1.9
1.2
7.7
1.2
16.2
0.9
3.8
2.5
0.0
0.1
0.5
0.2
0.5
0.9
0.0
0.6
0.5
0.4
0.7
0.4
1.1
0.4
0.1
2010
Cervix uteri
Corpus uteri
Uterus
Ovary
Female genital organs, NOS
Placenta
Kidney
Renal pelvis
Ureter
Bladder
Urinary organs, NOS
Eye and adnexa
Meninges
Brain
Spinal cord, cranial nerves and CNS, NOS
Thyroid gland
Adrenal gland
Endocrine glands, NOS
Hodgkin's disease
Non-Hodgkin-lymphoma
Malignant immunoproliferative diseases
Multiple myeloma
Lymphoid leukaemia
Myeloid leukaemia
Monocytic leukaemia
Leukaemia other
Lymphoid, haematopoietic and related tissue, NOS
Other and ill-defined sites
Unknown primary site
Myeloproliferative Disorders
Myelodysplastic syndromes
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70
C71
C72
C73
C74
C75
C81
C82-C86
C88
C90
C91
C92
C93
C94-C95
C96
C76
C80
MPD
MDS
4
61
40
195
7
2
9
8
71
88
114
32
WSR: age standardised incidence rate, using the World Standard Population (n/100,000 person years)
EAPC: Estimated annual percentage change (%)
8,400
8,491
8,901
53
38
183
5
2
4
8
68
66
82
18
248
38
36
288
-
10
221
4
109
4
9
1
136
7
21
168
2
12
288
25
441
190
14
55
3,061
14
28
-
5
229
9
93
6
16
2
116
12
21
150
1
10
276
35
451
219
21
49
8,638
Vagina
C52
Total excl. non-melanoma and MDS, MPD
Vulva
C51
3,179
9,124
Breast
C50
7
8,739
Retroperitoneum and peritoneum
C48
3
55
Total excl. non-melanoma
Soft tissues
C47,C49
Total
Kaposi's sarcoma
C46
4
8,397
8,511
8,868
68
46
163
3
4
3
8
75
67
99
38
256
37
2
9
229
3
102
4
20
1
99
14
22
161
-
16
280
7
406
166
19
55
3,079
18
45
1
8,697
8,780
9,239
40
43
191
-
5
4
7
83
75
93
40
289
42
3
8
220
5
101
3
12
-
124
4
26
147
2
4
304
6
430
229
16
66
3,098
14
50
3
8,946
9,073
9,553
66
61
203
2
5
5
10
80
82
90
25
291
42
2
2
262
-
100
2
14
-
157
8
23
162
-
19
270
1
437
211
11
52
3,233
17
53
4
8,963
9,103
9,571
68
72
140
1
5
7
10
80
116
114
30
280
42
4
5
279
2
117
2
20
3
156
14
24
147
1
16
246
4
445
169
12
60
3,156
15
41
1
9,284
9,428
9,906
83
61
147
2
4
6
15
82
127
92
36
286
53
2
6
277
3
102
2
14
4
142
13
23
144
-
15
272
4
474
206
12
69
3,250
12
41
0.1
287.9
290.4
298.0
1.4
1.0
4.8
0.2
0.1
0.2
0.2
2.6
3.6
3.2
1.0
8.8
1.9
-
0.3
10.0
0.4
4.2
0.2
0.8
0.0
2.6
0.4
0.5
5.1
0.0
0.4
9.0
1.1
13.5
8.9
0.5
1.3
115.0
0.3
2.2
279.2
281.7
290.6
1.5
1.0
4.9
0.3
0.2
0.1
0.2
2.5
2.7
2.2
0.6
7.7
2.4
-
0.8
9.7
0.3
5.0
0.1
0.5
0.0
3.0
0.1
0.4
5.6
0.1
0.4
9.3
0.8
13.3
7.8
0.4
1.5
107.9
0.5
1.1
0.1
273.3
276.9
283.9
2.0
1.6
4.5
0.1
0.1
0.1
0.1
2.6
2.6
2.7
1.1
7.2
1.8
0.1
0.4
10.2
0.2
3.8
0.1
0.8
0.0
2.6
0.4
0.5
4.8
-
0.5
8.9
0.2
12.3
6.6
0.4
1.4
109.2
0.6
1.7
0.1
280.8
282.9
292.1
0.9
1.2
5.0
-
0.2
0.2
0.2
3.1
2.5
2.6
1.2
8.7
2.4
0.2
0.4
10.0
0.3
4.1
0.1
0.5
-
2.5
0.0
0.6
4.3
0.1
0.2
9.6
0.2
12.3
9.2
0.5
1.6
107.7
0.5
1.8
0.0
appendix
284.9
287.9
297.5
1.5
1.5
5.0
0.1
0.4
0.1
0.2
2.6
3.2
2.4
0.9
8.9
2.4
0.2
0.1
11.3
-
4.5
0.1
0.5
-
3.4
0.2
0.4
5.2
-
0.5
8.6
0.0
12.3
8.6
0.2
1.3
109.1
0.5
1.8
0.1
3.1
2.6
304.8
295.2
291.6
294.8
286.3
282.8
belgian cancer registry
1.7
2.0
2.1
3.7
3.4
1.4
0.2
0.0
0.3
0.0
0.5
0.2
2.3
0.2
2.7
4.2
0.2
2.3
4.5
2.6
7.8
0.1
0.1
0.9
0.4
0.4
0.7
12.0
12.2
8.0
4.3
0.3
0.1
0.1
0.1
5.2
0.1
0.6
0.1
0.8
0.3
3.0
3.2
0.5
0.4
0.3
4.5
8.2
0.4
7.3
0.6
0.1
0.1
0.1
4.4
8.1
12.7
6.6
12.2
2.0
0.4
1.7
108.5
106.1
0.3
1.4
0.4
0.5
0.0
0.1
1.3
135
Koningsstraat 215 / Rue Royale 215
1210 Brussel / Bruxelles
Belgian Cancer Registry
T +32 2 250 10 10
F +32 2 250 10 11
www.kankerregister.org
www.registreducancer.org